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1. Viral diagnostics and genomics 
We live in a globalized society where people move increasingly between countries and 
continents, and livestock animals are farmed and traded extensively. Emerging and 
reemerging infectious diseases are a constant threat to livestock and the human population. A 
recent example is the current Ebola virus disease epidemic in West Africa which started in 
March 2014. This virus has already affected more than 22,000 people, and killed over 9,000 
(according to data from World Health Organization on 8 February 2015). Furthermore, recent 
reviews indicate that the majority of emerging human infections are zoonotic. Therefore, 
contact with livestock or wildlife increases the probability of infections threatening human 
populations and individuals lacking immunity. About 15 million (>25 %) of 57 million annual 
human deaths worldwide are estimated to be linked to infectious diseases [1]. Moreover, 
livestock diseases may result in significant economic losses and socio-economic 
consequences. Viral diseases are often spread and transmitted by vectors such as 
bloodsucking mosquitoes, ticks and wildlife animals. Sometimes, an intermediate host like a 
domestic animal is the link between viral circulations in wildlife and humans. For instance, 
some human infections originating from bats, such as Nipah, Hendra, SARS and Ebola viral 
infections, may involve intermediate amplification in pigs, horses, civets and primates 
respectively [2].  Complex pathogen lifecycles complicate the control of diseases. Rapid 
diagnosis of infectious diseases is essential in order to take appropriate action to control 
livestock and human diseases. Characterization of new pathogens will help to understand 
diseases and is an important step in the development of vaccines and better diagnostic tests. 
Viruses are the most abundant infectious agents on the planet. In an apparently sterile 
environment like sea water, the number of virus particles is estimated at 106 to 109 particles 
per milliliter [3]. A virus needs living cells of other organisms to reproduce. They infect all 
life forms, including bacteria, plants, protista, fungi and animals. The species they infect and 
use to replicate is called a host. Morphologically speaking, viral particles, known as virions, 
consist of only 2 major parts: (1) genetic material and (2) a protein coat that protects the 
genetic material called capsid. Some viruses may also contain an envelope of lipids that 
surrounds the protein coat when they are outside host cells. The genetic material can be either 
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), linear or circular, single stranded 
and double stranded, segmented or non-segmented. Viruses are classified according to the 
type and organization of their genomes, viral replication strategy, and the morphological 
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structure of the virion. In Figure 1 an overview is given of the morphologies and genome 
structures of the 26 virus families known to cause disease in animals and humans.  
The detection and identification of viruses in clinical samples relies on a range of traditional 
techniques. Samples are examined for the presence of virus particles (e.g. by electron 
microscopy), virus antigens (e.g. by ELISA, the enzyme-linked immunosorbent assay) and/or 
viral nucleic acids (e.g. DNA microarrays, PCR, DNA sequencing). Virus isolation attempts 
the multiplication of viruses in cell culture, eggs or laboratory animals. Cell cultures are 
checked for lysis of cells caused by infecting viruses known as cytopathic effect (CPE). In 
most cases, viral infection is diagnosed by the detection of specific antiviral antibodies in the 
serum (i.e. the phase that remains after centrifugation of clotted blood) using reference 
antigens (e.g. inactivated viruses). 
Rapid development of novel molecular techniques like (1) PCR and (2) DNA sequencing, has 
resulted in the strong advancement of disease diagnostics during the last decades. PCR allows 
the detection of virus-specific nucleic acids directly from the clinical samples in a very 
sensitive way. It has become the most widely used molecular diagnostic technique in clinical 
virology [4]. The technique amplifies a single or few copies of a stretch of DNA in an 
exponential manner, thereby generating thousands to millions of copies of a particular DNA 
sequence in a short period of time. A pair of primers (i.e. short DNA fragments which are 
complementary to target regions you want to amplify) along with a thermostable DNA 
polymerase, are the key components to enable selective and repeated amplification [5]. By 
inclusion of a step converting RNA into complementary DNA (cDNA), PCR can be adapted 
to detect viral RNA in a reverse transcription PCR reaction (RT-PCR). Using a mix of 
different primer pairs, several different target nucleic acid sequences can be detected 
simultaneously (multiplex PCR). Using fluorescently labeled short DNA fragments (probes) 
or double stranded DNA (dsDNA) intercalating dyes, PCR amplification can be monitored 
and quantified in real-time in a closed tube format. This allows highly sensitive, accurate and 
rapid detection of viral nucleic acids, whilst alleviating contamination issues (real-time PCR). 
Most PCR-based virus detection approaches use primers of which the sequence is 
complementary to conserved regions in the targeted virus genome, whereby at least partial 
sequence knowledge of the target viral genome is needed. Unfortunately, there is no gene 
which may serve as universal molecular marker for viruses as no single gene is common to all 
viral genomes. This is in contrast to, for instance the 16S ribosomal RNA (rRNA) gene which 
is used as universal amplification target for identification of nearly all bacteria species [6]. 
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Figure 1: Morphology and genomic organization of virus families that include animal, 
zoonotic and human pathogens. *: viruses only known to infect animals, ds: double stranded, 
ss: single stranded, +: sense strand, -: antisense strand, S: segmented, nm: approximate 
dimensions of capsid/envelope expressed in nanometers (Reprinted from Murphy et al., 1999 
[7] with kind permission from Elsevier; virion sizes are taken from 
http://viralzone.expasy.org). 
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DNA consists of a sequence of four nucleotides. Nucleotides are composed of a nitrogenous 
base, a five-carbon sugar and at least one phosphate group. The four possible nitrogenous 
bases are adenine (A), guanine (G), thymine (T), and cytosine (C). The process of 
determining the precise order of nucleotides within a DNA molecule is called DNA 
sequencing. The amount of sequenced viral nucleic acids has increased exponentially during 
the last 20 years (Figure 2). Currently there are over 1.8 million viral sequences available in 
public databases. An overview of the rapid evolution of DNA sequencing technologies and 
their applications is presented in section 2 of this introduction. The most obvious strategy for 
sequencing full viral genomes involves the design of overlapping PCR fragments (also known 
as amplicons) that span the entire genome followed by the targeted amplification. PCR primer 
design could be based on conserved regions of viral genomes, requiring prior knowledge of 
the genome sequence of the target pathogen. Conserved regions can be identified by aligning 
available sequences for a virus of interest from public databases. In the absence of perfect 
sequence conservation in a region, a primer containing some degenerated nucleotides may be 
designed (e.g. [8]). Specific viral PCR amplification is the most sensitive method for 
detecting and sequencing small amounts of viral nucleic acids. However, this method is not 
useful for obtaining genomic information from viruses with little or no available sequence 
data. 
Correct diagnosis of viral infections is not possible in some instances. Some viruses are 
difficult to culture in existing cell culture or biological model systems.  In other cases, the 
available specific diagnostic tests fail because an unexpected virus, new variant or totally new 
virus is involved. In addition, the viral replication biology, in particular that of RNA viruses, 
poses its own unique problems. The lack of proofreading mechanisms (i.e. when an incorrect 
base pair [bp] is incorporated during replication, proofreading polymerases have the ability to 
correct this error) provided by the viral RNA polymerase and a short generation time result in 
a very high mutation rate. Consequently, RNA viruses exist as a complex mix of differing 
genomes (a “swarm” of closely related viruses) within a single host, often termed as 
“quasispecies” (reviewed in [9]). Moreover, when a host cell is infected by more than one 
virus strain, recombination between genomic regions and reassortment of genomic segments 
(of segmented viral genomes) frequently occurs, enhancing genetic variation and viral 
evolution [10]. Thus, rapid virus evolution makes detection and control of virus infections 
even more challenging. 
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One promising solution for failing viral diagnostics is sequencing all genetic material directly 
in a clinical sample in a random manner, and subsequently analyzing the obtained sequencing 
data for viral sequences. This approach is often referred to as viral metagenomics (reviewed in 
[11, 12]) and has the benefit of not requiring prior knowledge about any virus that may be 
present in a sample. Besides virus identification, the viral metagenomic workflow has the 
ability to provide a detailed characterization of viruses, including the full genome sequence 
[13]. In the next section, a summary will be given of available DNA sequencing technologies 
on the market, and their applications in virology (section 2). In section 3, an overview will be 
given of frequently used steps to generate viral metagenomes (also known as viromes) in 
order to characterize new and known viruses from animal and human clinical samples. In the 
last section (4) of this general introduction, the remaining challenges of the viral metagenomic 
workflow will be listed for its application in viral diagnostics and genomics. 
 
Figure 2: Number of bases from all viral DNA/RNA sequences in the NCBI genetic sequence 
database GenBank (extracted from the bimonthly release notes 
ftp://ftp.ncbi.nih.gov/genbank/release.notes/). 
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2. The DNA sequencing revolution 
The first modern DNA sequencing technologies were developed in 1977, of which the 
Frederick Sanger chain-termination method was the most important one. For decades this 
technology has been the gold standard for DNA sequencing. Since 2005, various “next-
generation” DNA sequencing (NGS) technologies were developed at a fast rate, increasing the 
sequencing throughput enormously and reducing the costs dramatically.  
2.1 Classical Sanger sequencing  
2.1.1 Method 
In 1977, Sanger and coworkers developed a sequencing method that was initially known as 
the chain-termination or dideoxynucleotide method [14]. Briefly, a radioactive-labelled (32P) 
primer was annealed to a specific known region on the template DNA, which provided a 
starting point for DNA synthesis. Subsequently complementary strand synthesis was 
performed in the presence of DNA polymerase, deoxynucleoside triphosphates (dNTP) and a 
modified 2’,3’-dideoxy nucleotides  (ddNTP). Since the ddNTP lack a 3’-OH group necessary 
for incorporation of a next base, the reaction is terminated with the incorporation of a ddNTP 
into the growing chain. This method was performed in four separate chain-termination 
reactions, each containing one of the four terminators (ddATP, ddGTP, ddCTP, ddTTP). All 
the generated fragments had the same 5’ end, whereas the residue at the 3’ end was 
determined by the ddNTP used in the reaction. After all four reactions were completed; the 
mixture of different-sized DNA fragments was separated by electrophoresis on a denaturing 
polyacrylamide gel in four lanes, allowing a size difference resolution of one nucleotide. The 
pattern of bands showed the distribution of the termination in the synthesized strand of DNA 
and the unknown sequence could be read by autoradiography. At that time, DNA sequencing 
was slow, laborious and radioactive reagents were required. Since this first version of the 
Sanger method, several adaptations have been implemented to improve the method. The 
major technological breakthroughs were:  
• The use of fluorescent detection integrated into a partially automated platform. A 
different colored fluorophore label is used for each of four terminators (ddATP, ddGTP, 
ddCTP, ddTTP). This makes it possible to carry out the four termination reactions - for 
A, C, G and T - in a single tube, and separate the termination products in a single 
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polyacrylamide gel lane. Sequence information is acquired directly by a computer when 
the bands on the gel pass in front of a fluorescent detector [15]. 
• Introduction of capillary gel electrophoreses (a miniaturized polyacrylamide gel) for 
separation and detection of DNA sequencing samples [16].   
• Introduction of thermal cycle sequencing which is carried out in a similar way to PCR but 
uses just one primer [17]. Because there is only one primer, only one of the strands of the 
starting molecule is copied, and the product accumulates in a linear fashion, not 
exponentially as is the case in a traditional PCR. 
Finally, the DNA fragments could be detected in real-time by a laser and raw sequencing 
traces were converted by base calling software into sequence reads with associated quality. 
This automatic capillary sequencing was later termed as “first-generation sequencing”. 
Nowadays, a 96-capillary machine can produce about half a million nucleotides (0.5 
megabases [Mb]) per day.   
2.1.2 Genome sequencing strategies  
As only relatively short DNA strands (100 to 1,000 bp) can be sequenced with the Sanger 
method, longer DNA fragments must be subdivided into smaller fragments and subsequently 
re-assembled back into the original overall sequence. Two different strategies have been 
developed for the sequencing of whole (large) genomes: the “whole-genome shotgun” 
approach and the “clone contig” approach [18].  
Whole genome shotgun sequencing 
The genome is randomly broken (e.g. by sonication or nebulization) into short fragments of 
appropriate size for sequencing (Figure 3). Subsequently these DNA fragments are inserted 
into a cloning vector (e.g. plasmid or lambda phage) and molecularly cloned. End sequences 
of the clonal DNA inserts are obtained and software is used to identify overlaps between 
sequences. The resulting sequences are examined for overlaps and are used to build up the 
contiguous genome sequence (referred as de novo assembly). When the original genome is 
not fully covered yet, gaps can be filled by (1) sequencing more clones, (2) molecular cloning 
using a different vector, or (3) primer walking. The primer walking approach is quite time 
consuming and extensive primer design is needed. First, a sequencing reaction is performed 
using primers which bind to part of a known sequence.  A second priming site is then chosen 
inside the newly generated sequence, following the same sequencing direction as the first one. 
In this manner, you “walk” along the strand in order to complete the sequence.  The whole 
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genome shotgun approach has been used for sequencing small genomes (e.g. viruses and 
bacteria) and in metagenomics. The shotgun approach is straightforward and does not require 
any prior knowledge of the genome sequence. However, the whole genome shotgun 
sequencing of viruses, possesses its own unique problems (see section 3, viral metagenomics). 
Clone contig sequencing 
The de novo assembly of shotgun sequences of more complex (e.g. eukaryotic) genomes can 
be very computationally demanding, and is complicated by the presence of repeated 
sequences (i.e. patterns of nucleic acids that occur in multiple copies throughout the genome). 
One solution is the clone contig sequencing approach (also known as hierarchical shotgun 
sequencing), where a low-resolution physical map of the genome is made prior to actual 
sequencing (Figure 3). The genome is first broken down into large fragments, referred to as 
“clone contigs”, which are cloned in a high-capacity cloning vector (i.e. large inserts possible, 
typically 100-200 kilobases [kb] each). Subsequently, overlaps between clone contigs and 
their relative orientation to the genome are identified and a low-resolution physical map is 
made. Each piece of cloned DNA is then sequenced by the random shotgun strategy and this 
sequence is placed at its appropriate position on the contig map in order to gradually build up 
the overall genome sequence. Although this method has clear advantages, the clone contig 
approach is much slower and more labor-intensive than the whole genome shotgun approach. 
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Figure 3: Schematic representation of the “clone contig” and “whole genome shotgun” 
sequencing strategies. In the clone contig approach, larger fragments are first cloned into 
large-fragment cloning vectors. The genomic DNA fragments represented in the cloning 
library are then organized into a physical map and individual clones are selected and 
sequenced by the random shotgun strategy. In the whole genome shotgun strategy, the 
genomic DNA is directly broken into fragments of appropriate sequencing lengths, cloned 
into small-fragment cloning vectors and sequenced. 
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2.1.3 Applications  
Sanger sequencing is used to sequence individual genes, larger genetic regions, full 
chromosomes or whole genomes. The first genome sequence ever determined was that  of 
bacteriophage MS2 [19]. The Sanger method was also the necessary foundation for the 
development of PCR, which is up to now the most successful molecular diagnostic method [5] 
(reviewed in [20]).  Using the shotgun approach, the first bacterial genome (Haemophilus 
influenza) was sequenced in 1995 [21], and more recently the first working draft sequence of 
the human genome [22, 23]. The whole Human Genome Project took more than a decade and 
involved multiple sequencing centers and cost over $3 billion. The final sequencing of this 
first draft sequence of the human genome is estimated to have cost $300 million and several 
years were needed to generate and process all of the sequencing data.  
Sanger sequencing is used extensively by clinical laboratories and has been useful for a wide 
range of applications such as molecular cloning, breeding, finding pathogenic genes, and 
comparative and evolutionary studies. Also in virology it has become an important tool for 
virus identification and genome characterization, including pathotyping and tracing 
evolutionary relationships. Full viral genome sequencing often relies on extensive primer 
design. For instance, the molecular characterization of an uncommon paramyxovirus involved 
the use of degenerated primers (matching conserved regions) and a primer walking approach 
[24]. Whole genome shotgun sequencing of viruses is a real challenge due their short genome 
lengths and low amounts of viral nucleic acids compared to massive amounts of background 
(mainly host) nucleic acids. These virus-specific challenges are discussed in section 3. 
2.2 Next-generation sequencing 
Since the beginning of this PhD project, much has changed in the field of DNA sequencing. 
Automated capillary sequencing based on the Sanger method is widely accessible and 
provides high quality data. However, the application to projects such as whole genome 
sequencing of species with large genomes is expensive and time-consuming. Limitations in 
throughput, scalability and speed have motivated the development of alternative, post-Sanger 
sequencing technologies which are referred as “Next-Generation Sequencing” or NGS. NGS 
platforms provide unprecedented throughput, generating hundreds of gigabases (Gb) of data 
in a single experiment. Sequencing with NGS platforms is also known as “deep sequencing” 
because the total number of reads is often many times larger than the number of reads 
required to cover the complete length of the studied DNA sequence; thereby overlapping a 
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certain position numerous times (referred to as coverage depth). Although the initial capital 
investment and cost per experiment remains high, the price per information unit (nucleotide) 
has been dramatically reduced in comparison with first-generation sequencing (Figure 4). 
Moreover, these technologies allow sequencing without prior knowledge of the complete 
DNA content in a sample (shotgun sequencing approach, but without the need for molecular 
cloning into vectors) whilst retaining the flexibility to allow targeted sequencing (e.g. PCR 
amplicons). A number of different NGS platforms are currently available, with each utilizing 
unique protocols and solutions for template preparation and sequencing. This has led to 
individual systems having their own strengths and limitations (reviewed in: [25-27]).  
 
Figure 4: The average cost (in U.S. dollar, logarithmic scale) per 1000 bases sequenced since 
2001 (http://www.genome.gov/sequencingcosts/). 
2.2.1 Second-generation technologies 
NGS platforms that require amplification of the template molecules prior to sequencing are 
referred to as “second-generation sequencing” platforms. Second-generation sequencing 
platforms vary in technology and chemistry used, but have the following properties in 
common: 
• A DNA library is made from the sample. This library represents either all DNA in the 
sample without prior knowledge of the sequence or a targeted library using PCR 
Chapter 1  General introduction 
     
18 
 
amplification or alternative enrichment methods. As the DNA template needs to be quite 
short (ranging from 200-1,000 bp), a mechanical or enzymatic DNA fragmentation step is 
performed. Subsequently, adapter sequences, containing primer binding sites for 
amplification and sequencing, are joined to DNA molecules by ligation or amplification. 
Adapter sequences may include a barcode sequence (also known as index, MID or tag) 
that allows multiplexing of several samples in an experiment.  
• Individual DNA molecules in each library are clonally amplified. 
• Clonal DNAs are sequenced in parallel, resulting in hundreds of thousands of DNA 
sequence reads. 
The second-generation sequencing platforms first emerged on the market with an emphasis on 
extreme high-throughput sequencing applications and were initially restricted to large genome 
sequencing centers or core facilities. These technologies use different detection principles 
including 454 pyrosequencing (454 Life Sciences, acquired by Roche, available since 2005, 
but planned to be discontinued by mid-2016 [28]), Illumina’s sequencing by synthesis 
(previously Solexa, available since 2007 [29]), SOLiD ligation based sequencing (Life 
Technologies, available since 2006), and since 2010, the Ion Torrent semiconductor 
sequencing technology [30]. 
• In 454 pyrosequencing (http://www.454.com/), a single template molecule is annealed to 
a bead-bound oligonucleotide and is clonally amplified via emulsion PCR (emPCR). 
emPCR is a PCR reaction that occurs within aqueous microdroplets separated by oil 
enabling up to thousands of independent reations per microliter (µl) of volume. emPCR 
results in each bead having a homogeneous set of template molecules. Millions of beads 
are loaded together with sequencing reagents onto a flat “picotiter” plate which contains 
multiple wells and is designed to allow only a single bead in each well. All beads are then 
sequenced in parallel by pyrosequencing. When a polymerase-mediated incorporation 
event occurs, a chemiluminescent enzyme generates an observable light signal that is 
recorded by a CCD camera. Consecutive flows of A, C, G, and T reagents over the 
picotiter plate allow the determination of the sequence.  Currently there are two platforms 
on the market using this technology, the GS FLX+ and the GS Junior+ system. The GS 
FLX+ system (developed from its ancestor GS20) can now generate around 700 Mb of 
sequence data in a day with read lengths of up to 1,000 bp. The GS Junior is essentially a 
smaller benchtop version generating around 70 Mb per run with read lengths of 700-800 
bp and longer. 454 pyrosequencing has been the most commonly used technology for 
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NGS to date. Reagents are quite expensive and the technology shows a high error rate in 
homopolymer regions (i.e. three or more consecutive identical DNA bases), caused by 
accumulated light intensity variance [28]. Although long read lengths offer considerable 
advantages for some applications, this technology has the highest cost per nucleotide of 
information, forcing Roche to discontinue the technology from 2016. 
• In Illumina sequencing (http://www.illumina.com/), individual library DNA fragments 
are captured on a solid glass surface and clonally amplified by bridge amplification. The 
library DNA fragments binds at both ends to oligo primers on the glass surface and 
successive round of PCR result in the generation of tiny islands or clusters of amplified 
molecules which serve as clones for subsequent sequencing using chain terminators 
similar to traditional Sanger sequencing. However, unlike the Sanger method, Illumina 
uses only fluorescently labelled reversible terminators, such that each base incorporation 
temporarily terminates the sequencing reaction. After imaging to determine which 
nucleotide is incorporated in each DNA clonal cluster, the dye is cleaved and more dye 
labelled terminators are added. The principle is called sequencing-by-synthesis. Currently 
three platforms are marketed: the HiSeq, MiSeq and NextSeq. Different read lengths may 
be chosen, from 36 bp to 2×300 bp on the MiSeq. HiSeq generates extreme throughput 
(ranging from 15 Gb to 1.8 Terabases [Tb] per run) and is most suitable for large 
sequencing centers.  The MiSeq is a smaller benchtop version generating up to 15 Gb 
output per run. The NextSeq is a medium throughput platform (up to 120 Gb). At the 
moment Illumina is the dominant NGS technology on the market as it is a proven 
technology, with good error rates and acceptable operational costs. 
• The SOLiD Sequencing by Oligonucleotide Ligation and Detection technology 
(http://www.lifetechnologies.com/) uses emPCR to generate clonal DNA fragments on 
beads. The beads are attached to a glass slide to allow sequencing by ligation and 
detection using fluorescently labelled di- or tri-base probes.  Whilst this approach 
provides very high accuracy, the maximum read length is relatively short (75 bp). The 
SOLiD platforms have therefore been used mainly for applications that do not require de 
novo assembly of reads (i.e. assembling overlapping short reads back into larger 
fragments, also known as contigs), such as transcriptomics, epigenomics and 
resequencing of large mammalian genomes. There are currently two SOLiD platforms 
available, the 5500 and the 5500xl, with an output up to 320 Gb. 
• Ion Torrent (http://www.lifetechnologies.com/) uses a sequencing strategy similar to 
454 pyrosequencing, except that hydrogen ions (H+) are detected instead of 
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chemiluminescence signals. The hydrogen ion is detected by a semiconductor as a small 
change in pH. Lasers, cameras or fluorescent dyes are no longer needed which highly 
reduces the costs. However, the technology remains still sensitive to misreading the 
length of homopolymers. There are currently three different sequencing chips available 
for the Personal Genome Machine (PGM), the first platform for Ion Torrent sequencing, 
ranges in capacity from 30 Mb to 2 Gb (read length up to 400 bp). With a short run time 
and flexible capacity, the PGM represents an affordable and rapid benchtop system 
designed for small projects. Recently the Proton platform was released to enable higher 
throughput. 
Over the last 5-7 years, all of the major platforms have made significant improvements, with 
notable advancements made in terms of protocol complexity, overall performance (including 
read length, fidelity, lower input DNA) and cost-efficiency. The development of smaller 
benchtop sequencers [31] have made the technology more accessible for use in routine 
microbiology laboratories. Whilst academic core facilities and commercial service providers 
have focused increasingly upon providing users with access to a range of the different 
sequencing technologies.  
2.2.2 Third-generation technologies 
In addition to the continuous improvement of existing second-generation sequencing 
platforms, newer methodologies are being developed. NGS platforms that do not require 
amplification of the template molecules prior to sequencing and directly sequence individual 
DNA molecules are referred to as single molecule sequencers or “third-generation” platforms 
(reviewed in: [27, 32]). These approaches promise additional advantages such as scalability, 
simplicity, long read length and low operational costs. As they do not require clonal 
amplification of template DNA molecules, potential errors associated with clonal 
amplification are avoided.  
• HeliScope (developed by Helicos BioSciences [33]) was the first commercial available 
single molecule sequencer. The high cost of the instrument and the very short read 
lengths (average of 32 bp) resulted in limited use. Consequently, the instrument is no 
longer sold. 
• Currently, PacBio RS (http://www.pacificbiosciences.com/) is the only third-generation 
platform available on the market (since 2011).  Their SMRT sequencing technology  
determines sequences of long single DNA molecules in real-time. Unlike other NGS 
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technologies, it is the DNA polymerase that is immobilized on the bottom of a microcell. 
Fragmented dsDNA is ligated to hairpin adapters to create circular DNA. These are 
amplified linearly using primers complementary to the hairpin sequence and then 
captured by a single molecule of DNA polymerase and sequenced in the bottom of a well 
(referred to as “zero-mode waveguide”). The sequence of individual DNA strands can be 
determined because each dNTP has a unique fluorescent label (no chain terminators 
unlike Sanger and Illumina sequencing) that is detected immediately prior to being 
cleaved off during synthesis [34]. Following incorporation, the fluorescent label is 
cleaved and diffuses away, allowing the DNA polymerase to continue to incorporate 
multiple bases per second. Even though its throughput (around 90 Mb) is lower than most 
NGS platforms on the market, the PacBIO RS II still has several advantages that make it 
attractive for clinical laboratories, in particular for microbiology research. Sample 
preparation is fast, there is no introduction of amplification artefacts, run times are 
relatively short (finished within 1 or 2 hours), and read length is the greatest currently 
available (average circa 12,500 bp, using the latest chemistry sequences of up to 40,000 
bp can be achieved). However, compared with other sequencing platforms, the PacBio 
RS has been reported to have the highest raw error rate. In addition, due to lack of clonal 
amplification, large amounts of input DNA material are required. 
Other 3rd generation technologies are still under development [25] such as DNA sequencing 
in nanopores that offer the potential of simple, inexpensive, single-molecule sequencing in 
miniaturized or highly scalable devices [35]. Although substantial validation data is still 
required, these technologies have the potential to make NGS even more widely available for 
clinical purposes. 
2.2.3 Applications in clinical virology 
The rapid evolution in DNA sequencing has resulted in the exponential increase of genetic 
data in public databases, including viral sequence data (Figure 2). The NGS platforms were 
originally designed for high-throughput sequencing of large genome sequencing projects. In 
2008, NGS made it possible to sequence a human genome for less than $1 million in only 2 
months [36]. Nowadays, it is even possible to re-sequence a human genome for $1000 in only 
a few days with the Illumina sequencing HiSeqX Ten platform. By contrast, viral genomes 
have very small genomes. Therefore, sequencing of, for instance, a single viral genome using 
a full NGS run would make the project very expensive. Multiplexing possibilities which allow 
sequencing of different samples on the same run, and the development of smaller benchtop 
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NGS sequencers, are making this new technology more accessible for the average clinical 
virology laboratory.   
NGS provides many new opportunities and is used increasingly to study etiology, genomes, 
evolution and outbreak management of human and animal infectious diseases as well as host-
pathogen interactions (Figure 5; comprehensive reviews: [26, 37, 38]). NGS offers high 
sensititive diagnostic potential to detect the full spectrum of viruses, including unknown and 
unexpected viruses.  For instance, metagenomics using 454 technology allowed the 
identification of a novel orthobunyavirus, subsequently named Schmallenberg virus (SBV), in 
an epidemiological cluster of diseased cattle in Germany [39]. The cattle showed symptoms 
of fever, decreased milk production, and diarrhea. The identified viral sequences were used to 
rapidly design targeted molecular tests that were used to confirm a clear association between 
the presence of the virus and affected animals. International adoption of these molecular tests 
identified a widespread occurrence of SBV in European countries 
(http://www.efsa.europa.eu/en/supporting/pub/429e.htm) and its detection in stillborn and 
malformed lambs [40, 41], as well as in insect vectors [42, 43]. The molecular tests were also 
helpful in targeting samples for isolation of the virus, which ultimately led to the development 
of vaccines [44-46]. This example shows the power of NGS to boost responsiveness to 
emerging diseases. Beside detection of candidate pathogens, NGS-based viral metagenomics 
often find a wealth of previously unrecognized viruses [47]. NGS is being used increasingly 
to explore the viral diversity in a wide range of environmental samples (determining what 
might be considered as “normal”) and in surveillance studies on vector-borne and zoonotic 
viruses (e.g. surveillance in mosquitos [48] or in bats [49]). 
NGS provides the ability to sequence and compare multiple full genomes of distinct types and 
to identify important genetic differences between them [50]. In contrast to Sanger sequencing, 
one NGS read represents one DNA fragment which does not need to be the major variant. 
Consequently, NGS makes it possible to study variations (single nucleotide variations, 
deletions, insertions…) beyond consensus level with great accuracy. This is extremely useful 
for the study of RNA virus quasispecies. For example, Wright and colleagues investigated the 
genetic diversity and resulting quasispecies population after inoculation of foot-and-mouth 
disease virus into a single animal [51]. The researchers identified genetically distinct 
populations originating from different lesions. The study of the viral swarm within individual 
hosts has implications for understanding the evolutionary dynamics of viral populations under 
selection pressures, e.g. antiviral drugs or host immune response. This has been a particularly 
Chapter 1  General introduction 
     
23 
 
active field in human medicine, e.g. with regard to human immunodeficiency virus (HIV) 
antiviral drugs response, drug resistance, and viral tropism (reviewed in: [52-54]), as well as 
studies on human influenza A (e.g. [55]). Deep sequencing was also used for quality control 
of live-attenuated viral vaccines [56, 57]. In this context, the method allowed identification of 
mutations of vaccine strains, minority variants of vaccine strains and sequences of 
adventitious viruses in vaccine seeds or stocks [57]. 
 
 
Figure 5: Different dimensions of animal infectious diseases and associated infection biology. 
High-throughput technologies can be applied to study etiology, genomes, evolution, and 
outbreak management of infectious diseases as well as host-pathogen interations. This both on 
the level of the individual sample as on a higher epidemiological scale (Reprinted from Van 
Borm et al., 2015 [37] with kind permission from Springer Science and Business Media). 
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3. The viral metagenomic workflow 
Viral metagenomics aims to provide the genetic composition of the viral populations present 
in a sample by directly sequencing genetic material in the sample. However, when sequencing 
all nucleic acids (through shotgun sequencing approach) present in an un-manipulated 
biological sample, the amount of viral nucleic acids will be very low or even undetectable. 
This is due to of the nature of viruses in viral infections. Firstly, the length of viral genomes 
ranges typically from 5 to 350 kb, which are smaller than genomes of bacteria (typically 
ranging from 500 kb to 10,000 kb) and eukaryotes (e.g. the human genome is approximately 
3,200,000 kb in size). Furthermore, in clinical samples virion concentrations (known as virus 
titer) are often very low, whereby after nucleic acid isolation (i.e. the process of purification 
of nucleic acids from a sample), virus genomes are present in extremely low quantities 
compared to background bacterial and host genomes in clinical samples.  Therefore, one will 
logically sequence much more background nucleic acids. Due to the small genome sizes and 
low virus titer, the key to a metagenomic based viral discovery workflow is enriching the 
levels of viral nucleic acids whilst reducing background prokaryotic and eukaryotic nucleic 
acids [11].   
In this section, the frequently used steps to generate viral metagenomes in order to 
characterize new and known viruses from animal and human samples will be outlined 
(partially based on reviews: [11, 12]). First, samples are selected and some virus enrichment 
steps may be performed (section 3.1). Subsequently, the workflow is often divided into an 
RNA virus and/or DNA virus discovery workflow. After isolation of nucleic acids, an 
amplification step is often needed to generate sufficient amounts of DNA (section 3.2). 
Thereafter, DNA is sequenced (section 3.3) and the resulting data are analyzed for similarities 
with viral sequence information in publicly available databanks (section 3.4). Depending on 
the purpose of the study, the outcome of a viral metagenomic study may be followed up to 
exclude possible false positive results or to confirm the result with different diagnostic tests 
(section 3.5). Besides virus discovery, this viral metagenomic workflow offers the possibility 
to determine the full genomic information of viruses with little or no available sequence 
information [13]. The more virus nucleic acids sequenced, the bigger the chance to overlap 
the full genome. When gaps are still present, gap filling using extensive primer design is 
needed (primer walking). Therefore, a sensitive workflow is critical for both virus 
identification and genome characterization.  
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3.1 Sample preparation  
The first and probably most important step is sample selection and collection. Depending on 
the observed clinical symptoms and recommendations of medical experts (or 
epidemiologists), samples which are expected to contain the highest virus titer should be 
collected. Furthermore, rapid collection and proper preservation will reduce bacterial growth. 
Clinical samples with a high virus titer and low background contamination (bacteria, host 
cells) are more appropriate for viral metagenomic studies. For these samples, pretreatment 
steps to enrich for viral nucleic acids are slightly less important compared to clinical samples 
with a low virus titer or a high amount of contaminating cells. Moreover, samples from which 
cells can be easily filtered and residual host nucleic acids removed by enzymatic digestion, 
while viral genetic material remains protected within viral capsids, are very useful for viral 
metagenomics studies. Examples of such samples are plasma, serum, respiratory secretions, 
cerebrospinal fluid, urine and feces [11]. Viral metagenomics is much more challenging for 
samples in which host nucleic acids and viral nucleic acids cannot be easily separated, such as 
in tissues. If the unknown virus can be grown in a cell culture system (often not the case), the 
cell supernatant is the preferred sample as it is likely to contain a high virus titer.  For clinical 
biopsy tissue samples, homogenization of the sample is the next step in order to disrupt 
cellular membranes and release all virions. Homogenates are often suspended in buffered 
solutions in a 10 % or 20 % weight to volume ratio (e.g. [58]). Solid feces samples are also 
suspended in buffered solutions like phosphate-buffered saline (e.g. [59]).  
Regardless of the initial procedure, low speed centrifugation of homogenates and liquid 
samples is a simple and widely used method to separate free virions from larger particles such 
as cellular debris. Subsequently, nucleic acids may be directly isolated using either 
commercial viral nucleic acid extraction kits or chaotropic agents like TRIzol LS reagent (e.g. 
[60]). However, most random-based viral discovery and genome sequencing studies perform 
some virion enrichment steps because otherwise little (or even no) viral nucleic acids would 
be sequenced compared to high amounts of background host and bacterial genomes.  
The most frequently used virion enrichment steps are: 
• Commercially available sterile filters used to remove bacteria, eukaryotic cells and other 
large aggregates from the sample. Filter pore sizes of 0.22 µm and 0.45 µm are frequently 
used in viral metagenomic experiments [13, 61]. Using 0.22 µm pore size filters has the 
disadvantage of retaining certain large viruses (Figure 1), whilst 0.45 µm pore size filters 
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may allow flow through of certain bacteria as the size of the largest viruses overlap the 
size of the smallest bacteria. Either way a compromise should be made. Treatment with 
antibiotics in order to destroy the cell walls of bacteria before filtration is a possible 
solution (e.g. [58]).  
• When large volume (milliliter [ml] amounts) of starting sample is available, different 
options exists to concentrate virions: 
o High-speed centrifugation with an ultracentrifuge has been proven to be a 
reliable method, especially in combination with a density gradient layered system. 
The density gradient is often made of cesium chloride or sucrose. After 
ultracentrifugation, purified virions are harvested at the height of expected density 
(for further details: [62, 63]). Disadvantages are: (1) the requirement for large 
starting volumes; (2) virions of certain families are lysed by cesium chloride; (3) 
the requirement for large amounts of virions due to significant loss of virions after 
recovery; (4) performing a density gradient layered ultracentrifugation requires 
some experience. For example, concentration with a cesium chloride gradient is 
used directly on blood plasma for the purification of human DNA viruses [64]. 
Stang and colleagues used a 30 % sucrose cushion to purify viral particles from 
cell culture [65], but high-speed centrifugation may also be used without a density 
gradient (e.g. [61]). However, ultracentrifuges are not readily available in all 
laboratories.  
o Filtration with filters having pore sizes that retain virions and thereby 
concentrate them. These filter membrane types are expressed in molecular weight 
limit, meaning the ability to retain molecules above a specified molecular weight 
(expressed in Dalton). For instance 100 kDa filters have been used to concentrate 
viruses in feces samples ([66, 67]), 30 kDa filters have been used to study the viral 
metagenome in mosquitos [68]. 
o Polyethylene glycol (PEG) precipitation is sometime used as an alternative to 
ultracentrifugation for concentrating virions (e.g. [69]). 
• Enzymatic removal of non-particle protected nucleic acids. Deoxyribonuclease 
(DNase) and ribonuclease (RNase) are enzymes capable of cleaving DNA and RNA 
respectively. They are frequently used to digest free bacterial and host nucleic acids. The 
viral nucleic acids are protected from enzymatic activity by viral capsids, and a lipid 
bilayer in the case of enveloped viruses [67, 70]. The disadvantage of this is that free 
viral nucleic acids will also be degraded. If the focus is restricted to DNA or RNA 
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viruses, nucleic acids obtained after nucleic acid isolation can be further digested with the 
appropriate nuclease (e.g. DNase I treatment on RNA extract [67]). 
• A treatment with chloroform is sometimes used to disrupt phospholipid bilayer 
membranes of eukaryotic cells, bacteria and/or mitochondria, and expose their DNA to 
enzymatic degradation (e.g. [64, 71]). However, this may disrupt also the stability of 
some lipid enveloped viruses. 
Regardless whether virion enrichment steps were performed or not, viral RNA and DNA has 
to be isolated. From this point, the RNA and DNA virus discovery workflow is often split 
[13]. In order to remove some extra background RNA after RNA isolation, rRNA (e.g. [48]) 
or messenger RNA (e.g. [72]) may be depleted by hybridization methods. 
3.2 Sequence independent amplification 
Virus discovery and whole genome sequencing of viruses is often hindered because of the 
need for large quantities of genomic material for subsequent cloning and/or sequencing 
reactions. Especially when pretreatment steps, such as nuclease treatment are performed, 
nucleic acid quantities will be limited. Therefore, an amplification step is often required to 
provide sufficient DNA input for downstream sequencing.  At the start of this PhD project, 
few virus discovery and whole genome sequencing studies were available using sequencing 
without performing an amplification step.  Most sequencing workflows at that time required 
microgram-range (µg) DNA input which limited the possibility of direct sequencing to very 
specific cases: 
• Random-based full viral genome sequencing was applied on well concentrated virus 
cultured samples. In the pre-NGS era, the whole genome shotgun approach was applied 
(Figure 3). First the genomic DNA was fragmented into random fragments (by sonication 
or enzymatic digestion) and subsequently subcloned into plasmid vectors and bacterial 
cells. This very labor intensive and time-consuming way of working was performed on 
various large dsDNA genome viruses like poxviruses [73-84] and herpesviruses [85-92]. 
With the introduction of NGS, direct 454 pyrosequencing using µg’s of input DNA 
allowed characterization of, for instance, Gallid herpesvirus type 2 [93], 
pseudocowpoxvirus [84], Human herpesvirus 5 [94] and  Rodent herpesvirus isolates 
[95]. 
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• A new polyomavirus was identified in human Merkel cell carcinoma tissue (aggressive 
human skin cancer) by directly sequencing the cDNA using the 454 technology [72]. Five 
µg input cDNA was used to prepare the pyrosequencing library. 
• The feasibility of detecting arthropod-borne viruses (known as arboviruses) was explored 
in mosquitoes experimentally infected with dengue virus and pooled with non-infected 
mosquitoes to simulate samples derived from ongoing arbovirus surveillance programs 
[48]. Total RNA (ng-range) was purified from mosquito pools and directly incorporated 
in a library preparation workflow of the GS FLX 454 pyrosequencing platform (using a 
slightly modified protocol from Simons et al., 2007 [96]). 
• The Illumina GA platform allowed identification and characterization of the 2009 
pandemic H1N1 influenza A virus from swab specimens [97]. 
• The Illumina GA platform allowed detection of viral pathogens in nasopharyngeal 
aspirates from patients with acute lower respiratory tract infections [98]. Approximately 1 
µg input DNA was needed to prepare the sequencing library. 
• Direct 454 pyrosequencing (cDNA Rapid library preparation protocol), using 200 
nanograms (ng) of input RNA, allowed identification of contaminating viruses in vaccine 
cell substrate cell lines [99]. 
In contrast, most applications aimed to sequence from clinical samples, required amplification 
of the target DNA. The most frequently used random whole genome amplification (PCR-
based) methods in viral metagenomics are reviewed below. The ideal whole genome 
amplification method should: 
• Introduce as little as possible amplification errors or bias. 
• Yield useful amounts of DNA needed for cloning and/or sequencing. 
• Be universally applicable to all types of viral genomes (RNA & DNA, single & double 
stranded, linear & circular, non-segmented and segmented) and samples (blood, tissues, 
etc). 
3.2.1 Phi29 DNA polymerase based random amplification 
Method 
Multiple displacement amplification (MDA) and multiple-primed rolling circle amplification 
are two approaches for whole genome amplification (WGA) based on the same principle. 
These methods use Phi29 DNA polymerase and random hexamer primers (5’-NNNNNN-3’) 
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to amplify ng’s of template DNA up to µg’s amplified product. After an initial denaturation 
step to make the template DNA single stranded and binding of the hexamer primers, 
isothermal genome amplification is performed at a constant temperature of 30°C.  Phi29 DNA 
polymerase originates from the bacteriophage Phi29 which uses this enzyme for the 
replication of its DNA. Besides (5’→3’) DNA synthesis activity, this enzyme possesses 
several remarkable features which makes it suitable for efficient in vitro amplification of 
DNA [100-102]: 
• 3’→5’ exonuclease activity: this is an error-correcting process which is also known as 
proofreading activity. While moving along the template DNA (5’→3’), the polymerase 
incorporates nucleotides complementary to the template strand. If an incorrect nucleotide 
is incorporated this nucleotide will be excised by the polymerase and DNA replication 
can continue. This proofreading activity enhances the Phi29 DNA polymerase fidelity 
(fewer errors are introduced) compared to Taq DNA polymerase which is commonly 
used in standard PCR reactions. 
• Strand displacement activity: When the enzyme encounters a double stranded region 
while moving along the template DNA, it will displace the complementary strand in the 
region and continue DNA synthesis. 
• Long products: After DNA-primed initiation, DNA is continuously synthesized by the 
Phi29 polymerase resulting in products with a length higher than 70,000 bp within 20 
min. 
• Phi29 DNA polymerase is very stable and has a long half-life durability. 
The principle for in vitro whole genome amplification by MDA is displayed in Figure 6. After 
a denaturation step, multiple random hexamer primers bind along the template DNA and 
initiate DNA synthesis with Phi29 DNA polymerase using its strand displacement activity. 
Other random hexamer primers present in the reaction mixture will bind to the displaced 
strands and are used as additional initiation points for DNA synthesis. Various branches are 
obtained and lead to an exponential amplification of the original template. The utilized 
random hexamers are usually modified (containing thiophosphate linkages) to prevent their 
degradation by the exonuclease activity of the Phi29 polymerase. The length of the 
amplification products can be verified by running on an agarose gel. The average product 
lengths exceeds 10 kb due the high processivity of the polymerase, and constant yields are 
obtained [103]. The reaction products are subsequently digested with restriction 
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endonucleases to obtain smaller fragments. By eliminating the denaturing step in the MDA 
reaction, only single stranded DNA (ssDNA) could be selectively amplified [104]. 
 
Figure 6: Principle of multiple displacement amplification (MDA) reaction using Phi29 DNA 
polymerase. At the bottom genomic DNA template is displayed. Arrows represent annealed 
random primers and following DNA synthesis of complementary strand in the direction of the 
arrow. 
When a circular DNA template is used, the strand displacement activity of Phi29 DNA 
polymerase causes the formation of large concatemeric DNA molecules (Figure 7). This 
process is often referred to as multiple-primed rolling-circle amplification (RCA) and results 
in an exponential amplification of the circular template. The multiple-primed RCA mimics the 
rolling-circle mechanism that occurs in nature for replication of circular DNA molecules, and 
amplifies short circular DNA more efficiently when compared to linear DNA. Ten thousand-
fold amplification can be obtained in a few hours [100]. The obtained long dsDNA products 
may subsequently be cut with a restriction enzyme, expected to cut once within the circle 
sequence, to release linear full genome fragments (Figure 7). As cloned DNA is typically 
obtained in circular vectors, these can easily be amplified by multiple-primed RCA [105]. 
 
Figure 7: Principle of multiple primed rolling circle amplification (RCA) using Phi29 DNA 
polymerase (Reprinted from Delwart et al., 2007 [11] with kind permission from John Wiley 
and Sons). 
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Various commercial WGA kits are available that use Phi29 DNA polymerase based 
amplification (Table 1). Kit selection is based on the amount of input genomic DNA, desired 
yield, degradation state of DNA, source of DNA and whether the WGA process must be 
automated [101].  
Phi29 DNA polymerase cannot be used to amplify RNA directly or to efficiently amplify 
small cDNA obtained from viral RNA genomes. However, Berthet and colleagues [106] 
described a Phi29 polymerase based random amplification approach for viral RNA by 
modifying the MDA based protocol of the QuantiTect Whole Transcriptome kit (Qiagen; 
Table 1). First, cDNA is made from the RNA by reverse transcription using only random 
hexamer primers. Then, all cDNAs are ligated together into longer linear chains which serve 
as the template for an MDA reaction.  
Use in viral metagenomics and evaluation 
Thurber and colleagues recommended use of the GenomiPhi DNA amplification kit (Sigma-
Aldrich, Table 1) to amplify viral DNA in a viral metagenomic sequencing study [62]. Table 
2 summarizes the viral metagenomic studies in veterinary and human medicine which made 
use of Phi29 DNA polymerase based random amplification. Only studies of 2011 and earlier 
are listed to outline the situation at the start of this PhD project.  Although a version of the 
protocol is described to amplify RNA genomes [106], no RNA virus metagenomic studies 
were available in the literature. Nevertheless, the amplification method seems well suited for 
discovery and genome sequencing of circular DNA genomes (almost all studies in Table 2). It 
has been demonstrated that MDA preferentially amplifies short circular DNA over linear 
DNA, which results in preferential amplification of ssDNA viruses over dsDNA viruses in the 
viral metagenome [104, 107]. Moreover, multiple primed RCA is less suitable for amplifying 
linear genomes and larger circular viral genomes [102]. This method, combined with Sanger 
sequencing is frequently applied on tissue samples, especially on tumor tissues for the 
characterization of papillomaviruses. Notwithstanding lack of data demonstrating sensitivity 
for virus identification, the method seems fit-for-purpose for circular DNA viruses.  
Yields by Phi29 DNA polymerase based random amplification methods are very reproducible 
and are often in µg-range (Table 1). MDA has been associated with statistically significant 
amplification bias relative to an unamplified control [108] and with production of artifacts 
such as the formation of chimeric DNA rearrangements in the amplified DNA [109]. 
Chimeric reads are artificial reads which map ambiguously to different genomic regions and 
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will complicate de novo assembly of the genome.  Phi29 DNA polymerase based random 
amplification methods may result in overrepresentation of certain genomic regions and/or a 
biased representation of the ratio between different species present in a sample [110-112]. 
This bias seems to be pronounced when low starting DNA amounts are used. 
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Table 1: Commercial whole genome amplification kits based on sequence-independent amplification (information is based on manufactures’ 
data on their websites and/or on the manual of the kit in question). MDA: multiple displacement amplification, RCA: rolling circle amplification, 
RT: reverse transcription, rPCR SISPA: random PCR sequence-independent single primer amplification. 
Name of kit Company Template Amplification method Input  Yield Product size Time 
illustra GenomiPhi V2 
DNA amplification kits 
GE Health Care 
Life Sciences 
genomic DNA MDA (at 30°C) ≥10 ng 4-7 µg >10 kb 1,5-2 h 
illustra GenomiPhi HY 
DNA amplification kits 
GE Health Care 
Life Sciences 
genomic DNA MDA (at 30°C) ≥ 10 ng 40-50 µg >10 kb 4 h 
illustra TempliPhi DNA 
amplification kits 
GE Health Care 
Life Sciences  
< 30 kb circular 
DNA  
RCA (at 30°C) 1 pg – 10 ng 1-1,5 µg not described 4-18 h 
illustra TempliPhi large 
construct kits 
GE Health Care 
Life Sciences  
> 30 kb circular 
DNA 
RCA (at 30°C) 1-10 ng 5 µg not described 18 h 
REPLI-g Mini kit Qiagen genomic DNA MDA (at 30°C) > 10 ng 10 µg >10 kb (range 2-100 kb) 10-16 h 
REPLI-g UltraFast Mini kit Qiagen genomic DNA MDA (at 30°C) > 10 ng 7-10 µg >10 kb (range 2-100 kb) 1,5 h 
REPLI-g Midi kit Qiagen genomic DNA MDA (at 30°C) > 10 ng 40 µg >10 kb (range 2-100 kb) 8-16 h 
QuantiTect Whole 
Transcriptome 
Qiagen total RNA RT followed by ligation and 
MDA  
> 10 ng up to 40 µg not described 5 -11 h 
GenomePlex WGA kits Sigma-Aldrich genomic DNA Chemical fragmentation + 
rPCR SISPA (14 cycles) 
≥10 ng (1 ng for less 
complex genomes) 
>10 µg 0.1-1 kb < 3 h 
Transplex WTA kit & 
Complete WTA kit 
Sigma-Aldrich total RNA rPCR SISPA  
(RT + 17 cycles PCR) 
5-300 ng µg-range 100-1000 bp < 4 h 
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Table 2: Review of viral metagenomic studies in veterinary and human medicine which make use of Phi29 DNA polymerase based random 
amplification. Only studies of 2011 and earlier are listed to outline the situation at the start this PhD project. MDA: multiple displacement 
amplification, RCA: multiple-primed rolling-circle amplification, rPCR SISPA: random PCR sequence-independent single primer amplification, 
ss: single stranded, ds: double stranded, PV: papillomavirus, *: the identified virus is a new virus species. 
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Cell culture 
supernatant 
[113] Viruses associated with unexplained illness in 
human patients (as part of an enterovirus 
surveillance programme) 
2BK polyomavirus (Polyomaviridae, circular 
dsDNA); herpes simplex virus (Herpesviridae, 
dsDNA) 
MDA cloning + Sanger 
ʺ [114] Determination of complete genomic coding 
sequence of a virus isolated from pigs showing 
clinical signs of African swine fever 
African swine fever virus (Asfarviridae, dsDNA) MDA 454 GS FLX 
Lymph 
nodes 
[115] DNA virus discovery in pigs suffering with 
postweaning multisystemic wasting syndrome 
Porcine boca-like virus* (Parvoviridae, ssDNA); 
Porcine circovirus type 2 (Circoviridae, circular 
ssDNA); Torque Teno virus (Anelloviridae, 
circular ssDNA) 
MDA 454 GS FLX 
Sputum [116] Exploration of DNA viruses in respiratory tract of 
diseased (cystic fibrosis) and non-diseased humans 
Phages, human herpesviruses,  human retroviruses 
and various other DNA viruses 
MDA 454 GS FLX 
Feces [117] Examination of DNA viral flora in feces of 
monozygotic twins and their mothers 
Mainly phages MDA 454 GS FLX 
Blood [64] Screening for novel DNA viruses in blood of 
healthy humans (blood donors) 
Human anellovirus* (Anelloviridae, circular 
ssDNA) 
MDA + rPCR 
SISPA 
cloning + Sanger 
ʺ [118] Screening for novel DNA viruses in serum of 8 
humans (4 blood donors and 4 patients with AIDS) 
and 4 pigs 
Human and Porcine Torque teno virus 
(Anelloviridae, circular ssDNA) 
RCA cloning + Sanger 
ʺ [119] Screening for novel DNA viruses in 4 samples of 
human plasma and 1 sample of saliva from a cat 
nine anelloviruses (Anelloviridae, circular ssDNA) RCA + ligation-
based SISPA 
cloning + Sanger 
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Table 2 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Tissue  Identification and genome sequencing of viruses 
associated with: 
Viruses belonging to the Papillomaviridae (circular 
dsDNA): 
  
ʺ [120] • bovine fibropapillomatous wart Bovine PV type 1* RCA  cloning + Sanger 
ʺ [121] • papillomatous skin lesion of a Florida manatee Trichechus manatus latirostris PV 1* RCA  cloning + Sanger 
ʺ [122] • cutaneous papillomatous lesion of a North 
American porcupine 
Erethizon dorsatum PV type 1* RCA  cloning + Sanger 
ʺ [123] • malignant lesion of a dog with 
epidermodysplasia verruciformis 
Canine PV 3* RCA  cloning + Sanger 
ʺ [124, 125] • condylomatous lesions of bottlenose dolphins Tursiops truncatus PV type 1, 2, 3* RCA  cloning + Sanger 
ʺ [126] • healthy skin of a female goat Capra hircus PV 1* RCA  cloning + Sanger 
ʺ [127] • papillomatous lesions of the bobcat, Florida 
panther, and Asian lion 
Lynx rufus PV 1*, Puma concolor PV 1*, Panthera 
leo persica PV 1*, and Uncia uncia PV 1* 
RCA  cloning + Sanger 
ʺ [128] • cutaneous papilloma from cattle Bovine PV type 7 RCA  cloning + Sanger 
ʺ [129] • papillomatous lesion on the oral mucosa of a 
polar bear 
Ursus maritimus PV type 1* RCA  cloning + Sanger 
   Other (mostly circular) viruses:   
ʺ [130, 131] • lesional tissue from bandicoots affected with 
papillomatosis and carcinomatosis syndrome 
Bandicoot papillomatosis carcinomatosis virus type 
1, 2* (Papillomaviridae-like and Polyomaviridae-
like, circular dsDNA) 
RCA  cloning + Sanger 
ʺ [132] • fibropapillomatosis in sea turtles Sea turtle tornovirus 1* (unclassified, circular 
ssDNA) 
MDA + rPCR 
SISPA 
cloning + Sanger 
ʺ [133] • morality event in lung tissue of captive sea 
lions 
California sea lion anellovirus* (Anelloviridae, 
circular ssDNA) 
MDA + rPCR 
SISPA 
cloning + Sanger 
ʺ [134, 135] • liver and spleen samples of fatally diseased 
birds 
Finch polyomavirus*, Crow polyomavirus*, Canary 
polyomavirus* (Polyomaviridae, circular ssDNA) 
RCA cloning + Sanger 
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Table 2 (continued)    
Sample Ref. Application Virus (family, genome type) Amplification Sequencing 
Tissue [136] • spleen samples of wild starlings found dead 
during an epidemic outbreak of septicemic 
salmonellosis 
Starling circovirus* (Circoviridae, circular ssDNA) RCA cloning + Sanger 
ʺ [137] • mixture of liver and spleen from mute swans 
found dead 
Swan circovirus  (Circoviridae, circular ssDNA) RCA cloning + Sanger 
ʺ [138] • cardiomyopathy syndrome in heart samples of 
affected salmon 
Piscine reovirus (Reoviridae, dsRNA) , Piscine 
totivirus*(Totiviridae, dsRNA) 
MDA 454 GS FLX 
Arthropod 
vectors 
[68] DNA viral flora in three mosquito samples i.a. human papillomavirus-like virus 
(Papillomaviridae, circular dsDNA) 
MDA 454 GS20, GS 
FLX 
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3.2.2 Sequence-Independent Single Primer Amplification 
Commonly used sequence-independent single primer amplification (SISPA) approaches can 
be categorized as either (1) adapter ligation-based and (2) partially degenerated primer-based 
SISPA approaches.  The latter is better known as “random PCR” (rPCR). 
3.2.2.1 Adapter ligation-based SISPA approach 
Method 
The adapter ligation-mediated SISPA approach was first introduced as a technique to identify 
viral nucleic acids of unknown sequence present at low concentration [139]. Extracted DNA 
and RNA are processed separately (Figure 8). RNA is first converted into double stranded 
cDNA in a random primed reverse transcriptase reaction. The double stranded cDNA could 
either be digested first by restriction enzymes into smaller fragments [70, 140] or left intact 
[139, 141]. To detect viral DNA, first a complementary DNA strand is made from the DNA 
extract as ssDNA could be present. The dsDNA can be either fragmented by restriction 
enzymes at restriction enzyme recognitions sites (e.g. Csp 6.1 in [70, 140]), or physically at 
random sites by a shearing instrument (e.g. HydroShear, DIGILAB). The physical shearing 
approach is known as the Linker Amplified Shotgun Library (LASL) method [142, 143]. 
Subsequently a short DNA oligonucleotide linker is ligated to both ends (overhangs or blunt) 
of the dsDNA. A common end sequence of the adapter allows the unknown DNA to be 
amplified in a subsequent PCR using a single primer where the sequence is complementary to 
the adapter sequence. After amplification, the random fragments result in a smear (at complex 
samples) or more discrete bands (at low complexity samples) on an agarose gel [70]. The used 
adapter may contain restriction endonuclease sites to facilitate subsequent molecular cloning 
and sequencing. 
Different variants of this approach specific for double stranded RNA (dsRNA) viruses exist, 
whereby oligonucleotides are directly ligated to the dsRNA [144-149].  After the ligation, the 
dsRNA is denaturated in presence of DMSO (dimethyl sulfoxide; a chemical that assists with 
strand separation) and converted to cDNA in a reverse transcription reaction. Subsequently, 
the remaining RNA is removed by hydrolysis with an alkali and full-length cDNA can be 
amplified (using a single primer), cloned and sequenced. 
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Figure 8: Schematic overview of the different adapter ligation-based SISPA workflows. 
Use in viral metagenomics and evaluation 
Table 3 reviews the viral metagenomic studies in veterinary and human medicine which made 
use of adapter ligation-based SISPA (again, limited to studies of 2011 and earlier). The 
method has been applied to identify and sequence nearly all types of viral genome structures, 
except for negative sense single stranded RNA (ssRNA) viruses for which there was no 
published evidence prior to 2011. The dsRNA version of the protocol seems useful for the full 
genome cloning and sequencing of viruses having a segmented dsRNA genomic organization 
like viruses of the Reoviridae family. Overall, the adapter ligation-based SISPA is not 
uniform as different versions exist. In addition, the workflow includes laborious steps such as; 
adapter ligations, restriction enzyme digestions or physical DNA shearing (which requires 
relatively high initial DNA concentration), use of denaturation enhancing chemicals and so 
on. It has been demonstrated that the LASL version of the method shows a clear amplification 
bias towards dsDNA viruses over ssDNA viruses [107]. Notably, most ligation-based SISPA 
were applied to liquid samples (e.g. cell culture supernatants, blood and feces). A single study 
documents the use of adapter ligation-based SISPA in combination with NGS performed on a 
tissue (intestine) sample [47]. 
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Table 3: Review of viral metagenomic studies (2011 and earlier) in veterinary and human medicine which make use of adapter ligation-based 
SISPA. SISPA: sequence-independent single primer amplification, ss: single stranded, ds: double stranded, +: sense strand, -: antisense strand, 
dsDNA-RT: replicate through an RNA intermediate, *:  the identified virus is a new virus species, °: variant method for dsRNA viruses. 
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Cell culture 
supernatant 
[150] Complete sequence determination and genetic 
analysis of Banna (can cause meningoencephalitis 
in humans) and Kadipiro viruses 
Banna virus, Kadipiro virus (Reoviridae, dsRNA) ligation-based 
SISPA° 
cloning + Sanger 
ʺ [149, 151, 
152] 
Virus characterization from diseased sheep and 
cows during an outbreak of Bluetongue disease 
Bluetongue virus serotype 6, 8 (Reoviridae, 
dsRNA) 
ligation-based 
SISPA° 
cloning + Sanger 
ʺ [153] Characterization of the virus that causes epizootic 
hemorrhagic disease in ruminants 
Epizootic hemorrhagic disease virus (Reoviridae, 
dsRNA) 
ligation-based 
SISPA° 
cloning + Sanger 
ʺ [154] Characterization of viruses isolated from outbreaks 
of disease that occurred in horses, donkeys, cattle 
and sheep in Peru 
Peruvian horse sickness virus*,  Rioja virus* 
(Reoviridae, dsRNA) 
ligation-based 
SISPA° 
cloning + Sanger 
ʺ [155] Characterization of (zoonotic) tick-borne viruses Great Island virus, Kemerovo virus, Lipovnik virus 
and Tribec virus (Reoviridae, dsRNA) 
ligation-based 
SISPA° 
cloning + Sanger 
 [149] Improving strategy for full genome sequencing 
viral dsRNA genomes 
African horse sickness virus 1, Equine encephalosis 
virus (Reoviridae, dsRNA) 
ligation-based 
SISPA° 
454 GS20 & GS 
FLX 
Feces [156] Characterization of Norwalk virus, an important 
cause of acute gastroenteritis in humans 
Norwalk virus (Caliciviridae, +ssRNA) ligation-based 
SISPA 
cloning + Sanger 
ʺ [157] Characterization of cause of non-A and non-B 
hepatitis epidemic outbreaks in humans 
Hepatitis E virus* (Hepeviridae, +ssRNA) ligation-based 
SISPA 
cloning + Sanger 
ʺ [144, 158-
161] 
Clone and sequence all 11 segments of a Human 
group C rotavirus from a family outbreak of 
diarrhea that resulted in the death of an infant 
Human group C rotavirus (Reoviridae, dsRNA) ligation-based 
SISPA° 
cloning + Sanger 
ʺ [66, 67, 
162] 
Examination of viral flora in feces of healthy 
humans 
Various unknown viruses, many phages 
(Siphoviridae, dsDNA), plant RNA viruse … 
ligation-based 
SISPA 
cloning + Sanger 
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Table 3 (continued)    
Sample Ref. Application Virus (family, genome type) Amplification Sequencing 
Feces [143] Examination of viral flora in equine feces Mosty phages, 1 Orthopoxvirus (Poxviridae, 
dsDNA) 
ligation-based 
SISPA 
cloning + Sanger 
ʺ [149] Improving strategy for full genome sequencing 
viral dsRNA genomes 
Human rotavirus G9P (Reoviridae, dsRNA) ligation-based 
SISPA° 
454 GS20 
Blood [70] Identification of viral contaminants in commercial 
bovine sera 
Bovine parvoviruses 2 and 3* (Parvoviridae, 
ssDNA) 
ligation-based 
SISPA 
cloning + Sanger 
ʺ [140] Screening 25 plasma samples from humans with 
multiple symptoms of acute viral infection 
Hepatitis G virus (Flaviviridae, +ssRNA), Hepatitis 
B virus (Hepadnaviridae, dsDNA-RT), Human 
parvovirus 4* (Parvoviridae, ssDNA) and small 
anellovirus 1, 2* (Anelloviridae, circular ssDNA) 
ligation-based 
SISPA 
cloning + Sanger 
ʺ [64] Discovery of novel DNA viruses in blood of 
healthy humans (blood donors) 
Several anellovirus-like sequences (Anelloviridae, 
circular ssDNA) 
ligation-based 
SISPA 
cloning + Sanger 
ʺ [163] Screening of sera for causal virus associated with 
outbreak of porcine myocarditis (sudden death in 
piglets; birth of stillborn fetuses) 
Bungowannah virus* (Flaviviridae, +ssRNA) ligation-based 
SISPA 
cloning + Sanger 
ʺ [149] Improving strategy for full genome sequencing 
viral dsRNA genomes 
African horse sickness virus 2 (Reoviridae, dsRNA) ligation-based 
SISPA° 
454 GS FLX 
Tissue [47] RNA virus community of the gut (intestine tissue) 
from a turkey presenting with enteric disease 
Members of Reoviridae (dsRNA), Picobirnaviridae 
(dsRNA) , Caliciviridae (+ssRNA), 
Picornaviridae (+ssRNA) and Astroviridae 
(+ssRNA) 
ligation-based 
SISPA 
454 GS FLX 
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3.2.2.2 Random PCR SISPA approach 
Method 
The rPCR SISPA approach was originally described to amplify cDNA from low amounts of 
RNA [164, 165].  This approach makes use of a partially degenerated primer consisting of a 
random sequence at its 3’ end (e.g. hexamer of N’s) and a defined universal sequence tag at 
its 5’ end (e.g. 20 nucleotides). This partially degenerated primer is actually a mixture of 
similar sequences. Each N position may be an A, C, G or T nucleotide. Therefore, a partially 
degenerated primer containing, for instance, 6 N’s exists as a mixture of 4096 (64) different 
primer sequences.   
In the first step, the random 3’ part of the primer is annealed to random places of the target 
RNA or DNA, and a complementary strand is made (Figure 9). When the target is RNA, 
reverse transcriptase is used for generating first strand cDNA; when the target is DNA, 
Klenow fragment DNA polymerase is used for generating complementary DNA. In a second 
cycle (using the Klenow fragment) dsDNA is generated which now contains the universal tag 
sequence at its two ends. In a subsequent PCR reaction these random dsDNA fragments are 
amplified using a single primer complementary to the universal 5’ end sequence of the tagged 
primer.  After SISPA amplification, random amplified fragments are usually visualized and 
size selected on an agarose gel. Amplification of template DNA of high complexity (i.e. 
variety of DNA sequences are present) and high concentration will lead to a homogeneous 
size distribution of the SISPA PCR products, which resolve as a smear after size separation by 
agarose gel electrophoresis. A low concentration and low complexity of template DNA will 
produce distinct bands after agarose gel electrophoresis [65]. After size selection on agarose 
gel, SISPA fragments of desired length range are purified, cloned and sequenced.  
Different universal 5’-tag sequences have been used in viral metagenomic experiments, as 
well as different numbers of random N’s at the 3’ end of the tagged primer (Table 4). The 
universal 5’-tag sequences may contain restriction enzyme sites which could facilitate 
subsequent molecular cloning and sequencing. Sometimes, in addition to random primers with 
a random N part, tagged oligos with a poly-T sequence at their 3’ end could be used to help 
amplify and sequence viruses with poly-A tails (e.g. +ssRNA viruses). 
Two types of commercial rPCR SISPA-based kits are available on the market (Table 1). The 
GenomePlex Whole Genome Amplification kits and the Whole Transcriptome Amplification 
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kits (Sigma-Aldrich) amplify genomic DNA and total RNA respectively, starting from ng-
range input to yield µg-range amplified product. 
 
Figure 9: Schematic overview of the random PCR single primer amplification method. First 
complementary double stranded DNA is made using a partially degenerated primer (“primer 
1”) which consists of a random sequence at its 3’ end (e.g. hexamer of N’s) and a defined 
universal sequence tag at its 5’ end (e.g. 20 nucleotides). In a subsequent PCR reaction these 
random dsDNA fragments are amplified using a single primer complementary to the universal 
5’ end sequence of the tagged primer (“primer 2”). 
Use in viral metagenomics and evaluation 
An overview of the applications of this method for virus discovery and genome sequencing in 
veterinary and human medicine is given in Table 5 (studies 2011 and earlier). The method has 
been widely used both in combination with Sanger and next-generation sequencing, and 
permits amplification and subsequent detection of any type of viral genome structure. The 
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method is relatively easy to perform, as there is no need for adapter ligation steps and 
enzymatic digestion. Djikeng and colleagues proved the utility of the method for full genome 
sequencing of various types and sources of viruses including viral isolates and feces [13]. 
Limited by using a cloning and Sanger sequencing approach, they observed a need for 
samples containing a minimum of 106/ml particles for generation of (nearly) full viral 
genomes.  Careful examination of the sequence data obtained in rPCR-based studies shows a 
lack of homogeneous distribution of randomly generated sequence reads over the target 
genome [13, 48, 57, 59]. In particular, difficulties to obtain viral 3’ and 5’ end sequences have 
been observed.  For +ssRNA viruses which have 3’ end poly-A sequence, tagged poly-T 
primers have been used to solve this problem [13]. If the virus genome end sequences are 
known, primers complementary to these sequences may be used to generate full genome 
sequence (e.g. [166]).  
Most of the studies in Table 5 were performed on liquid sample types, although the method is 
also repeatedly used on tissues. rPCR SISPA is increasingly used in combinations with 454 
pyrosequencing, which results in a higher sequencing output and thereby higher virus 
discovery sensitivity [59].  Nakamura et al. used rPCR SISPA combined with 454 
pyrosequencing to sequence directly (without virion enrichment steps) nasopharyngeal 
aspirates from an influenza virus infection [167]. The majority (>90 %) of the reads were host 
sequences, which emphasizes the importance of performing virion enrichment step. 
Table 4: Overview of the different random PCR SISPA “single primer” sequences used in 
viral metagenomic studies in veterinary and human medicine (2011 and earlier). 
Primer name Universal 5’ sequence tag  Random 3’ oligo Publications 
universal primer-dN6 GCCGGAGCTCTGCAGAATTC NNNNNN [164, 165, 168] 
17-mer primer GTTTCCCAGTAGGTCTC NNNNNN [169] 
primer D/primer E GTTTCCCAGTAGGTCTC NNNNNNNN [49, 170-176] 
pirmer A/primer B GTTTCCCAGTCACGATC NNNNNNNNN [177-182] 
pirmer A/primer B GTTTCCCAGTCACGATA NNNNNNNNN [183] 
pirmer K-random-s/primer K-s GACCATCTAGCGACCTCCAC MNNMNM [65] 
pirmer K-8N/primer-K GACCATCTAGCGACCTCCAC NNNNNNNN  [58, 59, 184, 185] 
FR26RV-N/FR20RV GCCGGAGCTCTGCAGATATC NNNNNN [13, 55, 60, 61, 166, 
186-193] 
primer RA01 /primer RA02  " NNNNNNNNNN [59, 71, 194] 
454-A,B,C,D,E,F,G,H,I,J different tag / sample (10 in total) NNNNNNNN  [57, 59, 195-199] 
primer 18-Hex/primer 18-Univ CCATGGATCCACTTCATC NNNNNN [200] 
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Table 5: Review of viral metagenomic studies (2011 and earlier) in veterinary and human medicine which make use of random PCR SISPA. 
rPCR: random PCR, SISPA: sequence-independent single primer amplification, ss: single stranded, ds: double stranded, +: sense strand, -: 
antisense strand, ssRNA-RT: replication through a DNA intermediate, *: the identified virus is a new virus species. 
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Cell culture 
supernatant 
[177] Characterization of an unknown virus from a 
human patient suffering from severe acute 
respiratory syndrome (SARS) 
SARS virus (Coronaviridae, +ssRNA) rPCR SISPA  cloning + Sanger 
ʺ [65] Identification of unknown virus from mouth-
washing material of a patient with chronic fatigue 
syndrome 
Herpes simplex virus type 1 (Herpesviridae, 
dsDNA) 
rPCR SISPA  cloning + Sanger 
ʺ [178] Identification of unknown virus isolated from stool 
specimens of a patient presenting with 
gastroenteritis 
Human adenovirus-52* (Adenoviridae, dsDNA) rPCR + ligation- 
based SISPA 
cloning + Sanger 
ʺ [179] Identification of unknown virus isolated from stool 
specimens of a patient presenting fever of 
unknown origin 
SAF-V* (Picornaviridae, +ssRNA) rPCR + ligation- 
based SISPA 
cloning + Sanger 
ʺ [201] Testing random based molecular amplification and 
sequencing for Avian influenza virus surveillance 
Avian influenza virus (Orthomyxoviridae, -ssRNA) rPCR SISPA  cloning + Sanger 
ʺ [194] Examination of a nasal swab from a seal that gave 
CPE in cell culture 
Seal picornavirus 1* (Picornaviridae, +ssRNA) rPCR SISPA  cloning + Sanger 
ʺ [200] Examination of an viral isolated in a patient who 
developed a lethal case of pneumonia following a 
peripheral blood stem cell transplant 
Avian paramyxovirus 1 (Paramyxoviridae, -
ssRNA) 
rPCR SISPA  cloning + Sanger 
ʺ [166] Full genome sequencing 70 Human rhinovirus 
reference serotypes and 10 field sample isolates 
Human rhinovirus (Picornaviridae, +ssRNA) rPCR SISPA  cloning + Sanger 
ʺ [168] Examination of virus isolated from bat fecal 
samples 
Bat adenovirus strain TJM* (Adenoviridae, 
dsDNA) 
rPCR SISPA  cloning + Sanger 
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Table 5 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Cell culture 
supernatant 
[113] Examination for viruses associated with 
unexplained illness in human patients (as part of 
an enterovirus surveillance programme) 
Newcastle disease virus (Paramyxovirinae, -
ssRNA), Saffold viruses (Picornaviridae, 
+ssRNA) 
rPCR SISPA  cloning + Sanger 
ʺ [192] Identification of virus associated with a clinical 
outbreak of Cardiomyopathy syndrome at 
Atlantic salmon 
Piscine myocarditis virus* (Totiviridae, dsRNA) rPCR SISPA  cloning + Sanger 
ʺ [193] Investigated the causal agent of a viral infection in 
3 hospitalized infants of which one has died 
Astrovirus type 4* (Astroviridae, +ssRNA) rPCR SISPA  cloning + Sanger 
ʺ [169, 176] Examination of an viral isolated from mosquitos Leanyer virus* (Bunyaviridae, -ssRNA), Moussa 
virus* (Rhabdoviridae, -ssRNA) 
rPCR SISPA  454 GS FLX 
ʺ [175] Examination of a virus isolated from an aborted 
fetus of a sea lion 
Steller sea lion reovirus* (Reoviridae, dsRNA) rPCR SISPA  454 GS FLX 
ʺ [202] Test rPCR cloning technique for detection and 
genotyping of a PRRSV strain isolated from an 
aborted porcine fetus 
Porcine reproductive and respiratory syndrome virus 
(Arteriviridae, +ssRNA) 
rPCR SISPA cloning + Sanger 
Respiratory 
tract 
samples 
[61, 183, 
186] 
Virus detection in nasopharyngeal aspirates from 
patients with symptoms of acute respiratory tract 
infection 
Coronavirus HKU1* (Coronaviridae, +ssRNA), 
Human bocavirus* (Parvoviridae, ssDNA), 
Influenza A (Orthomyxoviridae, -ssRNA), 
Adenovirus (Adenoviridae, dsDNA), Respiratory 
syncytial virus & Metapneumovirus 
(Paramyxoviridae, -ssRNA), TT virus-like 
(Anelloviridae, circular ssDNA), KI polyomavirus* 
& WU virus* (Polyomaviridae, circular dsDNA) 
rPCR SISPA cloning + Sanger 
ʺ [167] Analyzing nasopharyngeal samples collected during 
seasonal influenza 
Influenza A virus (Orthomyxoviridae, -ssRNA), WU 
polyomavirus (polyomaviridae, circular dsDNA) 
rPCR SISPA 454 GS FLX 
ʺ [60] Characterization of a new Avian paramyxovirus 
from penguin oropharyngeal and cloacal swabs 
Avian paramyxovirus serotype  10* 
(Paramyxoviridae, -ssRNA) 
rPCR SISPA cloning + Sanger 
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Table 5 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Feces [203] To recover additional sequences of a divergent 
enterovirus identified in nose and throat swab 
specimens from a patient presenting with 
influenza-like illness 
Enterovirus 109* (Picornaviridae, +ssRNA) rPCR SISPA 
(modified 
Solexa 
protocol) 
Illumina GAII 
ʺ [180, 181, 
189] 
Examination of viral flora in unexplained cases of 
human diarrhea 
i.a. Astrovirus MLB1* (Astroviridae, +ssRNA), 
Human rhinovirus* (Picornaviridae, +ssRNA), 
Picobirnavirus (Picobirnaviridae, dsRNA), 
rPCR SISPA cloning + Sanger 
ʺ [71] Examination of stool samples of children with non-
polio acute flaccid paralysis 
Human cosavirus A1* (Picornaviridae, +ssRNA) rPCR SISPA cloning + Sanger 
ʺ [59] Examination of 35 stool samples of children with 
non-polio acute flaccid paralysis 
i.a. Torque teno virus (Anelloviridae, circular 
ssDNA), Rotavirus (Reoviridae, dsRNA), 
Adenovirus (Adenoviridae, dsDNA), Picobirnavirus 
(Picobirnaviridae, dsRNA), Human enterovirus 
species A-C*, cosavirus, parechovirus, Aichi virus, 
rhinovirus, and Human cardiovirus (Picornaviridae, 
+ssRNA); nodavirus-like* (Nodaviridae, +ssRNA), 
Dicistrovirus-like* (Dicistroviridae, +ssRNA), 
Circovirus-like* (Circoviridae, circular ssDNA), 
Human bocavirus* (Parvoviridae, ssDNA) 
rPCR SISPA cloning + Sanger 
& 454 GS FLX 
ʺ [167] Analyzing human fecal samples collected during 
norovirus outbreaks 
Norovirus (Caliciviridae, +ssRNA),  Human 
coronavirus HKU1 (Coronaviridae, +ssRNA) 
rPCR SISPA cloning + Sanger 
ʺ [184] Examination for viruses in 3 stool samples of wild-
living chimpanzees 
Chimpanzee stool-associated circular viruses* 
(unknown family, circular DNA) 
rPCR SISPA cloning + Sanger 
ʺ [185, 188] Examination for viruses in porcine stool of healthy 
piglets (<15 days of age) 
Porcine bocaviruses 1*, 2* , V1-H18*, V2-A6* 
(Parvoviridae, ssDNA) 
rPCR SISPA cloning + Sanger 
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Table 5 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Feces [195] Explorations of viral flora bat guano i.a. Bat adeno-associated virus GF-4a* 
(Parvoviridae, ssDNA), cyclovirus GF-4*, 
circovirus-like virus TM6* (Circoviridae, circular 
ssDNA), kobuvirus TM246k* (Picornaviridae, 
+ssRNA), adenovirus GF-4* (Adenoviridae, 
dsDNA), astrovirus GF-7a* (Astroviridae, +ssRNA) 
and coronavirus TM5* (Coronaviridae, +ssRNA) 
rPCR SISPA 454 GS FLX 
ʺ [204] Characterization of virus associated with mink 
epizootic catarrhal gastroenteritis 
Mink Coronavirus WD1127*, WD1133* 
(Coronaviridae, +ssRNA) 
rPCR SISPA cloning + Sanger 
ʺ [197] Characterization of fecal viral flora of California 
sea lions 
California sea lion: Astroviruses* (Astroviridae, 
+ssRNA), Sapeloviruses* (Picornaviridae, 
+ssRNA), Sapoviruses*, Norovirus* (Caliciviridae, 
+ssRNA), Rotaviruses* (Reoviridae, dsRNA); 
Bocaviruses* (Parvoviridae, ssDNA) 
rPCR SISPA 454 GS FLX 
ʺ [199] Characterization of fecal viral flora of 105 wild 
rodents (mouse, vole, and rat) 
i.a. Rodent circo-like viruses* (circular ssDNA), 
Rodent picobirnaviruses* (Picobirnaviridae, 
dsRNA), Mouse kobuvirus*, Mouse mosavirus*,  
Rosavirus* (Picornaviridae, +ssRNA), Murine 
astrovirus* (Astroviridae, +ssRNA), Adenovirus-
associated virus* (Parvoviridae, ssDNA), Deer 
mouse papillomavirus 1* (Papillomaviridae, circular 
dsDNA), Adenovirus* (Adenoviridae, dsDNA) 
rPCR SISPA 454 GS FLX 
ʺ [196] Characterization of fecal viral flora of 18 diarrhoeic 
dogs 
Canine kobuvirus* (Picornaviridae, +ssRNA), 
Canine sapovirus* (Caliciviridae, +ssRNA), Canine 
parvoviruses (Parvoviridae, ssDNA), Coronaviruses 
(Coronaviridae, +ssRNA) , Rotaviruses (Reoviridae, 
dsRNA) 
rPCR SISPA 454 GS FLX 
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Table 5 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Blood [171] Full genome sequencing of Ebola virus associated 
with hemorrhagic fever outbreaks in Uganda 
(serum sample) 
Bundibugyo ebolavirus (Filoviridae, -ssRNA) rPCR SISPA 454 GS FLX 
ʺ [49] Virus discovery in serum as part of surveillance 
study of Nipah virus in bats  
GB virus D* (Flaviviridae, +ssRNA) rPCR SISPA 454 GS FLX 
ʺ [182] Quality control for detection of adventitious agents 
in bovine serum 
Bovine parvovirus* (Parvoviridae, ssDNA) rPCR SISPA 454 
Tissue [187] Examination for viruses in intestinal samples of 
poultry exhibiting characteristic signs of enteric 
disease 
Chicken parvovirus ABU/84*, Turkey parvovirus 
TuPV/87* (Parvoviridae, ssDNA) 
rPCR SISPA cloning + Sanger 
ʺ [58] Examination for viruses in brain and muscle of 
mouse showing pathology after inoculation for 
investigating samples originating from insect 
pools, skunk brain, human feces and sewer 
effluent 
Coxsackie A virus*, Simian sapelovirus-49* 
(Picornaviridae, +ssRNA), Eyach virus*, Skunk 
Orthoreovirus*,  California 
   Mosquito Pool Virus* (Reoviridae, dsRNA) 
rPCR SISPA cloning + Sanger 
ʺ [172] Examination of tissue samples from patients who 
received organ transplants from a single donor 
and died of a febrile illness 4 to 6 weeks after 
transplantation 
Dandenong virus* (Arenaviridae, -ssRNA) rPCR SISPA 454 GS FLX 
ʺ [205] Characterization of candidate pathogen in a crop 
biopsy tissue from a live psittacine bird (parrots) 
suffering from proventricular dilatation disease 
Avian bornavirus* (Bornaviridae, -ssRNA) rPCR SISPA 
(modified 
Solexa protocol) 
Illumina GAII 
ʺ [173] Virus discovery in serum and tissue samples of an 
outbreak of hemorrhagic fever in humans with a 
high case fatality rate of 80% 
Lujo Virus* (Arenaviridae, -ssRNA) rPCR SISPA 454 GS FLX 
ʺ [190] Examination of viral flora in fecal, oral, urine, and 
tissue samples from bats 
i.a. Appalachian Ridge Coronaviruses* 
(Coronaviridae, +ssRNA) 
rPCR SISPA 454 GS FLX 
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Table 5 (continued)    
Sample Reference Application Virus (family, genome type) Amplification Sequencing 
Tissue [174] Deep sequencing of heart muscle biopsies of 
farmed salmon with heart and skeletal muscle 
inflammation disease 
Piscine reovirus* (Reoviridae, dsRNA) rPCR SISPA 454 GS FLX 
ʺ [191] Deep sequencing of brain tissue of mink suffering 
from shaking mink syndrome 
Mink astrovirus* (Astroviridae, +ssRNA) rPCR SISPA 454 GS FLX 
ʺ [198] Investigate for viruses in spleen and lung samples 
from a sick wild fox 
Gray fox amdovirus* (Parvoviridae, ssDNA) rPCR SISPA 454 GS FLX 
Arthropod 
vectors 
[170] Screening of candidate pathogens for significance 
of association with honey bee colony collapse 
disorder 
Israeli acute paralysis virus* (Dicistroviridae, 
+ssRNA) 
rPCR SISPA 454 GS FLX 
Vaccines [57] Quality control for detection of adventitious agents 
in 8 live-attenuated viral vaccines 
Besides viral of vaccins: Retroviruses (Retroviridae, 
ssRNA-RT), Porcine circovirus-1 (Circoviridae, 
circular ssDNA) 
rPCR SISPA 454 GS FLX 
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3.2.3 VIDISCA 
Method 
Virus-Discovery-cDNA-Amplified fragment length polymorphism (VIDISCA) was originally 
described by van der Hoek and colleagues [206] and is similar to ligation-mediated SISPA 
(section 3.2.2.1). This process uses two different adapters and primers in the ligation and 
amplification step respectively.  The workflow (Figure 10) is based on the cDNA-AFLP 
(Amplified fragment length polymorphism) technique [207] and begins with some virion 
enrichments steps, nucleic acid isolation and dsDNA synthesis using random hexamer primers 
(2nd strand for viral DNA, cDNA synthesis for viral RNA). Then, two frequently cutting 
restriction enzymes are used to digest the dsDNA (e.g. MseI and HinPII) and oligonucleotide 
adapter sequences are ligated. Subsequently, a PCR reaction is performed using two primers 
with sequence complementarity to an adapter sequence. Thereafter, a second “selective” PCR 
amplification is performed using the same primers extended by one extra 3’ random N. The 
second PCR will simplify the resultant PCR products from a DNA smear to specific bands, 
when visualized on agarose gel. In 2011, the method was optimized by adjusting the reverse 
transcription enzymes and including a step to discourage ribosomal RNA amplification [208]. 
The optimized protocol was called VIDISCA-454, because the amplification products were 
sequenced by a 454 pyrosequencing platform. 
Use in viral metagenomics and evaluation 
VIDISCA helped to identify and sequence a new human coronavirus (+ssRNA, 
Coronaviridae) from cell culture showing CPE [206]. The virus was isolated from a 
nasopharyngeal aspirate specimen of a 7-month-old child suffering from bronchiolitis and 
conjunctivitis.  The authors were also able to amplify hepatitis B (dsDNA-RT, 
Hepadnaviridae) and parvovirus B19 (ssDNA, Parvoviridae) from plasma, and HIV-1 
(ssRNA-RT, Retroviridae) from cell culture. In another study, VIDISCA was used to type 
uncommon picornaviruses in cell cultures which were previously untypeable using serology 
[209, 210]. The optimized VIDISCA-454 was successfully used to identify human respiratory 
syncytial virus (-ssRNA, Paramyxoviridae), human coronavirus OC43 (+ssRNA, 
Coronaviridae), influenza virus A & B (-ssRNA, Orthomyxoviridae), and adenovirus 
(dsDNA, Adenoviridae) in nasopharyngeal specimens [208]. Two new parvoviruses (ssDNA, 
Parvoviridae) were also identified by VIDISCA-454 from serum and plasma samples of bats 
[211]. 
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Figure 10: Schematic workflow of the Virus-Discovery-cDNA-Amplified fragment length 
polymorphism amplification method. dsDNA is fragmented by restriction enzyme digestion 
using two different enzymes. Subsequently two different adapters are ligated and their 
sequence is used to selectively amplify the dsDNA. 
Theoretically, the method can be applied to all possible viral genome structures. By choosing 
frequently cutting restriction enzymes, the method could be fine-tuned such that most viruses 
would be amplified. In practice the method was of limited use in virus discovery and genome 
sequencing studies prior to 2011. In addition, it is time-consuming and technically demanding 
(restriction digestion, adapter ligation and two stages of PCR). Whether a virus can be 
identified depends on the presence of endonuclease restriction site in its genome. 
Furthermore, the protocol includes two amplification steps which will give a biased 
representation of the viral content of the sample. Like the other random amplification 
methods, the approach works best for the identification of viruses from cell cultures or clinical 
samples containing high viral concentrations [212].  
3.3 DNA sequencing 
As listed in Tables 2, 3 and 5, Sanger sequencing of amplified DNA has been successfully 
applied to all kind of sample types and using various pre-amplification methods in viral 
metagenomic studies. It is not surprising that most of the studies were performed on liquid 
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samples (e.g. cell culture supernatants, blood) containing relatively low amounts of 
background contaminating nucleic acids. Studies on tissue samples are rare. 
NGS is now changing the way we understand viruses. At the start of this PhD project, an 
increasing number of viral metagenomic studies were integrating high-throughput sequencing, 
mainly 454 pyrosequencing, in their workflow (Tables 2, 3, 5).  The higher associated 
sequencing output enhanced sensitivity of virus discovery [59]. As such, it is not surprising 
that recent studies which did not use a sequence-independent amplification step to enrich viral 
nucleic acids make use of NGS [48, 72, 93, 97, 98]. 454 pyrosequencing has the advantage of 
producing relatively long sequence reads compared to other NGS platforms; increasing the 
chance of unique identification of novel viral sequences and facilitating de novo assembly 
(see further in section 3.4). A comparative study of the analytical sensitivity of two 
technologies, 454 pyrosequencing (GS FLX) and Illumina (GAII), for the detection of viruses 
in biological samples was done on a set of samples which were artificially spiked with 11 
different single or double stranded RNA and DNA viruses [213]. MDA was used to generate 
appropriate input DNA amounts. The researchers experienced that the higher output of 
Illumina sequencing is associated with a much greater sensitivity for virus discovery 
compared to 454 pyrosequencing, and that nearly full-length genomes could be obtained when 
the virus load was sufficiently high. However, at low viral concentration, the number of reads 
generated by the Illumina platform (shorter reads) was too small for generating de novo 
contigs of viral sequences [213]. The use of NGS without pre-amplification can be sufficient 
if the viral nucleic acids are present in sufficient quantity relative to background nucleic acids. 
However, strategies for viral enrichment and reduction of host background sequences remain 
essential for detection sensitivity. 
3.4 Bioinformatic data analysis 
Unlike re-sequencing of viral genomes, the analysis of datasets from metagenomic studies is 
complicated by the fact that the datasets contain a mixture of different species. Therefore, 
identification of the sequences is needed. Identification of reads is based on sequence 
similarity to previously sequenced data and is usually done by the Basic Local Alignment 
Search Tool, better known as BLAST [214]. Nucleotide sequences may be aligned to (1) 
nucleotide databases using megablast (search for highly similar sequences; works fast) or 
blastn (search for more divergent similarities; is slower), (2) protein databases using blastx 
(very slow), or to (3) translated nucleotide databases using a translated nucleotide query with 
tblastx (extremely slow).  BLAST tools produce alignment scores which indicate similarity of 
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the query sequence to a certain blast hit and an E-value which describes the statistical 
significance of the blast hit (the closer to zero, the more significant the match is). However, 
these parameters depend on the length of the used query sequence and the content and size of 
the used database. There is also a lack of a validated scoring system that permits confident 
identification of a certain read. Moreover, public databases are biased to sequences of 
organisms which are more abundant (e.g. Human genomic data). For instance, 30% of all 
viral nucleotide sequences data in GenBank are HIV sequences (see Figure 11). In addition, 
existing reference sequence databases are fraught with annotation errors. The criterion for 
classifying sequences into virus-like sequences is arbitrary. An E-value threshold of <0.001 is 
often used to classify a viral sequence [59, 66, 67], although others have used a more stringent 
cutoff (e.g. E-value <10-5 [61]; <10-25 [13]). BLAST tools can detect known and highly 
divergent viruses, but it remains extremely challenging to detect the presence of completely 
new viral sequences. A large fraction of sequences derived from metagenomic studies shows 
no significant nucleotide and amino acid sequence similarities to any known sequence [11]. 
As reads are relatively short and the original DNA/RNA fragment is often much larger, the 
analysis can attempt to re-assemble sequences back into the original overall sequence. Doing 
this without the use of a reference sequence to map reads is called de novo assembly. 
Assembly software (or assemblers) uses various algorithms to find overlaps between single 
reads and combine them into contiguous overlapping sets of sequences (contigs). 
Subsequently, contigs can be identified using BLAST and different contigs may be combined 
together to obtain, for instance, a full viral genome sequence (known as scaffolding). When 
BLAST analysis fails to classify contigs, other strategies can be explored. For instance, Dutilh 
and colleagues used the cross-assembly analysis tool ‘crAss’ for comparing unknown contigs 
originating from different metagenomics datasets in order to identify co-occurrence of similar 
contigs [215]. By this means, they identified and sequenced a new bacteriophage crAssphage 
which has a high prevalence in published human fecal metagenomes [216].  
After scaffolding contigs, genomic gaps may still occur and could be completed by direct 
sequencing of the gap region using e.g. PCR priming sites lying before and after the gap (e.g. 
using the inverse PCR technique [217]).  In viral metagenomics, often the genomic 5’ and 3’ 
ends are challenging to sequence by the shotgun approach [13]. For RNA genomes, the Rapid 
Amplification of cDNA Ends (RACE) technique is often used to sequence these ends [176, 
218]. In this method, an unknown sequence (5’ or 3’) end sequence is copied by first reverse 
transcription into cDNA using a known nearby sequence which is more centrally located in 
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the genome. Following reverse transcription, PCR is used to amplify the unknown region 
from a known starting point.  
 
Figure 11: Classification of the 1.8 million viral sequences in NCBI Genbank on 25/12/2014. 
The use of high-throughput NGS platforms in viral metagenomic workflows results in new 
challenges. NGS is associated with a higher error rate compared to Sanger sequencing [25]. 
Therefore, it is recommended to filter NGS raw sequences for quality. NGS platform specific 
quality scores typically indicate the probability of base miscalling and can be used to identify 
and remove low quality reads or parts of reads (called trimming). Moreover, the analysis of 
NGS data can be computationally challenging and requires minimum level of computational 
capacity and bioinformatics expertise. No standard data analysis strategy exists. In viral 
metagenomics, one strategy is to first filter for contaminating background organisms (host, 
bacterial and other non-viral) by computation subtract them from the dataset. This can be 
done by aligning all the reads to a reference sequence representing the host species (also 
known as reference assembly or mapping). The remaining reads are then compared with viral 
databases using BLAST-like software.  To facilitate metagenomic analysis of the data as well 
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as visualization of the results, several programs and platforms have been developed such as; 
MEGAN [219], PathSeq [220], CAMERA [221, 222], RIEMS [223] and Galaxy [224, 225]. 
3.5 Follow-up   
Depending on the purpose of a study and on the identified viral nucleic acids, the results of a 
metagenomic study need to be interpreted with care.  For instance in the discovery of 
candidate pathogens, identification of virus-like nucleic acids is only the first step in 
determining whether or not an association with the observed clinical symptoms is evident. 
The use of random instead of targeted primers to amplify all of the nucleic acids in samples 
and the high depth of NGS platforms (easy to generate millions to billions of sequences per 
run) result in significant potential for laboratory and reagent contamination, in addition to 
sample carryover between subsequent NGS runs. The availability of sequence information 
facilitates the development of, for instance, specific PCR-based assays for detection. For 
example, PCR assays identified contaminating mouse retroviral DNA originating from 
Qiagen nucleic acid extraction columns [226]. In another study of nasopharyngeal swabs 
taken from individuals in the 2009 H1N1 pandemic, one sample contained a pair of reads that 
mapped with 97% nucleotide identity to Ebola virus, but after further investigation, this 
finding was concluded to be contamination [97]. The assembled data of different disciplines 
(serology, pathology, epidemiology, metagenomic data, PCR prevalence studies, isolation, 
characterization, etc.) should be used to identify the most likely candidate etiologic agent and 
exclude possible contaminations.  These strategies were previously applied to conclusively 
determine that the retrovirus Xenotropic murine leukemia virus-related virus (XMRV) is not 
associated with chronic fatigue syndrome or prostate cancer in humans and, in fact, originated 
as a mouse cell line-derived laboratory contaminant [227-233]. The synergistic and parallel 
use of molecular and classical methods not only results in detection of infectious agents and 
development of targeted diagnostic tests, but also has the potential to make isolates or strains 
available shortly after the occurrence of outbreaks. Virus isolation of candidate pathogens is 
required to assign causality by addressing Koch’s postulates for pathogen-disease association 
[234]. In addition, the availability of isolates or strains is of special importance to allow the 
design of effective vaccines or antimicrobial drugs. A good recent example in veterinary is the 
identification and follow-up of the Schmallenberg virus (see above in section 2.2.3 [39-44]). 
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4. The challenges 
Viral metagenomic workflows attempt to detect and identify infectious agents based on the 
presence of their nucleic acid molecules in the sample. This application has been successfully 
used in the characterization of new and unexpected viruses in both veterinary and human 
health studies. In addition, it obviously has a value in the complete genome characterization, 
in a random manner, of known and unknown pathogens. However, different challenges 
remain: 
• The application of metagenomics to viruses has not been a straightforward process and no 
standard workflow exists. Pretreatment steps for separation and concentration of virions 
in samples are key concerns for enhancing the chance of detecting viral nucleic acids. 
Strategies often include filtration, centrifugation, and enzymatic digestion of non-viral 
DNA, but little is known about their true beneficial effect or the bias they may introduce.   
• Viral metagenomic investigations typically require amplification of viral nucleic acids in 
order to generate sufficient input DNA for subsequent DNA sequencing. Various 
sequence-independent amplification strategies are used to generate appropriate DNA 
amounts. However, they may introduce amplification bias such as (1) biased relative 
frequencies of different species in the sample or (2) biased genomic overlap. The origin 
of amplification bias should be identified and kept to a minimum.  
• Although there is a lack of knowledge about the sensitivity (i.e. amount of virus needed 
for proper identification) of the various workflows used for viral identification, it is 
assumed that the sensitivity depends on both the characteristics of the clinical sample and 
the properties of the virus. Sensitivity issues may also limit its applicability for whole 
genome sequencing. The real challenge is to improve sensitivity of the metagenomic 
workflow in order to identify viral nucleic acids in samples with a low virus titer and in 
samples (e.g. tissues) containing a high level of contaminating background nucleic acids.  
During the course of this thesis, NGS became increasingly available for use in viral 
metagenomic and genomic studies, providing opportunities for improving sensitivity 
significantly. NGS can easily generate many million bases of sequence, which entails 
new challenges regarding data analysis and data storage.  Decent computer skills and 
expertise in bioinformatics are needed, because no standard data analysis workflow 
exists.  
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• Sequenced reads are usually compared to known viral nucleotide and protein sequences 
in databases through BLAST programs. Although viral sequence data is increasingly 
becoming available in databases, truly novel sequences that do not show any homology to 
known viruses remain a major challenge.  However, obtaining more sequences from the 
same new virus will enhance the chance of obtaining sequences showing at least a low 
degree of conservation within a virus family. Sensitivity of the workflow is of crucial 
importance.  
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Rapid diagnosis of an infectious disease is essential in order to take appropriate action to 
control it. During the last decades, rapid and highly sensitive molecular diagnostics (e.g. PCR) 
became extremely important in disease control. Being highly specific and dependent upon 
knowledge of the genome sequence of the target pathogen, these tests are vulnerable to 
emerging variants that have altered sequences. Moreover, sequence information for the design 
of specific tests is missing for emerging novel pathogens. Therefore, sequence independent 
methods are increasingly being used for the identification of unknown viruses.  
One promising approach is sequencing all of the genetic material within a clinical sample in a 
random way, and subsequently analyzing the obtained sequencing data for presence of viral 
sequences. Veterinary diagnostic samples include liquid samples like serum and more 
complex samples like feces and tissue. Due to the small viral genome sizes and low virus 
titers, when compared to the enormous background genetic material from host and bacterial 
cells, enrichment and amplification of viral nucleic acids is of crucial importance. This virus-
focused random sequencing workflow is referred to as viral metagenomics, and generally 
includes the following steps: sample selection, sample preparation, random amplification (if 
included), sequencing, bioinformatics data analysis and follow up.  
Various workflows have been described, using different methodologies to target the viral 
nucleic acids within a sample as much as possible.  They provide an interesting new approach 
for the identification of unknown pathogens and the characterization of their genomic 
sequence, complementing classical virology and specific molecular diagnostic tools, both in 
terms of virus identification & virus genome characterization. However, different challenges 
remain. This thesis aims to prove the diagnostic potential of viral metagenomics, and to 
address some of the remaining challenges associated with viral metagenomics. 
The main aims of this thesis were: 
1. To adopt and fine-tune a universal viral identification method based on random 
amplification and DNA sequencing, and to evaluate its applicability and value for a 
diagnostic laboratory. At the start of this PhD project, NGS technologies became more 
and more accessible. After initial workflow optimizations using cloning and Sanger 
sequencing, most final studies were carried out using NGS platforms (Chapter 3). 
2. To investigate the feasibility and relative value of NGS of random amplified (c)DNA 
libraries for viral identification in clinical samples, and characterization of high quality 
complete genome sequences in virus isolates and clinical samples (Chapter 3).  
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3. Furthermore, to implement appropriate metagenomic bioinformatics analysis tools 
(Chapter 3, 4).  
4. To investigate the nature and origin of amplification bias resulting from the most 
promising pre-amplification method in viral metagenomic workflows (Chapter 4). 
5. To investigate the value of different sample preparation methods and their relative 
sensitivity for virus discovery (Chapter 4).  
Due to the continued improvement of data outputs generated by NGS platforms during the 
course of the project, a sixth aim was added: 
6. To evaluate whether current NGS technologies allow direct characterization and 
identification of viral genomes in a sample without being preceded by a random 
amplification step, and compare both approaches in terms of sensitivity and specificity 
(bias)  (Chapter 4). 
The general objectives of this study were thus to implement, optimize, and apply novel NGS-
based viral metagenomics workflows for the generation, without prior knowledge, of viral 
sequence information for the identification and molecular characterization of viral pathogens. 
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CHAPTER 3 
Implementation and 
Case studies 
 
The first goal of this thesis was to adopt one promising and widely applicable viral 
metagenomics workflow which allows both sensitive virus detection and high quality full 
genome sequencing.  The initial implementation of the workflow was combined with 
molecular cloning and Sanger sequencing, and is briefly outlined in Chapter 3.1. After 
successful implementation in the lab, the workflow was combined with NGS (454 
pyrosequencing) and applied to ongoing diagnostic and research projects (Chapter 3.2-3.5). 
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CHAPTER 3.1 
Implementation of a viral metagenomic 
workflow 
 
 
 
 
In this Chapter the selection of a viral metagenomic workflow is discussed and an overview is 
given of the initial tests of the workflow using different model viruses representing different 
genomic structures. 
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An initial important consideration which had to be made was the selection of an appropriate 
sequence independent amplification method, as various methods are described in the 
literature. An amplification method is often required to provide sufficient DNA input for the 
sequencing reaction (e.g. the rapid library preparation workflow of 454 pyrosequencing needs 
500 ng of input DNA). The four most frequently used random amplification methods in viral 
metagenomics are: Phi29 DNA polymerase based random amplification, adapter ligation-
mediated SISPA, random PCR SISPA (rPCR; uses a partially degenerated primer) and 
VIDISCA. The ideal whole genome amplification method should (1) introduce no 
amplification errors or biases, (2) yield useful amounts of DNA needed for cloning and/or 
sequencing, and (3) be universal applicable to all types of viral genomes (RNA & DNA, 
single & double stranded, linear & circular, non-segmented & segmented) and samples 
(blood, tissues...).  
Careful literature review of these four amplification methods was performed in Chapter 1. All 
methods seem to produce appropriate amounts of DNA needed for the subsequent sequencing. 
Applications of VIDISCA have been very limited. The method also seems time-consuming 
and technically demanding. The Phi29 DNA polymerase based random amplification methods 
are powerful in amplifying genomes of DNA viruses, but are not efficiently applicable to 
viruses possessing RNA genomes. Furthermore, the method is biased to preferentially amplify 
circular DNA over linear DNA and ssDNA over dsDNA [1-3]. For the adapter ligation-based 
SISPA, different versions of the workflow exist, all of which include some laborious steps 
(adaptor ligations, restriction enzyme digestions, physical DNA shearing, use of denaturation 
enhancing chemicals, etc.). In addition, only one study prior to 2011 reported using the 
method on a clinical tissue sample, which could indicate limited sensitivity of the assay. On 
the other hand, the rPCR SISPA method has been widely used on different sample types. The 
workflow is relatively easy to perform and permits detection and sequencing of any type of 
viral genome structure. Based on the above arguments, the rPCR SISPA method was selected 
as the preferred sequence independent amplification method for the workflow. For the rPCR 
SISPA primer, the FR26RV-N primer was selected (5’-
GCCGGAGCTCTGCAGATATCNNNNNN-3’), as this was the most widely used partially 
degenerated primer (Chapter 1: Table 4). 
Initial adoption of the protocol was based on the workflow in the paper of Djikeng et al. and 
Allander et al. [4, 5]. As virion enrichment steps, low-speed centrifugation, 0.22 µm filtration, 
DNase I treatment (overkill DNase amount) and nucleic acid isolation were included. 
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Subsequently, the workflow was subdivided into an RNA virus discovery workflow 
(requiring cDNA synthesis) and/or a DNA virus discovery workflow (requiring dsDNA 
synthesis), and sequence independent amplification was performed by rPCR SISPA. After 
some initial tests using different SISPA primer concentrations, the method was implemented 
in the lab in combination with molecular cloning (TOPO TA cloning with pCR2.1 plasmid 
vector and competent E. coli cells, Invitrogen, Life technologies) and Sanger sequencing. By 
sequencing a limited amount of bacterial colonies (i.e. their plasmid inserts), correct 
identification for a range of model viruses with diverse genomic characteristics was possible 
(Table 1). 
Table 1: Summary of used model viruses to test the viral metagenomic workflow.  
Virus (family) Genome 
structure (size) 
Lipid 
envelope 
Sample type Virus 
quantity 
Identification 
Newcastle  disease 
virus, La Sota strain 
(Paramyxoviridae) 
-ssRNA (15 kb) none isolate - allantoic 
fluid 
108 EID50/ml 14 of 20 colonies 
Chicken infectious 
anemia virus 
(Circoviridae) 
circular, ssDNA 
(2.3 kb) 
none live attenuated 
vaccine 
≥ 106 
TCID50/ml 
28 of 50 colonies 
Avian influenza 
virus, H5N1 strain 
(Orthomyxoviridae) 
segmented,  
-ssRNA (14 kb) 
yes isolate - allantoic 
fluid 
≥ 109 
EID50/ml 
12 of 16 colonies 
Bluetongue virus, 
BTV-8 strain 
(Reoviridae) 
segmented, 
dsRNA (19 kb) 
yes isolate – cell 
culture supernatant 
≥ 105 
TCID50/50µl 
2 of 6 colonies 
Goat pox virus, 
Bangladesh strain 
(Poxviridae) 
dsDNA (150 
kb) 
yes isolate – cell 
culture supernatant 
unknown 50 of 57 colonies 
(DNA workflow) 
Bovine viral diarrhea 
virus (Flaviviridae) 
+ssRNA (12.5 
kb) 
yes contaminant in 
above Goat pox 
virus isolate 
unknown 2 of 10 colonies 
(RNA workflow) 
For the Goat pox virus isolate, a filter with pore size of 0.45 µm was needed as members of 
the Poxviridae family (size range: 220-450 nm long and 140-260 nm wide) are often too big 
to pass efficiently through a filter with 0.22 µm pore size (Chapter 1: Figure 1). In addition to 
the correct identification of the pox virus in the DNA virus identification workflow, a 
contaminating Bovine viral diarrhea virus (a common cell culture contaminant) could be 
detected in the RNA virus identification workflow.  In addition to virus identification, the 
percentage of genome coverage for Newcastle disease virus at an infectivity titer of 109 
EID50/ml was determined by sequencing different numbers of colonies. When sequencing 24, 
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48, 96, 192 and 288 colonies, 37 %, 60 %, 76 %, 91 % and 97 % of the genome was covered 
respectively.  Remarkably, genome coverage was unevenly spread, with high overlap in some 
regions and low overlap in other regions. This coverage bias will be further investigated in 
depth using NGS (Chapter 4.1). 
Furthermore, a preliminary evaluation was performed to compare different virus 
concentration techniques. Newcastle disease virus (an RNA virus belonging to the 
paramyxoviridae family) was used as test virus and diluted from an isolate virus stock (1010 
EID50/ml) to a concentration of 107 EID50/ml with PBS (phosphate buffered saline) buffer as 
well as allantoic fluid. Each time 4 ml sample was concentrated using each of the different 
concentration methods under evaluation to a final volume of 40 µl, and the virus RNA 
quantity was estimated by specific real-time quantitative RT-PCR assay [6]. An 
unconcentrated control was each time processed along. The results are displayed in Table 2. 
The tested PEG precipitation protocol seemed inappropriate to concentrate the tested virus 
from four ml sample. Ultracentrifugation and ultrafiltration performed similarly for the 
allontoic fluid samples with a concentration factor of 20× to 25× (calculate using a standard 
curve). Ultrafiltration with an Amicon Ultra filter seems a good and easy to perform virion 
concentration method. Moreover, there is no need to have an ultracentrifuge. Ultrafiltration 
filters exist for several starting volumes, but it is possible use higher sample volumes on the 
filter as long as the filter is not saturated. 
 
Table 2: Preliminary evaluation of different virion concentration techniques. Starting sample 
volume was each time four ml PBS or allontoic fluid containing 107 EID50/ml Newcastle 
disease viruses. Elution volume at RNA extraction was 40 µl (using the QIAamp Viral RNA 
Mini kit from Qiagen). 
Concentration technique Sample diluent Ct value 
concentrated 
Ct value 
control 
PEG Virus Precipitation Kit (BioVision) - protocol 
according to manufacturer’s intrustions 
PBS 26.47 23.93 
Allontoic fluid 21.1 23.64 
Ultracentrifugation - 30,000 RPM for 2h at 4°C PBS 23.1 23.72 
Allontoic fluid 18.93 23.59 
Ultrafiltration with Amicon Ultra-4 centrifugal filter; 50 
kDA membrane (Merck Millipore) – 1,500×g for 40min 
PBS 17.51 21.66 
Allontoic fluid 17.22 21.75 
Ultrafiltration with Amicon Ultra-4 centrifugal filter; 100 
kDA membrane (Merck Millipore) – 1,500×g for 40min 
PBS 18.41 21.66 
Allontoic fluid 17.49 21.75 
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In conclusion, a viral genome sequencing method based on random genome amplification and 
Sanger sequencing was implemented in the lab. Tests with model viruses, representing 
different genome structures, were successful and demonstrate the potential of the workflow as 
a tool for virus genome sequencing.  
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CHAPTER 3.2 
Identification and complete genome 
sequencing of paramyxoviruses in mallard 
ducks (Anas platyrhynchos) using random 
access amplification and next generation 
sequencing technologies 
 
Toon Rosseel, Bénédicte Lambrecht, Frank Vandenbussche, Thierry van den Berg and Steven 
Van Borm 
Published in Virology Journal (2011) 8: p. 463. 
  
After successful implementation of a viral metagenomic workflow combined with traditional 
Sanger sequencing, the workflow was combined with NGS (454 pyrosequencing) and the 
feasibility was tested on different case studies. As a first case study, the workflow was tested 
on two non-characterized avian paramyxoviruses (-ssRNA genome organization) isolated 
during a wildlife screening program for avian influenza A and paramyxoviruses. Avian 
paramyxoviruses (APMV) belong to the paramyxoviridae family with a negative-stranded 
RNA genome. APMV consist of 11 distinct known serotypes at the time of the writing of this 
thesis (APMV1, APMV2… APMV11). APMV1 includes Newcastle disease virus which 
causes Newcastle disease, a devastating disease in poultry, and is included in List A of the 
Office International des Epizooties. Other serotypes appear to be present in natural reservoirs 
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of specific feral avian species, although other host species are usually susceptible. APMV 
infection may vary in virulence depending on strain, serotype or host species.  
The term sequence independent single primer amplification or SISPA used in this Chapter 
refers to rPCR SISPA as defined in Chapter 1. The expression random access amplification 
refers to sequence independent amplification as defined in Chapter 1. 
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Abstract  
During a wildlife screening program for avian influenza A viruses (AIV) and avian 
paramyxoviruses (APMV) in Belgium, we isolated two hemagglutinating agents from pools 
of cloacal swabs of wild mallards (Anas platyrhynchos) caught in a single sampling site at two 
different times. AIV and APMV1 were excluded using hemagglutination inhibition (HI) 
testing and specific real-time RT-PCR tests. 
To refine the virological identification of APMV2-10 realized by HI subtyping tests and in 
lack of validated molecular tests for APMV2-10, random access amplification was used in 
combination with next generation sequencing for the sequence independent identification of 
the viruses and the determination of their genomes. 
Three different APMVs were identified. From one pooled sample, the complete genome 
sequence (15,054 nucleotides) of an APMV4 was assembled from the random sequences. 
From the second pooled sample, the nearly complete genome sequence of an APMV6 
(genome size of 16,236 nucleotides) was determined, as well as a partial sequence for an 
APMV4. This APMV4 was closely related but not identical to the APMV4 isolated from the 
first sample. Although a cross-reactivity with other APMV subtypes did not allow formal 
identification, the HI subtyping revealed APMV4 and APMV6 in the respective pooled 
samples but failed to identify the co-infecting APMV4 in the APMV6 infected pool.  
These data further contribute to the knowledge about the genetic diversity within the 
serotypes APMV4 and 6, and confirm the limited sensitivity of the HI subtyping test. 
Moreover, this study demonstrates the value of a random access nucleic acid amplification 
method in combination with massive parallel sequencing. Using only a moderate and 
economical sequencing effort, the characterization and full genome sequencing of APMVs 
can be obtained, including the identification of viruses in mixed infections. 
Keywords: APMV4, APMV6, avian paramyxovirus, mallard, next generation sequencing, 
random amplification, SISPA 
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Introduction 
A large number of viruses of humans and animals are classified in the family 
Paramyxoviridae [1]. Their single stranded, unsegmented, RNA genomes of negative 
orientation vary in length from 13-19 kb and contain 6-10 genes encoding up to 12 different 
proteins [1].  Avian paramyxoviruses (APMV) are frequently isolated from domestic and wild 
birds throughout the world. Recently they are classified in the genus Avulavirus of the 
subfamily Paramyxovirinae, family Paramyxoviridae [2]. Ten serological types (APMV1–10) 
of APMVs are described so far based on hemagglutination inhibition (HI) and neuraminidase 
inhibition tests [3-5]. APMV1, including Newcastle disease virus (NDV, defined in [6]) is the 
most characterized among all APMV types because it can cause severe disease outbreaks in 
poultry. In contrast to the well-studied APMV1 or NDV, very little is known about the 
biological characteristics, pathogenicity, and diversity (both genetic and antigenic) of other 
APMV serotypes 2–10. APMV types 2, 3, 6 and 7 have been associated with disease in 
domestic poultry [7-13]. APMV6 viruses have been associated with mild respiratory disease 
and decreased egg production in turkeys [14]. APMV3 and APMV5 (Kunitachi virus) caused 
severe pulmonary disease in wild birds [15, 16]. Other serotypes, including APMV4, 8, 9 and 
10 have been isolated from ducks, waterfowls, and other wild birds with no clinical signs of 
disease [3, 5, 17-20]. APMV4 viruses have been isolated predominantly from feral birds of 
the order Anseriformes [21, 22] and from commercial ducks and geese, presumably as a result 
of their direct contact with feral waterfowl [21, 23, 24].  Experimental infection of chickens 
with APMV4 and APMV6 showed mild respiratory pathology, suggestive of possible viral 
disease in poultry [8, 25]. 
Molecular characterization through whole genome sequencing of APMV2-10 remains 
technically challenging because these viruses are poorly represented in public sequence 
databases, complicating the design of sequencing primers. Recent efforts to sequence whole 
genomes of representative strains for all serotypes (APMV2 [26], APMV3 [27, 28], APMV4 
[29, 30], APMV5 [31], APMV6 [25, 32], APMV7 [33], APMV8 [34], APMV9 [35], 
APMV10 [5]) have significantly contributed to our understanding of the Avulavirus genus 
genome organisation. However, further studies are needed to explore the diversity within the 
serotypes. 
Random access sequencing using sequence independent single primer amplification was 
previously described for NDV genome sequencing [36], based on resource demanding 
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sequencing of high number of cloned random amplicons to achieve completion of a genome. 
This protocol contains efficient steps to enrich viral nucleic acids and deplete contaminating 
and host sequences, including size selective filtration and extensive nuclease treatments [36, 
37]. It was also used for the molecular identification of an APMV in penguins [5] where 
existing protocols did not allow a starting point for primer walking. This resulted in the 
identification of a new serotype, APMV10. 
Massive parallel sequencing technologies were developed to accommodate the need of higher 
sequencing capacity and lower costs per nucleotide for large genome sequencing projects 
[38]. One main advantage of these second generation sequencing technologies is the 
possibility to sequence DNA samples without any prior knowledge of the sequence, which is 
required for priming [38]. 
During a wildlife screening program for avian influenza A viruses (AIV) and APMVs, we 
isolated two hemagglutinating agents from two pools consisting of each four cloacal swabs of 
wild mallards. The birds were caught in a same location at two different times. AIV and 
APMV1 were excluded using HI testing and specific real-time RT-PCR tests. To refine HI 
test based identification of these viruses and in lack of validated molecular tests for APMV2-
10, this study applied random access amplification in combination with next generation 
sequencing for the sequence independent identification of the viruses and the determination of 
their complete genome sequences.  
Materials and Methods 
Viruses 
Two non-characterized APMVs (mallard/Belgium/12245/07 and mallard/Belgium/15129/07) 
were isolated from two pools consisting of each four cloacal swabs from healthy wild mallard 
ducks according to standard diagnostic procedures (OIE, diagnostic manual 2005/94/CE). The 
wild birds were caught in a funnel trap located along a pond at 20 km SE of Brussels in 
Belgium. The trap was visited every two to three days during the entire survey period. All 
new birds were ringed, weighted, the wings measured, and a cloacal swab was collected. A 
maximum of four cloacal swabs from the same bird species, sex and sampling time were 
pooled for laboratory analysis.  
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HI-tests 
Briefly, the hemagglutination (HA) titer of the different viruses was standardized to a 
concentration of four units of HA activity/25 µl to perform the test (methodology according to 
Council Directive 92/66/EC (1992)). All HI tests referenced in this study were conducted with 
the AIV and APMV1-9 reference sera provided by the European reference laboratory VLA 
(Weybridge, U.K.). The titer of a serum is defined by the last dilution giving a complete 
inhibition of HA. A titer below 16 is considered as negative and a titer above or equal to 16 is 
considered as positive. Absence of APMV1 was confirmed using specific real-time RT-PCR 
assays (data not shown).  
Random access to viral nucleic acids using DNAse I SISPA  
Virus particles from samples mallard/Belgium/12245/07 and mallard/Belgium/15129/07 were 
purified starting from one ml of allantoic fluid. This was first centrifuged at 3,200 × g for 15 
minutes at four °C to remove cell debris. The supernatants were then filtered at 3,000 × g for 
eight minutes or longer at four °C (200 µl/filter) using 0.22 µm filters (Ultrafree-MC GV 
sterile, Millipore) to remove remaining cell fragments and bacteria. The resulting eluates were 
subsequently subjected to nuclease treatment with 100 U of DNase I (New England Biolabs) 
at 37 °C for one hour to remove all nucleic acids that are not protected within virions. The 
resulting virion-enriched samples were used for viral RNA extraction using the QIAamp Viral 
RNA Mini Kit (Qiagen) according to the manufacturer’s instructions.   
Sequence independent single primer amplification (SISPA) was performed essentially as 
previously described [36] with some modifications. Briefly, the extracted RNA was converted 
into single-stranded cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche) 
and one µM (final concentration) random primer FR26RV-N (5’-GCC GGA GCT CTG CAG 
ATA TCN NNN NN-3’, [36, 37]).  Ten µl extracted RNA was denatured at 95 °C for five 
minutes in the presence of primer FR26RV-N, immediately followed by cooling on ice.  The 
remaining reagents were added. The 20 µl reaction mix contained 1× Transcriptor Reverse 
Transcriptase Reaction Buffer, dNTP mix (1mM final concentration each), 20 U Protector 
RNase Inhibitor, ten units Transcriptor Reverse Transcriptase and one µl PCR-grade H2O. 
The reaction was incubated at 25 °C for ten minutes followed by 50 °C for 60 minutes. After 
a reverse transcriptase inactivation step at 85 °C for five minutes and chilling on ice, 2.5 U of 
3’-5’ exo- Klenow Fragment of DNA polymerase (New England Biolabs) were added for 
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second strand synthesis using random primer FR26RV-N for one hour at 37 °C. An enzyme 
inactivation step was performed at 75°C for ten minutes.  
Five microliters of the reaction mix was used as template for a subsequent PCR amplification. 
The 50µl reaction mix consisted of 1× AmpliTaq Gold® 360 DNA buffer, 2.5 mM MgCl2, 
dNTP mix (0.2 mM final concentration each), 2.5 U AmpliTaq Gold® 360 DNA polymerase 
(Applied Biosystems), 32.7 µl RNase free water and 1.6 µM FR20RV primer (5’-GCC GGA 
GCT CTG CAG ATA TC-3’, [36, 37]). This PCR primer is complementary to the 
amplification tag of FR26RV. The reaction was incubated at 95 °C for ten minutes, 40 cycles 
at 95 °C for one minute, 48 °C for one minute and 72 °C for two minutes followed by a final 
elongation for seven minutes at 72 °C. 
The random amplified DNA fragments were visualised on a one % agarose gel. Fragments of 
400-1,000 base pairs (bp) were excised and purified from the gel with the High Pure PCR 
Product Purification Kit (Roche). The purified PCR fragments were quantified by 
spectrophotometry (Nanodrop-1000).  
Sequencing 
Five micrograms of size selected (400-1,000 bp) purified random amplified DNA was 
sequenced on a GS FLX (Roche, Mannheim, Germany) by the Genomics Core of the 
University Hospital, University of Leuven, Belgium. They used multiplex identifier (MID) 
identification during library preparation (standard Roche MID tag sequences) and GS FLX 
Titanium series reagents (Roche, Mannheim, Germany) according to their standard 
procedures, aiming for 5,000-10,000 reads per library. Briefly, adaptors including standard 
MID tag sequences (for our samples RL3 and RL10) were ligated to the size selected double 
stranded DNA library (Rapid Library Preparation Method Manual, GS FLX Titanium Series 
reagents, Roche, Mannheim, Germany), followed by single stranded DNA library isolation 
and library quality assessment and quantitation. The resulting libraries were then pooled with 
other MID identified libraries and emulsion PCR clonal amplification was performed as 
described by the provider. The amplified libraries were then loaded on a Pico Titer Plate for 
sequencing by the Genome Sequencer FLX.  Data were provided to the authors by secured 
ftp-server. 
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DATA Analysis 
The obtained raw sequence data were assembled using SeqMan NGen® version 3.0 
(DNASTAR, Madison, WI, USA). The reads were trimmed to remove primer sequences as 
well as low quality ends. Standard assembling and filtering parameters were used. First we 
performed a de novo assembly and entered the resulting contigs (i.e.  sets of overlapping 
sequence reads) into a Blastn similarity search against public sequence databases 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi; [39]) for identification. When we identified a certain 
APMV serotype, we used the blast hit with the highest identity of the biggest APMV contig 
as reference genome for a subsequent reference assembly with the same raw data set. The 
resulting reference assembly was used to obtain a complete genome consensus sequence. The 
sequence reads contributing to the consensus were also checked for variability. When at a 
certain position along the consensus two different nucleotides were present, the variability 
was indicated as an ambiguous nucleotide when the minor nucleotide exceeded the threshold 
of one third of the reads. 
Analysis of the virus specificity of the protocol 
Sequences failing to align with the used reference genome were subjected to a metagenomics 
assembly in SeqMan NGen. The obtained contigs containing more than two sequence reads 
were identified with megablast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences were 
classified as previously described [36]. Briefly, viral blast results were considered reliable if 
the best hit had an E-value less than 10-25. Non-viral sequences were identified as Gallus 
gallus (chicken embryos were used for virus isolation), other birds, bacteria, … if their best 
hit was below an E-value of 10-10. If no blast results were found or the E-value was below the 
10-10 cut off value, the sequences were not given a specific designation. 
Phylogenetic analysis  
Consensus sequences were edited, aligned and translated, and sequence identities were 
calculated using Bioedit v7.0.5.3 (http://www.mbio.ncsu.edu/bioedit/bioedit.html) [40]. 
Nucleotide (nt) sequence identities with selected complete genome sequences were 
determined (GenBank accession codes: EU877976, FJ177514, EF569970, NC003043, 
GQ406232, EU622637). Amino acid (aa) alignments (ClustalW algorithm) using all available 
complete coding sequences for the F and HN genes of APMV4 (GenBank accession codes 
FJ177514, EU877976) and APMV6 (GenBank accession codes EF569970, NC003043, 
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EU622637, GQ406234, GQ406233) and selected sequences representative of other APMV 
serotypes (GenBank accession codes AF077761, DQ097393, HQ896024, HQ896023, 
HM159993-HM159995, AY129676, EU338414, EU782025, EU403085, GU206351, 
FJ231524, FJ619036, FJ215864, GU068584-GU068587, EU910942, HM147142) were used 
for phylogenetic analysis. Mega v5.01 [41] was used to construct phylogenetic trees by 
bootstrap analysis (1,000 replicates) using the neighbour-joining of the Poisson-corrected 
values for aa differences. All positions containing alignment gaps and missing data were 
eliminated only in pairwise sequence comparisons, allowing the inclusion of the incomplete 
aa F and HN sequences of APMV4/mallard/Belgium/12245/07 (APMV4-BE12245) in the 
analysis.   
Results 
Identification and genome sequence of avian paramyxoviruses 
Two pooled samples, consisting of each four swab samples from wild mallards, were positive 
for hemagglutinating agents without inducing mortality of embryonated chicken eggs. AIV 
and APMV1 could be excluded using specific real-time RT-PCR tests (data not shown) and 
HI tests using reference sera for AIV and APMV1. The HI assays with reference sera specific 
for APMV2-9 identified sample mallard/Belgium/15129/07 as APMV4 positive and sample 
mallard/Belgium/12245/07 as APMV6 positive. A cross reactivity with the APMV2 reference 
serum P/Robin/Hiddensee/57 was observed for both samples, but not with another APMV2 
reference serum P/chicken/Yucaipa/Cal/56. The HI titers for the APMV3 and APMV7 
reference sera showed for sample mallard/Belgium/15129/07 the borderline value of 16, still 
we considered this as nonspecific reactivity (Table 1). 
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Table 1: Hemagglutination inhibition tests (HI-titers) of pooled samples 
mallard/Belgium/15129/07 (07/15129) and mallard/Belgium/12245/07 (07/12245). 
Antisera (used inactivated virus strain)  07/15129 07/12245 
Polyclonal serum APMV1 <4 <4 
Monoclonal serum 12B7 anti APMV1  <4 
Monoclonal serum 8C11 + 4D6 anti APMV1  <4 
Polyclonal serum APMV2 (P/robin/Hiddensee/15/75) 32 64 
Polyclonal serum APMV2 (P/chicken/Yucaipa/Cal/56) <4 8 
Polyclonal serum APMV3 (P/tk/1087/82) 16 4 
Polyclonal serum APMV4 (P/duck/Hong Kong/D3/75) 128 <4 
Polyclonal serum APMV6 (P/duck/Hong Kong/199/77) <4 64 
Polyclonal serum APMV7 (P/dove/TN/4/75) 16 8 
Polyclonal serum APMV8 (P/goose/Del/1053/76) <4 4 
Polyclonal serum APMV9 (P/duck/NY/22/78) <4 <4 
28 influenza A reference sera tested *  <4 <4 
Genetic identification APMV4 APMV6 + APMV4 
* sera specifications available on request  
Combining the advantages of random amplification and massive parallel sequencing, 5,225 
and 12,310 sequence reads were produced from the library resulting respectively from sample 
mallard/Belgium/12245/07 and mallard/Belgium/15129/07. More than 95 % of these reads 
were specific for APMVs, and host-derived or contaminating sequences were negligible.  
Assembly of random generated sequences for sample mallard/Belgium/15129/07 produced a 
15,054 nucleotides (nt) contig representing the complete genome sequence of an APMV4. 
APMV4/mallard/Belgium/15129/07 (APMV4-BE15129) was assembled from 9,767 sequence 
reads of raw data (APMV4/KR/YJ/06 [GenBank: EU877976] used as reference in the 
reference assembly). Assembly of 4,715 sequences generated for sample 
mallard/Belgium/12245/07 produced a nearly complete (98.89%) APMV6 genome of length 
16,236 nt (APMV6/mallard/Belgium/12245/07; APMV6-BE12245). 
APMV6/Goose/FarEast/4440/2003 [GenBank: EF569970] was used as a reference sequence 
in this reference assembly. Surprisingly, APMV4 sequences were also identified in sample 
mallard/Belgium/12245/07. APMV4/KR/YJ/06 [GenBank: EU877976] was used as a 
reference and 21 sequences mapped to various regions (total of 2,977 nt representing 19.75 % 
of the APMV4 genome sequence). The APMV4 virus was named 
APMV4/mallard/Belgium/12245/07 (APMV4-BE12245). Unfortunately the original 
individual cloacal swabs were no longer available at the time of the genetic analysis, so we 
could not find out which of the four animals in the pool were infected and whether we were 
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dealing with a mixed infection of one bird. The missing 1.11 % of the APMV6 genome 
represents two small internal gaps and some nucleotides (24 nt at 5’ and 37 nt at 3’) at the 
genome termini. A low coverage at the genome termini was also observed for the fully 
sequenced APMV4 genome (41 terminal 5’ nt and 42 terminal 3’ nt, with depth ≤ 3x).   
Database accession numbers 
The consensus sequences were submitted to GenBank under the following accession numbers: 
JN571485 (APMV4/mallard/Belgium/15129/07, complete genome), JN571486 
(APMV6/mallard/Belgium/12245/07, nearly complete genome) and JN571487, JN571488, 
JN571489, JN571490 (APMV4/mallard/Belgium/12245/07, partial sequences of 
phosphoprotein, fusion protein, hemagglutinin-neuraminidase and large polymerase genes). 
Genomic features of APMV4/mallard/Belgium/15129/07 
The virus has a genome length of 15,054 nt as previously described for APMV4 viruses, 
consisting of six transcriptional units (Table 2) encoding from 3’ to 5’ the NP (nucleoprotein), 
P/V/W (phosphoprotein and additional proteins through RNA editing), M (matrix), F (fusion), 
HN (hemagglutinin-neuraminidase) and L (large polymerase) proteins. The 3’ leader and 5’ 
trailer sequences of the genome were respectively 55 nt and 17 nt in length. Gene start and 
gene end sequences were as previously described for APMV4 [30].  The NP protein encoded 
a 457 amino acids (aa) protein, as previously described for other APMV4. The P gene 
encodes a 393 aa phosphoprotein. A putative RNA editing site at genome position 2,057-
2,065 (5’AAAGGGGGG-3’) was identified, where insertion of one non-templated G residue 
would encode a 224 aa V protein. Alternatively, the insertion of two non-templated G 
residues would result in a putative W protein of 137 aa.  The matrix gene open reading frame 
(ORF) encodes a 370 aa long matrix protein, unlike the 367 aa or 369 aa previously described 
for APMV4 genomes [29, 30]. The lengths of the other proteins encoded by their ORF’s are 
the same as previously described for APMV4 (F 566 aa; HN 569 aa; L 2,211 aa).  The fusion 
protein has a monobasic cleavage site (DIQPR↓F).   
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Table 2: APMV4/mallard/Belgium/15129/07 genome organization and characterization 
(genome size 15,054 nt). 
Gene Genome 
position 
5’UTR (nt) 
(incl. gene-
start) 
ORF(nt) 3’UTR (nt)  
(incl. gene-
end) 
Intergenic 
region (nt) 
Deduced 
protein size 
(aa) 
NP 56-1,606 60 1,374 117 9 457 
P (V;  W)* 1,616-2,979 46 1,182 
(675; 413) 
136 34 393 
(224; 137) 
M 3,014-4,306 77 1,113 103 16 370 
F 4,323-6,210 71 1,701 116 40 566 
HN 6,251-8,161 78 1,698 135 45 565 
L 8,207-15,037 92 6,636 103  2,211 
*putative RNA editing site at position 2,057-2,065 (5’-AAAGGGGGG-3’) 
Genomic features of APMV6/mallard/Belgium/12245/07  
The genome length of 16,236 nt is consistent with that of “class I” of APMV6 [32], 
containing seven transcriptional units (Table 3) encoding from 3’ to 5’ the NP, P/V/W , M, F, 
SH (small hydrophobic protein), HN  and L proteins. The F protein has a monobasic cleavage 
site, PEPR↓L. The 3’ leader and 5’ trailer sequences of the genome were respectively 55 and 
54 nt in length. Gene start and gene end sequences were as previously described for APMV6 
[32]. The lengths of the proteins encoded by the ORF’s are the same as previously described 
for APMV6 (NP 465 aa; P 430 aa, V 268 aa, W 177 aa, M 366 aa, F 555 aa, 142 aa, HN 613 
aa, L 2,241 aa). 
Table 3: APMV6/mallard/Belgium/12245/07 genome organization and characterization 
(genome size 16,236 nt). 
Gene Genome 
position** 
5’UTR (nt) 
(incl. gene-
start) 
ORF 3’UTR(nt) 
(incl. gene-
end) 
Intergenic 
region (nt) 
Deduced 
protein size 
(aa) 
NP 56-1,626 72 1,398 101 7 465 
P (V;  W)* 1,634-,3119 53 1,293 
(807; 534) 
140 2 430 
(268; 177) 
M 3,122-4,526 113 1,101 191 59 366 
F 4,586-6,420 12 1,668 155 49 555 
SH 6,470-7,043 72 429 73 28 142 
HN 7,072-9,102 50 1,842 139 63 613 
L 9,166-16,182 112 6,726 179  2,241 
* putative RNA editing site at position 2,148-2,156 (5’-AAAAAAGGG-3’) 
** The indicated position is relative to the position of the used reference APMV6/Goose/FarEast/4440/2003 
[GenBank: EF569970] 
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Phylogenetic analysis based on F and HN proteins 
Phylogenetic trees based on amino acid sequence alignments of the F and HN proteins clearly 
classify APMV4-BE15129 and APMV6-BE12245 within respectively serotype APMV4 and 
APMV6 (Figure 1 and Figure 2). APMV6-BE12245 is most closely related to the “class I” of 
APMV6 viruses described by Xiao and colleagues [32]. This is confirmed by its high whole 
genome nucleotide sequence identity with APMV6/Goose/FarEast/4440/2003 (GenBank: 
EF569970; Table 4). The F and HN amino acid sequences of APMV4-BE15129 are most 
closely related to APMV4/KR/YJ/06 (GenBank: EU877976), which is confirmed by a high 
whole genome nucleotide homology to this virus (Table 5). APMV4-BE15129 is more closely 
related to both previously sequenced APMV4 whole genomes than these are to each other 
(Table 5).  
 
Table 4: APMV6 complete genomes nucleotide identity matrix. Sites with missing data were 
deleted from the alignment. 
Hong 
Kong/18/199/77 
Italy/4524-
2/07 
Taiwan/Y1
/98 
FarEast/44
40/03 
APMV-6 
BE/12245/07 
APMV-6/duck/HongKong/18/199/77 ID     
APMV-6/duck/Italy/4524-2/07 70% ID    
APMV-6/duck/Taiwan/Y1/98 94.2% 70.2% ID   
APMV-6/Goose/FarEast/4440/2003 93.8% 70.3% 98.3% ID 
 
APMV-6/Anas 
platyrhynchos/BE/12245/2007 
91.9% 69.2% 96% 96.5% ID 
 
 
Table 5: APMV4 complete genomes nucleotide identity matrix. 
  Hong Kong/D3/75 KR/YJ/06 BE/15129/2007 
APMV4/duck/Hong Kong/D3/75 ID   
APMV4/KR/YJ/06 91.6% ID 
 
APMV4/Anas platyrhynchos/BE/15129/2007  91.9% 97.6% ID 
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Figure 1: Phylogenetic tree based on the aa sequences of the F protein. 
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Figure 2: Phylogenetic tree based on the aa sequences of the HN protein. 
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Although no complete F and HN sequences were available for APMV4-BE12245 (in sample 
with APMV6-BE12245), we included the partial sequence information in the phylogenetic 
analysis using pairwise deletion of positions with gaps and missing data. This may have 
resulted in biased distance estimations. However, there are clear indications that although it is 
most closely related to APMV4- BE15129, it is not identical. This is also evident from 
nucleotide sequence identity calculated over all available sequence information (2,977 nt) for 
the partial genome APMV4-BE12245 (Table 6). The partial sequence APMV4-BE12245 is 
98.4% identical to APMV4- BE15129 considering all positions allowed by the partial 
sequence of APMV-BE12245. In contrast, its identity with previously sequenced APMV4 
genomes is only 97.5 % (APMV4/KR/YJ/06; GenBank: EU877976) and 90.9 % 
(APMV4/duck/Hong Kong/D3/75; GenBank: FJ177514).  
Table 6: Nucleotide identity of partial genome sequence (2,977nt) of 
APMV4/mallard/Belgium/12245/07 with APMV4/mallard/Belgium/15129/07 and other 
APMV4 genomes. Sites with missing data were deleted from the alignment. 
  
Hong 
Kong/D3/75 
KR/YJ/06 BE/15129/2007 APMV-4 
BE/12245/2007 
APMV4/duck/Hong Kong/D3/75 ID    
APMV4/KR/YJ/06 91.4% ID   
APMV4/Anas 
platyrhynchos/BE/15129/2007  
91.3% 97.5% ID 
 
APMV4/Anas 
platyrhynchos/BE/12245/2007 
90.9% 97.1% 98.4% ID 
Discussion 
Wild birds are increasingly recognized as a reservoir for important livestock diseases. This 
has been extensively shown for avian influenza A viruses (AIV) and to a lesser degree for 
avian paramyxoviruses of serotype 1 (APMV1). Moreover, other viruses, including APMV2-
10 have been shown to circulate in wild birds. Some of these viruses have been shown to 
infect poultry species and induced major outbreaks in flocks. 
Apart from the well-characterized serotype APMV1 associated with the economically 
important Newcastle disease in poultry, knowledge of the antigenic and genetic diversity in 
the APMV serotypes of the genus Avulavirus is limited. The determination of complete 
genome sequences of an additional APMV4 and APMV6 widens our understanding of the 
genetic diversity in these serotypes. Interestingly, we could identify two different viruses from 
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single pooled samples. In one tested pool of four cloacal swabs, taken in beginning of 
September, at least one of the four animals was infected with an APMV4. In the other tested 
pool, taken at the end of this month in the same capture location, two different APMV 
serotypes APMV6 and APMV4 were identified. The latter APMV4, although closely related 
to the APMV4 in the first pool, was not identical to it. Contamination artifacts during virus 
isolation are very unlikely to have occurred as the two APMV4 viruses characterized in this 
study are not identical based on the sequence information (2,977 nt partial sequence of 
APMV4-BE12245) obtained, and no other APMV4 viruses were manipulated in the 
laboratory.  
It is difficult to assess whether both APMV4 viruses characterized in this study fall within the 
normal range of quasispecies genetic variation. This is because of the limited availability of 
sequence information for this serotype and the lack of studies investigating the genetic 
variability within circulating populations of paramyxoviruses. To prove the economic 
feasibility of the method of random amplification combined with deep sequencing, the 
number of sequence reads per sample was intentionally kept below 10 000 in this study. This 
turned out to be sufficient for the completion of the APMV4 genome in one pool. In the 
mixed APMV infected pool, this number of reads did not allow the determination of the last 
1.11 % of the APMV6 genome because part of the sequencing effort resulted in 19.75% of the 
genome of a co-infecting APMV4. Most probably, the APMV4 virus was present in a lower 
amount in the original samples, and a higher number of sequence reads would have resulted in 
completion of the APMV6 genome. However, we cannot fully exclude preferential growth of 
either virus during virus isolation or a slight bias in our random amplification protocol. This 
means that quantitative statements about the relative presence of either virus in the original 
pooled sample based on the distribution of sequence reads are not possible.  As the original 
swabs were no longer available, we could not determine (1) in which proportion the two 
viruses were present in the original sample/pool before the propagation in eggs, (2) which of 
the four animals in the pool were infected and (3) whether we were dealing with a mixed 
infection of one bird. Moreover, the analytical sensitivity of the method remains to be 
determined and may limit the applicability to field samples containing relatively high virus 
titers. The presented methodology has the potential to identify viruses present in minor 
proportions in a pooled sample, and mixed infections in single samples. Clearly our 
methodology, using a sequence independent methodology for genome determination, has 
allowed the detection of sequence information from both viruses without bias. In contrast, the 
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use of serotype specific tests such as HI or serotype specific PCR methods may fail to 
characterize the full complexity of an isolate. Further passage of “double isolates” may give a 
selective advantage to either virus, changing the biological properties of the isolate, as was 
suggested by Shihmanter and colleagues [42]. They described that an APMV1 had a selective 
advantage over co-infecting APMV viruses during passaging in embryonated chicken eggs.  
Our genetic identification of the APMVs revealed some difficulties in the HI based 
identification of APMVs other than APMV1.  The APMV6 reference serum did detect the 
APMV6 virus in sample 07/12245 (titer 1/64) and the APMV4 reference serum detected the 
APMV4 virus in sample 07/15129 (titer 1/128). However, the HI test failed to detect the 
APMV4 virus co-present at low titer with the APMV6 virus in pooled sample 07/12245. This 
most likely indicates that our molecular method is much more sensitive to the identification of 
viruses present at very low concentrations. Additionally, a cross reactivity with the APMV2 
reference serum P/Robin/Hiddensee/57 was observed for both samples (titer 1/32 or 1/64 – 
Table 1). However another APMV2 reference serum P/chicken/Yucaipa/Cal/56 did not show 
cross reactivity with these samples, which makes the HI subtyping interpretation difficult. In 
the context of mixed infections, where it’s likely that one virus has a higher concentration 
than the other, genetic information seems more informative for the identification. Further 
studies are obviously needed to gain insight in the genetic and antigenic diversity of APMV2-
10. 
Recently Xiao and colleagues [32] increased the amount of whole genome sequences 
available for APMV6 to six, identifying two classes with APMV6.  APMV6 class I isolates 
differed less than five % from each other but differed 29-31 % to the single class II isolate 
IT4524-2. The additional APMV6 genome identified in this study clustered within class I, 
maintaining the separation with class II (31 % distance) while slightly increasing the genetic 
diversity within class I to a maximum of 8 % distance.  
On the other hand, whole genome sequences of only two representative strains of APMV4 
have been reported so far [29, 30]. The complete genome of APMV4-BE15129 determined in 
this study further extends our knowledge of this serotype. This additional APMV4 complete 
genome does not increase the maximum genetic distance previously documented within the 
APMV4 serotype. The genetic distance now ranges from two to eight % nucleotide sequence 
distance (based on only three complete genome sequences). The amount of sequence data 
compared to APMV1 remains low and further studies are needed to get a better estimate of 
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genetic diversity within serotypes APMV2-10. The sequencing methodology used in this 
study may facilitate this. 
The genome length of 15,054 nt for APMV4 and 16,236 nt for APMV6 complies with the 
“rule of six*” for efficient genome replication of Paramyxovirinae [43]. The genomic 
characteristics and genome organizations, including putative mRNA editing of the P gene, are 
as previously described for APMV4 and APMV6 genomes [29, 30, 32, 33]. Further variability 
in protein length of the APMV4 M protein was shown. Variability in the intergenic sequence 
length, as is known for the genus Avulavirus, was also confirmed here. A monobasic fusion 
protein cleavage site was present in both viruses.  However, fusion protein cleavage site 
sequences in APMV2-9 are not necessarily predictive of protease activation phenotype [33], 
as it is in Newcastle disease virus [44]. Interestingly, the terminal amino acid of the fusion 
protein cleavage site of APMV4/mallard/Belgium/15129/07 is a phenylalanine. As previously 
shown for other APMV4 [29, 30], this did not require an exogenous exonuclease for in vitro 
replication on chicken embryonic fibroblasts [29]. A phenylalanine at this position is known 
to contribute to the in vitro growth characteristics and in vivo pathogenicity of velogenic 
Newcastle disease [4]. Further in vivo and in vitro phenotypic characterization of this virus 
would be interesting. 
This study clearly demonstrates the value of a sequencing strategy combining next generation 
sequencing and random access amplification for the identification and whole genome 
determination of APMVs. Although the method allows sequencing of complete APMV 
genomes, an unequal distribution of sequencing depth results in low coverage at the genome 
termini when only a modest sequencing effort is applied. Efforts to optimize the homogenous 
distribution of sequencing reads along the genome and to determine the optimal sequencing 
effort for reproducible whole genome sequencing, could further improve the applicability of 
the method. Previous studies determining complete genomes of APMV2-9 often relied on a 
round of amplification using degenerated or custom designed oligonucleotides, followed by 
primer walking [29, 31-35]. The use of random access amplification alleviates the problem of 
oligonucleotide design in a context of poor representation in sequence databases. Moreover, it 
allows for the identification of potential co-infection with other APMVs or other viruses 
* Many paramyxovirus genomes follow the "rule of six". The total length of the genome is almost always a 
multiple of six. This is probably due to the advantage of having all RNA bound by NP protein (since NP binds 
hexamers of RNA). If RNA is left exposed, the virus does not replicate efficiently. 
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 without methodological bias. Sequence independent single primer amplification (SISPA) was 
originally described by Reyes and Kim [45]. It was later modified to include enrichment steps 
for viral nucleic acids using filtration and nuclease treatment (DNase-SISPA, [36, 37]). Miller 
and colleagues [5] used a similar approach for the identification and sequencing of a new 
serotype of APMV10 in penguins. Unlike their method, that relied on the molecular cloning 
and sequencing of hundreds of random amplicons, this study used the power of next 
generation to provide the necessary sequence information. The preparation of a next 
generation sequencing library includes the process of emulsion PCR, which isolates single 
DNA molecules on beads and clonally amplifies them ([38], reviewed in [46]). There is no 
longer a need for molecular cloning and the generated random amplicons can directly be 
processed in the sequencing library workflow. An additional advantage is that this 
methodology avoids biological biases induced by the virological analysis of mixed infections. 
Conclusion 
Within a single sampling location, three different APMVs were identified in wild mallards 
using random access amplification in combination with next generation sequencing. From one 
pooled sample, the complete genome sequence of an APMV4 was assembled from the 
random sequences. From a second pooled sample, the nearly complete genome sequence of an 
APMV6 (genome size of 16,236 nt) was determined, as well as a partial sequence for an 
APMV4 closely related but not identical to the APMV4 virus isolated from the first sample.  
These data further contribute to the knowledge about the genetic diversity within serotypes 
APMV4 and APMV6. Moreover, this study demonstrates the value of a random access 
nucleic acid amplification method in combination with massive parallel sequencing for the 
characterization and full genome sequencing of APMVs. Moreover, the sequence independent 
nature of this method allows the detection of potential co-infections with other viruses and is 
applicable to other viruses.  
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As a second case study, the workflow was used for the molecular characterization of 9 
different avian influenza virus isolates (segmented -ssRNA genome organization) from a 
surveillance program in wild gulls and shorebirds.  
Avian influenza viruses (AIV) are influenza type A viruses belonging to the orthomyxoviridae 
family containing a segmented negative-stranded RNA genome (8 segments). Influenza A 
viruses are divided into subtypes on the basis of two proteins on the surface of the virus, 
hemagglutinin (HA) and neuraminidase (NA). There are 18 known HA subtypes and 11 
known NA subtypes. Many different combinations of HA and NA proteins are possible. Three 
prominent subtypes of AIV are known to infect both birds and humans, influenza A H5, H7 
and H9.  Avian influenza A viruses are designated as low pathogenicity avian influenza 
(LPAI) or highly pathogenic avian influenza (HPAI).  
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Abstract  
Nine influenza viruses isolated from gulls and shorebirds in Belgium (2008-2010), including 
H3N8, H5N2, H6N1, H11N9, H12N5, H13N6, H13N8, and H16N3 subtypes, were targeted 
using random amplification and next-generation sequencing. The gene segments of these 
viruses segregated into three phylogeographic lineage types: (1) segments circulating in 
waterfowl in Eurasia with sporadic introduction in other species and in the Americas 
(“Eurasian avian”), (2) segments circulating in American waterfowl with sporadic 
introduction to other species and regions (“American avian”), and (3) segments circulating 
exclusively in gulls and shorebirds and having increased connectivity between the two 
hemispheres (“Charadriiformes specific”). Notably, an H6N1 and an H5N2 isolated from L. 
argentatus had mainly Eurasian avian genes but shared a matrix segment of American avian 
origin (first documentation in European gulls of transhemispheric reassortment). These data 
support the growing evidence of an important role of Charadriiformes birds in the dynamic 
nature of avian influenza ecology. 
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Introduction 
Avian influenza A viruses (AIV, Orthomyxoviridae) possess a segmented single stranded 
RNA genome with negative polarity. Eight unlinked RNA segments encode 11 proteins [1, 2], 
including the hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins. 16 HA and 
9 NA subtypes have been described [3, 4], of which the HA16 and HA13 seem to be specific 
to birds of the order Charadriiformes (gulls, terns and shorebirds) [4]. Genetic diversity is 
mainly generated by mutation and reassortment of complete RNA segments during 
coinfection with multiple viruses [1, 5]. The genetic diversity of AIV is maintained by 
circulation in aquatic wild birds.   The highest prevalence of avian influenza infection is 
observed in birds belonging to the orders of Anseriformes (geese, ducks and swans) and 
Charadriiformes (gulls, terns and shorebirds) [6]. These viruses are occasionally transmitted 
to other species like domesticated poultry and mammals [1] where they can establish 
themselves, including strains with pandemic potential [7-9]. Regarding avian influenza, wild 
birds typically carry low-pathogenic strains (LPAI), some of which - confined to subtypes H5 
and H7 - can mutate and produce highly pathogenic forms (HPAI) after introduction into 
poultry species [1]. 
Geographical constraints on migratory bird movements result in a broad division of all genes 
of avian influenza A viruses into two large phylogenetic lineages evolving independently, the 
American and the Eurasian lineages (including Oceania and Africa) [1, 6].  Within 
hemispherically separated gene pools, wild migratory bird ecology contributes to frequent 
interspecies reassortment of gene segments resulting in transient ‘‘genome constellations’’ in 
wild birds. These gene segment combinations are continually reshuffled by reassortment, in 
contrast to the spread of a limited number of stable genome constellations that characterizes 
the evolution of mammalian-adapted influenza A viruses [10]. Exchange of AIV gene 
segments between these geographically separated gene pools is a relatively rare event [10-17]. 
Although AIV prevalence in Charadriiformes is typically low [18], genomic data of AIV 
isolated in these birds in North America provide evidence of intercontinental reassortment 
across the North Atlantic ocean [17, 19] and across the Bering Sea between Alaska and 
Russia [13, 15, 20, 21], representing mostly areas along continental margins where migratory 
flyways overlap.  Interspecies transmission of AIV may occur in wild birds at migration 
stopover sites or breeding habitats where flocks of mixed species congregate [20, 22]. These 
introduced Eurasian AIV genome segments in the Americas are sporadically established in 
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other species of the wild avifauna [17, 19]. On the contrary, North American origin genes in 
Europe are less frequently detected [11, 17]. The current evidence of American origin gene 
segments in Eurasia is limited to individual cases in guillemots in Sweden [12], a tern in 
Australia [23], ducks in Japan[14, 24] and India [25], and domestic ducks in Italy [26]. Entire 
genomes of Eurasian origin in America or vice versa have not been reported. Although 
transhemispheric movement of gene segments is relatively infrequent [11], implications for 
AIV population structure may be large. For example, all currently circulating PB1, PA and 
HA of the H6 lineages  in North America have a Eurasian origin and have replaced previously 
circulating American lineages [27]. 
In addition to sporadically demonstrated transhemispheric reassortment events in AIV 
isolated from Charadriiformes, genetic lineages exist that are specific to Charadriiformes [6, 
28, 29]. For example, the H13 and H16 hemagglutinin genes seem to occur almost exclusively 
in Charadriiformes birds [4, 15, 30]. Charadriiformes specific clades are also documented in 
PB2, PB1, PA, NP, M, NS (allele B) genes [17]. These Charadriiformes specific H13 and 
H16 viruses have all been suggested to have genomes with a mosaic of geographic origins 
[10, 11], and increased intercontinental mobility of gene segments compared to other AIV 
occurring in wild birds. Charadriiformes, however are also infected with viruses whose 
sequences are shared with those from other wild bird hosts.  
During the annual active surveillance for avian influenza in wild birds in Belgium from 2008 
to 2010, several avian influenza viruses were isolated from shorebirds (Arenaria interpres, 
Ruddy Turnstone) and gulls (Larus sp.).  In this study, we targeted the complete genome of 
these viruses using next-generation sequencing technology and compare the genetic data with 
sequences available in public databases in a phylogeographic analysis framework to provide 
additional insights in the evolutionary ecology of avian influenza viruses in Charadriiformes 
in Western Europe. 
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Materials and Methods 
Viruses 
We selected nine viruses isolated from the target species 
Arenaria interpres (Ruddy Turnstone) and gull species, 
including  Larus argentatus (Herring Gull) and Larus 
michahellis (Yellow-legged Gull), for whole genome 
sequencing (Table 1). The HA and NA subtype diversity in 
these samples included: H3N8, H5N2, H6N1, H11N9, 
N13N6, H13N8, and H16N3 (Table 1).  These virus isolates 
originated in ongoing active AIV monitoring during the 
period 2008-2010. These samples were taken in the 
framework of active surveillance of wildlife for LPAI. The 
description of the results of the monitoring program is not 
within the scope of this study. Briefly, the screening 
methodology was as follows. Captured birds were ringed or 
identified, their age and sex were determined and cloacal and 
oropharyngeal swabs were taken from individual birds. 
Swabs were placed in brain heart infusion broth (BHI) 
medium containing appropriate antibiotics concentrations 
(gentamicin 0.5 % [v/v] and glutamine (1% [v/v]). Swab 
samples were kept at 4°C until laboratory analysis or frozen 
below -70 °C if they could not be processed immediately. 
The swabs were screened for AIV by realtime RT-PCR as 
previously described [31]. Samples positive for influenza A 
were processed for virus isolation by inoculation of 8-10 day 
old specific-pathogen-free embryonated chicken eggs using 
standard procedures (OIE, diagnostic manual 2005/94/CE). 
The subtypes of hemagglutinating allantoic fluids were 
determined using reference sera (OIE, diagnostic manual 
2005/94/CE) and partial sequencing of the HA and NA 
genes (amplification primers and sequencing protocol 
available on request).  
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Random access to viral nucleic acids using DNAse I SISPA  
Virions in samples were purified starting from 1 ml of allantoic fluid (non-passaged original 
from virus isolation described above), which  was first centrifuged at 3,200 × g for 15 minutes 
at 4 °C to remove cell debris. The supernatant was then filtered at 3,000 × g for 8 min or 
longer at 4 °C (200 µl/filter) using 0.22 µm filters (Ultrafree-MC GV sterile, Millipore) to 
remove remaining cell fragments and bacteria. The resulting eluate was subsequently 
subjected to nuclease treatment with 100 U of DNase I (New England Biolabs) at 37 °C for 1 
hour to remove all nucleic acids not protected within virions. The resulting virion-enriched 
samples were used for viral RNA extraction using the QIAamp Viral RNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  Sequence independent single primer 
amplification (SISPA) was performed essentially as previously described [32]. Briefly, the 
extracted RNA was converted into single-stranded cDNA using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche) and 1 µM (final concentration) random primer FR26RV-N 
(5’GCC GGA GCT CTG CAG ATA TCN NNN NN 3’, [33]).  Ten µl extracted RNA was 
denatured at 95 °C for 5 min in the presence of primer FR26RV-N, immediately followed by 
cooling on ice.  The remaining reagents were added. The 20 µl reaction mix contained 1× 
Transcriptor Reverse Transcriptase Reaction Buffer, 2 µl dNTP mix (10 mM each), 20 U 
Protector RNase Inhibitor, 10 U Transcriptor Reverse Transcriptase and 1 µl PCR-grade H2O. 
The reaction was incubated at 25 °C for 10 min followed by 50 °C for 60 min. After a 
transcriptase inactivation step at 85 °C for 5 min and chilling on ice, 2.5 U of 3’-5’ exo- 
Klenow Fragment of DNA polymerase (New England Biolabs) were added for second strand 
synthesis using random primer FR26RV-N for 1 h at 37 °C. An enzyme inactivation step was 
performed at 75 °C for 10 min. Five microliters of the reaction mix was used as template for a 
subsequent PCR amplification. The 50 µl reaction mix consisted of 1× AmpliTaq Gold® 360 
DNA buffer, 2.5 mM MgCl2, dNTP mix (0.2 mM each), 2.5 U AmpliTaq Gold® 360 DNA 
polymerase (Applied Biosystems), 32.7 µl RNase free water and 1.6 µM FR20RV primer (5’-
GCC GGA GCT CTG CAG ATA TC-3’, [33]) which is complementary to the amplification 
tag of FR26RV. The reaction was incubated at 95 °C for 10 min, 40 cycles of 95 °C 1 min, 48 
°C 1 min and 72 °C 2 min followed by a final elongation for 7 minutes at 72°C. The random 
amplified DNA fragments were visualised on a 1 % agarose gel. Fragments of 400-1,000 bp 
were excised and purified from the gel with the High Pure PCR Product Purification Kit 
(Roche). The purified PCR fragments were quantified by spectrophotometry (Nanodrop-
1000).  
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Sequencing and sequence assembly 
Five micrograms of size selected (400-1,000 bp) purified random amplified DNA was 
sequenced on a GS-FLX (Roche, Mannheim, Germany) by the Genomics Core of the 
University Hospital, University of Leuven, Belgium, using multiplex identifier (MID) 
identification during library preparation and their standard procedures using GS FLX 
Titanium series reagents (Roche, Mannheim, Germany), aiming for 5,000-1,0000 reads per 
library. The obtained raw sequence data were assembled using SeqMan NGen® version 2 
(DNASTAR, Madison, WI, USA). The reads were trimmed to remove primer sequences 
(including the primer-encoded random N positions) as well as low quality ends. Standard 
assembling and filtering parameters were used. Contigs (i.e. sets of overlapping sequence 
reads)  produced in an initial de novo assembly were compared to  public sequence databases  
for identification (http://blast.ncbi.nlm.nih.gov/Blast.cgi; [34]). The complete coding 
sequence (CDS) with the highest identity score to the largest contig representing each 
identified segment was then used  as reference genome for a subsequent reference assembly 
with the same raw data set (closest genbank entries summarized in Figure 3) . The resulting 
reference assembly was used to deduce a genome consensus sequence. At polymorphic 
positions (contradictory sequence reads), we included a degenerate nucleotide in the 
consensus sequence if the minor nucleotide alternative was present in at least one third of the 
sequence reads. Polymorphic sites were considered as an indication of genetic heterogeneity 
in the sampled virus population if the positional sequencing depth was at least 20 x and the 
number of minor variant nucleotide reads was larger than 10 and represented at least 10 % of 
the positional sequencing depth (variability analysis summarized in Table 3).  
Phylogenetic and phylogeographic analysis 
The resulting 72 genome segment consensus sequences (GISAID epiFlu accession codes 
EPI345365-EPI345436; http://platform.gisaid.org) were compared to other publicly available 
sequences using a  BLASTn search (http://blast.ncbi.nlm.nih.gov/Blast.cgi; [34]). For each 
segment, a selection of 10 complete coding sequences form the first 20 Blastn results, 
supplemented with selected  reference sequences representing Eurasian and American 
lineages and gull H13/H16 viruses and a selection of viruses isolated from Charadriiformes 
were included in the phylogenetic analysis (genbank accession codes of reference sequences 
available on request). Selected sequences were aligned using the ClustalW algorithm within 
BioEdit v7.0.5.3 software [35]. Neighbor-joining phylogenetic trees (pair wise deletion of 
Chapter 3.3   Implementation and case studies 
     
113 
 
gaps/missing data and maximum composed likelihood substitution model) were deduced 
using MEGA v5.01 [36] using 1,000 bootstrap replicates to assess the statistical significance 
of nodes. 
To determine the phylogeographic origin of each segment, the highest order monophyletic 
bootstrap supported clades (bootstrap support value > 80%) were determined containing each 
segment. The isolation location of the majority of viruses from these clades determined the 
phylogeographic origin of these clades as either American (North + South American 
continents) or Eurasian (Europe + Asia + Oceania + Africa).  However, several segments of 
H13 and H16 that circulate exclusively in Charadriiformes birds have a dynamic 
phylogeographic pattern with near equal likelihood of being isolated in Eurasia or Americas. 
These clades were labeled Charadriiformes specific.  It should be noted that phylogeographic 
grouping of isolates does not necessary signify a close phylogenetic relationship, as (1) 
considerable genetic diversity may be present within these highest order monophyletic clades, 
and (2) in principle multiple monophyletic highest order highly bootstrap supported clades of 
the same phylogeographic origin may arise from a phylogenetic analysis, indicating separate 
well established introductions in a geographic region.  
Results 
Next-generation sequencing of random amplified viral RNA  
We sequenced partial or complete open reading frames of all 72 individual segments from the 
9 virus isolates. Although a variable number of AIV sequence reads was available per sample 
(ranging from 2,043 to 10,330 reads), we obtained for most viruses > 90 % of the coding 
sequence of the genome in a single experiment not needing prior sequence information for 
primer design (Table 2). The largest RNA segments (PB2, PB1, PA, HA, NP) have an 
excellent coverage well above 90 % of the coding sequence (CDS).  Only the PB1 and NP 
genes from the sample with the smallest number of available sequence reads (L. 
argentatus/BE/17429-1’/2008, H13N6), and the HA gene from the sample L. 
argentatus/Belgium/14469-20/2008 and NP from sample L.argentatus/BE/14469-16/08 had 
<90 % of its CDS covered (Table 2). The average sequencing depth (number of reads 
available at a given position) for these large segments is as expected from the limited 
sequencing effort and depended on the number of AIV reads available per sample. The 
sequence coverage of the smaller segments, especially the Matrix and NS gene segments is 
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considerably lower for some samples. The lowest coverage of 27 % was again documented in 
the sample with the lowest number of available reads (M1/M2 segment). For regions with 
sufficient sequencing depth (≥ 20), genetic polymorphisms in the virus isolates were analysed 
(Table 3). Genetic polymorphisms were detected both in shorebird and gull viruses. The 
Charadriiformes specific viruses from gulls (H13 and H16 strains) contained less 
polymorphic sites than the other isolated viruses. The H12N5 and H6N1 viruses had the 
highest number of polymorphic sites, respectively eight and six.  The number of polymorphic 
sites in regions with sufficient sequence depth was independent of the total sequencing effort 
since the amount of used AIV specific reads for H12N5 (5,851) and H6N1 (3,737) was not 
the highest among sequenced viruses. The number of polymorphic sites was also independent 
of the average depth of a specific RNA segment.  For example the PB1, NP and NA segments 
of H11N9 had no polymorphic sites while their average depths were respectively 290, 760 
and 302. However, the segment with the highest number of polymorphic sites (HA of the 
H12N5 virus) had only an average sequence depth of 152.  Polymorphic sites were most 
frequently found in the HA segments. The sequence depth of the small M and NS segments 
was too low to allow a reliable variability analysis.  
Phylogenetic analysis of AIV from Charadriiformes 
Our phylogenetic analysis (Figure 1, Figure 2, Supplementary Figures S1-S17) indicated the 
presence of three phylogeographic lineage types for all internal genes: (1) gene segments 
circulating mostly in wild waterfowl in Eurasia whith sporadic introduction in other species 
and in the Americas (“Eurasian avian”); (2) gene segments circulating almost exclusively in 
American wild waterfowl with sporadic introduction to other species and regions (“American 
avian”) and (3) gene segments circulating exclusively in gulls and shorebirds and having 
increased connectivity between the hemispheres (“Charadriiformes specific”).   The H3, H5, 
H6, H11, and H12 hemagglutining segments of our studied viruses were of Eurasian avian 
origin (Supplementary Figures S6-S10), while the H13 and H16 were Charadriiformes 
specific genes which are known to make frequent contact between different hemispheres 
(Figures 2). The neuraminidase segments N1, N2, N5, N8, and N9 showed a clear Eurasian 
avian origin (Supplementary Figures S11, S12, S14, S16), while the N3 and N6 belonged to 
Charadriiformes specific clades (Supplementary Figures S13, S15). 
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Table 2: Summary of the next-generation sequencing results of 9 avian influenza genomes.  
 A.interpres/B
E/17044-
27/08  
(H3N8) 
A.interpres/B
E/06765cls2/
09 (H11N9) 
A.interpres/B
E/02936pcs1/
10 (H12N5) 
L.michahellis 
/BE/17429-
3/08(H13N6) 
L.argentatus/ 
BE/17429-1 
’/08(H13N6) 
L.argentatus/ 
BE/14469-20 
/08(H13N8) 
L.argentatus/ 
BE/14469-16 
/08(H16N3) 
L.argentatus/ 
BE/02936pcs
3/10 (H6N1) 
L.argentatus/
BE/02936cls
9/10 (H5N2) 
AIV reads (Total reads) 2,395 
(10,420) 
10,330 
(11,009) 
5,851 (6,388) 6,535 
(11,893) 
2,043 (5,742) 4,544 (4,816) 4,167 (7,694) 3,737 (4,055) 3,102 (3,310) 
Coverage of genome/of CDS 
(%) 
90.4/92.6 95.5/96.9 93.9/95.0 90.2/91.8 77.5/79.3 87.2/89.0 92.0/93.6 96.3/97.6 94.2/96.3 
PB2 CDS coverage (%) 98.4 96.0 100 100 90.3 99.5 100 100 100 
PB2 seq. depth avg. (max.) 96.7 (417) 110.9 (274) 217.9 (872) 184.3 (1,155) 57.1 (368) 86.95 (394) 162.23 (865) 71.9 (224) 61.7 (165) 
PB1 CDS coverage (%) 93.5 99.4 100 98.9 89.3 91.8 97.2 100 99.7 
PB1 seq. depth avg. (max.) 52.5 (178) 290 (1,200) 133.1 (574) 316.4 (1,528) 119.2 (550) 44.6 (154) 96.5 (256) 82.2 (145) 66.6 (236) 
PA CDS coverage (%) 97.7 99.7 97.5 97.1 91.7 99.9 100 100 99 
PA seq. depth avg. (max.) 19.1 (53) 22.5 (82) 59.6 (574) 33.1 (130) 8.3 (27) 48.4 (127) 59.1 (167) 41.4 (138) 38.2 (85) 
HA CDS coverage (%) 92.4 99.3 100 97.5 90.1 67 91.7 100 98.9 
HA seq. depth avg. (max.) 9.0 (21) 113.4 (326) 152.7 (382) 152.2 (433) 42.1 (138) 237.5 (521) 127.8 (422) 44.2 (93) 97.58 (190) 
NP CDS coverage (%) 93.4 100 98.1 95.7 81.8 92.6 87.7 100 99.5 
NP seq. depth avg. (max.). 43.9 (111) 756.9 (1,700) 107.7 (249) 94.9 (287) 29.5 (80) 44.6 (93) 18.7 (50) 119.2 (223) 86 (228) 
NA CDS coverage (%) 96 94.7 100 75.3 64.9 95.3 83 90.5 94.5 
NA seq. depth avg. (max.) 100.6 (250) 301.6 (713) 90.2 (303) 17 (68) 3 (8) 286.6 (630) 7.7 (34) 110.2 (259) 26.1 (60) 
M1/M2 CDS coverage (%) 91.9 97.4 74.9 81.7 26.9 50.7 81.9 92.2 98.3 
M1/M2 seq. depth avg. (max.) 3 (6) 24.3 (56) 6.45 (12) 3.5 (6) 1.5 (2) 3.9 (8) 8.2 (20) 14.8 (28) 5.7 (12) 
NS1/NS2 CDS coverage (%) 55.5 78.5 60.4 58 49.4 93.2 95.6 86.2 60.1 
NS1/NS2 seq. depth avg. 
(max.) 
0.9 (1) 6.7 (12) 1.9 (3) 6.3 (28) 1.5 (6) 1.8 (3) 3.35 (6) 8 (16) 3.2 (5) 
Genome segments are ranked according to decreasing size. Seqment CDS coverages < 70% are highlighted in bold type.
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Figure 1: Evolutionary 
relationship between the 
M1/M2 complete coding 
sequences of nine AIV 
isolated from Charadriiformes 
and selected reference isolates 
(inferred using the Neigbor-
Joining method). Confidence 
levels in bootstrap analysis 
(1,000 replications) above 
70% are indicated at nodes. 
Bootstrap support values used 
for defining the 
phylogeographic groupings 
are circled. Colored boxes 
indicate the phylogeographic 
clades (Orange: Eurasian 
avian, Light blue: American 
avian, Green: Charadriiformes 
specific). The green star 
indicates the node defining an 
America-to-Eurasia 
reassortment event. Viruses 
characterized in this study are 
indicated in bold type. Viruses 
isolated from poultry are 
indicated in red.  Asian HPAI 
H5N1 viruses are indicated in 
blue.   
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Figure 2: Evolutionary 
relationship between the 
hemagglutinin H13 and H16 
complete coding sequences of 
nine AIV isolated from 
Charadriiformes and selected 
reference isolates (inferred 
using the Neigbor-Joining 
method). Confidence levels in 
bootstrap analysis (1,000 
replications) above 70 % are 
indicated at nodes. Viruses of 
American geographic 
isolation location are 
indicated in green to 
demonstrate the frequent 
transhemispheric movements 
of these genes.  
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Table 3: Polymorphisms detected in the genomes of the sequenced virus isolates.  
Virus strain Segment Position Read distribution 
(major/minor) 
% of minor 
variant 
Consensus 
at position 
A.interpres/BE/06765cls2/2009 
(H11N9) 
PB2 
HA 
HA 
113 
1,224 
1,239 
14A/10G 
278G/37T 
236T/73G 
41.6 % 
11.7 % 
23.6 % 
R 
G 
T 
A.interpres/BE/02936pcs1/2010 
(H12N5) 
PB2 
PB1 
657 
1,852 
106C/21T 
36C/18A 
16.5 % 
33.3 % 
C 
M 
HA 127 294A/80T 21.4 % A 
HA 
HA 
HA 
HA 
NP 
195 
1,270 
1,313 
1,443 
1,108 
331T/40C 
157A/30G 
165A/27G 
112T/13A 
156C/34A 
10.8 % 
16 %  
14.1 % 
10.4 % 
17.9 % 
T 
A 
A 
T 
C 
L. michahellis/BE/17429-3/2008 
(H13N6) 
PA 
 
239 
 
59G/20A 
 
25.3 % 
 
G 
 
L. argentatus/BE/14469-16/2008 
(H16N3) 
HA 545 137A/73G 34.8 % R 
L. argentatus/BE/02936pcs3/2010 
(H6N1) 
PB1 729 63T/61A 49.2 % W 
PB1 782 60C/53T 46.9 % Y 
PA 183 58C/23A 28.4 % C 
HA 834 26A/14C 35 % M 
HA 846 22G/11A 33.3 % R 
NA 733 167G/57A 25.4 % G 
L. argentatus/BE/02936cls9/2010 
(H5N2) 
HA 540 74A/46C 38.3 % M 
HA 1,023 66C/44T 40 % Y 
The polymorphism analysis includes only genomic sites with positional sequencing depth ≥ 20-fold, percentage 
of minor variant ≥ 10 %, and the number of minor variant nucleotide reads ≥ 10. Degenerate nucleotide codes 
were included at the position when presence of minor variant was ≥ one third of the positional depth. 
Phylogeographic analysis of AIV from Charadriiformes 
Figure 3 summarizes the phylogeographic origin of all RNA segments of all viruses. All gene 
segments of the three Ruddy Turnstone viruses (H3N8, H11N8, H12N5) sampled over 3 
consecutive years on the North Sea coast had a typical Eurasian avian origin (Figure 3) and 
were most closely related to virus segment sequences found in Anseriformes from western and 
central Europe as indicated by the closest BLASTn results for each segment (Figure 3).  
Although having a similar geographic origin, these viruses had phylogenetically 
distinguishable internal genes (Figure 1; Supplementary Figures 1-5). The H3N8 virus was 
the only virus in this study having an allele B NS segment (Supplementary Figure S5).  The 
viruses isolated from gulls fell into two groups: typical Charadriiformes H13 and H16 viruses 
on the one hand and Eurasian avian viruses (H5N2 and H6N1) on the other hand. The two 
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H13N6 viruses isolated from L. michahellis and L. argentatus on a single sampling location 
and time (Mont-Saint-Guibert landfill, September 25, 2008) in 2008 were highly similar for 
all segments (Figures 1-3, Supplementary Figures S1-S5, S15). Apart from the well-known 
H13 gull specific hemagglutinin subtype, their PB2, PB1, NP, NA6, M1/M2 and NS1/NS2 
(allele A) segments clustered in Charadriiformes-specific lineages (Figure 3).  These 
Charadriiformes specific clades included viruses isolated in both Eurasian and American 
hemispheres. Both viruses were reassorted: they shared a PA segment of Eurasian avian 
origin most closely related to A/Mongolian gull/Mongolia/ 405/2007 (H13N6) (Figure 3; 
Supplementary Figure S3). Two viruses isolated on the same landfill location from Larus 
argentatus, one H16N3 virus and one H13N8 virus also shared similar segments (PB2, PB1, 
PA, NP, M, NS; Figure 1; Figure 2, Supplementary Figures S1-S5). The NP gene of the 
H13N8 virus was closely related to the NP genes of the two previous mentioned H13N6 
viruses which were also isolated on the same location, but one month later (Supplementary 
Figure S4). All segments of these viruses clustered in supported Charadriiformes specific 
lineages, including the neuraminidase N3 and the neuraminidase N8, although the N8 
belonged to a lower order Charadriiformes specific clade within a large Eurasian avian origin 
clade (Figure 3; Supplementary Figures S13, S16). The latter belonged to a bootstrap 
supported clade containing only NA sequences from Charadriiformes sampled in Eurasia. 
The two viruses (H5N2 and H6N1) isolated from Larus argentatus on the North Sea shore in 
Oostende on the same day in 2010, were of reassorted origin (Figure 3). They had a majority 
of gene segments of Eurasian avian origin (Figure 3).  They shared a near identical PB2 and 
M1/M2 gene (Figure 1; Supplementary Figure S1), but have distinguishable other genes 
(Supplementary Figures S2-S5, S7-8, S11-12). The NP gene of the H6N1 isolated from gulls 
was similar to the NP gene of the H11N9 virus isolated a year earlier in the same coastal 
region from a Ruddy Turnstone (Supplementary Figure S4). The PA and NS genes of H5N2 
isolated from a gull were similar to the respective RNA segments from the H12N5 virus 
isolated from a Ruddy Turnstone on same day and place (Supplementary Figures S3, S5). 
Most interestingly, the shared Matrix segment of the H5N2 and H6N1 gull viruses was of 
American avian origin (Figure 1; Figure 3) and was closely related to a previously 
documented transhemispheric reassortant Matrix segment from domestic ducks in Italy.  
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A. interpres/BE/17044-27/  
2008 (H3N8) 
A. interpres/BE/06765cls2/ 
2009 (H11N9) 
A. interpres/BE/02936pcs1/ 
2010 (H12N5) 
PB2 mallard/Italy/3401/2005  
(H5N1) CY095584 
teal/Chany/444/2009 
(H8N8) CY098521 
mallard/Czech Republic/ 
14516/2007 (H3N8) JF682611 
PB1 mallard/Sweden/48/2002 
(H11N9) CY060292 
mallard/Netherlands/14/2007 
(H2N2) CY041240 
mute swan/Hungary/5973/ 
2007(H7N7) GQ240811 
PA black-headed gull/ 
NL/1/2005(H6N8) CY041383 
tufted duck/PT/13771/ 
2006(H7N3) HM849008 
duck/Beijing/40/04(H3N8) 
EU492500 
HA mallard/Netherlands/5/2001 
(H3N6) CY060343 
mallard/Netherlands/17/2007 
(H11N8) CY043880 
teal/Norway/10_1836/2006 
(H12N2) FM179754 
NP mallard/Czech Republic/ 
14924-1/2007(H6N5)JF789627 
greylag goose/Netherlands/4/ 
1999 (H6N1) CY060199 
mallard/Netherlands/28/2006 
(H3N1) CY076908 
NA mallard/Netherlands/17/2007 
(H11N8) CY043882 
goose/Czech Republic/1848-
T14/2009 (H7N9) HQ244417 
mallard/Switzerland/WV406016
7/2006 (H3N5) GQ415323 
M1/M2 mallard/Sweden/90/2005 
(H11N9) CY076961 
mallard/Netherlands/29/2006 
(H7N2) CY043833 
mallard/Czech Republic/15307-
17/2008 GQ404573 
NS1/NS2 mallard/Czech Republic/15902-
17K/2009 (H6N2) HQ244434 
Allele B 
mallard/Netherlands/14/2007 
(H2N2) CY041238  
Allele A 
mallard/Netherlands/7/2007 
(H4N2) CY076925  
Allele A 
    
 
L. michahellis/BE/17429-3/ 
2008 (H13N6)  
L. argentatus/BE/17429-1’/ 
2008 (H13N6) 
L. argentatus/BE/14469-20/ 
2008 (H13N8) 
PB2 Mongolian gull/Mongolia/ 
401/2007 (H13N6) GQ907317 
black-headed gull/Sweden/ 
1/2005 (H13N8) CY077007  
herring gull/Mongolia/454/2008 
(H13N8) JF775477 
PB1 black-headed gull/Sweden/ 
1/2005 (H13N8) CY077006 
black-headed gull/Sweden/ 
1/2005 (H13N8) CY077006 
black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907300 
PA Mongolian gull/Mongolia/ 
405/2007(H13N6) GQ907323 
Mongolian gull/Mongolia/ 
405/2007(H13N6) GQ907323 
black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907299 
HA gull/Astrakhan/3483/2002 
(H13N6) EU835897 
gull/Astrakhan/3483/2002 
(H13N6) EU835897 
herring gull/Mongolia/454/2008 
(H13N8) JF775470 
NP great black-headed gull/Atyrau/ 
743/2004 (H13N6) GU982289  
great black-headed gull/Atyrau/ 
743/2004 (H13N6) GU982289 
great black-headed gull/Atyrau/ 
743/2004 (H13N6) GU982289 
NA great black-headed gull/Atyrau/ 
773/2004 (H13N6) GU982288 
great black-headed gull/Atyrau/ 
773/2004 (H13N6) GU982288 
black-headed gull/Sweden/1/ 
2005 (H13N8) CY077002 
M1/M2 Mongolian gull/Mongolia/405/ 
2007 (H13N6) GQ907319 
Mongolian gull/Mongolia/405/ 
2007 (H13N6) GQ907319 
black-headed gull/Sweden/1/ 
2005 (H13N8) CY077001 
NS1/NS2 Mongolian gull/Mongolia/405/ 
2007 (H13N6) GQ907322 
Allele A 
Mongolian gull/Mongolia/405/ 
2007 (H13N6) GQ907322 
Allele A 
black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907298 
Allele A 
    
 L. argentatus/BE/14469-16/ 
2008 (H16N3)  
L. argentatus/BE/02936pcs3/ 
2010 (H6N1)  
L. argentatus/BE/02936cls9/ 
2010 (H5N2)  
PB2 herring gull/Mongolia/454/2008 
(H13N8) JF775477 
mallard/Netherlands/20/2005 
(H12N8) CY076975 
mallard/Netherlands/20/2005 
(H12N8) CY076975 
PB1 black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907300 
duck/Primorie/2633/2001 
(H5N3) GQ227611 
common eider/Netherlands/ 
1/200 (H3N8) CY041344 
PA black-headed gull/Sweden/ 
1/99 (H13N6) AY684883 
duck/Shiga/8/2004 
(H4N6) AB304146 
mallard/Netherlands/17/2007 
(H11N8) CY043885 
HA black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907294 
mallard/Czech Republic/15902-
17K/2009 (H6N2) HQ244430 
mallard/Sweden/74/2003 
(H5N2) CY076929 
NP great black-headed gull/Atyrau/ 
773/2004 (H13N6) GU982292 
duck/Italy/775/2004 (H5N3) 
CY024749  
mallard/Sweden/48/2002 
(H11N9) CY060295 
NA black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907296 
aquatic bird/India/NIV-17095/ 
2007 (H11N1) CY055177  
gull/Moscow/3100/2006 (H6N2) 
EU152239 
M1/M2 black headed gull/Mongolia/ 
1766/2006 (H13N6) GQ907303 
duck/Italy/775/2004 (H5N3) 
CY024747  
ruddy turnstone/New Jersey/ 
1049/2000 (H6N4) GU051408 
duck/Italy/775/2004 (H5N3) 
CY024747  
ruddy turnstone/New Jersey/ 
1049/2000 (H6N4) GU051408 
NS1/NS2 black headed gull/Mongolia/ 
1756/2006 (H16N3) GQ907298 
Allele A 
common gull/Ust-Ilimsk/121/ 
2008 CY080586  
Allele A 
mallard/Czech Republic/13438-
29K/2010 (H11N9) JF789606 
Allele A 
 
 
Chapter 3.3  Implementation and case studies 
     
121 
 
Figure 3 (previous page): Geographical mosaicism in AIV isolated from Charadriiformes 
(gulls and shorebirds) isolated in Belgium, 2008-2010.  The phylogeographic origin of each 
segment was deduced in a detailed phylogenetic analysis. A color code is used for the 
geographical origin of the corresponding gene segments (orange: Eurasian avian, light blue: 
American avian, green: Charadriiformes specific, grey: Eurasian Charadriiformes specific 
subclade). For each segment, the accession code and name of the most identical complete 
coding sequence in a BLASTn search is indicated (Genbank accessed 14 October 2011). Grey 
table gridlines: isolates from Ruddy Turnstone (Arenaria interpres); black table gridlines: gull 
isolates (Larus sp.). 
Discussion 
Although less frequently infected than waterfowl [18], gulls and shorebirds have an important 
role in AIV ecology in wild birds. Their migratory biology has been shown to facilitate 
sporadic contacts between the mainly separated American and Eurasian gene pools of avian 
influenza [16, 17]. In addition to infections with typical avian hemisphere-specific AIV, 
Charadriiformes, notably gulls, perpetuate lineages of AIV that seem to circulate exclusively 
in Charadriiformes. We selected nine AIV isolated from gulls and shorebirds for whole 
genome sequencing. Due to the diversity of strains and subtypes, a generic sequencing 
protocol was needed. As part of a feasibility study testing the applicability scope of random 
amplification, we opted for random access amplification in combination with next-generation 
sequencing (NGS).  
The protocol resulted in an efficient enrichment of the RNA library in viral RNA. Although 
we intentionally only used a moderate sequencing effort (< 10,000 sequencing reads) to test 
the feasibility of sequencing a high number of viruses, the methodology proved to target all 
segments with a typical whole genome coverage of 90-95 %. This allowed a phylogeographic 
analysis covering all gene segments of all nine viruses. The methodology seems to be less 
efficient for smaller segments M and NS where the % of the coding sequence (CDS) covered 
and the average sequencing depth were considerably lower. One sample only yielded 2,043 
AIV specific sequence reads, resulting in <65 % coverage of the CDS of the three smallest 
RNA segments. Regions where sequence information was missing were mostly situated at 
segment extremities and sequence depth at extremities was generally speaking lower (data not 
shown).  It is obvious that to achieve complete genomes including the 5’ and 3’ noncoding 
regions, more AIV specific reads would be needed.  Alternatively, additional Sanger 
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sequencing may be used to complete the genome sequences. Since completing this study, 
other methods based on AIV-specific PCR amplification [37, 38] have become available that 
may be more suitable for targeted influenza A virus sequencing. AIV specific library 
preparation tools may be especially useful for studies aiming at genome wide polymorphism 
analysis and quasispecies characterization.  Our data show the value of NGS technology to 
produce large volumes of sequence data of segmented RNA genomes using a universal 
amplification and sequencing approach in a single experiment.  
An important added value of NGS methods is the documentation of genetic variants and 
multiple infections [32, 39]. Multiple infections are a prerequisite for AIV dynamic evolution 
through reassortment [1], and have been previously demonstrated [31, 39]. Although the 
sequencing effort in this study was not sufficient to allow a genome wide quantitative analysis 
of genetic polymorphisms, our data show the power of NGS technology for the 
characterization of genetic variability within samples. This contributes to an increased 
reliability of the consensus sequence as uploaded to public databases compared to Sanger 
sequencing-based consensus sequences which are mostly based on a sequence depth below 5. 
Degenerate nucleotide codes in consensus sequences now become an indication of an actual 
polymorphism in the sample, instead of a doubtful base calling as a result of a limited number 
of contradictory sequence reads.  Although a prerequisite for using NGS for large numbers of 
viruses is the diminished cost of NGS (can be facilitated through multiplexed sequencing, 
evolution of sequencing platform and service market, enhanced sample preparation methods), 
these data clearly show the power of complete genome sequencing using next-generation 
sequencing to provide improved insights in the phylogenomic/geographic ecological 
dynamics of avian influenza in wild birds.   
Our phylogeographic analysis confirms the circulation of diverse viruses in gulls and 
shorebirds, with strict segregation of gene segments in three phylogeographic lineage types: 
(1) gene segments circulating mostly in waterfowl in Eurasia with sporadic introduction in 
other species and in the Americas (“Eurasian avian”); (2) gene segments circulating almost 
exclusively in American waterfowl with sporadic introduction to other species and regions 
(“American avian”) and (3) gene segments circulating exclusively in gulls and shorebirds and 
having increased connectivity between the two hemispheres (“Charadriiformes specific”). 
The single gene segment for which our phylogenetic analysis did not result in a strict 
geographical separation, the hemagglutinin H6, can be attributed to the historical replacement 
of American H6 sequences by a sustainably introduced Eurasian-origin H6 lineage.  In fact, 
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all currently circulating H6 genes in the Americas are of Eurasian origin [27]. In addition, 
interaction between these AIV lineages was demonstrated as shown by chimeric 
Charadriiformes specific viruses having an Avian Eurasian PA segment and also by chimeric 
Eurasian avian H5N2 and H6N1 viruses having an American avian Matrix gene. The M1/M2 
segments of the intercontinental reassortant viruses we documented in gulls are closely related 
to American origin Matrix gene sequences from Italian domestic ducks in 2004, where also an 
American origin H11 gene was reported [26]. This introduction of American segments in 
Eurasia seems to have resulted in sustained circulation in Eurasian avifauna and sporadic 
occurrence in domesticated ducks. Gulls may have had important role in the introduction 
event. Importantly, the other segments of these chimeric gull viruses were of diverse avian 
Eurasian origin, indicating a dynamic evolutionary ecology of these segments in their natural 
reservoir.  These Eurasian avian chimeric H5 and H6 viruses were isolated during the winter 
at a coastal location. On the contrary, the typical Charadriiformes specific H13 and H16 
viruses we isolated from gulls were isolated at an inland landfill site during late summer. In 
Belgium, a year-round population of herring gulls is joined during the winter by the 
population of L.argentatus breeding in the arctic regions and moving south for the winter. 
Based on only a small sample size, it remains unclear whether this difference in gull 
population or the sampling site may have contributed to the detection of completely different 
viruses. Intercontinental reassortment events involving typically avian American and Eurasian 
clades have been mainly documented in North America.  The migration ecology of the main 
reservoir species (Anseriformes) of these clades and the general phylogeographic patterns 
indicate a stringent separation between American and Eurasian avian clades.  This has led to 
the suggestion that other species (Charadriiformes) may act as “bridge species” to facilitate 
contact between geographical regions. Indeed, both Eurasian avian and American avian 
lineages seem to be able to sporadically infect Charadriiformes species.  The migratory 
ecology of these species allows overlap of Eurasian and American population in arctic 
breeding grounds. Moreover these birds come together in breeding grounds or migration 
stopover sites with numerous other migratory birds including migratory Anseriformes, 
allowing exchange of viruses between these bird species.  In North America, this has led to 
increasing evidence of hemispheric chimeric viruses in Charadriiformes species.  On the 
contrary, documentations of American genes in Eurasia remain limited in spite of a 
representative sampling of these species in Eurasia [18]. Notably, this is the first 
documentation of such a transatlantic reassortment in a Eurasian gull.  The three AIV 
genomes from Ruddy Turnstones characterized in this study showed a strictly Eurasian gene 
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constellation. In contrast to the well-studied shorebird population in North America, very 
limited AIV sequence data exists from shorebirds in Eurasia. The fact that no geographic 
reassortments were documented in these species in Eurasia may be due to a difference in 
sampling size [18].  It remains unexplained why the patterns of intercontinental reassortment 
differ between the continents. It has been suggested that AIV ecology is different in both 
continents [17]. Our data indicate that these chimeric viruses do occur in Western Europe, 
although their frequency must be low considering that sampling of Charadriiformes in Europe 
is representative [17, 18].  
In conclusion, we show that next-generation sequencing technology allows efficient 
phylogenetic and phylogeographic analyses targeting all influenza viral segments. This may 
facilitate new insights in avian influenza in wild birds in the near future. Our data confirm the 
dynamic nature of LPAI in wild birds. Moreover, we provide the first evidence of a 
transhemispheric reassortant of AIV in gulls in Europe, reinforcing available evidence of a 
key role of Charadriiformes birds in the dynamic nature of avian influenza ecology. These 
birds should be considered as important target species for surveillance programs.  
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Supplementary figures are available in the online version of this publication: 
http://link.springer.com/article/10.1007%2Fs00705-012-1323-x 
Acknowledgements 
The authors would like to thank all technicians of the Veterinary and Agrochemical Research 
Center that contributed to this work. This work was supported by funding from the EU 
Network of Excellence, EPIZONE (FOODCT-2006-016236) and EU Project INN-FLU 
(SSPE-CT-2006-44372).  
References 
1. Webster, R.G., et al., Evolution and ecology of influenza A viruses. Microbiol Rev, 
1992. 56(1): p. 152-79. 
2. Kawaoka, Y., et al., Orthomyxoviridae, in Virus Taxonomy: Eighth Report of the 
International Committee for the Taxonomy of Viruses., C.M. Fauquet, et al., Editors. 
2005, Elsevier Academic Press: San Diego, U.S.A. p. 681-693. 
3. Alexander, D.J., Newcastle disease and other avian Paramyxoviruses. Rev Sci Tech 
Off int Epiz, 2000. 19(2): p. 443-462. 
Chapter 3.3  Implementation and case studies 
     
125 
 
4. Fouchier, R.A., et al., Characterization of a novel influenza A virus hemagglutinin 
subtype (H16) obtained from black-headed gulls. J Virol, 2005. 79(5): p. 2814-22. 
5. Rambaut, A., et al., The genomic and epidemiological dynamics of human influenza A 
virus. Nature, 2008. 453(7195): p. 615-9. 
6. Olsen, B., et al., Global patterns of influenza a virus in wild birds. Science, 2006. 
312(5772): p. 384-8. 
7. Scholtissek, C., et al., On the origin of the human influenza virus subtypes H2N2 and 
H3N2. Virology, 1978. 87(1): p. 13-20. 
8. Kawaoka, Y., S. Krauss, and R.G. Webster, Avian-to-human transmission of the PB1 
gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol, 1989. 63(11): p. 
4603-8. 
9. Li, K.S., et al., Genesis of a highly pathogenic and potentially pandemic H5N1 
influenza virus in eastern Asia. Nature, 2004. 430(6996): p. 209-13. 
10. Dugan, V.G., et al., The evolutionary genetics and emergence of avian influenza 
viruses in wild birds. PLoS Pathog, 2008. 4(5): p. e1000076. 
11. Krauss, S., et al., Influenza in Migratory Birds and Evidence of Limited 
Intercontinental Virus Exchange. PLoS Pathog, 2007. 3(11): p. e167. 
12. Wallensten, A., et al., Multiple gene segment reassortment between Eurasian and 
American lineages of influenza A virus (H6N2) in Guillemot (Uria aalge). Arch Virol, 
2005. 150(8): p. 1685-92. 
13. Koehler, A.V., et al., Genetic evidence of intercontinental movement of avian 
influenza in a migratory bird: the northern pintail (Anas acuta). Mol Ecol, 2008. 
17(21): p. 4754-62. 
14. Manzoor, R., et al., Phylogenic analysis of the M genes of influenza viruses isolated 
from free-flying water birds from their Northern Territory to Hokkaido, Japan. Virus 
Genes, 2008. 37(2): p. 144-52. 
15. Ramey, A.M., et al., Intercontinental reassortment and genomic variation of low 
pathogenic avian influenza viruses isolated from northern pintails (Anas acuta) in 
Alaska: examining the evidence through space and time. Virology, 2010. 401(2): p. 
179-89. 
16. Pearce, J.M., et al., Limited evidence of trans-hemispheric movement of avian 
influenza viruses among contemporary North American shorebird isolates. Virus Res, 
2010. 148(1-2): p. 44-50. 
17. Wille, M., et al., Extensive geographic mosaicism in avian influenza viruses from gulls 
in the northern hemisphere. PLoS ONE, 2011. 6(6): p. e20664. 
18. Munster, V.J., et al., Spatial, temporal, and species variation in prevalence of 
influenza A viruses in wild migratory birds. PLoS Pathog, 2007. 3(5): p. e61. 
19. Wille, M., et al., Reassortment of American and Eurasian genes in an influenza A 
virus isolated from a great black-backed gull (Larus marinus), a species demonstrated 
to move between these regions. Arch Virol, 2011. 156(1): p. 107-15. 
20. Ramey, A.M., et al., Transmission and reassortment of avian influenza viruses at the 
Asian-North American interface. Virology, 2010. 406(2): p. 352-9. 
21. Wahlgren, J., et al., Gene segment reassortment between American and Asian lineages 
of avian influenza virus from waterfowl in the Beringia area. Vector Borne Zoonotic 
Dis, 2008. 8(6): p. 783-90. 
22. Garamszegi, L.Z. and A.P. Moller, Prevalence of avian influenza and host ecology. 
Proc Biol Sci, 2007. 274(1621): p. 2003-12. 
23. Kishida, N., et al., H2N5 influenza virus isolates from terns in Australia: genetic 
reassortants between those of the Eurasian and American lineages. Virus Genes, 
2008. 37(1): p. 16-21. 
Chapter 3.3  Implementation and case studies 
     
126 
 
24. Liu, J.H., et al., Interregional transmission of the internal protein genes of H2 
influenza virus in migratory ducks from North America to Eurasia. Virus Genes, 2004. 
29(1): p. 81-6. 
25. Pawar, S., et al., An avian influenza A(H11N1) virus from a wild aquatic bird 
revealing a unique Eurasian-American genetic reassortment. Virus Genes, 2010. 
41(1): p. 14-22. 
26. Fusaro, A., et al., Gene segment reassortment between Eurasian and American clades 
of avian influenza virus in Italy. Arch Virol, 2010. 155(1): p. 77-81. 
27. zu Dohna, H., et al., Invasions by Eurasian avian influenza virus H6 genes and 
replacement of the virus' North American clade. Emerg Infect Dis, 2009. 15(7): p. 
1040-5. 
28. Obenauer, J.C., et al., Large-scale sequence analysis of avian influenza isolates. 
Science, 2006. 311(5767): p. 1576-80. 
29. Widjaja, L., et al., Matrix gene of influenza a viruses isolated from wild aquatic birds: 
ecology and emergence of influenza a viruses. J Virol, 2004. 78(16): p. 8771-9. 
30. Kawaoka, Y., et al., Is the gene pool of influenza viruses in shorebirds and gulls 
different from that in wild ducks? Virology, 1988. 163(1): p. 247-50. 
31. Van Borm, S., et al., Genetic characterization of low pathogenic H5N1 and 
cocirculating avian influenza viruses in wild mallards (Anas platyrhynchos) in 
Belgium, 2008. Avian Pathology, 2011. available online: 22 Sep 2011. 
32. Rosseel, T., et al., Identification and complete genome sequencing of paramyxoviruses 
in mallard ducks (Anas platyrhynchos) using random access amplification and next 
generation sequencing technologies. Virol J, 2011. 8: p. 463. 
33. Allander, T., et al., Cloning of a human parvovirus by molecular screening of 
respiratory tract samples. Proc Natl Acad Sci U S A, 2005. 102(36): p. 12891-6. 
34. Altschul, S.F., et al., Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs. Nucleic Acids Res, 1997. 25(17): p. 3389-402. 
35. Hall, T.A., BioEdit: a user-friendly biological sequence alignment editor and analysis 
program for Windows 95/98/NT. http://www.mbio.ncsu.edu/bioedit/bioedit.html. Nucl 
Acids Symp Ser, 1999. 41: p. 95-98. 
36. Tamura, K., et al., MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) 
software version 4.0. Mol Biol Evol, 2007. 24(8): p. 1596-9. 
37. Höper, D., B. Hoffmann, and M. Beer, A comprehensive deep sequencing strategy for 
full-length genomes of influenza A. PLoS One, 2011. 6(4): p. e19075. 
38. Kampmann, M.L., et al., A simple method for the parallel deep sequencing of full 
influenza A genomes. J Virol Methods, 2011. 178(1-2): p. 243-8. 
39. Dugan, V.G., et al., Phylogenetic analysis of low pathogenicity H5N1 and H7N3 
influenza A virus isolates recovered from sentinel, free flying, wild mallards at one 
study site during 2006. Virology, 2011. 417(1): p. 98-105. 
 
 
Chapter 3.4  Implementation and case studies 
     
127 
 
CHAPTER 3.4 
What's in a strain? Viral metagenomics 
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isolates of pigeon paramyxovirus type 1 
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In a third case study the workflow was used to characterize 11 pigeon type 1 paramyxoviruses 
(PPMV1) which were isolated during routine diagnostics for avian influenza and avian 
paramyxoviruses in pigeons. The random access to sequence information allowed the 
identification of contaminating pigeon circoviruses.  
PPMV1 are serotype 1 avian paramyxoviruses which infects pigeons (see introduction of 
Chapter 3.2 for a brief introduction about APMV). In the past, a number of Newcastle disease 
outbreaks in poultry have been attributed to PPMV-1, which makes these pigeon-derived 
viruses a real and continuous threat to the poultry industry.  
Pigeon ciroviruses are classified in the circoviridae family, having a circular single-stranded 
DNA genome. Pigeon circovirus infections have been described in several regions of the 
world. Infected pigeons may develop symptoms such as anorexia, weight loss, reduced race 
performance, lethargy, respiratory distress and diarrhea.  
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Abstract 
We used next-generation sequencing on random amplified viral nucleic acids to determine the 
genome sequence of 11 pigeon paramyxovirus type 1 (PPMV-1) isolates from Belgium 
(period 1998–2011). The PPMV-1 deep sequence data allowed identification of sequence 
variability in multiple PPMV-1 isolates, including one STOP codon in the Matrix gene which 
was present in 15 % of the viral population of one isolate. Notably, mutations that were 
previously associated with pathogenicity in chickens were identified as minor sequence 
variants in one parent laboratory strain. A phylogenetic analysis of the consensus PPMV-1 
genome sequences was performed. In addition to providing nearly complete paramyxovirus 
genome sequences, our sequence-independent approach identified the presence of pigeon 
circovirus (PiCV) sequences in four of these viral stocks. Real-time quantitative RT-PCR 
analysis specific for PMV-1 and PiCV showed that these contaminations were present in 
seven viral stocks consisting of allantoic fluids and was occasionally also detected in stocks 
passaged in embryonated chicken eggs. Phylogenetic analysis of the PiCV consensus genome 
sequences showed a circulation of PiCV covering the full genetic diversity of known PiCV. 
This study shows the value of novel sequence independent technologies for access to 
sequence information for the control of reference virus stocks and other biological materials, 
as co-infecting viruses or sequence variants from the original sample may persist in the stocks 
without being identified by the routine virus-specific diagnostic tools. The exact role of PiCV 
in pigeon disease - in particular Newcastle disease - and its potential interference with PPMV-
1 diagnostics remains to be investigated. 
Keywords: next-generation sequencing, avian paramyxovirus type 1, pigeon circovirus, viral 
metagenomics, random access amplification 
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Introduction 
Newcastle disease (ND) is caused by avian paramyxovirus type 1 (APMV-1) strains (family 
Paramyxoviridae, genus Avulavirus) [1]. It affects many species of birds, and has the 
potential to cause severe economic losses in the poultry sector worldwide. According to their 
virulence in poultry, ND virus (NDV) isolates can be classified as lentogenic*, mesogenic* or 
velogenic [2]. Velogenic strains cause severe disease and high mortality in poultry. The 
pathogenicity in poultry can be determined using in vivo tests, such as the intracerebral 
pathogenicity index** (ICPI). Alternatively, the determination of the amino acid sequence at 
the cleavage site of the fusion gene precursor glycoprotein F0 is recognized as a molecular 
marker of pathogenicity [3]. During the 1980’s, the disease spread worldwide among racing 
and show pigeons. APMV-1 viruses isolated from affected birds were shown to be 
antigenically and genetically similar to each other but distinct from classical NDV strains. 
These APMV-1 variants could be discriminated by monoclonal antibodies [4] and are referred 
to as pigeon paramyxovirus type 1 (PPMV-1) [5, 6], forming a distinguished phylogenetic 
group, lineage VIb [7, 8], and retaining the potential to cause disease  in poultry [5, 9]. 
PPMV-1 continues to circulate worldwide [7, 10] and are regularly isolated from 
unvaccinated racing and show pigeons. However, vaccinated adults can also 
asymptomatically carry the virus and infect young pigeons after the waning of maternally 
derived antibody and before efficient vaccination*** could be established. Interestingly, 
PPMV-1 provides some examples of unusual viruses that have a cleavage site motif that is 
generally associated with virulent viruses and a contrasting ICPI result indicating an avirulent 
virus [11]. Fuller and collaborators [12] isolated several PPMV-1 clones by limiting dilution 
in embryonated specific-pathogen-free (SPF) egg starting from a Belgian PPMV-1 isolate 
with an ICPI of 0.32 (avirulent classification) and a velogenic F protein cleavage site. They 
identified two genetically similar PPMV-1 clones that differed significantly in their  
* lentogenic strains are NDV strains which are nonvirulent and cause only mild clinical signs; mesogenic 
strains have an intermediate virulence and cause coughing, affect egg quality and production and result in up to 
10% mortality  
** The Intracerebral pathogenicity index (ICPI) is a bioassay for the characterization of a Newcastle disease 
virus isolate recommended in international diagnostic guidelines, and involves the intracerebral injection of 
chicks, followed by a standardized scoring of the pathology of the birds. 
*** Both live and killed vaccines for Newcastle disease exist. An introduction about available vaccines 
worldwide can be found at http://www.fao.org/docrep/005/ac802e/ac802e04.htm 
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pathogenicity for 1-day-old chickens, despite the fact that they were comparable in in vitro 
infection characteristics such as syncytium formation, plaque size and morphology, and cell-
to-cell spread. One virus had an ICPI of 0.025 and the other of 1.3 [12]. The consensus 
genome of these variants having an ICPI of 0.025 and 1.3 was completely characterized [13] 
and sequence differences were identified. We previously demonstrated the value of 
combining random amplification methods with next-generation sequencing technology for the 
generation of deep sequence data from avian paramyxoviruses [14]. In this study, we apply 
this sequence independent methodology to historical and recent PPMV-1 isolates, and 
investigate the viral nucleic acid sequence diversity detected in these isolates.  
In addition, the analysis of viral sequence data showed the presence of PiCV in addition to 
PPMV-1 in some virus stocks. We further investigated this issue using PPMV-1 and PiCV 
specific quantitative real time (RT-)PCR. 
Materials and Methods  
Viruses 
Eleven viruses isolated from pigeons were selected for in-depth molecular characterization. 
These viruses were isolated during the routine diagnostic activities of the Belgian reference 
laboratory for avian influenza and Newcastle disease and were selected to represent a wide 
timescale (1998-current) and to include isolates that were previously biologically 
characterized and have different pathogenicity indices (Table 1).  The viruses were isolated 
from diverse avian sample types according to routine virus isolation procedures (OIE, 
diagnostic manual 2005/94/CE). Briefly, samples were inoculated into the allantoic cavity of 
8-10 day-old embryonated specific pathogen free chicken eggs. After incubation for 3-5 days 
at 37 °C allantoic liquids were harvested and their hemagglutinating activity for chicken red 
blood cells was investigated. Allantoic liquids with hemagglutinating activity were further 
characterized in hemagglutination inhibition tests using reference sera [4, 15]. Where 
possible, the original allantoic fluid was selected for molecular characterization (i.e. without 
further passages on chicken embryos). Passages on chicken embryos were carried out 
following routine virological techniques (methodology according to Council Directive 
92/66/EC (1992)). 
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DNAse SISPA and next-generation sequencing 
DNase SISPA and 454 sequencing 
Sample pretreatment and SISPA were performed independently on the 11 samples (to avoid 
contamination) as previously described [14, 16]. Briefly, after a centrifugation and filtration 
step using 0.22 µm filters, the eluate was subjected to DNase I treatment (100 U/200µl 
sample). The resulting virion-enriched samples were subjected to a viral RNA extraction 
using the QIAamp Viral RNA Mini Kit (Qiagen). The random first- and second strand cDNA 
synthesis (using Transcriptor reverse transcriptase, Roche, and Klenow Fragment (exo- ), 
New England Biolabs) was performed as previously described [14] with the primer FR20RV-
12N (5’-GCC GGA GCT CTG CAG ATA TCN NNN NNN NNN NN-3’). Subsequently, 
primer FR20RV (5’-GCC GGA GCT CTG CAG ATA TC-3’) was used in PCR (using 
AmpliTaq Gold 360, Applied Biosystems) to amplify the resulting cDNA as previously 
described [14]. After visualisation of the random amplified DNA fragments on a 1 % agarose 
gel, the fragments larger than 400 bp were excised, purified and quantified using a Nanodrop 
spectrophotometer (Nanodrop Technologies). Five micrograms of each size selected and 
purified random amplified sample were sequenced on a GS FLX (Roche, Mannheim, 
Germany) by the Genomics Core of the University Hospital (University of Leuven, Belgium) 
using multiplex identifier (MID) identification during library preparation  and their standard 
procedures using GS FLX Titanium series reagents (Roche, Mannheim, Germany). 
 
Table 1: Selected virus isolates used for viral (meta)genomic characterization. 
Isolate Year isolated F cl site sequence Additional information (reference) 
98/238 1998 112RRQKRF117 ICPI 1.25 [11] 
98/248 1998 112RRQKRF117 ICPI 0.32 [11]. Cloning and sequencing 
[12, 13] 
98/321 1998 112RRQKRF117 ICPI 0.33 [11] 
98/324 1998 112RRKKRF117 ICPI 1.27 [11] 
03/05843 2003 112RRQKRF117 From brain sample 
05/01824 2005 112RRQKRF117 From lung sample 
05/03936/8 2005 112RRQKRF117 From intestine sample 
07/04943 2007 112RRQKRF117 From cloacal swab sample 
11/07574 2011 112RRQKRF117 From intestine sample 
11/08304 2011 112RRQKRF117 From lung sample 
11/09620 2011 112RRQKRF117 From brain sample 
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Data analysis 
The raw sequence data were assembled using SeqMan NGen® version 3.1 (DNASTAR, 
Madison, WI, USA). The reads were trimmed to remove primer sequences (including the 
primer-encoded random N positions) as well as low quality ends. Standard assembling and 
filtering parameters were used. Contigs (i.e. sets of overlapping sequence reads)  produced in 
an initial de novo assembly were compared to  public sequence databases for identification 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi; [17]). When we identified a PPMV-1, we used the 
complete genome with the highest identity score to the largest PPMV-1 contig as reference 
genome for a subsequent reference assembly with the same raw data set. Any other identified 
viruses were analyzed in the same way. The resulting reference assembly was used to deduce 
a genome consensus sequence. At polymorphic positions (contradictory sequence reads), we 
included a degenerate nucleotide in the consensus sequence if the minor nucleotide alternative 
was present in at least one third of the sequence reads. Polymorphic sites were considered as 
an indication of genetic heterogeneity in the sampled virus population if the positional 
sequencing depth was at least 20-fold. Reference assemblies were manually checked for 
presence of significantly deviating sequences. If this was the case, reads were manually sorted 
and separate assemblies and consensus sequences were made. All consensus sequences were 
submitted to Genbank (accession codes in Table 2). Polymorphisms in the reference 
assemblies were identified using the single nucleotide polymorphism calling tool in SeqMan 
NGen® version 3.1 (DNASTAR, Madison, WI, USA). The combined error rate of the 
enzymes used in the SISPA protocol was estimated to be below 1.5 x 10-3 errors/base. 
However, given the unequal distribution of sequence coverage and the low average coverage 
in several samples, only clear polymorphisms present in at least 10 % of the reads and at 
genome positions with a minimum sequence depth of 20-fold were taken into account. 
Moreover, sequence variants present only in the last 20 nucleotides of a read were excluded. 
Phylogenetic analysis and molecular characterization 
Consensus sequences were edited, aligned and translated, and sequence identities were 
calculated using Bioedit v 7.0.5.3 [18]. Selected reference sequences were included to reflect 
the available sequence diversity of the analyzed viruses in public databases (accession codes 
specified in figures 1 and 2). For PPMV-1, complete genome sequences were analyzed, while 
for PiCV an 822 bp region of the ORF2 encoding the capsid protein was analyzed to allow 
inclusion of more reference data.  Multiple sequence alignments were processed using 
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ClustalW  in Bioedit v 7.0.5.3 [18]. 
Neighbor-Joining phylogenetic trees were 
constructed in Mega v5.01 [19] using the 
Tamura-Nei model, 1,000 bootstrap 
pseudoreplicates, and pairwise deletion of 
missing data and alignment gaps, 
allowing the inclusion of incomplete 
sequences in the analysis. The observed 
phylogenetic trees were confirmed using 
Maximum Likelihood analysis (Mega 
v5.01, data not shown). 
Virus specific q(RT-)PCR 
To allow a more sensitive and 
quantitative measurement of PPMV-1 and 
PiCV in allantoic fluid stocks, specific 
realtime quantitative (RT-) PCR assays 
were performed.  
PPMV-1 specific quantitative real time 
RT-PCR 
Viral RNA was extracted from allantoic 
liquids using the QIAamp Viral RNA 
Mini Kit (Qiagen). Viral RNA was 
quantified as previously described using  
a specific real time RT-qPCR [20] using 
the QuantiTect Probe RT-PCR Kit 
(Qiagen) on a LightCycler® 480 real time 
PCR system (Roche, Mannheim, 
Germany). A standard curve consisting of 
tenfold dilutions of viral RNA ranging 
from 7 to 1 log10 RNA copies per reaction 
was included in each reaction.  
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PiCV specific quantitative real time PCR 
PiCV viral DNA was extracted using QIAamp DNA Mini Kit (Qiagen) and quantified using a 
specific realtime qPCR [21] as previously described using the  LightCycler® 480 SYBR 
Green I Master kit on a LightCycler® 480 real time PCR system (Roche, Mannheim, 
Germany).  A standard curve consisting of tenfold dilutions of plasmid DNA (a 367 bp 
amplicon, spanning the realtime PCR priming sites in a pcDNA3.1/V5-his-TOPO vector 
kindly provided by J.P. Duchatel) ranging from 7 to 1 log10 plasmid copies per reaction was 
included in each reaction.  
 
 
Figure 1: Neighbor-Joining phylogenetic tree of pigeon paramyxovirus-1 complete genomes 
determined in this study and available complete genome sequences. Bootstrap support values 
> 70 are indicated next to nodes. Bold type: characterized in this study. 
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Results 
DNAse SISPA and next-generation sequencing 
The MID-sorted sequence output varied for the different sequencing libraries (14,733 to 
181,711 raw sequence reads, average read length 211.55 nucleotides, Table 2). This was 
probably due to a poor quantification of the sequencing libraries prior to pooling them for the 
454 titanium emulsion PCR and sequencing workflow (out of our hands due to outsourcing of 
the sequencing workflow including library preparation, emulsion PCR and sequencing).  
Using a reference assembly (PPMV-1 sequence EF025683 as reference, except for isolate 
98/324 where GQ429292 was used), 99-100 % of the genome sequence of six isolates could 
be determined. For three additional isolates, about 98 % of the genome was assembled. The 
two remaining isolates where only < 1,000 PPMV-1 reads were available had respectively 47 
and 92 % of their genomes sequenced, indicating the need of a minimum sequencing effort 
for completion of paramyxovirus genomes by this method. The sequence depth was not 
homogenously distributed over the genome, but the distribution of sequence depth in function 
of the PPMV-1 genome position was reproducible across all PPMV-1 assemblies (data not 
shown).  
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Figure 2: Neighbor-Joining phylogenetic tree of pigeon circovirus ORF2 sequences detected 
in laboratory isolates of PPMV-1 and available reference sequences. Previously described 
clade terminology [22] is depicted next to the clusters. Bootstrap support values > 70 are 
indicated next to nodes. Bold type: characterized in this study. 
Molecular characterization 
Fusion gene cleavage site 
All isolates sequenced in this study have amino acid sequence 112-RRQKRF-117 at their 
fusion gene cleavage site (Table 1), except 98/324 which has amino acid sequence  112-
RRKKRF-117  like the other viruses in its phylogenetic cluster (Figure 1: AV324/6 and 
dove/Italy/2736/00). No sequence variability could be detected at the cleavage site. 
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Sequence variability 
Strain 98/248 was previously determined to have an ICPI of 0.32. Two clones with 
contrasting ICPI values (0.025 vs. 1.3) were previously isolated [12] from this virus and 
sequence differences between these clones were determined at the consensus level [13]. We 
sequenced the parental isolate 98/248 that was used by Fuller et al for cloning.  98/248 had 
average genome coverage of > 850-fold (more than 45,000 reads mapped to PPMV-1 
reference sequence), which allowed a detailed analysis of variability.  Interestingly, all 
previously documented mutations differentiating the consensus genome of clones 0.025 and 
1.3 [13] were present at variable prevalence in the quasispecies population of the parental 
virus isolate (Table 3). 
Table 3: Sequence variability detected in PPMV-1 isolate 98/248 in relation to previously 
detected markers of pathogenicity in a cloning experiment by [12, 13]. The last column 
indicates the consensus nucleotide when comparing all available PPMV-1 genome sequences 
at this position. Degenerate nucleotide R = A+G. Nt: nucleotide. 
Genome position (gene) Minor/major nt 
(%minor) 
Consensus 
sequence 
Strain 
“0.025” 
EF026579 
Strain  “1.3” 
EF026583 
Other 
PPMV-1 
1,771 (NP, synonymous) 43T/92C (31.9 %) C C C C 
3,593 (M) 46A/90G (33.8 %) R G (Asp) A (Asn) G  
5,906 (F) 3C/2555T (0.12 %) T C (Pro) T (Ser) T  
12,518 (L) 108G/373A (22.5 %) A G (Val) A (Met) A  
14,220 (L) 5G/1559A (0.32 %) A G (Asn) A (Ser) A  
Sequence variability in other samples: Reliable sequence variants were detected in 98/248 
(see above) and 5 additional isolates (Table 4). We identified a single nucleotide 
polymorphism in isolate 98/324 in the coding region of the F gene, although we only had 
limited sequence information for this sample because more PiCV was present than PPMV-1. 
Isolate 05/03936/8 showed one non-synonymous and one synonymous minor sequence 
variant in the polymerase gene (L). One sequence variant in the 3’ synonymous region and 
two additional synonymous sequence variants (one in the matrix (M) gene and one in the 
polymerase (L) gene) were observed in 07/04943.  The nucleoprotein gene (NP) of 11/08304 
showed one synonymous sequence variant, while one non-synonymous sequence variant was 
detected at 18% prevalence in its phosphoprotein (P) gene. Isolate 11/09620 showed three 
synonymous sequence variants in its matrix, fusion and polymerase genes. Interestingly, a 
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sequence variant resulting in a stop codon at amino acid position 118 of its matrix gene was 
present at 14.8 % in isolate 11/09620. 
Table 4: Sequence variability detected in other isolates. Bold type: non-synonymous 
mutations. Degenerate nucleotides: R = A+G, Y = C+T. AA: amino acid. Nt: nucleotide 
Isolate Genome position 
cf. EF026583 
Major/minor nt (%minor) Consensus 
sequence 
Gene 
AA position 
98/324 6,305 308A/94T (23.4 %) A F synonymous 
05/03936/8 8,802 8T/4C  (33,3 %) Y L  Leu139Ser 
11,011 35T/5C  (12.5 %) T L Cys875Cys 
07/04943 95 31C/17T (35.4 %) Y 3’ NCR 
4,303 357T/76C (17.6 %) T M Ala336Ala 
14,572 204T/120C (37.0 %) Y L Ser2062Ser 
11/08304 418 197G/91A (31.6 %) G NP Leu99Leu 
2,158 62C/14T (18.04 %) C P Pro89Leu 
11/09620 3,647 98A/17T (14.8 %) A M Lys118STOP 
4,441 155C/41T (20.9 %) C M synonymous 
6,276 36A/25G (41.0 %) R F synonymous 
11,675 15T/9C (37.5 %) Y L Val1096Val 
 
Phylogenetic analysis 
Pigeon paramyxovirus type 1. The Belgian viruses isolated in 1998 clustered in two 
distinctive groups (Figure 1). Three isolates cluster with derived strains 0.025 en 1.30 [12, 
13]. These include the parental strain of the latter clones, 98/248 (deep sequenced in the 
present study), and two additional isolates 98/238 and 98/321 isolated in Belgium during the 
same period. A single isolate (98/324) clusters with dove/Italy/2736/2000 and AV324/96 
(strain from Ireland), and also contained 69 sequence reads of a second virus identical to 
98/321. This isolate represents a co-infection of 2 viruses. 
The Belgian isolates from 2003 to 2007 cluster in a separate clade, related to a PPMV-1 
isolated in Ireland in 2004, with the exception of a single Belgian strain (05/3936/8) from 
2005 that clusters with the most recent Belgian isolates (Figure 1).  
Pigeon circovirus. PiCV sequences were present in four isolates from 1998, 2005, and 2011. 
An 822 bp region of the PiCV ORF2 encoding the capsid protein was chosen for phylogenetic 
analysis to allow inclusion of a large number of PiCV data from public databases. These 
Belgian PiCV sequences encompass the complete diversity of PiCV sequence data previously 
demonstrated to circulate endemically in Europe [22, 23], including Genotypes A (two 
Chapter 3.4  Implementation and case studies 
     
140 
 
viruses), B (one virus) and D (one virus) (Figure 2). As previously documented [23], there 
was no evidence of clustering according to geographical origin. There seemed to be no co-
segregation of PiCV and PPMV-1 sequence data. 
Quantification of PiCV and PPMV1  
Specific realtime (RT-)PCR assays allowed for the quantification of PiCV and PPMV1 in 
allantoic fluid stocks (Table 5). Apart from confirming the presence of high quantities of 
PiCV (> 4 log10 genome copies) in isolates where the virus was detected by metagenomics, 
lower quantities of PiCV DNA were detected in three additional virus stocks. In some 
instances PiCV could still be detected when these viruses were passaged on embryonated 
chicken eggs (Table 5). In one incidence (11/07574) PiCV was maintained after passage, 
while the quantity of PPMV1 dramatically decreased. However, in most cases the PiCV 
quantities detected after passage on embryonated chicken eggs decreased.  
Interestingly, in one isolate (98/324), more PiCV was present than PPMV1, although this 
isolate was readily identified using classical virology tools as PPMV1. This virus stock 
proved unviable upon our attempt to passage it in eggs. 
 
Table 5: Quantification of PiCV and PPMV1 in viral stocks by real time (RT-) PCR. na: 
material was not available for analysis. Isolates indicated in bold type: PiCV sequences 
detected in original allantoic fluid by SISPA-NGS. “<det” : below detection limit.  
Isolate Original allantoic fluid Allantoic fluid first passage (1P) 
 
PPMV-1 log10 
genome copies/ml 
PiCV log10 genome 
copies/ml 
PPMV-1 log10 
genome copies/ml 
PiCV log10 genome 
copies/ml 
98/238 na na 7.65 2.83 
98/248 na na 7.23 <det 
98/321 na na 7.05 1.16 
98/324 2.33 5.34 na na 
03/05843 5.98 3.07 7.93 <det 
05/01824 7.65 4.09 7.20 2.60 
05/03936/8 5.93 <det 7.50 <det 
07/04943 7.76 <det 7.79 1.48 
11/07574 5.53 4.53 2.60 5.00 
11/08304 7.31 4.75 7.79 3.36 
11/09620 8.06 <det na na 
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Discussion 
In an effort to characterize historical and recent PPMV-1 isolates by random access next-
generation sequencing as previously described [14], we identified pigeon circovirus 
contamination in four laboratory isolates diagnosed with virus-specific diagnostic tools as 
PPMV-1. This is somewhat surprising as there have been no reports describing the isolation 
or propagation of PiCV in culture cells or allantoic cavities [21]. Typically these viruses were 
isolated from suspected clinical samples (identified as PMV-1 positive by real time RT-PCR 
for the recent samples) by inoculation in the allantoic cavity of embryonated specific 
pathogen free chicken eggs. Allantoic fluids are then harvested and checked for presence of 
hemagglutinating activity, and an identification of hemagglutinating agent was done the using 
hemagglutination inhibition tests using anti-NDV or anti-AIV reference sera. Although it is 
not sure that the biological characteristics (notably virulence as measured by ICPI) of PPMV1 
stocks are affected by the mixed infection, their presence in PPMV1 positive pigeon material 
needs further consideration.  This must be related, at least in part, to the limitation of current 
diagnostics to detect PiCV and to the pooling of suspected organs. Although the exact role of 
PiCV in pigeon disease and its potential interference with diagnostic tests is the subject of an 
ongoing follow-up study (in preparation), our data show the importance of in-depth 
characterization of viral isolates for studies on virus pathogenicity and/or evolution. In 
particular, the potential immunosuppressive role of PiCV that has previously been suggested 
[24] may interfere with in vivo paramyxovirus infections. 
Nearly complete genome sequences could be obtained for all but one PPMV1 and for the four 
pigeon circoviruses. Although our SISPA-NGS workflow was focused on the enrichment of 
RNA virus sequence data (use of an RNA extraction kit), we did not treat the enriched virions 
with an RNase. The resulting DNA virus reads are thus the result of either (1) DNA virus 
transcribed RNA co-purified with the virions (no RNase treatment of virions) and/or (2) viral 
DNA co-purified during the viral RNA extraction procedure (as no additional DNase 
treatment was performed during the RNA extraction procedure). The fact that we obtained 
near complete PiCV genomes, including non transcribed sequences (e.g. the origin of 
replication and the Rep promotor), suggests that viral DNA co-purification is, at least in part, 
contributing to the detection of viral DNA sequences.  
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Applying PPMV-1 and PiCV specific quantitative real time RT-PCR to DNA and RNA 
extracted from these virus isolates, we confirmed the presence of PiCV in PPMV-1 stocks and 
showed that PiCV seemed to be present in high quantities in several PPMV-1 stocks.  
PiCV has a worldwide distribution with high prevalence in young pigeons [21, 23]. A high 
prevalence in young feral and domestic pigeons has been described [25, 26], although it can 
also be present in older pigeons [21]. Its worldwide distribution and lack of geographical 
clustering is most likely related to the extensive worldwide trade in ornamental and racing 
pigeons. PiCV is involved in the “young pigeon disease syndrome”, where morbidity and 
mortality are reported in pigeons aged 4-12 weeks [24]. However, experimental infection with 
PiCV could not reproduce the disease, indicating a multifactorial cause [27]. A potential 
immunosuppressive role has been suggested [24], facilitating other pathogenic infections. 
The selected Belgian isolates for deep sequencing included strain 98/248, the parent strain 
with an intermediate pathogenicity index of 0.32 that was used by Fuller et al [12] for the 
isolation by cloning of variants with contrasting pathogenicity indices (1.3 and 0.025). These 
clones with contrasting pathogenicity phenotype were later completely sequenced [13]. Our 
deep sequencing data (average coverage > 850 x) allowed a quasispecies analysis of the viral 
population in the parental strain used for these cloning experiments. Interestingly, all 
sequence differences previously identified between these variants were confirmed as minority 
mutations in the parental strain 98/248.  The intermediate low pathogenic phenotype (ICPI 
0.32) of the parent strain was thus most likely related to the presence of multiple genetic 
variants, some of which contained markers for increased pathogenicity in poultry that were 
subsequently selected from the quasispecies virus stock population in the cloning experiments 
by Fuller et al.  In addition, a mutation in the synonymous region of the NP gene was 
identified in the parent strain that did not appear in the selected variant viruses. The deep 
sequencing approach allows for a quantification of these quasispecies in the original isolate. 
While some genetic variants seem to be present in about one third of the viral population, 
others seem to be present at a very low frequency in the seed viral stock. 
Another study documented molecular changes of PPMV-1 isolate Av324 after passaging in 
chickens [28]. None of the 3 mutations that were associated with enhanced replication 
efficiency in that study (at positions 2,001, 13,077 and 13,467) were found in any of the 
viruses characterized in our study, although one virus was closely related to Av324.  
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The sequence depth in several of our strains allowed the documentation of additional 
polymorphic sites.  
These data show the power of deep sequencing technologies in characterizing the 
quasispecies composition of RNA virus isolates. We could confirm that the intermediate 
pathogenicity phenotype that Fuller and colleagues [12] attributed to mixed viral populations 
is indeed at the genetic level due to a complex mixture of genetic variants. 
For some isolates, although sufficient sequence information (average coverage > 300x) was 
available (e.g. 05/01824 and 11/07874), no sequence variation present in at least 10 % of the 
reads was detected.  As we have no formal or experimental data describing the error 
introduction of the random amplification and 454 sequencing processes used in this study, we 
did not want to hypothesize on the importance of these minor sequence variants (< 10%).  
The sequence independent approach used here allowed the identification of contaminating 
viruses in biological material, including unexpected circoviruses and co-infection (or 
contamination) with multiple avian paramyxoviruses in a single laboratory stock. These 
findings show the power of next-generation on random amplified viral nucleic acids for the 
quality control of virus reference isolates and other biological materials. As the methodology 
provides a sequence independent probing of the viral nucleic acid content of a sample, 
minority variants and adventitious viruses present in the stock can be identified while 
identifying high quality genomic data of the reference isolates. As such, NGS technology may 
provide a powerful quality control tool to reference laboratories and producers of biological 
materials such as vaccines and cell lines. 
Caution should be taken not to overestimate the sensitivity of this methodology for the 
identification of contaminating viruses. Our preliminary data (not shown) indicated that at 
least 5 log10 virions need to be present in the sample to allow identification in a background of 
host and contaminating nucleic acids. This was confirmed in this study, where about 4 log10 
PiCV copies were sufficient to allow detection by SISPA-NGS. Lower copy numbers did not 
yield PiCV sequence data. Samples containing high virus titers (as determined by realtime 
quantitative (RT-) PCR) yielded high quality genome sequences. In one instance (98/324) the 
isolate actually contained more PiCV than PPMV-1, but a relatively low quantity (2.3 log10) 
of PPMV-1 could still reliably be identified by SISPA-NGS. Follow-up (multiplex) PCRs 
should be designed to confirm and accommodate the limited sensitivity of metagenomic 
findings.  
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As future technology developments promise to increase the accessibility of NGS to virology 
labs and to decrease its costs, its application as a quality control and diagnostic technique with 
high information content for biological reagents such as viral stocks will be worth considering 
as a complementary methodology to virus-specific test design. 
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CHAPTER 3.5 
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In the 3 previous Chapters virus isolates were used to evaluate the protocol, containing high 
virion concentrations and low background nucleic acid contaminants. The case study in this 
Chapter aimed to test the sensitivity of the workflow on real clinical samples. Brain tissue 
samples of sheep naturally infected with a recently emerging orthobunyavirus were selected. 
The expression “SISPA” refers to rPCR SISPA amplification method as defined in Chapter 1, 
and “DNase” emphasizes that pretreatment steps were performed, including a DNase 
treatment for the removal of unprotected nucleic acids. 
Orthobunyavirus is a genus of the bunyaviridae family with a segmented negative-stranded 
RNA genome (3 segments). The genus is most diverse in Africa, Australia and Oceania, but 
occurs almost worldwide. Most orthobunyavirus species are transmitted by mosquitoes or 
ticks and cause diseases of cattle; on the other hand, the California encephalitis virus and the 
La Crosse virus, are North American species that cause encephalitis in humans. 
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Schmallenberg virus (SBV), a novel orthobunyavirus, was first isolated in 2011 in Germany. 
SBV preferentially infects the central nervous system of cattle and sheep and causes fever, 
diarrhea, a drop in milk yields, congenital malformations and stillbirths. 
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Abstract 
In 2011, a novel Orthobunyavirus was identified in cattle and sheep in Germany and the 
Netherlands. This virus was named Schmallenberg virus (SBV). Later, presence of the virus 
was confirmed using real time RT-PCR in cases of congenital malformations of bovines and 
ovines in several European countries, including Belgium. In the absence of specific 
sequencing protocols for this novel virus we confirmed its presence in RT-qPCR positive field 
samples using DNase SISPA next generation sequencing (NGS), a virus discovery method 
based on random amplification and next generation sequencing. An in vitro transcribed RNA 
was used to construct a standard curve allowing the quantification of viral RNA in the field 
samples. Two field samples of aborted lambs containing 7.66 and 7.64 log10 RNA copies per 
mL total RNA extract allowed unambiguous identification of SBV. One sample yielded 192 
SBV reads covering about 81 % of the L segment, 56 % of the M segment and 13 % of the S 
segment. The other sample resulted in 8 reads distributed over the L and M segments. Three 
weak positive field samples (one from an aborted calf, two from aborted lambs) containing 
virus quantities equivalent to 4.27-4.89 log10 RNA copies per mL did not allow identification 
using DNase SISPA-NGS. This partial sequence information was compared to the whole 
genome sequence of SBV isolated from bovines in Germany, identifying several sequence 
differences. The applied viral discovery method allowed the confirmation of SBV in RT-
qPCR positive brain samples. However, the failure to confirm SBV in weak PCR-positive 
samples illustrates the importance of the selection of properly targeted and fresh field samples 
in any virus discovery method. The partial sequences derived from the field samples showed 
several differences compared to the sequences from bovines in Germany, indicating sequence 
divergence within the epidemic. 
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Introduction 
During the summer and autumn of 2011, a novel disease with symptoms including fever, 
decreased milk production and diarrhea, was identified in dairy cattle in Germany and The 
Netherlands [1, 2]. Using a metagenomic analysis on next generation sequence data produced 
from the blood of symptomatic animals, a novel Orthobunyavirus was shown to be associated 
with the disease [1]. The virus was preliminary named Schmallenberg virus (SBV) according 
to the geographical location of the index case. A specific real time RT-PCR test was 
developed, confirming the presence of the virus in diseased bovines. Animal experiments with 
the isolated virus further supported a causal relationship between the virus and the disease [1]. 
In addition, the virus proved to be associated with an outbreak of congenital malformations 
and abortions in both ovine and bovine [1, 3, 4]. The dissemination of real time RT-PCR 
protocols to laboratories throughout Europe allowed the detection of Schmallenberg virus in 
six additional countries, including Belgium, France, Luxembourg, United Kingdom, Italy, and 
Spain [5] and provided evidence for the involvement of Culicoides sp. midges as possible 
vectors [6].  
In the absence of targeted sequencing protocols for this novel virus, we applied a virus 
discovery strategy based on random amplification of purified nucleic acids in combination 
with next generation sequencing on SBV real time RT-PCR positive tissue samples to confirm 
the presence of SBV and obtain preliminary sequence data on SBV from Belgium.  We 
previously validated this DNase SISPA (Sequence Independent Single Primer Amplification, 
[7]) approach on other RNA viruses [8, 9]. It consists of a viral nucleic acid enrichment step 
(size selective filtration in combination with a nuclease treatment to remove nucleic acids that 
are not encapsidated in virions) followed by a random cDNA synthesis and amplification step. 
The random amplicons are subsequently exploited by next generation sequencing [10]. The 
combination with quantitative real time RT-PCR results from the field tissue samples allowed 
a first estimate of the sensitivity of this approach using field samples infected with an 
emerging disease.   
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Materials and Methods 
Samples  
Diagnostic field samples from suspected cases of SBV related congenital malformations in 
lambs and calves were selected based on their geographical location (Table 1) and on the Cp 
values of the RT-qPCR detecting the L-segment of the virus that was used for diagnosis [1]. 
This study was conducted under the authorization and supervision of the Bioethics Committee 
at the Veterinary and Agrochemical Research Center (VAR), following national and 
European regulations. 
Viral RNA quantification 
 Briefly, approximately 0.5 cm3 of brain tissue was added to 1ml PBS and homogenized 
(2min, 25Hz) in a TissueLyser (Qiagen, Venlo, The Netherlands). The RNA was extracted 
using the RNeasy minikit (Qiagen) following manufacturer instructions and eluted in 50µl. 
2µl of this RNA mixture was further analyzed by a one-step PCR using the LightCycler 480 
RNA Master Hydrolysis Probes kit (Roche Diagnostics, Vilvoorde, Belgium) on  a 
LightCycler 480 Real-time PCR system following manufacturer instructions. Primers and 
probe sequences for the SBV L segment detection were kindly provided by Dr. B. Hoffmann 
(FLI, Germany, available on request) and used at a final concentration of 1 and 0.1875 µM 
respectively. Two highly positive brain tissue samples (Cp < 21) from aborted lambs were 
selected for confirmation by DNase SISPA-NGS. In addition, two weak positive brain tissue 
samples from lambs and one weak positive sample form a calf were selected (Cp > 28). The 
viral RNA load in RNA directly extracted from these samples was quantified in the above 
described real time RT-PCR using a standard curve consisting of in vitro transcribed L 
segment RNA spanning the diagnostic RT-qPCR, which was run in five replicates. The in 
vitro transcribed RNA was independently quantified using three different approaches: 
NanoDrop Spectrophotometer (Nanodrop Technologies, Wilmington DE, USA), Qubit® 
RNA assay kit on Qubit® fluorometer (Invitrogen-Life Technologies, Gent, Belgium), and 
RNA 6000 Pico chip on the Agilent 2100 Bioanalyser (Agilent Technologies, Diegem, 
Belgium). 
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DNase SISPA and 454 sequencing 
The maximum available quantity of the limited tissue samples (< 1.5 g; Table 1) was 
homogenized in about 1,500 µL PBS per g of tissue using gentle homogenization in a 
TissueLyser (Qiagen). Sample pretreatment and SISPA was largely performed as previously 
described [8, 9]. Briefly, after a centrifugation and filtration step using 0.22 µm filters, the 
eluate was subjected to DNase I treatment (100 U/200µl sample). The resulting virion-
enriched samples were subjected to a viral RNA extraction using the QIAamp Viral RNA 
Mini Kit (Qiagen). Forty units of Protector RNase inhibitor (Roche) were added to the eluted 
RNA, and RNA quality was checked using a Bioanalyzer 2100 (Agilent Technologies). The 
random first- and second strand cDNA synthesis was performed with the primer FR26RV-N 
(5’GCC GGA GCT CTG CAG ATA TCN NNN NN 3’) and primer FR20RV (5’-GCC GGA 
GCT CTG CAG ATA TC-3’) was used in subsequent PCR to amplify the resulting cDNA. 
After visualisation of the random amplified DNA fragments on a 1 % agarose gel, the 
fragments between 200 and 1,000 bp were excised, purified and quantified using a Nanodrop 
spectrophotometer (Nanodrop Technologies). Five micrograms of each size selected (200-
1,000 bp) and purified random amplified sample were sequenced on a GS FLX+ (Roche, 
Mannheim, Germany) by the Genomics Core of the University Hospital (University of 
Leuven, Belgium) using multiplex identifier (MID) identification during library preparation  
and their standard procedures using GS FLX Titanium series reagents (Roche, Mannheim, 
Germany). The DNA fragmentation step by nebulization was skipped and the intention was to 
obtain 30,000-40,000 reads per library. 
Metagenomic analysis 
As an additional control to exclude reads originating from potential DNA contamination 
during the library preparation steps, only reads containing the SISPA primer sequence were 
included in the assembly.  Subsequently, the SISPA primer sequences plus additional six 
bases were trimmed off the reads. By using a combination of BLAST [11] and sequence 
mapping with the 454 reference mapper application (version 2.6; Roche), contigs (i.e. sets of 
overlapping sequence reads) and reads were classified into different taxa.      
Reference assembly 
To map the obtained raw sequence data to the genome of Schmallenberg virus,  the complete 
coding sequence of SBV isolate BH80/11-4 (accession codes HE649912-HE649914) was 
used as reference genome in the reference assemblies of our different field samples using 
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SeqMan NGen® version 3 (DNASTAR, Madison, WI, USA). The reads were first trimmed to 
remove primer sequences (including the primer-encoded random N positions) as well as low 
quality ends. Standard assembling and filtering parameters were used, except for a reduced 
minimum match percentage. The partial sequence information was made accessible through 
GenBank accession numbers JQ861686-JQ861692, except for fragments that were less than 
200 bp in length due to the minimum fragment length requirements dictated by GenBank.  
Variability analysis 
The obtained partial sequence information of SBV was compared to the sequence of isolate 
BH80/11-4 (accession codes HE649912-HE649914). Single nucleotide polymorphisms 
(SNP’s) were identified using SeqMan Pro version 9 (DNASTAR, Madison, WI, USA) and 
are listed in Table 3. Only sequence differences where we had at least 2 sequence reads were 
included. Observed sequence variants at a position with more than 2 reads and/or with reads 
in both cDNA and complementary sense and/or with reads having different start positions 
were assigned a high support (Table 3).  
Results and Discussion 
To test the feasibility of virus identification using DNase SISPA-next generation sequencing 
(NGS) and to get a first estimate of its sensitivity on field samples, we selected both strong 
and weak positive SBV infected field samples. For viral RNA quantification, in vitro 
transcribed RNA was used as a standard curve in the previously described L gene real time 
RT-PCR. The curve showed a linear range at least from 2.75 to 7.75 log10 RNA copies per 
µL, and a sensitivity of less than 2.75 log10 RNA copies per µL (Figure 1).  
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Figure 1: Quantification of Schmallenberg virus L segment RNA using quantitative real time 
RT-PCR. The viral RNA load in field  samples was quantified with real time RT-PCR using a 
standard curve consisting of in vitro transcribed L segment RNA spanning the diagnostic RT-
qPCR, which was run in five replicates (blue crosses). The linear trendline and the associated 
standard curve equation are displayed. The samples are indicated by red squares. 
Two field samples of aborted lambs with Cp values of 20.59 and 20.65 corresponding to 7.66 
and 7.64 log10 RNA copies per µL (Table 1) allowed unambiguous identification of 
Schmallenberg virus. One sample (BE/12-2478) yielded 2 S segment sequences (covering 
about 13 % of the S segment), 81 M segment sequences (covering about 56 % of the M 
segment) and 109 L segment sequences (covering about 81 % of the L segment) (Table 1, 
Figure 2). The other strong positive sample (BE/12-2068) resulted in a total of 8 SBV specific 
sequence reads distributed over the L and M genomic segments. This difference in sequence 
coverage for two samples with a comparable SBV RNA load is most likely due to the 
difference in the amount of raw sequence data (Table 1). While the sequencing of BE/12-2478 
yielded about 95,000 reads, BE/12-2068 only resulted in circa 25,000 reads probably due to 
DNA library quantification issues at the sequencing facility. Moreover, more tissue sample 
was available for DNase SISPA protocol from sample BE/12-2478 (Table 1), although the 
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ratio of viral reads to total raw reads was superior (0.01) in sample BE/12-2068 compared to 
sample BE/12-2478 (0.002 ; Table 2). 
Table 1: SBV virus quantification and confirmation by DNase SISPA-NGS in selected field 
samples from Belgium. 
Sample (location, date) Description 
SBV log10 
RNA copies/µl  
(Cp value) 
Total 
no. 
reads 
No. SBV reads per segment 
(% of RNA segment covered) 
S M L 
BE/12-2068 (Ghoy, 
13.01.2012) 
Brain tissue, 180 mg, 
aborted lamb 
7.664 (20.59) 25,701 - 1 (8.59) 6 (8.69) 
BE/12-2478  
(Deinze, 18.01.2012) 
Brain tissue, 1000 mg, 
aborted lamb 
7.642 (20.65) 94,722 2(13.68) 81(59.1) 109(81.9) 
BE/12-2649 
(Reningelst, 22.01.2012) 
Brain tissue, 1130 mg, 
aborted lamb 
4.331 (29.83) 50,308 - - - 
BE/12-1235  
(Sivry, 06.01.2012) 
Brain tissue homogenate, 
1.8 ml, aborted calf 
4.630 (29.00) 27,979 - - - 
BE/12-3610  
(Izenberge, 28.01.2012) 
Brain tissue, 620 mg, 
aborted lamb 
4.270 (30.00) 98,648 - - - 
Isolate BE/12-2068 (Ghoy, 
13.01.2012) 
Tissue culture supernatant. 
5 log10 TCID50/ml  
8.418 (18.50) nd nd nd nd 
 
Figure 2: Mapping of Schmallenberg virus specific reads of sample BE/12-2479 against the 
German isolate BH80/11-4. Positional sequence coverage (number of sequence reads for 
given nucleotide position) of the M and L segments of sample BE/12-2478, based on 
reference assembly to HE649912 and HE649913. 
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Table 2: Output of the metagenomic analysis on raw sequence data from the sequencing 
libraries from SBV-positive samples. 
Sample 
Total 
no. 
reads 
Reads with 
primer tag 
identification 
No. reads classified into superkingdom 
No. 
unclassified 
reads Eukaryota Archaea Bacteria Viruses  
BE/12-2068 25,701 23,370 2,270 5 15,543 284 (Phycodnaviridae, 
Myoviridae, 
Siphoviridae, 
Podoviridae, 
Bunyaviridae, 
Mimiviridae) 
3,977 
BE/12-2478 94,722 86,178 36,690 11 36,106 167 (Myoviridae, 
Siphoviridae, 
Podoviridae, 
Bunyaviridae) 
5,543 
BE/12-2649 50,308 46,181 6,730 - 36,044 8 (Siphoviridae, 
Podoviridae, 
Mimiviridae) 
2,468 
BE/12-1235 27,979 26,214 13,216 5 17,89 1 (Siphoviridae) 9,812 
BE/12-3610 98,648 91,458 12,403 13 69,057 15 (Myoviridae, 
Podoviridae) 
5,053 
Three weak positive field samples (one from an aborted calf, two from aborted lambs) 
containing virus quantities equivalent to 4.27-4.63 log10 RNA copies per µL did not allow 
identification using DNase SISPA-NGS (Table 1). This is consistent  with an approximate 
sensitivity of 104-106 virions per ml estimated in previous studies using in vitro virus dilutions 
[12] or tissue biopsy samples [13]. However, it should be noted that the exact ratio between 
viral RNA quantities and intact virion quantities in field samples (the intact virions being 
detected in this method) remains to be determined. Our preliminary data indicate that RNA 
extracted from an SBV isolate containing 105 TCID50/ml may contain up to 8.46 log10 RNA 
copies per µL (Table 1). This indicates that precaution should be taken in interpreting RNA 
quantities in terms of DNase SISPA-NGS sensitivity, which is determined by the amount of 
viral nucleic acids that remain protected in intact virions during nuclease treatment. 
Moreover, a comparison of approximate sensitivity with other viral discovery methods is 
almost impossible, as the utilized sequencing effort varies from a few 100 Sanger sequencing 
reads [12, 14] to about 30 million Illumina GAII reads [13]; and different sample types 
(targeted tissue selection, freshness of the sample) may result in different levels of host and 
contaminating nucleic acids. Given the limited approximate sensitivity of DNase SISPA-
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NGS, as any virus discovery method, careful selection of properly targeted and fresh field 
samples is necessary. 
As expected in any metagenomic approach, a considerable part of the sequence reads 
represented diverse bacterial species and host nucleic acids (Table 2).   It should be noted that 
the field samples were stored for a considerable time before the pretreatment and RNA 
extraction, during which opportunistic bacteria probably grew in the samples. Although we 
use a 0.22 µm filter to remove remaining cell fragments and bacteria, nucleic acids from 
disrupted cells can pass through the filter. 
Other viral reads could be mainly identified as bacteriophages belonging to the families 
Myoviridae, Siphoviridae and Podoviridae (Table 2). Three reads showed partial similarity to 
a virus belonging to the Phycodnaviridae and two reads showed some similarity to viruses of 
the Mimiviridae family. None of these viruses have relatives known to infect animals. These 
sequences most likely represent contamination of the tissue samples during storage until 
analysis.  
Compared to the metagenomic approach used by Hoffmann and colleagues [1] that initially 
identified this novel Orthobunyavirus by shotgun sequencing of total RNA extracted from 
clinical samples, our virus discovery protocol attempts an enrichment in viral nucleic acids by 
selective filtration and nuclease treatment. A direct comparison between both data sets is 
impossible as we treated limited amounts of tissue samples representing a different host 
species. Moreover, the sequencing effort per library was not identical. Both studies indicate 
the need of high sequence throughput and proper sample selection as critical factors for 
successful virus discovery using metagenomics.  
The partial SBV sequence info we obtained was compared to the whole genome sequence that 
was determined from the virus originally isolated from diseased bovines in Germany.  Several 
coding and noncoding mutations could be observed (Table 3). The partial data from the two 
Belgian ovine field samples showed together 16 nucleotide differences (of which 9 well-
supported by the sequence data, Table 3) corresponding to 9 amino acid differences (of which 
5 well-supported).  Although this can be expected for an RNA virus that has now shown a 
distribution throughout a large part of Western Europe, this is to our knowledge the first 
documentation of genetic diversity within the Schmallenberg virus outbreak. Based upon the 
8134 nucleotides in common between our partial sequence (BE/12/2478) and the genome of 
the virus isolated from diseased bovine in Germany (accession codes HE649912-HE649914), 
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a mutation frequency of 1.7 10-3 mutations per site was observed. The time frame between the 
two samples was about three months and the geographical distance between the sampling sites 
roughly 325 km. Although only based on a three month period, the observed mutation 
frequency is within the documented range of Bunyavirus variability (10-2 to 10-4  
mutations/site/year documented for Hantavirus ; [15]) and within the documented range of  
RNA virus variability  (10-3  to 10-4  mutations/site/year ; [16, 17]).  It should be noted that, 
while the samples in Germany were taken from acutely infected bovines, the ovine samples 
from Belgium present aborted lambs, making an estimation of the infection time of the 
maternal animal impossible. Future targeted molecular epidemiological studies including 
samples from the complete geographic range of the virus may shed light on the origin and 
time of introduction of this novel virus in Europe. 
Our data show that DNase SISPA-NGS viral discovery technology can be used on limited 
amounts of field tissue samples to identify emerging diseases. However, the sensitivity of the 
method seems to limit its applicability to samples containing about 104 to 106 virions per ml. 
Consequently, when applying this methodology to a cluster of cases of an undiagnosed 
disease, it is important to select properly targeted and fresh samples as well as to test multiple 
diseased animals to allow correct identification of an associated virus.  
  
Chapter 3.5  Implementation and case studies 
     
159 
 
Table 3: Differences observed in Belgian SBV sequences in comparison with the German 
genome sequence of isolate BH80/11-4. 
Strain, genome segment 
Covered 
regions* 
Number 
of reads 
Differences observed in Belgian sequences 
compared to the genome of the German isolate 
BH80/11-4 
Nucleic acid Amino acid Depth Support° 
BE/12-2068, M segment 1,095-1,456 1     
BE/12-2068, L segment 1,271-1,426 2     
 3,313-3,744 4 G 3,490 C E 1,159 Q 4 Low 
   G 3,637 A A 1,208 T 4 Low 
BE/12-2478, S segment 428-467 1     
 669-733 1     
BE/12-2478, M segment 823-1,354 12 G 836 A S 275 S 3 Low 
   A 983 G T 324 T 5 High 
   C 998 T F 329 F 4 High 
   A 1,041 G K 344 E 4 High 
   T 1,201 C F 397 S 8 High 
 1,920-2,211 4 G 1,930 A R 640 Q 4 Low 
   A 1,969 T Q 653 L 4 Low 
 2,248-2,390 1     
 2,412-3,935 64 A 3,558 G N 1,183 D 29 High 
BE/12-2478, L segment 383-1,844 44 G 1,017 A E 334 E 9 High 
 1,873-2,682 6     
 2,966-3,744 19 C 3,097 T H 1,028 Y 2 High 
 3,770-4,209 4 C 3,937 T H 1,308 Y 3 High 
 4,502-4,754 1     
 4,835-5,888 21 T 5,736 A P 1,907 P 6 High 
 5,950-6,690 13 C 6,045 T P 2,010 P 2 Low 
   T 6,156 C F 2,047 F 5 Low 
* the indicated position is relative to the position of the used reference sequence: Schmallenberg virus, isolate 
BH80/11-4 (Genbank: HE649912, HE649913, HE649914). 
° assessment based on low/high depth, single/double orientation of the reads, equal/different starting and end 
position of the reads, and quality of reads. 
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CHAPTER 3.6 
False-positive results in metagenomic virus 
discovery, a strong case for follow-up 
diagnosis 
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After gaining experience with the viral discovery protocol, the time had come to test the 
workflow on a case study where presence and type of virus were unknown. In an attempt to 
increase the virus discovery sensitivity, the protocol was slightly changed when compared to 
that used in previous Chapters. To be sure not to exclude identification of large viruses, 0.45 
µm pore size filters were used instead of 0.22 µm. In the nuclease treatment step, RNases 
were added in addition to DNase in order to remove non-particle protected RNA from the 
sample. The composition of the nuclease mixture was optimized by comparing different 
combinations of commercial DNases and RNases on a model DNA/RNA extract, thereby 
measuring the nucleic acid concentrations before and after treatment (data not shown). The 
workflow was divided into a RNA and DNA virus discovery workflow. The RNA and DNA 
extracts were treated with DNase and RNase enzymes respectively to remove remaining DNA 
or RNA.  
During the preceding studies, we often noticed that a large part of contaminating background 
nucleic acids consisted of host and bacterial ribosomal RNA (rRNA). Preliminary testing with 
a rRNA depletion kit indicated a good removal of rRNA, thereby enhancing virus discovery 
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sensitivity (data not shown). This led to addition of an rRNA removal step in the RNA virus 
discovery workflow.   
A different reverse transcriptase enzyme and a different random SISPA primer concentration 
were used. Complementary DNA was also purified in order to remove remaining random 
SISPA primers to be sure they could not interfere with the subsequent PCR reaction.   
Finally, bioinformatics data analysis was optimized to allow quick and reliable classification 
of contigs and singletons. BLAST databases were installed locally on a powerful computer 
server, and a dedicated software tool was used to process and visualize BLAST output files.  
As a case study, a cluster of diseased dairy cattle with undiagnosed etiology was selected. We 
could not associate any viral sequences with the disease. However, our careful follow-up 
approach provided clear warnings for the potential of false positive results in metagenomics. 
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Abstract 
A viral metagenomic approach using virion enrichment, random amplification and next-
generation sequencing was used to investigate an undiagnosed cluster of dairy cattle 
presenting with high persistent fever, unresponsive to anti-microbial and anti-inflammatory 
treatment, diarrhoea and redness of nose and teat. Serum and whole blood samples were taken 
in the predicted hyperviraemic state of an animal that a few days later presented with these 
clinical signs. Bioinformatics analysis of the resulting data from the DNA virus identification 
workflow (a total of 32,757 sequences with average read length 335 bases) initially 
demonstrated the presence of parvovirus-like sequences in the tested blood sample. Thorough 
follow-up using specific real-time RT-PCR assays targeting the detected sequence fragments 
confirmed the presence of these sequences in the original sample as well as in a sample of an 
additional animal, but a contamination with an identical genetic signature in negative 
extraction controls was demonstrated. Further investigation using an alternative extraction 
method identified a contamination of the originally used Qiagen extraction columns with 
parvovirus-like nucleic acids or virus particles. Although we did not find any relevant virus 
that could be associated with the disease, these observations clearly illustrate the importance 
of using a proper control strategy and follow-up diagnostic tests in any viral metagenomic 
study. 
Keywords: Contamination, next generation sequencing, parvovirus, viral metagenomics 
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Introduction 
Next Generation Sequencing technologies’ (NGS) ability to produce a spectacular number of 
sequence reads from a nucleic acid sample resulted in an exponential increase of characterized 
pathogens over recent years (reviewed in  [1-3]). In veterinary virology, virion enrichment 
followed by random amplification [4, 5] and NGS has resulted in the characterization of an 
increasing number of viral nucleic acid sequences from outbreaks of unknown etiology [6, 7], 
well-known disorders presumed to be of multifactorial etiology [8-10] and reservoir species 
and vectors [11-15]. 
In Belgium, since 2009, over 50 dairy herds had been confronted with a sudden decrease in 
milk drop, with or without other clinical signs. Despite, that in several herds, pathogens such 
as bovine viral diarrhea virus (BVDV), Anaplasma phagocytophilum, Leptospira hardjo or 
Schmallenbergvirus had been identified (besides to nutritional issues), several outbreaks 
remained without etiology. In July 2013, again 4 outbreaks of milk drop were reported in 
Flanders, and this time typically accompanied by high fever (40-41°C), unresponsive to 
antimicrobial or anti-inflammatory treatment, characteristic nose lesions (“red nose”), and 
vasculitis-suggesting teat injuries (redness, necrosis, edema). Given the negative test results 
for known pathogens with a mucosal distribution, a metagenomic virus discovery workflow 
was used in an attempt to identify whether a viral pathogen was associated with these 
symptoms. 
Materials and Methods 
Herd anamnesis, clinical signs and diagnostics 
In July 2013, in an 81 head mixed herd (Holstein Friesian and Belgian Blue beef cattle), in 
one week five dairy cows and one dairy heifer developed anorexia and milk drop. The 
animals were between a few days up to one month in lactation. Next to milk drop, the animals 
showed a marked reddening of the nasal (“red nose”) and vaginal mucosae, teat and in some 
cases the interdigital space. All animals demonstrated high fever (40-41°C), which was 
unresponsive to treatment with non-steroidal anti-inflammatory drugs or corticosteroids. 
Fever could last up to 14 days. Four of the five initially ill animals also demonstrated 
moderate to severe diarrhea, which was bloody in one animal. Two of them showed marked 
tachypnea. In contrast, Belgian Blue animals and young stock were unaffected. 
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Two animals became recumbent and died after two weeks. The other animals needed more 
than six weeks for full recovery. At necropsy (one animal) the redness of nose, teat and 
vagina was no longer visible, suggesting a vascular (hyperemia) origin. Histologically, there 
was only a mild perivascular infiltration of lymphocytes and plasma cells. Other lesions were 
a pyometra (Escherichia coli and Trueperella pyogenes), focal ulcerative glossitis, reactive 
splenitis, udder abscess (Escherichia coli) and a multifocal ulcerative abomasitis, with 
histologically intralesional mycosis. It was concluded that the animal died from a secondary 
septicemia. No signs of vasculitis were seen. Case animals tested negative for BVDV, 
malignant catarrhal fever, bluetongue, epizootic haemorrhagic disease virus, 
Schmallenbergvirus by PCR and A. phagocytophilum. A gE-specific antibody ELISA for 
bovine herpesvirus 1 was negative as well.  
Sampling and pretreatment 
After these negative results, the herd was daily monitored for the appearance of new cases. 
Rectal temperature was taken daily. Whole blood (with EDTA as anticoagulant)  and serum 
were taken from a cow on the 2nd day of high fever (>40 °C), aiming to sample a 
hyperviremic state should a viremic agent be involved, and immediately frozen at -20°C. A 
severe neutropenia (0.27 x 109 cells/ml (reference: 0.68-6.94)), with left shift was present at 
that time. Three days later a red discoloration of nose and teat appeared which was maximal at 
day 8. In addition, blood and serum samples were stored from a diseased animal from the first 
clinical series, which were sampled on the 10th day of high fever. Sample pretreatment and 
sequence independent single primer amplification (SISPA) was performed on the blood 
sample of the first animal similar as described before [16], with multiple modifications to 
increase viral identification sensitivity. Briefly, after a centrifugation step (45 min at 4,000×g 
at 4°C) the supernatants was filtered through 0.45 µm filters (Ultrafree-MC HV sterile, 
Millipore) at 4,000 ×g. Then the workflow was split for RNA virus and DNA virus 
identification. Before nucleic acid extraction, non-particle protected RNA and DNA were 
digested for 1 hour at 37°C with a mixture of filtrate (100 µl in RNA virus workflow; 134µl 
in DNA virus workflow), TURBO DNase (2 U/µl, Ambion; 50 U in RNA virus workflow; 68 
U in DNA virus workflow), 1× TURBO DNase Buffer and RiboShredder RNase Blend (1 
U/µl, Epicentre; 10 U in RNA virus workflow; 13 U in DNA virus workflow).  
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RNA virus workflow 
RNA extraction was performed with the QIAamp Viral RNA Mini Kit (Qiagen, Venlo, the 
Netherlands) according the manufacturer’s instructions. Low binding tubes were used for 
storing the extract or performing further treatments. Forty units of Protector RNase inhibitor 
(Roche) were added to the eluted RNA, and residual DNA was subsequently digested with 2.8 
U of TURBO DNase at 37 °C (15 min). Before heat inactivation at 75 °C (for 15min), EDTA 
was added to a final concentration of 15mM to protect the RNA from chemical scission. RNA 
concentration was measured with the Qubit RNA Assay kit (Molecular Probes).  
Subsequently a ribosomal RNA (rRNA) removal step was performed with the Ribo-Zero 
Magnetic Gold Epidemiology kit (Epicentre) using the low input protocol described in the 
manual of the ScriptSeq Complete Gold Epidemiology Kit (Epicentre). First strand cDNA 
synthesis was subsequently done with the SuperScript III First-Strand Synthesis System 
(Invitrogen) using 10 µl RNA and 3 µM (final concentration) of FR26RV-N primer (5’-GCC 
GGA GCT CTG CAG ATA TCN NNN NN-3’). An initial denaturation was done at 95 °C for 
5 min and placed on ice for at least 1 minute. After adding the cDNA synthesis mix, the 
mixture was incubated at 25°C for 10 min, 50 °C for 50 min and 5 min at 85 °C. After 2 min 
incubation on ice, an RNaseH treatment was performed according to the manual instructions. 
Second strand cDNA synthesis was accomplished by adding 2.5 U of 3’-5’ exo- Klenow 
Fragment of DNA polymerase (New England Biolabs) and incubation for one hour at 37 °C. 
After having inactivated the enzymes at 75 °C for 20 min, the cDNA was purified with 
Agencourt AMPure XP beads (1.8:1 bead:DNA ratio; Beckman Coulter) to remove residual 
primers and eluted in 20 µl nuclease free water.  
DNA virus workflow 
DNA extraction was performed with the QIAamp DNA Blood Mini Kit (Qiagen) according to 
manufacturer’s instructions. The extracted DNA was treated for 10 min at 37 °C with 4 U 
RiboShredder RNase Blend (Epicentre) to remove residual RNA. The extracted DNA was 
amplified as described in Allander et al., 2005 [4] with modified FR26RV-N primer 
concentration (1 µM final concentration). After the second denaturation, binding and 
elongation cycle the polymerase was heat inactivated at 75 °C for 20 min. 
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Random amplification and NGS 
A subsequent PCR was performed using 5 µl amplified DNA (respectively cDNA) as 
descripted before [16] with minor modifications (1.2 µM final concentration FR20RV primer 
5’-GCC GGA GCT CTG CAG ATA TC-3’ and 51.8 °C annealing temperature). The random 
amplified fragments were size selected on 1% agarose gel and 300-800 bp fragments were 
excised and purified from the gel with the High Pure PCR Product Purification Kit (Roche). 
The purified PCR fragments were quantified by spectrophotometry (Nanodrop-1000).  
Sequencing libraries for the Genome Sequencer Junior (GS Junior, Roche) were prepared 
from the purified and size selected random amplified DNA according to the manufacturer’s 
instructions for Titanium Series reagents making use of multiplex identifiers (MID) to 
identify the different libraries. The resulting libraries were sequenced with a GS Junior with 
Titanium Series reagents and run protocol (200 cycles).  
Metagenomic data analysis 
The sequence output files were sorted per sequencing library according their MID sequences. 
The PCR primer sequence was trimmed off the reads and de novo assembly was performed 
using the GS De Novo Assembler software v2.7 with default parameters. The resulting contigs 
(contiguous sequences assembled from overlapping sequence reads) and singletons (single 
sequences) were subjected to a BLAST (Basic Local Alignment Search Tool) sequence 
alignment analysis using locally installed blast-2.2.27+ software [17]. First, a megablast 
search was carried out. If no result (hits) was found, we proceeded to a blastn search, followed 
by a blastx and ultimately a tblastx search if no hits were found in the preceding BLAST 
analyses. The E-value cutoff was set at 0.001. BLAST output files were subsequently 
processed with the MEtaGenome ANalyzer software (MEGAN v4.70.4 , [18]) to classify the 
reads according to the NCBI taxonomy. As lowest common ancestor (LCA) parameters 
default values were used, except for the Min Support (1) and Min Complexity (0.3) 
parameters. 
Follow-up SYBR green real-time PCR 
Relevant singletons* were subjected to a de novo assembly with Lasergene SeqMan pro  
* Singletons with similarity to viral sequences 
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(DNASTAR) in order to find overlapping regions. Specific SYBR green real-time PCR assays 
were designed targeting relevant contig or singleton sequences using Primer-BLAST [19] and 
the reactions were performed with the LightCycler 480 SYBR Green I Master kit (Roche) 
using 1 µM final concentration of each primer and an annealing temperature of 52 °C. A 
melting curve analysis was included to verify the specificity of the PCR reaction. PCR’s not 
yielding a specific melting curve profile were abandoned, resulting in 3 reliable and specific 
real-time SYBR green PCR tests targeting Parvovirus-like contigs and singletons, and 1 test 
targeting 2 overlapping circovirus-like singletons [supplementary Table S1: primer 
sequences). DNA was re-extracted (QIAamp DNA Blood Mini Kit (Qiagen)] from the 
original samples and tested to confirm the presence of Parvovirus-like nucleic acids. 
Follow-up nucleic acid extraction 
Three negative control extractions were performed with the QIAamp Viral RNA Mini Kit 
(Qiagen) using only elution buffer. As an alternative extraction method the NucleoSpin RNA 
Virus kit (Macherey-Nagel) was used according to the manufacturers’ instructions. 
Results and Discussion 
As we have emphasized previously [20], the selection of properly targeted and fresh (field) 
samples is of great importance in any virus discovery method. The sample that was subjected 
to our optimized metagenomic virus discovery workflow was therefore selected with great 
care in order to increase the probability to detect viruses. The DNA virus identification 
workflow yielded in total 32,757 sequences (average length of 335 bases). A de novo 
assembly resulted in 1,463 contigs (comprising 16,993 reads) and 12,421 singletons. Table 1 
summarizes the BLAST analysis results. A very low number of host genome sequences 
indicated a successful removal of host nucleic acids by the nuclease treatments.  The BLAST 
analysis could identify 56 contigs and 450 singletons similar to viruses. Most viral 
contigs/singletons were similar to bacteriophage sequences. Five singletons showed a nearly 
exact match to the goatpox and lumpy skin disease virus genome. These sequences matched 
exactly the sequence of a goatpox virus strain of which we made a sequencing library in the 
lab 1 week earlier. As a specific pox qPCR tested negative on a new DNA extraction of the 
original sample (data not shown), we could exclude involvement of a poxvirus. Three contigs 
(comprising 25 reads) and 17 singletons were similar to marine virus sequences, mostly to 
regions associated with capsid or replication proteins. One contig (comprising 17 reads) and 9 
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singletons were similar (ranging from 68 % to 99 % identity when identified by megablast or 
blastn; ranging from 29 % to 50 % identity when identified by blastx) to the Parvovirus NIH-
CQV (GenBank: KC617868.1). Another singleton was similar (82 % identity) to a densovirus 
which also belongs to the parvoviridae. Parvovirus NIH-CQV was discovered and sequenced 
by Xu et al. [21] using a similar metagenomic virus discovery approach. This study claimed 
this virus was highly prevalent in human patients with seronegative hepatitis and phylogenetic 
analysis indicated that the NIH-CQV was located at the interface of Parvoviridae and 
Circoviridae. The origin of this new virus was later questioned by Naccache and colleagues as 
a likely reagent contaminant [22-25]. Our blast analysis (Table 1) identified also 8 circovirus-
like singletons (≥ 71% identity when identified by blastn; ≥ 43% identity when identified by 
blastx). To confirm the presence of these parvo/circovirus-like sequences in our sample we 
developed 4 qPCR tests based on relevant contigs and singletons. We did not develop qPCR 
tests for every singleton as multiple singletons represented similarity to the same viral 
(replication) protein. The tests confirmed the presence of these sequences in new DNA 
extractions of the original blood and serum sample, as well as in DNA extractions of a blood 
and serum sample from a second animal with the same characteristic symptoms (Table 2). 
Surprisingly, a negative extraction control (elution buffer extracted with QIAamp DNA Blood 
mini kit) also contained qPCR detectable Parvovirus-like sequences, while negative extraction 
controls using a different extraction kit (NucleoSpin, Macherey-Nagel) tested negative (Table 
2). After our initial metagenomic data analysis, new Parvovirus-like hybrid virus (PHV) 
sequences were submitted in GenBank (accession numbers KF170373 and KF214637 to 
KF214647) by Naccache et al. [23]. The authors used a similar NGS strategy and discovered a 
novel highly divergent DNA virus that was at the interface between the Parvoviridae and 
Circoviridae. The genome sequence was nearly identical to the NIH-CQV sequence. They 
demonstrated the origin of the PHV DNA to be contaminated silica-binding spin columns 
used for the nucleic acid extraction (RNeasy MinElute, RNeasy Mini, QIAamp MiniElute and 
QIAampMini spin columns). The authors detected also PHV sequences in environmental 
metagenomic datasets of coastal marine waters of North America. They suggested that a 
potential association between the hybrid virus and algae (diatoms), that generated the silica 
matrix used in the spin columns, may have resulted in unintended viral contamination during 
manufacture. Our findings confirm the risk of reagent contamination stressed by Naccache et 
al. [23] and are also in accordance with Lysholm et al. [26] where the authors used a similar 
metagenomic sequencing strategy to characterize viruses in human patients with severe lower 
respiratory tract infection. Lysholm et al. could link detected densovirus-like and circovirus-
Chapter 3.6  Implementation and case studies 
     
170 
 
like contigs to the use of the QIAamp DNA Blood Mini Kit (Qiagen). The remaining 
identified viral sequences in our study (Herpesvirus-like, Mimivirus-like; Table 1) were low 
complexity reads or showed only limited similarity to the blast hits. Low complexity 
sequences frequently occur in metagenomic datasets and are most likely artifactual 
amplification products. The RNA virus identification workflow yielded in total 31,365 
sequences with an average length of 323 bases. De novo assembly resulted in 648 contigs 
(comprising 26,019 reads) and 1,088 singletons. BLAST analysis (Table 1) indicated again a 
successful removal of host nucleic acids by the nuclease treatments as almost no sequences 
were similar to the host genome. Eighteen contigs and 26 singletons were similar to virus 
sequences, again mostly bacteriophages and marine virus-like sequences. As in the DNA 
virus workflow, we identified 6 goatpox and lumpy skin disease virus-like sequences. The 
fact that we found these DNA virus sequences also in the RNA virus discovery workflow 
(where a DNase treatment was performed on the RNA extract), confirms the likelihood of 
contamination after amplification. Three singletons were similar to primate retroviruses and 
genomic sequences, unlikely to be involved in bovine pathologies. These sequences were 
found in the root of the MEGAN analysis, indicating that BLAST results with both eukaryotic 
and viral genome taxonomy were found (most likely due to un-annotated retroviral sequences 
in mammalian genomic sequences in public sequence databases).  
In conclusion, using a metagenomic virus discovery workflow, we did not find any indication 
for the involvement of a viral agent in the disease of these dairy cattle. However, this case 
study clearly demonstrates the importance of potential contamination at different levels in 
metagenomic workflows. Contamination can occur for instance at the time of sampling, 
during the laboratory work (cf. the goatpox virus-like sequences in our dataset), reagent 
contamination (cf. parvo/circo hybrid virus sequences), etc. The false positive results detected 
here, stress the importance of careful interpretation of metagenomic sequencing data and 
emphasize the importance of thorough follow-up diagnosis. We illustrated that PCR-based 
prevalence studies in matching disease cases and healthy controls can provide a tool to detect 
false positive metagenomic results. While such studies can provide further evidence for 
disease association [27], isolation of candidate pathogens is required to assign causality by 
addressing the Koch’s postulates [28]. The assembled data from such a multidisciplinary 
approach (pathology, epidemiology, metagenomic data, PCR prevalence studies, isolation, 
characterization, …) should be used to identify the most likely candidate etiological agent and 
to make informed intervention decisions.  
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Table 1: Results of BLAST analysis (E-value threshold = 0.001) of contigs (≥ 100 bp) and 
singletons from a de novo assembly with GS De Novo Assembler. 
Table 2: Cp (crossing point = the threshold cycle on a Roche LightCycler480 real-time PCR 
instrument) values of qPCR tests on new DNA extractions of blood and serum samples from 
two diseased animals and negative extraction controls. N = negative result. 
DNA virus identification 
workflow 
RNA virus identification 
workflow 
  
32,757 raw reads  
(10,984,762 bases) 
31,308 trimmed reads  
(9,649,226 bases) 
31,365 raw reads  
(10,116,997 bases) 
28,742 trimmed reads 
(8,884,507 bases) 
Classification Virus family Number of 
contigs (reads) 
Number of 
singletons 
Number of 
contigs (reads) 
Number of 
singletons 
Archaea  4 (62) 27 2(56) 4 
Bacteria  514 (6,036) 3,575 242 (9,402) 271 
Eukaryota  285 (3,461) 1,642 222 (9,569) 312 
Unclassified  604 (6,803) 6,727 164 (6,375) 475 
Viruses  56 (631) 450 18 (617) 26 
Bacteriophage-like Myoviridae, Podoviriae, 
Siphoviridae, 
Microviridae, … 
52 (608) 400 16 (575) 17 
(uncultured) Marine virus -
like 
Phycoddnaviridae, 
environmental samples 
3 (25) 17 2 (73)  
Parvovirus NIH-CQV-like, 
densovirus-like 
Parvoviridae 1 (17) 10   
Circovirus-like (circovirus-
like genome RW-E, beak and 
feather disease virus, ...) 
Circoviridae  8   
Herpesvirus-like (ROOT) Herpesviridae  6   
Goat pox/ lumpy skin disease/ 
sheep pox  virus-like 
Poxviridae  5  6 
Mimivirus-like (ROOT, low 
complexity) 
Mimiviridae  4   
Retrovirus-like (ROOT) Retroviridae    3 
 PCR contig 1 
(parvo-like) 
PCR contig 2 
(parvo-like) 
PCR contig 3 
(parvo-like) 
PCR contig 4 
(circo-like) 
Animal 1 – blood 33,96 30,19 40 N 
Animal 1 – serum 32,62 31,43 39,96 35,11 
Animal 2 – blood 34,76 31,6 40 34,87 
Animal 2 – serum 33,88 31,79 40 36,86 
Qiagen extraction control 1 33,44 31,18 40 32,22 
Qiagen extraction control 2 33,19 30,9 N 36,57 
Qiagen extraction control 3 34,19 28,85 36,87 32,71 
NucleoSpin extraction control N N N N 
Negative qPCR control N N N N 
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Supplementairy material 
Table S1 – Primers used for the specific SYBR green PCR detection of contigs and 
singletons detected in the metagenomic dataset. 
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Primer  Sequence (5’-3’) Contig classification Length         
(n° of reads) 
Contig1F CGACATGGACGTGGAATCGT parvovirus NIH-CQV-like contig 533 bp (17) 
Contig1R GGGAAGATCGAAGACGCTCG 
Contig2F TACGCGGACTTTCCAGTTCC 2 overlapping parvovirus NIH-CQV-like 
singletons 
328 bp (2) 
Contig2R TTCAAGAATACCCGGCGCCTT 
Contig3F CCACATCTGGCTATCTGGCG 2 overlapping parvovirus NIH-CQV-like 
singletons 
271 bp (2) 
Contig3R TGCCGTGATCCACGTCTTG 
Contig4F 
Contig4R 
GCCGGATCGAGTGTTGGATA 
GGAGATATCGACGTGGCACA 
2 overlapping circovirus-like genome RW-E 
singletons 
404 bp (2) 
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CHAPTER 4 
Fine-tuning of 
methodology 
 
 
 
 
This chapter tackles another objective of this thesis, namely the investigation of potential bias 
and added value of sample preparation and amplification methods. Moreover, the potential for 
direct sequencing without an extra pre-amplification step is evaluated. 
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CHAPTER 4.1 
The origin of biased sequence depth in 
sequence-independent nucleic acid 
amplification and optimization for efficient 
massive parallel sequencing 
 
Toon Rosseel, Steven Van Borm, Frank Vandenbussche, Bernd Hoffmann, Thierry van den 
Berg, Martin Beer and Dirk Höper 
Published in PLoS ONE (2013) 8(9): p. e76144. 
 
In this chapter, evidence is provided that the rPCR SISPA pre-amplification method results in 
an amplification bias. In this chapter rPCR SISPA is referred as just “SISPA”. 
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Abstract 
Sequence independent single primer amplification (SISPA) is one of the most widely used 
random amplification approaches in virology for sequencing template preparation. This 
technique relies on oligonucleotides consisting of a 3’ random part used to prime 
complementary DNA synthesis and a 5’ defined tag sequence for subsequent amplification. 
Recently, this amplification method was combined with next generation sequencing to obtain 
viral sequences. However, these studies showed a biased distribution of the resulting sequence 
reads over the analyzed genomes. The aim of this study was to elucidate the mechanisms that 
lead to biased sequence depth when using random amplification. Avian paramyxovirus type 8 
was used as a model RNA virus to investigate these mechanisms. We showed, based on in 
silico analysis of the sequence depth in relation to GC-content, predicted RNA secondary 
structure and sequence complementarity to the 3’ part of the tag sequence, that the tag 
sequence has the main contribution to the observed bias in sequence depth. We confirmed this 
finding experimentally using both fragmented and non-fragmented viral RNAs as well as 
primers differing in random oligomer length (6 or 12 nucleotides) and in the sequence of the 
amplification tag. The observed oligonucleotide annealing bias can be reduced by extending 
the random oligomer sequence and by in silico combining sequence data from SISPA 
experiments using different 5’ defined tag sequences. These findings contribute to the 
optimization of random nucleic acid amplification protocols that are currently required for 
downstream applications such as viral metagenomics and microarray analysis.  
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Introduction 
The determination of complete viral genome sequences is a growing field in human, animal, 
and plant virology. Complete genome sequences and their exponential growth in public 
databases (roughly 1.5 million sequences representing more than 100,000 viral taxa in 
GenBank at the moment of writing of this manuscript) not only allow for a better 
understanding of virus evolution, molecular phylogeny (phylogenomics) and epidemiology, 
but also facilitate functional analysis of virus genes in comparison with other sequences in 
databases. Traditionally, viral genome sequencing approaches are based on amplification of 
overlapping genome regions followed by Sanger sequencing [1]. As a result, efficient 
sequencing approaches rely very much on prior sequence knowledge and are often focused on 
specific groups of viruses to allow for robust design of amplification primers (e.g.[2]). Viral 
isolates from highly divergent families or less frequently studied viruses often require a 
cumbersome approach for genome completion, partly because of the lack of sufficient 
available sequence information for robust primer design, and partly because of frequent need 
for primer walking and redesigning primers.  
Next generation sequencing (NGS) technologies were developed to accommodate the need of 
higher sequencing capacity and lower cost per nucleotide for large genome sequencing 
projects  (e.g. [3], reviewed in [4]). One main advantage of NGS platforms is the possibility to 
sequence DNA samples without any prior knowledge of the sequence for priming [3]. 
However, virus samples are typically loaded with host and contaminating nucleic acids. 
Enrichment for nucleic acids of interest is thus needed before these technologies become 
useful. This enrichment is often established by a targeted amplification of viral nucleic acids 
using virus or taxon specific primers. Examples include streamlined sequencing protocols for 
influenza A viruses [5, 6], classical swine fever virus [7] and foot-and-mouth disease virus 
[8]. These protocols allow completion of the viral genome(s) in a single experiment and 
provide sufficient sequencing depth to analyze the variability of RNA virus populations in a 
single sample (e.g. [9, 10]). 
Truly sequence independent access methods to viral genomes have been developed in the 
field of viral discovery (reviewed in [11-13]). One of the most prominent technologies for 
random access to viral nucleic acids is Sequence Independent Single Primer Amplification 
(SISPA), and was originally described by Reyes and Kim [14]. Several modifications have 
been published, some including enrichment steps for viral nucleic acids using filtration and 
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nuclease treatment (DNase SISPA, [15, 16]). After a filtration step and nuclease treatment, 
nucleic acids protected within virion particles are purified. The random primers used in 
subsequent complementary DNA production have a fixed amplification tag which is used in 
downstream PCR amplification. The resulting random amplicons are cloned and selected 
clones from this library are sequenced. Although the method was developed as a tool for 
identification of unknown viruses, Djikeng and colleagues [16] demonstrated its potential use 
for full genome sequencing of different model genomes, albeit at a high sequencing effort 
(100’s of colonies picked and sequenced for genome completion) and requiring a reasonable 
amount of virus (minimum 106 virus particles). This method was also applied to the partial 
sequencing of a novel paramyxovirus in penguins [17], influenza viruses [18] and the 
identification of unknown viruses from experimentally infected mice [19]. 
Recent studies have combined random priming approaches with NGS to obtain sequence 
information from viruses. These include the identification of a novel mink astrovirus [20], the 
metagenomic analysis of Dengue virus infected mosquitoes [21], metagenomic analyses of 
viruses in human stool samples [22], and the control of live-attenuated vaccines [23] and other 
biological products [24].  
Careful examination of the sequence data obtained in these studies shows a lack of 
homogeneous distribution of randomly generated sequence reads over the target genome [16, 
21-23, 25] exposing one limitation of these random access methods for the determination of 
complete viral genomes.  This does not only lead to gaps and areas of low coverage, but also 
to areas of exaggerated sequence depth that may result in bioinformatic artifacts during 
sequence assembly, even with  high sequencing efforts. Although these shortcomings were 
noted before, no systematic experimental analysis of this phenomenon was undertaken. 
The aim of this study was to elucidate the mechanisms that lead to biased sequence depth 
when using random amplification. Moreover, we sought to use gained knowledge to improve 
random amplification methods, aiming for high quality viral genomes at a limited cost 
without prior sequence knowledge. Avian paramyxovirus type 8 was used as a model RNA 
virus to investigate these mechanisms. 
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Materials and Methods  
Viral sample 
Avian paramyxovirus type 8 virus (APMV-8) was kindly provided by the German reference 
laboratory for Newcastle disease of the Friedrich-Loeffler-Institut, Greifswald - Insel Riems, 
Germany. APMV-8 has a linear single stranded RNA genome of negative orientation with a 
length of 15,342 bases. Virus propagation was performed in 8-10 day old specific pathogen 
free embryonated chicken eggs. Allantoic fluid was collected and the virus titer was 
determined by hemagglutination assays according to the Council Directive 92/66/EC (1992) 
using 1% chicken erythrocytes.  
Random access to viral nucleic acids using DNase SISPA 
APMV-8 virions were purified starting from one milliliter (ml) of allantoic fluid. 
Centrifugation, filtration with 0.22 µm filters, nuclease treatment with 100 units DNase I, 
viral RNA extraction and sequence independent single primer amplification (SISPA) were 
performed as previously described [26]. Briefly, the RNA was denatured at 95 °C for five 
minutes in the presence of random SISPA primer FR20RV-6N (5’-
GCCGGAGCTCTGCAGATATCNNNNNN-3’, [15]) which was used in the double stranded 
complementary DNA (cDNA) synthesis reaction. This primer was composed of a random 6N 
oligomer tagged with a known sequence which was subsequently used as PCR primer 
binding-extension sequence with complementary primer FR20RV (5’-
GCCGGAGCTCTGCAGATATC-3’). Purified, size selected (400-1,200 nucleotides [nt]) 
random PCR fragments were quantified with the Nanodrop-1000 spectrophotometer and used 
for the preparation of 454 sequencing libraries as described below. 
Optimization of DNase SISPA  
The following modifications of the DNase SISPA protocol (on APMV-8) were performed to 
test whether annealing effects during cDNA synthesis and/or RNA secondary structures 
contributed to biased sequence depth.  
RNA fragmentation. To test whether viral RNA secondary structures assisted in causing the 
unequal sequencing depth, we fragmented the extracted RNA according to the GS FLX 
Titanium cDNA Rapid Library Preparation Method Manual protocol (Roche, Mannheim, 
Germany, October 2009 Rev. Jan2010) starting from approximately 40 ng of viral RNA. 
Chapter 4.1  Fine-tuning of methodology 
     
183 
 
RNA size distribution before and after fragmentation was measured using the RNA 6000 Pico 
chip (Agilent, Böblingen, Germany) on the Agilent 2100 Bioanalyzer. The fragmented RNA 
was used in SISPA under identical reaction conditions as described above. 
Effect of the Primer-tag sequence. To check whether the primer tag sequence (designed for 
downstream PCR amplification) had an influence on the binding of the random primer along 
the genome during cDNA synthesis, alternative primer sequences were tested during first and 
second strand cDNA synthesis (summarized in Table 1). A primer with an alternative PCR 
amplification tag (K-6N, 5’-GACCATCTAGCGACCTCCACNNNNNN-3’, modified from 
[27]) was tested to investigate whether other regions in the genome would be preferentially 
targeted compared to the original FR20RV-6N (5’-
GCCGGAGCTCTGCAGATATCNNNNNN-3’) primer. Primer K (5’-
GACCATCTAGCGACCTCCAC-3’, modified from [27]) was used for downstream PCR 
amplification under identical reaction conditions as for FR20RV.  Additionally, a 12N 
random sequence version was tested for both tag sequences in comparison to the 6N random 
sequence primers (FR20RV-12N, 5’-GCCGGAGCTCTGCAGATATCNNNNNNNNNNNN-
3’ and K-12N, 5’-GACCATCTAGCGACCTCCACNNNNNNNNNNNN-3’).   
Sequencing  
Purified, size selected (400-1,200 nt), random amplified DNA originating from the different 
random amplifications of APMV-8 was used to prepare sequencing libraries for the Genome 
Sequencer FLX (GS FLX; Roche, Mannheim, Germany). This was performed according to 
the manufacturer’s instructions for Titanium Series reagents, using multiplex identifiers 
(MID) to identify the different libraries. The resulting libraries were sequenced with a GS 
FLX with Titanium Series reagents and run protocol (200 cycles). 
Data analysis  
The sequence output file was sorted per sequencing library according their MID sequences. 
All raw sequence files were submitted to the Sequence Read Archive (SRA) under accession 
number SRP028373.  Sequence reads were trimmed to remove the primer sequence including 
the random (6N or 12N) part as well as low quality ends. Non-APMV-8 specific reads were 
filtered out. Of each dataset approximately 7.7 Mb of raw data (≈ 500× theoretical genome 
wide sequencing depth) were randomly picked to allow direct comparison between all 
conditions. Reference guided assemblies were performed relative to APMV-
8/pintail/Wakuya/20/78 (GenBank: FJ215864) using the GS Reference Mapper software 
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(version 2.6; Roche, Mannheim, Germany). Data output files were further processed with R 
([28]; http://www.r-project.org/). To investigate if the 5’ specific amplification tag of SISPA 
primer influenced the sequence depth distribution, we mapped short sections of the 
amplification tag of the SISPA primers of increasing length adjacent to the random part of the 
primer along the genome sequence using R. Consensus sequences from each of the 
amplification strategies were compared in a clustalW alignment.  Variant analysis was 
performed by mapping of all raw sequencing reads (complete datasets) of a certain condition 
relative to reference sequence APMV-8/pintail/Wakuya/20/78 (GenBank: FJ215864) using 
SeqMan NGen® version 3.0 (DNASTAR, Madison, WI, USA). After mapping, the reference 
was deleted and single-nucleotide polymorphisms were called. At polymorphic positions, we 
included a degenerate nucleotide in the consensus sequence if the minor nucleotide alternative 
was present in at least 30 % of the sequence reads.  
Modeling secondary structure  
RNAfold from the Vienna RNA Package version 2.0 ([29], http://www.tbi.univie.ac.at/RNA/) 
was used to predict partition function and base pairing probability matrix (dot plot). The pair 
probabilities were extracted and plotted in a mountain plot (Perl script mountain.pl, 
http://www.tbi.univie.ac.at/RNA/utils.html). This plot represents the secondary structure in a 
plot of height (number of base pairs enclosing the base at a certain position, i.e. a measure of 
local secondary structure complexity) versus position. As our SISPA protocol used 95 °C to 
denature the RNA before cDNA synthesis and 50 °C at first strand cDNA synthesis, we 
modeled the minimum free energy secondary structure of the RNA genome sequence at these 
temperatures. 
Positional genomic GC-content 
Positional GC percentage was calculated with a sliding window of fixed size of 401 bp. The 
window was centered at a particular position and expanded 200 bp to either side of the center.  
Analysis of the virus specificity of the protocol   
In order to establish the virus specificity of the protocol, all sequence data generated for each 
library were classified according to the species they belong to. To this end, a combination of 
BLAST and the GS FLX software suite (v2.6; Roche) was used to sort the reads. 
Subsequently, the percentages of reads identified as viral sequences were calculated as a 
measure of the virus specificity. 
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Table 1: Summary of experimental conditions tested on APMV-8 and their assembly and coverage statistics.  
Primer condition 
RNA 
(F/N)* 
Assembly statistics Coverage statistics 
n raw bases n mapped bases n raw reads (% 
mapped  reads) 
Min Q1 Med Q3 Max IQ
R 
% bases 
depth <100× 
FR20RV-6N° N rep1 7 695 675 7 695 553 24 522 (100) 1 138 326.5 653 3 286 515 23.09% 
 
N rep2 7 695 161 7 695 029 31 372 (100) 1 139 333 734 2 109 595 19.56% 
 
F 7 695 068 7 694 932 26 683 (100) 1 149 307 650 2 458 501 17.31% 
FR20RV-12N N 7 693 226 7 692 897 26 770 (100) 1 253 394 647 1 609 394 2.11% 
 
F 7 693 689 7 693 254 27 565 (100) 1 268 435 672 1 418 404 3.25% 
K-6N° N rep1 7 695 878 7 695 698 25 834 (100) 1 140 271 579 3 096 439 15.72% 
 
N rep2 7 695 826 7 695 623 32 746 (100) 1 97 236 607 3 709 510 25.65% 
K-12N N 7 694 987 7 694 677 31 097 (100) 1 171 320 556 3 611 385 8.98% 
FR20RV-6N + K-6N  N rep1 7 696 111 7 695 907 25 181 (100) 1 206 362 697 2 026 491 5.91% 
 
N rep2 7 695 231 7 695 032 32 115 (100) 1 178 371 724 2 208 546 7.68% 
FR20RV-12N + K-12N N 7 694 566 7 694 158 28 885 (100) 1 261 385 553 2 387 292 2.31% 
° To rule out any random effects, the experimental conditions FR20RV-6N and K-6N were repeated independently starting from fresh virus culture aliquots of the same virus 
lot 
* RNA fragmented (F) or not fragmented (N) 
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Figure 1: Distribution of sequence depth and enhanced annealing sites for two alternative 6N 
SISPA primers. (A) FR20RV-6N primer condition, repeat 1 (black) & 2 (blue). (B) K-6N 
primer condition, repeat 1 (black) & 2 (blue). The X-axis represents the position on the 
APMV-8 genome. Arrows to the right (>) represent potential enhanced annealing sites in the 
first strand cDNA synthesis direction, arrows to the left (<) in the second strand cDNA 
synthesis reaction. Black arrows symbolize enhanced annealing sites on the genome with five 
consecutive nucleotides in common with the 3’ end of the tag of the given SISPA primer; red 
arrows represent six or more common consecutive nucleotides. 
RNA secondary structure and GC-content do not significantly influence sequence depth 
We could find no evidence of an overall correlation between areas below average sequence 
depth and global secondary structure of the viral RNA at denaturation and annealing 
temperatures (Figure 2 compared to Figure 1). However, the most complex region in the viral 
RNA secondary structure model (peaking approximately at position 6,000) coincides with a 
region of low coverage under all conditions tested. To investigate the effect of RNA 
secondary structure experimentally, we compared libraries obtained from fragmented and 
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non-fragmented RNA. The fragmentation of the RNA was successful with a shift of median 
RNA fragment size from 1,400 nt for non-fragmented RNA to 400 nt for fragmented RNA 
(RNA 6000 Pico chip results on the Agilent 2100 Bioanalyzer). To allow comparison with 
other conditions, we used approximately 7.7 Mb of raw data in the reference assembly. The 
coverage statistics were similar to the data obtained from non-fragmented RNA versus 
fragmented RNA (Table 1, FR20RV-6N and FR20RV-12N), and the distribution of coverage 
along the genome did not change (Figure 3 A).  
The unique depth, roughly described as depth where reads with identical starts are omitted, 
did not show extreme variability over the genome (Figure 3 B).  
We found no clear correlation between the GC-content (calculated with a shifting frame of 
size 401) and sequence depth (Figure 3 B; Spearman rank correlation coefficient of repetition 
1: 0.09, P-value < 0.005; repetition 2: 0.06, P-value < 0.005). 
  
Figure 2: Mountain plot representation of viral RNA secondary structure. Based on base pair 
probabilities of genomic position. The Y-axis represents the number of base pairs enclosing 
the base at a certain position in the predicted RNA secondary structure (direct measure of 
secondary structure complexity). The X-axis represents the position on the APMV-8 genome. 
The equilibrium pair probabilities were predicted at 95°C (black) and 50°C (blue). 
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Figure 3: Effect of RNA fragmentation and GC-content on sequence depth distribution. (A) 
Fragmented (blue) and unfragmented (black) RNA, random amplified with the FR20RV-6N 
SISPA primer. The X-axis represents the position on the APMV-8 genome. (B) Total (black) 
and unique (blue) depth distribution of the FR20RV-6N SISPA primer condition. At unique 
depth, reads with identical starts are omitted. Also positions GC-content (window size 401) of 
the APMV-8 genome is displayed (red). 
Fixed SISPA primer amplification tag sequence induces biased annealing  
To analyze if the 5’ specific amplification tag of SISPA primer FR20RV-6N influenced the 
sequence depth, we mapped stretches of nucleotides adjacent to the random part of the primer 
along the genome sequence. The first one, two, three and four consecutive 3’ nucleotides of 
the amplification tag sequence occurred frequently along the genome (data not shown). 
Mapping of the possible annealing events on the APMV-8 genome during first strand or 
second cDNA strand synthesis aided by five, six, or even seven consecutive 3’ nucleotides 
revealed a clear correlation with the variability of the sequence depth (arrows on Figure 1 A).  
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The six-nucleotide-enhanced annealing sites (red arrows) were found at the positions 5,843; 
10,487; 10,549; 13,031; 13,490 along the APMV-8 genome. They were found both in first 
and second strand cDNA synthesis direction because of the palindromic nature of this 
sequence. Position 10,487 in the first strand direction and position 13,031 in the second strand 
direction even had 7 nucleotides in common with the 3’ end of the tag sequence. This resulted 
in an extreme increase of sequence depth in the adjacent regions (Figure 1 A). The 
combination of first strand annealing positions with some adjacent second strand positions 
located in antisense direction were associated with pronounced peaks in sequencing depth in 
both independent SISPA-NGS repetitions.  In addition, a higher density of possible annealing 
sites resulted in more pronounced peaks in sequence depth (Figure 1 A; data not shown for 
shorter stretches).  In contrast, genomic areas with a low density of enhanced annealing sites 
had lower sequence depth. It is worth noting that although region 12,851-13,483 had the 
highest density of potential annealing sites (stretches ranging from 3 to 7 nucleotides) of the 
whole genome, this region did not have the highest depth of the genome.  
Optimization of DNase SISPA annealing 
In order to experimentally confirm the primer annealing bias and to improve the randomness 
of the SISPA protocol, we repeated the SISPA library preparation with modified conditions.  
These modifications included (a) a random annealing sequence extended from 6 to 12 
nucleotides, (b) an alternative primer amplification tag sequence, and (c) the combination of 
the two primers with alternative tag sequences. The amount of raw data used in all assemblies 
was again kept at about 7.7 Mb to allow direct comparison between all conditions. 
Extended random annealing part of the SISPA primer reduces bias. In order to minimize the 
impact of the tag sequences on primer annealing we extended the random part of the primer 
while keeping the tag sequence constant. The 12N oligomer condition was performed on both 
non-fragmented and fragmented RNA. The use of a 12N SISPA primer resulted in a lower 
maximum depth, to the advantage of a higher first quartile and median sequence depth (Table 
1).  The number of genomic bases with depth less than 100 × was almost negligible (2.11 %) 
compared to the 6N oligomer conditions (23.1 %). The number of bases with depth above 
500× stayed the same, but extreme heights disappeared (Figure 4 A). A decreased 
interquartile range (IQR, Table 1) indicated more homogenous distribution of sequence depth 
across the genome. Increases and decreases in sequence depths could still be correlated with 
annealing influence of the amplification tag, but the effect was reduced compared to the 6N 
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oligomer condition resulting in a more equally distributed sequence depth over the genome 
(Figure 4 A). Again, fragmentation of the RNA prior to cDNA production did not seem to 
exert any significant effect (Table 1) and no clear correlation between GC-content and 
sequence depth was found (Spearman rank correlation coefficient: 0.02, P-value < 0.005). 
 
Figure 4: Effect of the SISPA primer sequence (random part and tag) on sequence depth 
distribution. (A) FR20RV-6N (black) and FR20RV-12N (blue). (B) K-6N (black) and K-12N 
(blue). (C) In silico combined conditions “FR20RV-6N + K-6N” (black) and “FR20RV-12N 
+ K-12N” (blue). 
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An alternative amplification tag sequence relocates bias. Using a random 6N oligomer with 
an alternative amplification tag sequence, K-6N, the median and Q3 sequence depth were 
lower compared to sequences resulting from SISPA primer FR20RV-6N (Table 1).  Again, 
highly variable sequence depth was obvious with peaks up to 3,709 × coverage and a high 
proportion (15.72 %) of genomic positions with depth less than 100 × (Table 1). The use of an 
alternative amplification tag relocated the areas of extreme coverage to other genomic areas 
(Figure 1 B, repeat 1). When mapping the possible annealing bias introduced by the 
alternative amplification tag sequence to the APMV-8 consensus sequence, the correlation 
between strong annealing sites (of five, six , seven and now even eight 3’ nucleotides of the 
tag sequence) and coverage extremes was confirmed for this alternative tag sequence (arrows 
on Figure 1 B). The six nucleotide tag sequences (red arrows) were found at the positions 
5,888; 6,416 and 13,957 along the APMV-8 genome in first strand cDNA synthesis direction 
and at positions 1,886, 4,271 and 7,966 in the second strand cDNA synthesis direction. 
Position 5,888 had seven nucleotides in common with the alternative tag sequence, position 
7,966 even eight nucleotides.  The high coverage peak in region after position 7,966 could be 
explained by annealing bias. On the other hand, no extreme coverage depth was visible near 
position 5,888. An independent SISPA repetition was performed from the same virus stock 
and confirmed our general findings (Table 1; Figure 1 B, repeat 2). 25.62 % of genomic 
positions had a depth less than 100 ×. The maximum sequence depth of the peak observed in 
region 2,166-2,580 differed substantially between the two repetitions (repeat 1: 1,716×; repeat 
2: 3,610×).  
When comparing the number of enhanced annealing sites on the APMV-8 genome using 
primer K-6N and FR20RV-6N, we observed fewer enhanced annealing sites at K-6N (arrows 
on Figure 1 B compared to 1 A). This could contribute to the lower median depth of this K-
6N condition (repeat 1: 271 ×; repeat 2: 236 ×) compared to the FR20RV-6N condition 
(repeat 1: 327 ×; repeat 2: 333 ×). 
Using a 12N SISPA primer with identical amplification tag to K-6N (K-12N), the Q1 and 
median depth was increased, and both the IQR and number of positions with a depth of less 
than 100 × was decreased compared to the K-6N condition (Table 1). The extremes in the 
coverage plot were respectively flattened or raised, but the effect was less pronounced 
compared to the FR20RV-12N SISPA primer (Figure 4 B).  The sequence depth extreme of 3 
709 × in region 1,560-2,210 of the genome (Figure 4 B) might be explained by a remaining 
annealing bias effect as this region had the highest concentration of enhanced annealing 
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places of 3 and 4 common nucleotides with the 3’ end of the primer tag, especially in the 
second strand direction (data not shown).  A second unexpected observation was the peak at 
the 3’ end (14,500-15,000) which had increased enormously compared to the 6N oligomer 
condition. Moreover, this region did not show a concentration of enhanced annealing places. 
For logistical reasons, we were unable to perform an independent repetition of the K-12N 
condition for confirmation.  
Combined primer sets reduce bias in silico. Because of the use of an alternative amplification 
tag sequence resulted in relocation of areas where enhanced annealing induced sequence 
depth peaks, we tested whether combined libraries from two different SISPA primers might 
result in a more homogenous sequence depth distribution along the entire genome. We 
modeled this possibility by performing a combined APMV-8 reference assembly with equal 
amounts of raw sequence data (each about 3.8 Mb; reads were randomly picked) resulting 
from the libraries produced using 6N SISPA primers FR20RV-6N and K-6N. As each of these 
libraries was repeated independently, we modeled two combined libraries resulting from the 
two repeats of the respective libraries (Table 1, Figure 4 C). Combining the two first repeats 
resulted in improved coverage statistics (increased Q1 and median depth, and decreased 
number of bases with depth < 100×) compared to the single SISPA primer conditions alone 
(Table 1). Combining the two second repeats confirmed this more equal distribution. The 
decreased IQR indicated a better distribution of depth which was also visible on the sequence 
depth plot. A similar combined assembly using the 12N SISPA primer conditions (FR20RV-
12N and K-12N) resulted in an improvement of the coverage statistics of the stand-alone K-
12N data (Table 1, Figure 4 C). Interestingly, this condition had the lowest IQR, with 50 % of 
the genome positions having a coverage depth in between 261 x and 553 x (Table 1). 
However, combination of the two primer sets in a single reaction during reverse 
transcription/second strand cDNA synthesis/PCR repeatedly failed, probably due to 
interaction between the 2 different SISPA primers. Primer purification after 1st and 2nd 
cDNA strand synthesis would most likely solve this problem. 
DNase SISPA-NGS has high sequence fidelity and allows reliable variant calling. When 
aligning the consensus sequences of the tested reaction conditions we did not observe any 
sequence differences.  We looked for variation in the largest available dataset (FR20RV-12N 
condition) making use of all raw data. Only variant positions with depth >100 × and a 
percentage of minor nucleotide > 10 % were examined to allow reliable variant analysis 
(Table 2). In comparison we also evaluated variability in K-12N condition. Despite a variation 
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in average depth between the two conditions (FR20RV-12N: 2,300×; K-12N: 1,158×), we 
observed a very similar variation ratio at the variant positions. For example at genome 
position 3,279 there was a variant calling of 20 % ‘G’ and 80% ‘A’ in both FR20RV-12N 
(depth: 5,463×) and K-12N (depth: 1,378×). We found only big differences between 
conditions when the position was part of a homopolymer stretch (typical base-call errors 
caused by the 454 pyrosequencing technology). For example, position 2,102 had as major nt 
‘A’ and as minor nt ‘G’. At the FR20RV-12N condition the minor percentage was 11 % 
against 35 % at K-12N. This position is preceded by 4 A’s and followed by 3 G’s. Overall, 
these data show that sequence variants present in at least 10 % of the reads can be 
reproducibly identified using DNase SISPA-NGS.  
DNase SISPA-NGS is highly specific for viral sequences 
A metagenomics analysis of all sequenced raw data showed that all studied conditions were 
highly specific for APMV-8 RNA (Table 3). The proportion of APMV-8 specific sequences 
ranges from 87.7 % using SISPA primer FR20RV-12N condition to 95.8 % using SISPA 
primer K-6N (repeat 1).  The remaining fractions contained almost no contaminating host or 
bacterial sequences, and most of the unassigned sequences in all datasets could be attributed 
to unknown sequences (most likely technical or sequence database artifacts). The protocols 
based on 12N SISPA primers were slightly less specific to the advantage of the 
eukaryotic/host sequences compared to the 6N primers.  
The efficient targeting of the protocol enables sequencing complete viral genomes with very 
little sequencing effort. To investigate the relation between sequencing effort and sequence 
depth, we randomly picked increasing amounts of reads from the largest available dataset 
(FR20RV-12N) and looked at its coverage statistics. This random sampling was repeated 10 
times and averages are displayed in Figure 5. As expected, the median depth increased 
linearly with an increasing sequencing effort. We observed also a higher IQR for higher 
sequencing efforts, which indicated a higher variation of sequence depth (Figure 5). In 
summary, it was possible to obtain nearly complete (99.9 %) high quality genome sequences 
missing only a few nucleotides at the genome extremities using as few as 2,500 reads. 
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Table 2: Variant calling in 
the 12-mer datasets at 
genome positions with depth 
larger than 100 × (except for 
position 31 in the K-12N 
condition) and minor 
nucleotide percentage of at 
least 10 %. 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Metagenomic analysis of all sequence raw data from the different studied conditions. 
Condition Used reads APMV-8 Bacteria Eukaryotes Unassigned 
FR20RV-6N, repeat 1 90,137 94.99 % 0.09 % 0.31 % 3.72 % 
FR20RV-6N, repeat 2 69,860 94.40 % 0.58 % 0.81 % 3.62 % 
FR20RV-6N, fragmented RNA  80,473 93.61 % 0.34 % 1.13 % 4.34 % 
FR20RV-12N 147,004 87.73 % 1.00 % 2.45 % 6.35 % 
FR20RV-12N, fragmented RNA 133,895 88.87 % 0.79 % 2.35 % 6.40 % 
K-6N, repeat 1 141,400 95.75 % 0.15 % 1.10 % 2.69 % 
K-6N, repeat 2 116,494 93.84 % 0.44 % 0.86 % 4.34 % 
K-12N 80,258 91.20 % 0.42 % 2.52 % 3.87 % 
 
position condition depth major nt minor nt % minor  
31 FR20RV-12N 366 C T 28 % 
 
K-12N 63 C T 28 % 
1,908 FR20RV-12N 4,500 G A 20 % 
 
K-12N 5,279 G A 22 % 
2,102 FR20RV-12N 3,946 A G 11 % 
 
K-12N 1,110 A G 35 % 
3,188 FR20RV-12N 5,216 A G 19 % 
 
K-12N 1,073 A G 19 % 
3,279 FR20RV-12N 5,463 A G 20 % 
 
K-12N 1,378 A G 20 % 
4,972 FR20RV-12N 1,123 A G 17 % 
 
K-12N 515 A G 13 % 
6,526 FR20RV-12N 6,535 G A 19 % 
 
K-12N 2,136 G A 17 % 
6,705 FR20RV-12N 4,039 G A 18 % 
 
K-12N 1,357 G A 15 % 
7,760 FR20RV-12N 1,481 G A 20 % 
 
K-12N 321 G A 17 % 
7,890 FR20RV-12N 1,396 C G 41 % 
 
K-12N 724 C G 34 % 
7,895 FR20RV-12N 1,457 G A 11 % 
 
K-12N 756 G A 11 % 
8,055 FR20RV-12N 990 A G 26 % 
 
K-12N 214 A G 14 % 
12,803 FR20RV-12N 2,652 A C 33 % 
 
K-12N 1,026 A C 32 % 
13,410 FR20RV-12N 1,797 T G 39 % 
 
K-12N 872 T G 38 % 
14,913 FR20RV-12N 1,611 A G 18 % 
 
K-12N 2,786 A G 17 % 
15,155 FR20RV-12N 484 A T 20 % 
 
K-12N 430 A T 28 % 
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Figure 5: Effect of increasing sequencing effort on coverage statistics. Reads were randomly 
picked from the largest dataset (FR20RV-12N). This random sampling was repeated 10 times 
and averages of coverage statistics are displayed in boxplots. 
 
Discussion 
Sequence Independent Single Primer Amplification [14], also known as “random PCR”, is 
one of the most prominent random access techniques used in viral discovery research. The 
method provides an efficient enrichment in viral nucleic acids, avoiding excessive host and 
other contaminant sequence reads [15, 16]. The metagenomics analysis of our data shows that 
the enrichment procedure for viral nucleic acids is highly efficient, while being applicable to 
any virus genome and requiring no prior sequence knowledge. A current limitation of the 
random access protocol described here is the need for sufficient virus material.  Although 
combination of SISPA with NGS makes the protocol more sensitive, full genome sequencing 
of low titer samples directly from clinical material may be difficult as we recently discussed 
[30]. Virus genome specific amplification strategies may be better suited to increase the 
applicability to field samples for known viruses (e.g. [6]). Additionally, the method requires 
virion protected viral nucleic acids and as such is not applicable to cellular forms of viral 
nucleic acids (latent infections). 
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When combining random amplification with NGS, its tendency to create a biased distribution 
of sequence depth becomes evident (e.g. [22, 23]). Extreme variability in sequence depth does 
not only imply problematic regions of low coverage, also areas of exaggerated sequence depth 
compared to the median coverage may result in bioinformatic artifacts during data analysis 
such as de novo contig assembly and variant analysis. The tendency of the 454 technology to 
produce duplicate reads as a result of multiple beads present in the same micro-reactor during 
emulsion PCR [31, 32] alone cannot explain the dramatic differences between the coverage 
plots based on the total depth and those based on unique depth. Our study is the first to 
formally analyze the possible causes of this sequence depth variability.  
Victoria and colleagues [22] suggested that regions with overrepresented sequencing depth 
are associated with annealing bias of the used primer, while secondary structure may result in 
areas of low sequencing depth. Formally modeling secondary structure and annealing factors 
on the one hand and using experimental data on the other hand, our study identified annealing 
bias as the main cause of the overrepresented regions after performing random priming in the 
SISPA method. Annealing of the random 3’ end of SISPA primers seems to be locally 
enhanced when 3, 4, 5, 6, 7 or even 8 nucleotides from their specific 5’ amplification tag (20 
nucleotides in length) designed for PCR amplification assist the random oligomer part of the 
primer in annealing during the first strand and/or second strand cDNA synthesis. This results 
in regions of exaggerated sequence. The importance of this highly reproducible annealing 
effect seems to depend on the length of the complementary region between the primer and the 
genome and the proximity of first strand and second strand enhanced annealing positions. 
Going beyond a theoretical mapping of these annealing effects, our data show that the 
majority of sequence depth bias can be explained by this effect.  
Using a different specific amplification tag sequence, we observed a clear shift of the 
coverage extremes to other genomic regions caused by the shift of possible enhanced 
annealing sites. Again, the coverage depth was very variable, but the median depth was lower 
compared to original used primer. This is probably due to the lower number of potential 
strong annealing places on the APMV-8 genome for the alternative random primer K-6N. 
This confirms that the distribution of possible enhanced annealing sites depends on the SISPA 
primer amplification tag sequence and on the target genome sequence, which implies possible 
differential annealing dynamics when targeting other virus genomes. 
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Using any of these SISPA primers, regions in the genome existed where predicted enhanced 
annealing sites did not result in extreme sequence depth, for example the region around 
positions 6,416 and 5,888 at the K-6N primer condition have respectively 6 and 7 nucleotides 
in common with the tag sequence. Similarly, the region around position 5,843 at the FR20RV-
6N primer condition has high similarity with the tag sequence. However, these predicted 
enhanced annealing sites do not seem to coincide with increased sequence coverage in this 
region. When looking at the RNA secondary structure mountain plot at first strand cDNA 
annealing temperature (Figure 2, 50 °C) we see that these positions are located in the most 
complex region of the genome. It should be noted that we started our first strand cDNA 
synthesis step with a denaturation at 95 °C for a better removal of RNA secondary (Figure 2, 
95 °C) and tertiary structures. Nevertheless, it could be that the RNA locally refolds at lower 
temperature during cDNA synthesis. In addition, extreme coverage was also observed in 
regions which did not show a high concentration of enhanced annealing sites, for example 
genome region 14,500-15,000 at the K-12N primer condition. This region had a very low GC-
content and no complex RNA structures, but did not yield high coverage when targeted with 
primer K-6N. In none of the conditions, a clear overall correlation was found between GC% 
and sequencing depth (Spearman rank correlation coefficient was always between -0.15 and 
0.09, P-value < 0.005). These observations show that, although being a major correlate of 
sequence depth, annealing bias is not the only factor contributing to variations in sequence 
depth. These sequence coverage variations that remain unexplained by SISPA primer 
annealing/extension bias highlight the complexity of annealing and extension dynamics which 
can be locally influence by multiple interacting factors such as RNA secondary structure, GC 
content and oligomer length. Victoria and colleagues [22] suggested already that complex 
RNA secondary structures contributed to regions with problematic sequence depth. We did 
not observe a change in distribution of sequence depth after fragmentation of the viral RNA 
for the studied avian paramyxovirus genome. Although the global secondary structure of the 
viral RNA is thus successfully fragmented, it cannot be excluded that local RNA folding may 
still have influenced primer annealing. However, we could not further fragment the RNA in 
order to assure compatibility with the RNA sequencing workflow.  
These findings confirm earlier observations by Wong and colleagues [33]. That study used 
SISPA amplification in the context of a pathogen detection DNA microarray.  In initial 
experiments using random priming amplification to identify pathogens they observed 
frequently incomplete hybridization of the pathogen genomes marked by interspersed 
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genomic regions not detected by the probes that could not be explained by sequence 
polymorphisms, probes GC content and genome secondary structure. The composition of the 
SISPA primer tag had a significant impact on the efficiency of viral genome amplification – 
as suggested in our study. Using an algorithm to optimize primer sequences for uniform 
amplification efficiency across the viral genomes included in the DNA array, they managed to 
increase the sensitivity of pathogen detection of their microarray.  
Previous studies have used different lengths of the 3’ random annealing part of the SISPA 
primer. Examples include hexamer [16, 17, 20, 26, 30, 34-38], octamer [19, 22, 23, 39-42], 
nonamer [24, 43-45] and decamer random 3’ annealing parts [46]. Stangegaard and 
colleagues [47] studied the impact of different random primers (without 5’ specific 
amplification tag sequence) on the yield and quality of synthesized cDNA, concluding that 
reverse transcription using random pentadecamer primers increases yield and quality of 
resulting cDNA compared with hexa- and nonamers. In our study, we compared SISPA-
primers with hexamer and dodecamer random annealing stretches. Theoretically, the number 
of possible annealing sequences for a 12N primer is 412 (=16,777,216), compared to 46 
(=4,096) for a hexamer. In our study, increasing the random part of the SISPA primer from 
6N to 12N reduced the amplification tag induced sequence depth bias to the advantage of the 
regions with problematic coverage.  
We combined two factors affecting the distribution of sequence reads over the genome in a 
single assembly: (a) alternative SISPA primers are biased to alternative genome regions, and 
(b) longer oligomer-based SISPA primers tend to have a more equal distribution. The 
combination of data from libraries resulting from two different 12N SISPA primers 
(FR20RV-12N and K-12N) resulted in the best distribution of sequence reads over the 
APMV-8 genome. We suggest that in future efforts (using DNase SISPA for the 
determination of complete viral genomes), a combination of a longer random annealing part 
(e.g.12N) and the combined assembly of data resulting from libraries amplified with 
alternative amplification tags, may result in an improved homogeneity of sequence depth 
distribution over the genome. Ultimately, a more homogenous sequence depth distribution 
reduces the sequencing effort (and thus cost) needed for genome completion. In this study, 2 
500 GS-FLX titanium reads were enough to sequence 99.9 % of the APMV-8 viral genome 
with a median coverage of 38.3 ×. We have shown that median coverage increased with the 
increasing sequencing effort. 7,500 reads covered the full genome with a median depth of 
more than a 100 ×. This confirms our previous experience that only about 5,000 GS-FLX 
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titanium reads from a library of SISPA amplified viral RNA was enough in determining the 
complete genome of uncharacterized avian paramyxoviruses [26]. It should be noted that 
amplified viral stock was used in this study. 
Next generation sequencing is becoming increasingly accessible to laboratories, both through 
the evolution of sequencing platforms and chemistries and through the increasing availability 
of sequencing service providers. Combined with opportunities to multiplex samples during 
sequencing, this technology is now evolving towards a cost-effective methodology for 
genome sequencing. Generic, sequence independent access methods such as optimized DNase 
SISPA may facilitate access to viral genome sequences, without the need for prior sequence 
knowledge. In addition, our findings may be of value to other technologies requiring random 
nucleic acid amplification such as DNA microarrays.  
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Due to recent advances in library preparation methods, requiring significant lower input, 
direct sequencing without an extra pre-amplification step is evaluated in this chapter. Illumina 
sequencing on the MiSeq platform using the Nextera XT library preparation kit was selected. 
In addition, different convenient and widely used pretreatment methods are compared and 
evaluated for their relative virus discovery sensitivity in serum and tissue samples. TriPure 
isolation Reagent was selected as preferred extraction method to isolate high quality RNA. 
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Abstract  
Viral metagenomic approaches are increasingly being used for viral discovery. Various 
strategies are applied to enrich viral sequences, but there is often a lack of knowledge about 
their effective influence on the viral discovery sensitivity. We evaluate some convenient and 
widely used approaches for RNA virus discovery in clinical samples in order to reveal their 
sensitivity and potential bias introduced by the enrichment or amplifications steps. An RNA 
virus was artificially spiked at a fixed titer in serum and lung tissue, respectively low and high 
nucleic acid content matrices. For serum, a simple DNase treatment on the RNA extract gave 
the maximum gain in proportion of viral sequences (83×), and a subsequent ribosomal RNA 
removal nearly doubled once more the proportion of viral sequences. For lung tissue, a 
ribosomal RNA depletion step on the RNA extract had the biggest gain in proportion of viral 
sequences (32×). We show also that direct sequencing of cDNA is recommended above an 
extra random PCR amplification step, and a that the virion enrichment strategy (filtration and 
nuclease treatment) has a beneficial effect for sequencing-based virus discovery. Our findings 
provide sample-dependent guidelines for targeted virus discovery strategies. 
Keywords: RNA virus discovery, clinical samples, viral metagenomics, pretreatment, next-
generation sequencing, rRNA depletion 
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1. Introduction 
Viral metagenomics approaches can provide insights into the composition and structure of 
environmental viral communities [1] and are being increasingly used for viral discovery in 
diseased humans or animals [2-6]. The applied protocols usually start with a virion 
enrichment step such as (ultra)centrifugation, polyethylene glycol (PEG) precipitation, 
(ultra)filtration, chloroform treatment, or nuclease treatment [7]. Following pretreatment 
steps, a sequence independent genome amplification method may be used to generate 
sufficient DNA (reviewed in Ambrose et al., 2006). Finally, DNA sequencing is performed, 
followed by bioinformatics analysis of the sequences (comparing results to publicly available 
sequence information). In the past, viral metagenomics was accomplished by molecular 
cloning and Sanger sequencing [8, 9], whereas more recent techniques such as next generation 
sequencing (NGS) have made both the cloning and amplification (in the case of sufficient 
quantities of initial template DNA) steps unnecessary. Concordantly, the revolutions in 
sequencing output, coupled with the downward trends in running costs have greatly improved 
the potential of viral discovery [10-12]. However, particularly in complex biological samples 
(e.g. tissues),  the relatively low abundance of viral nucleic acids in comparison to a 
background of host, bacterial and other contaminating genetic material [13] remains a 
challenge. In short, increasing levels of viral genetic material, whilst reducing background 
signal (host) is the key to a successful metagenomic-based viral discovery pipeline. Numerous 
viral enrichment and sequence independent amplification approaches have been applied to a 
wide variety of sample types [7, 14, 15], but there has often been a paucity of knowledge 
regarding their impact on the sensitivity of viral discovery. Furthermore, few studies have 
specifically evaluated the efficiencies of either the viral enrichment steps, the sequence 
independent amplification methods or the sequencing platforms [11, 15-21]. Moreover, as a 
consequence of the lack of standardization between these studies, it is often difficult to 
directly compare conclusions. Therefore, additional evaluations of proof of concept focusing 
on the analytical sensitivity of the tested protocols in different sample types are required to 
estimate the diagnostic performance of the tested metagenomics approaches. 
In this study we focus on RNA virus discovery, as the majority of relevant (re)emerging viral 
threats are caused by RNA viruses [22]. We compare the sensitivity and bias of rapid and easy 
to use viral metagenomics approaches in different sample types. Newcastle disease virus 
(NDV) was taken to be representative of how pretreatment protocols would impact upon viral 
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RNA.  NDV has a single-stranded, non-segmented, negative-sense RNA genome of 
approximately 15 kb in size [23]. A widely used 2-step virion enrichment method (filtration 
and nuclease-treatment) was compared to a control without enrichment. Moreover, the impact 
of DNase treatment and ribosomal RNA (rRNA) depletion on the extracted RNA was also 
evaluated. Finally, the influence of sequence independent genome amplification was 
compared to direct sequencing of the complementary DNA (cDNA). 
2. Materials and Methods  
2.1. Sample selection and virus spiking 
The LaSota vaccine strain of Newcastle disease virus (NDV; family Paramyxoviridae, genus 
Avulavirus) was selected for the purposes of optimization and comparison of different 
pretreatment protocols. Samples were collected from specific pathogen free white leghorn 
chickens (lung, brain, intestine, whole blood, serum).  Extracted total nucleic acids (ssDNA, 
dsDNA, RNA) were quantified using the respective Qubit assays (Life Technologies) and 
quality assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies) (data not shown).   
Phosphate buffered saline, containing a mixture of antibiotics (107 U/l penicillin, 10 g/l 
streptomycin, 0.25 g/l gentamycin), was added to lung tissue (10 % w/v) and incubated for 1 h 
at 4 °C. The suspension was homogenized for 3 min at 30 Hz using a TissueLyser II (Qiagen). 
The lung homogenate and serum were centrifuged* and spiked with NDV to a final 
concentration of 104 EID50/ml, prior to storage at –80 °C. 
2.2. Sample pretreatments and RNA extraction 
Different pretreatment protocols were tested on both serum (‘S’) and tissue (‘T’) samples 
(Table 1 and Figure 1). The direct RNA extraction without enrichment (Section 2.2.1) was 
compared with the 2-step virion enrichment method (Section 2.2.2). For each group, untreated 
RNA was compared with DNase (Section 2.2.3) and rRNA removal (Section 2.2.4) treatments 
on the RNA extracts. Nucleic acid content of all RNA extracts were determined with Qubit 
RNA HS and dsDNA HS assays (Life Technologies). 
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Table 1: Overview of the used pretreatment protocols, virus specific CP values, nucleic acid concentrations of RNA extracts and amplification 
strategy. Both serum (S) and (lung) tissue (T) were spiked with 104 EID50/ml Newcastle disease virus (NDV). Viral RNA was quantified with an 
NDV specific qRT-PCR, The displayed CP values are the average of 2 replicates. Total RNA was quantified with Qubit RNA and dsDNA assays 
(Life Technologies).   
Protocol short name* 
Sample 
type 
Pretreatment protocols 
NDV  
CP value 
Nucleic acid concentration of 
RNA extract 
Amplification strategy 
2-step 
enrichment 
Dnase treatment 
on RNA extract 
rRNA remvoval 
on total RNA 
RNA 
(ng/µl) dsDNA (ng/µl) 
S-Control1 Serum No No No 28.58 11.65 12.55 cDNA synthesis 
S-Control2 Serum No No No 29.07 6.64 5 cDNA synthesis 
S-Control1 + Dnase Serum No Yes No 29.18 <0.02 <0.0005 cDNA synthesis 
S-Control2 + Dnase  Serum No Yes No 29.35 <0.02 <0.0005 cDNA synthesis 
S-Control2 + Dnase + Removal Serum No Yes Yes 30.69 <0.02 <0.0005 cDNA synthesis 
S-Control1 + Removal1 Serum No No Yes 29.02 Not tested Not tested cDNA synthesis 
S-Control1 + Removal2 Serum No No Yes 28.69 Not tested Not tested cDNA synthesis 
S-2-step Serum Yes No No 29.68 <0.02 0.413 cDNA synthesis 
S-2-step + Removal1 Serum Yes No Yes 30.2 Not tested Not tested cDNA synthesis 
S-2-step + Removal2 Serum Yes No Yes 28.75 Not tested Not tested cDNA synthesis 
S-2-step + rPCR Serum Yes No No 29.68 <0.02 0.413 cDNA + random PCR 
S-2-step + Removal2 + rPCR Serum Yes No Yes 28.75 Not tested Not tested cDNA + random PCR 
T-Control1 Lung tissue No No No 29.56 105 14.6 cDNA synthesis 
T-Control2 Lung tissue No No No 30.15 74.8 11.6 cDNA synthesis 
T-Control1 + Dnase Lung tissue No Yes No 30.14 Not tested Not tested cDNA synthesis 
T-Control2 + Dnase  Lung tissue No Yes No 29.39 72.5 10.3 cDNA synthesis 
T-Control2 + Dnase + Removal Lung tissue No Yes Yes 31.02 42.7 4.18 cDNA synthesis 
T-Control1 + Removal1 Lung tissue No No Yes Not tested 47.6 Not tested cDNA synthesis 
T-Control1 + Removal2 Lung tissue No No Yes 30.57 Not tested Not tested cDNA synthesis 
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Table 1 (continued)         
T-2-step Lung tissue Yes No No 31.28 2.4 0.152 cDNA synthesis 
T-2-step + Removal1 Lung tissue Yes No Yes 33.01 Not tested Not tested cDNA synthesis 
T-2-step + Removal2 Lung tissue Yes No Yes 33.23 Not tested Not tested cDNA synthesis 
T-2-step + rPCR Lung tissue Yes No No 31.28 2.4 0.152 cDNA + random PCR 
T-2-step + Removal2 + rPCR Lung tissue Yes No Yes 33.23 Not tested Not tested cDNA + random PCR 
* 1 and 2 are independent repetitions of either RNA extraction or rRNA removal reaction. 
Table 2: Average sequencing depth and NDV genome coverage per evaluated pretreatment approach. Both serum (S) & lung tissue (T) sample 
were spiked with 104 EID50/ml NDV. Control = no virion enrichment, 2-step = 2-step virion enrichment, DNase = DNase treatment on RNA 
extract, Removal = rRNA removal on RNA extract, rPCR = random PCR amplification, 1 and 2 are independent repetitions of either RNA 
extraction or rRNA removal. 
Serum condition Average depth % Overlap Lung tissue condition Average depth % Overlap 
S-Control1 0.193 10.338 T-Control1 0.029 1.442 
S-Control2 0.365 17.839 T-Control2 0.099 7.151 
S-Control1 + Dnase 17.546 97.847 T-Control1 + Dnase 0.062 3.339 
S-Control2 + Dnase  37.852 99.513 T-Control2 + Dnase  0.022 2.180 
S-Control2 + Dnase + Removal 50.647 99.987 T-Control2 + Dnase + Removal 1.364 45.423 
S-Control1 + Removal1 0.083 5.676 T-Control1 + Removal1 0.989 39.813 
S-Control1 + Removal2 0.055 5.143 T-Control1 + Removal2 0.360 19.913 
S-2step 0.739 35.263 T-2-step 0.109 7.211 
S-2-step + Removal1 0.476 24.891 T-2-step + Removal1 0.865 33.926 
S-2-step + Removal2 5.181 95.173 T-2-step + Removal2 0.655 33.537 
S-2-step + rPCR 2.050 35.506 T-2-step + rPCR 0 0 
S-2-step + Removal2 + rPCR 1.940 23.074 T-2-step + Removal2 + rPCR 0.013 1.277 
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Figure 1: Schematic overview of the tested sample pretreatment steps in the viral 
metagenomic workflow. 
2.2.1. No virion enrichment (‘control’) 
RNA was extracted (in duplicate - control1 and control2), from 1 ml of virus-spiked sample 
(processed in the absence of viral enrichment) using the TriPure isolation Reagent (Roche) 
according to manufacturer’s instructions. The aqueous phase was subsequently purified with 
the RNeasy Mini Kit (Qiagen) prior to elution in 60 µl nuclease-free water.  
2.2.2. Two-step viral enrichment (’2-step’) 
Two pretreatment steps (0.45 µm filtration followed by nuclease treatment) were performed 
on 1 ml of spiked sample as described previously [24]. The nuclease treatment step was 
performed using 50 U TURBO DNase (2 U/µl, Life Technologies), 1× TURBO DNase Buffer 
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and 10 U RiboShredder RNase Blend (1 U/µl, Epicentre Technologies) as reported previously 
[24].  
2.2.3. DNase treatment on RNA 
Extracted RNA duplicates were treated with TURBO DNase (20 U/30 µl RNA; Life 
Technologies) for 30 min at 37 °C, prior to purification using the RNeasy mini kit (Qiagen).   
2.2.4. Ribosomal RNA removal on RNA 
Cytoplasmic and mitochondrial ribosomal RNA depletion of both the ‘no virion enrichment’ 
control and ‘2-step enrichment’ were performed using the Ribo-Zero Magnetic Gold 
Epidemiology kit (Epicentre Technologies).  rRNA removal was performed using the Ribo-
Zero kit (Epicentre Technologies) as per manufacturer’s instructions.  If RNA quantity was 
less than 500 ng per 28 µl RNA, then a low-input protocol was used as described in the 
manual of the ScriptSeq Complete Gold Epidemiology Kit (Epicentre Technologies). 
Ribosomal RNA depletions were performed in duplicate (‘Removal1’ and ‘Removal2’). 
Additionally, an rRNA removal treatment upon previously DNase treated RNA (Section 
2.2.3) was also performed (‘DNase + Removal’). 
2.3. Virus quantification by q(RT-)PCR 
To measure the impact of pretreatment steps on the viral RNA, a specific real-time 
quantitative RT-PCR assay was performed (in duplicate) on the RNA extracts and on DNase 
or rRNA-removal treated RNA. Viral RNA was quantified using QuantiTect Probe RT-PCR 
(Qiagen) on a LightCycler 480 real-time PCR system (Roche) as previously described [25]. 
2.4. cDNA synthesis and amplification 
cDNA synthesis using random hexamer primers was performed according to the guidelines in 
the 454 sequencing cDNA Rapid library preparation method manual (Roche, version March 
2012, Section 3.2), but excluding RNA fragmentation. Briefly, double-stranded cDNA was 
synthesized with the cDNA Synthesis System kit (Roche) from 17 µl of RNA using 400 µM 
Primer “random” (Roche) and subsequently purified using Agencourt AMPure XP beads 
(1.6:1 bead/cDNA ratio; Beckman Coulter). 
Sequence independent PCR amplification was performed as previously described [24] on a 
single replicate of the 2-step virion enriched samples (control & rRNA removal). Random 
Chapter 4.2  Fine-tuning of methodology 
     
212 
 
PCR fragments were size selected on a 1 % agarose gel, and fragments between 200 and 800 
bp were excised and purified using the High Pure PCR Product Purification Kit (Roche).   
The purified random fragments and PCR-free cDNA were both quantified with the 
appropriate Qubit assay kit (Life Technologies) and quality checked with the Agilent 2100 
Bioanalyzer (Agilent Technologies). 
2.5. Sequencing 
Sequencing libraries were prepared using the Nextera XT sample preparation kit (Illumina) 
according the manufacturer’s instructions. Total dsDNA input of 1 ng was used unless cDNA 
was present at lower concentrations.  In these cases, the maximum available cDNA was used 
as an input (i.e. 5 µl). Libraries were quantified with the Kapa library quantification kit for 
Illumina sequencing (Kapa Biosystems) and their fragment length distribution was verified 
using the Agilent Bioanalyzer with the High Sensitivity DNA Kit (Agilent Technologies). 
Sequencing was performed on the MiSeq benchtop sequencer at The Pirbright Institute using 
a MiSeq Reagent kit v3 (Illumina) with 2×300 bp paired end sequencing. Eighteen libraries 
were multiplexed using standard Illumina indexing primers on an initial sequencing run. The 
remaining 6 libraries were sequenced on a second sequencing run. On the first run, samples 
were calculated to generate approximately 2 million paired end reads, with samples on the 
second run generating 4 million paired end reads. 
2.6. Data analysis 
2.6.1. Quality trimming 
Quality of sequences was checked with the FastQC tool v0.10.1 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  In the metagenomic data 
analysis we treated both paired end reads as independent reads in order not to lose information 
when one of the paired end reads would be discarded during trimming. Raw reads containing 
unidentified nucleotides (“N”) and those nucleotides adjacent to the 3’ end were trimmed 
using Cutadapt v1.3 [26] prior to quality trimming using Sickle v1.210 (Q-score <20 and 
reads with length <30 bp were removed) [27]. Cutadapt was also used to trim any PCR primer 
sequences in samples generated using random PCR.   
2.6.2. Data filtering and classification 
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Ribosomal RNA reads were filtered from quality trimmed data using the SortMeRNA tool 
v1.7 [28]. Thereafter, non-rRNA reads were mapped against the host (chicken) reference 
genome (Genbank accession numbers: NC_006088.3, NC_006115.3, NW_001471666.1, 
NC_006119.2, NC_006126.3, NC_006127.3, NC_008465.2, NC_008466.2, NC_001323.1) 
using BWA-MEM v.0.7.5a-r405 [29]. The unmapped reads were subjected to a megablast 
sequence alignment analysis against the NCBI nt database using blast-2.2.27+ software [30] 
employing an E value threshold of 0.001. Blast output files were processed with the 
MetaGenome Analyzer software MEGAN v4.70.4 [31] to classify the reads according to 
NCBI taxonomy. Reads were further categorized as ribosomal RNA (rRNA filtered reads), 
non-rRNA host (host mapped reads + unmapped reads which were classified by 
megablast/MEGAN as species Gallus) and non-rRNA bacteria, other eukaryotes, viruses 
(NDV & other), unclassified, and no megablast result. 
2.6.2 Genome coverage 
For each pretreatment protocol, raw sequences were mapped against a reference genome 
(GenBank accession number: AY845400.2) using GS Mapper v2.9 (Roche). The GATK v3.2 
(Genome Analysis Toolkit) ‘DepthOfCoverage’ tool was applied to the BAM file to 
determine coverage depth at each genomic position [32]. 
3. Results  
3.1. Quantification of nucleic acid content  
The effectiveness of pretreatment protocols for RNA virus discovery in simulated clinical 
samples was compared (Table 1). The results from the NDV-specific quantitative RT-PCR 
assay indicated that different treatments had a limited impact upon yields of extracted viral 
RNA (in each case maximum 1 CP difference compared to controls). The only observable 
differences were between the Tissue 2-step and 2-step + Removal which differed by 2 CP’s). 
The RNA concentration in the serum control (no virion enrichment) extraction was 
comparable to its dsDNA concentration (S-Control) whereas the tissue sample contained 
approximately 7-fold higher amount of RNA present compared to dsDNA (T-Control).  
The 2-step virion enrichment reduced the nucleic acid content in both serum and tissue to 
almost undetectable levels (S/T-Control vs. S/T-2-step). A single DNase treatment reduced 
the nucleic acid content to below the detection limit in serum, whereas it only marginally 
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impacted upon the DNA/RNA yield of the tissue sample (S/T-Control vs. S/T-Control + 
DNase). Increased quantities of DNase enzyme/different DNase enzymes were tested 
unsuccessfully in an attempt to eliminate the remaining 10 ng/µl dsDNA. By contrast, the 2-
step enrichment successfully removed dsDNA completely. We were unable to measure 
nucleic acid quantity in all rRNA depleted RNA extracts due to limited volumes, however in 
tissue-derived samples rRNA removal  halved the RNA content (T-Control1 vs. T-Control1 + 
Removal, T-Control2 + DNase vs. T-Control2 + DNase + Removal). 
3.2. Metagenomic analysis of the different protocols 
We investigated the impact of (1) 2-step virion enrichment (filtration and nuclease treatment), 
(2) DNase treatment on the RNA extract, (3) rRNA removal on the RNA extract, and (4) 
random PCR amplification, compared to direct sequencing of cDNA. In the tissue control 
sample, over 90 % of the reads were identified as rRNA, with the majority derived from the 
(chicken – Gallus gallus domesticus) host (Figure 2). The serum control sample contained 
only 0.45 % rRNA, whereas the largest class was classified as non-rRNA host (>90 % 
compared to 6.9 % in tissue; Figure 2). In these control samples more NDV specific reads 
could be identified in serum compared to tissue (Figure 3 & Table S1).  
3.2.1. Effect of 2-step virion enrichment 
Performing both the filtration and nuclease pretreatment improved the identification of NDV 
reads in the context of both serum (Figure 3 & Table S1: 17× compared to Control1; 19× 
compared to Control2) and tissue (Figure 3 & Table S1: 3.5× compared to Control1; 1.5× 
compared to Control2). This increased incidence of NDV specific reads resulted in larger 
overlaps of the genome (Table S1: S/T-Control vs. S/T-2-step). The distribution of taxonomic 
classes was similar to that observed in the control sample in tissue (Figure 2), whereas in 
serum the amount of non-rRNA host decreased in favor of more rRNA (9.61 %) (Figure 2). 
Furthermore, the amount of other (non-NDV) viral reads increased in both serum and tissue 
(Table S1). 
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(A) Serum 
 
(B) Tissue 
 
Figure 2: Taxonomic classification of sequencing output per investigated pretreatment 
approach in serum sample (A) and lung tissue sample (B). Control = no virion enrichment, 2-
step = 2-step virion enrichment, DNase = DNase treatment on RNA extract, Removal =  
rRNA removal on RNA extract,  rPCR = random PCR amplification, 1 and 2 are independent 
repetitions of either RNA extraction or rRNA removal. 
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Figure 3: Proportion of viral specific reads per tested pretreatment condition. Serum (blue lines) & lung tissue (red lines) sample were spiked 
with 104 EID50/ml NDV. Control = no virion enrichment, 2-step = 2-step virion enrichment, DNase = DNase treatment on RNA extract, 
Removal = rRNA removal on RNA extract, rPCR = random PCR amplification, 1 and 2 are independent repetitions of either RNA extraction or 
rRNA removal. 
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3.2.2. Effect of DNase treatment on extracted RNA 
A single DNase treatment on extracted RNA resulted in the identification of increased 
numbers of NDV reads in the serum-derived sample (Figure 3 & Table S1: 87× compared to 
Control1, 80× compared to Control2) and an increased genome coverage from 10 % to 17 % 
in the control samples to, respectively, 97.8 % and 99.5 % in the DNase treated samples 
(Table 2). In tissue samples, DNase did not improve the proportion of NDV reads (Figure 3 & 
Table S1: 1.69× compared to Control1, 0.33× compared to Control2), with similar trends 
observed for other viral reads (Table S1). In serum, non-rRNA host reads decreased 
significantly in favor of more rRNA reads (Figure 2: circa 42 % rRNA reads at Control-
DNase compared to 0.45 % in Control). This was also true for tissue (Figure 2: circa 96 % 
rRNA reads at Control+DNase compared to circa 92 % in Control).  
3.2.3. Effect of rRNA removal  
The depletion of rRNA from serum-derived RNA extracts did not improve the detection of 
NDV reads (Figure 3 & Table S1:  decrease of 3.5× in Control1+Removal1, 5× decrease in 
Control1+Removal2).  Conversely, rRNA depletion of tissue RNA resulted in the 
identification  of increased numbers of NDV reads (Figure 3 & Table S1: 37× in 
Control1+Removal1, 27× in Control1+Removal2) resulting in increased genome coverage 
(Table 2). The same trends were observed for non-NDV viral reads (Table S1). The overall 
distribution of taxonomic classes was not impacted in serum (Figure 2), whereas in tissue 
almost all rRNA has disappeared in favor of mainly non-rRNA host sequences (rRNA: 6.41 
%/ 9.69 % compared to 93.77 %/ 91.14 % in control samples).  
Similar trends were also observed for the rRNA depleted 2-step virion enrichment samples 
(Figure 2; Table S1). Ribosomal RNA removal from tissue samples decreased the amount of 
rRNA by 90 % (93 % in repetition), thereby increasing the number of NDV reads, ten-fold, in 
both duplicates (Figure 2). Similar proportions of NDV reads could be identified in both 
‘Control1+Removal’ and ‘2-step+Removal’ groups (Table S1). Although in the serum 
samples the rRNA removal on the 2-step virion enrichment sample successfully removed all 
rRNA completely in both repetitions, this did not lead to increases in NDV reads. The 
independent repetition of ‘2-step+rRNA removal’ yielded 383 NDV reads spanning 
approximately 95 % of the genome (Table 2).  
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When performing a rRNA depletion step on previously DNase treated RNA 
(DNAse+removal), the amount of NDV reads doubled in the serum sample compared to the 
‘DNase-only’ treated group (Figure 3 & Table S1). Using this pretreatment regimen, the 
entire NDV genome was obtained to an average depth of 50× (Table 3).  Furthermore, we 
identified no evidence of biases in coverage distribution, as was introduced with rRNA 
depletion protocols (Figure S1, A). The tissue ‘DNAse+removal’ sample exhibited increased 
numbers of NDV reads compared to its no virion enrichment control group (9.6×) and the 
‘DNase-only’ treated group (29×; Figure 3 & Table S1). In both serum and tissue, the 
depletion step reduced the numbers of rRNA reads that were present in the ‘DNase-only’ 
treated group (Figure 2). The efficiency of rRNA removal (Figure 2: decrease of 85 % rRNA 
compared to its control Tissue Control2+DNase) was similar to the efficiency of rRNA 
removal on No-DNase treated RNA (Figure 2: decrease of 87 % at Tissue 
Control1+Removal1 and 84 % at Tissue Control1+Removal2 compared to Tissue Control1). 
3.2.4. Effect random PCR amplification 
In both tissue and serum samples, random PCR (rPCR) amplification had a negative impact 
on the number of obtained NDV (and other viruses) reads compared to that of directly 
sequenced cDNA (Figure 3; Table S1). In the tissue rRNA depletion (2-
step+Removal2+rPCR) and control (2-step+rPCR) pretreatment one and no NDV sequences 
could be identified respectively. In the serum rPCR groups, non-rRNA host sequences were 
reduced in favor of more reads, of which megablast was unable to identify any result (Figure 
2: no megablast result: 34 % in 2-step+rPCR compared to 8 % in control; 49 % in 2-
step+Removal2+rPCR compared to 9 % average in 2-step+Removal2). In this instance, 
coverage appeared unevenly distributed along the genome (Figure S1, B). 
4. Discussion  
Numerous protocols for viral enrichment and genome amplification have been described in 
literature; however, their effect on the sensitivity of viral discovery methodologies has not 
always been documented. Moreover, the use of different reagents, sequencing platforms, 
sample matrices and virus types has made the conclusions of these studies difficult to 
compare directly with one another. In this investigation we directly compared viral 
enrichment approaches to determine their effect on RNA virus discovery in spiked tissue and 
serum, thereby simulating clinical samples.  
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Although increased sequencing capacity improves the chances of virus detection [17], not 
every lab has the access and budget to use the massive throughput NGS platforms. Currently, 
three smaller benchtop-level NGS sequencers are commonly used: 454 GS Junior (Roche), 
Illumina MiSeq and Ion Torrent Personal Genome Machine (PGM) ([33] update 
http://www.molecularecologist.com/next-gen-fieldguide-2014/). The GS Junior reagents are 
rather expensive and the library preparation requires a minimum input of 500 ng of DNA (GS 
Junior Titanium series, Rapid Library Preparation Method) or 200 ng of RNA (GS Junior 
Titanium series, cDNA Rapid Library Preparation Method). Moreover, its throughput is 
limited to 100k reads per run and the platform is only supported until mid-2016. Both the 
MiSeq and PGM have much higher throughput and reduced cost per sequenced Mb.  The 
MiSeq has been reported previously to be better suited to viral identification within a 
metagenomic context [11]. For these reasons, we chose to utilize the MiSeq in this study, 
although the PGM platform was also selected in a recent study evaluating a protocol for 
metagenomics virus detection in clinical specimens [21]. 
The sample matrix, in addition to sequencing throughput, has a significant impact upon 
method sensitivity, notably, the ability to detect small amounts of virus in high background of 
host nucleic acids [3]. For this reason, the detection of viral nucleic acids down to the 
“picogram range”, within tissue samples, poses significant challenges for sequencing-based 
virus discovery over liquid biological samples (e.g. plasma, serum, cerebrospinal fluid, 
respiratory secretion). We selected serum as model sample type for liquid biological samples 
(with a low level of contaminating and host nucleic acids) and lung tissue as model for high 
background nucleic acid content. NDV Virus was artificially spiked in these samples at a 
constant titer of 104 EID50 /ml to allow comparison. Although this may represent a bias 
compared to infected clinical samples, this enabled an exact quantification of the impact of 
pretreatment protocol modifications on the amount of NDV reads obtained. We believe that 
our approach is a correct approximation for the clinical reality, and will allow for the 
quantification of differences in viral discovery sensitivity. 
In this study, the DNase treatment of RNA extracted from serum exhibited the greatest 
increase in numbers of NDV reads (average coverage depth of 83.5× for the 2 independent 
repetitions). After DNase treatment we could no longer measure nucleic acids in the RNA 
extracts (DNA < 0.0005 ng/µl; RNA < 0.02 ng/µl). Nevertheless, quantifiable Nextera XT 
(Illumina) sequencing libraries could be made although the use of ultra-low nucleic acid input 
concentrations may be incompatible with alternative library preparation methods. DNase 
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appeared to preferentially remove host DNA, which resulted in more rRNA, non-rRNA 
bacterial and non-host eukaryotic reads being sequenced. By performing an additional rRNA 
depletion step on the ‘DNase treated’ RNA, we were able to double the numbers of NDV 
specific reads permitting full genome sequence to be obtained.  The removal of rRNA from 
non-DNAse-treated RNA from serum had no positive effect as the initial rRNA content of the 
control serum was already negligible. To a lesser extent, simple 2-step virion enrichment 
(0.45µm filtration and nuclease treatment) was also advantageous for the identification of 
NDV-specific reads in serum (average of 18× improvement for the 2 independent repetitions) 
due a significant reduction of host nucleic acids. This confirmed earlier findings of Hall and 
colleagues, who tested enrichment protocols in both bacterial and human cells, in recovery of 
DNA and RNA viruses [15]. However, we demonstrated that serum samples subjected to a 
DNase treatment resulted in increases in viral sequences for RNA virus identification. 
Furthermore, in-spite of the rRNA content of serum in the 2-step virion enrichment sample 
being minimal and completely removed after both rRNA depletion repetitions, we did not 
observe increases in NDV reads. It is probable that an additional DNase treatment on the 
RNA (whether or not followed by a rRNA depletion step) would improve the NDV 
identification power although this may adversely impact upon the cDNA synthesis. Although 
only one RNA virus was evaluated, the same trends were observed for the other identified 
viruses (Table S1). The other identified viruses consisted mainly of bacteriophages and 
retroviruses.  
Less viral reads (NDV) were identified in the tissue samples in comparison to serum. This 
was expected as the background nucleic acid content was much higher, whilst the spiked virus 
titer was kept constant. We demonstrated that the nucleic acid background of lung tissue 
consisted primarily of rRNA (92 %). This corresponded with earlier reports that a significant 
proportion of total cellular RNA consisted of rRNA [18] and was therefore unsurprising that 
the rRNA removal step exhibited the greatest impact in tissue samples. In this study we 
demonstrated a 93 % reduction in the rRNA that was present in the tissue sample. This was 
highly reproducible (independent repetition removed 90 % of the rRNA) and resulted in a 37× 
increase of viral reads (27× in the repetition). When performing a rRNA depletion on the 2-
step virion enrichment sample, the same trends were observed. Again, these findings were 
also observed for the other (non-NDV) viruses (Table S1). rRNA depletion pretreatments 
have been successfully used in transcriptomics research [34-36] and virus discovery in 
clinical samples [18, 21, 37, 38]. Bishop-Lilly and colleagues used a similar viral 
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metagenomics approach combined with direct cDNA sequencing using a 454 GS FLX 
platform to identify Dengue virus type 1 (DENV-1, enveloped, +ssRNA 10.7 kb genome) in 
mosquito samples. They demonstrated rRNA depletion (using the RiboMinus Kit, Life 
Technologies) doubled the sensitivity of DENV-1 detection, but skewed genome coverage 
towards the 5’end of the genome. Kohl and colleagues used  a eukaryote specific rRNA 
depletion kit and observed a reduction of virus nucleic acids after using the kit [21]. Our study 
failed to identify such biases using the Ribo-Zero Magnetic Gold Epidemiology Kit 
(Epicentre Technologies). It should be noted that the cost for including a rather expensive 
rRNA removal kit (approximately 70 € per sample at the time of writing this manuscript) 
should be balanced with its added value to viral discovery. An alternative approach to 
decrease rRNA sequences for detection of RNA viruses in clinical samples could be the use of 
a mixture of non-ribosomal hexanucleotides and/or rRNA blocking oligo’s as primers in the 
reverse transcription reaction [18, 39]. Although these non-rRNA hexamers were thoroughly 
tested to prime all the known mammalian viruses listed in public databases, biases may be 
introduced through the preferential amplification of certain sequence context, e.g. the 
inefficient amplification of low complexity regions. The performance of the 2-step virion 
enrichment or DNase treatment on extracted RNA derived from tissue also did not confer any 
advantage in terms of improving the virus identification power in tissue samples. After the 
filtration and nuclease treatment step, 93% of sequence reads were identified as rRNA 
(mainly host cytoplasmic 18S and 28S rRNA), indicating that the ribosomes were able to pass 
through the 0.45 µm filter and the rRNA stays well protected from the RNase treatment until 
they are released during nucleic acid extraction. Consequently, any pre-extraction viral 
enrichment step (e.g. ultracentrifugation, nucleases treatments, etc.) may also enrich 
ribosomes. Daly and colleagues tested the efficiency of a viral enrichment procedure based on 
repeated cycles of tissue homogenization and freeze/thaw using dry ice, followed by nuclease 
digestion of non-protected nucleic acids, nucleic acid extraction, rPCR amplification and NGS 
sequencing on an Illumina GAII sequencer [16]. Using Hepatitis C virus they tested 
enrichment protocols, demonstrating the resulting pretreatment regimens increased the 
proportion of HCV reads circa 15 times. The authors used the same sequence independent 
single primer random PCR amplification approach as we evaluated in this our study (rPCR).  
We observed that this random PCR amplification negatively impacted upon viral 
identification power. The observed biases in sequence distributing confirms our previous 
findings [40]. Moreover, rPCR amplification increased the proportion of reads for which 
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megablast could not find similar sequences in the NCBI nt database, suggesting the creation 
of amplification artefacts. 
Sequence independent genome amplification has been reported previously to introduce 
significant bias, including coverage bias and/or biased species representation [41, 42]. Several 
attempts have been performed to reduce amplification introduced bias [40, 43]. Although the 
sequencing library preparation kit (Illumina Nextera XT) used in this study is not completely 
PCR-free, it supports ultra-low DNA input of only a single nanogram which eliminates the 
need for extra sequence independent genome amplification step. Even with our lowest 
concentrated cDNA’s (some were <0.5 pg/µl), we were able to successfully produce 
quantifiable libraries.  Currently, PCR-free sequencing library preparation methods (e.g. 
Illumina TruSeq) require “microgram range” DNA input, making them incompatible with 
direct cDNA sequencing of certain clinical samples.  Although the Nextera technology and 
use of low copy number template input is not completely bias-free [44-46], we demonstrated 
that this library preparation method can be useful for viral identification studies. Furthermore, 
the Nextera XT workflow is rapid and non-laborious. 
In this experiment, we multiplexed different samples on a MiSeq sequencing run using default 
Illumina (Nextera XT) index barcodes. This allows a more economical use of the available 
sequencing capacity. In spite of a correct application of good laboratory practice and 
appropriate precautions, we identified a low level of cross contamination of a non-NDV virus 
that was sequenced along on the same run with a different dual index adaptor combination. 
The cross contamination was especially seen in libraries that share 1 index of the dual index 
combination of this library (data not shown). We also identified at least 0.1% carryover 
sequences of another non-NDV virus from previous sequencing runs.  Barcode cross 
contamination and sample carryover seems to be an issue for the MiSeq platform (http://core-
genomics.blogspot.ca/2013/04/miseq-and-2500-owners-better-read-this.html, 
http://seqanswers.com/forums/showthread.php?t=29110&page=2).  NGS workflows are 
highly sensitive and can detect low amounts of contaminant nucleic acids in biological 
samples or reagents [47]. For virus discovery experiments this is an important issue as false 
conclusions could be made. Of course molecular identification of viral sequences is only the 
first step in determining whether or not it is associated with disease. Follow-up studies are 
needed to prove a link between a candidate infectious agent and disease [24, 48, 49]. Some 
recommendations to minimize contamination issues would be (1) alternating use of a large set 
of barcodes, (2) do not simultaneously make libraries in the same PCR cabinet, (3) perform 
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the recommended maintenance wash steps of your sequencing instrument in between 2 
subsequent sequencing runs, (4) avoiding multiplexing samples of different metagenomics 
experiments on the same sequencing run, and (5) using a different NGS platform with less 
carryover issues.  
5. Conclusions  
Metagenomics-based detection of viruses in clinical biopsy samples remains a challenge as 
viral nucleic acids are predominantly present at a very low ratio compared to host and 
contaminating nucleic acids. Our study evaluated the impact of convenient pretreatment 
protocols on serum and lung tissue for RNA virus discovery. We demonstrated that the 
efficiency, and consequently the recommended strategy, depends strongly on sample nucleic 
acid amount and composition. Serum samples predominantly contained host DNA, and a 
single DNase treatment on the RNA extract resulted in the biggest gain in proportion of 
identified viral reads (circa 83× improvement). A subsequent rRNA removal almost doubled 
this effect. Lung tissues background consisted mainly of rRNA sequences, and once again a 
rRNA removal resulted in the greatest gain (circa 32× improvement) in the proportion of viral 
sequences. We also showed that random PCR amplification was not beneficial for the viral 
identification, and direct sequencing of the cDNA s recommended. Some of the tested 
pretreatment approaches reduced nucleic acid concentration in the RNA extract to below 
detection limits (<20 pg/µl RNA, <0.5 pg/µl DNA). Nevertheless, our workflow allowed 
successfully cDNA synthesis and NGS library preparation.  The present technical 
evaluation contributes to a more targeted virus discovery strategy. It would be interesting to 
test pretreatment efficiencies on a wider range of tissue sample and virus types. Moreover, in 
an attempt to further improve the virus detection sensitivity on clinical tissue samples, it 
would also be interesting to evaluate the analytical sensitivity of widely used virion 
concentration approaches like ultracentrifugation, ultrafiltration and PEG precipitation. 
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Supplementairy material 
Table S1: Sequencing output and identified NDV reads per investigated condition. Serum (S) & lung tissue (T) sample were spiked with 104 
EID50/ml NDV. Control = no virion enrichment, 2-step = 2-step virion enrichment, DNase = DNase treatment on RNA extract, Removal = 
rRNA removal on RNA extract, rPCR = random PCR amplification, 1 and 2 are independent repetitions of either RNA extraction or rRNA 
removal. 
condition name reads 
NDV 
reads 
% of NDV 
reads 
% of other 
viral reads 
condition name reads 
NDV 
reads 
% of NDV 
reads 
% of other 
viral reads 
S-Control1 1,144,348 10 0.000874% 0.000961% T-Control1 2,691,116 2 0.000074% 0.000186% 
S-Control2* 3,229,212 25 0.000774% 0.000434% T-Control2* 4,676,814 8 0.000171% 0.000086% 
S-Control1 + Dnase 2,072,774 1,577 0.076082% 0.112217% T-Control1 + Dnase 3,177,102 4 0.000126% 0.000630% 
S-Control2 + Dnase*  5,444,839 3,383 0.062132% 0.111592% T-Control2 + Dnase*  3,511,400 2 0.000057% 0.037051% 
S-Control2 + Dnase + Removal* 4,339,431 4,603 0.106074% 0.283539% T-Control2 + Dnase + Removal* 7,995,759 131 0.001638% 0.009655% 
S-Control1 + Removal1 2,410,250 6 0.000249% 0.000622% T-Control1 + Removal1 2,985,232 82 0.002747% 0.005159% 
S-Control1 + Removal2 2,325,942 4 0.000172% 0.000516% T-Control1 + Removal2 1,966,193 40 0.002034% 0.006307% 
S-2step 413,464 62 0.014995% 0.014028% T-2step 3,456,036 9 0.000260% 0.001128% 
S-2step + Removal1 1,438,088 40 0.002781% 0.013907% T-2step + Removal1 2,737,682 70 0.002557% 0.045769% 
S-2step + Removal2 3,043,698 383 0.012583% 0.024083% T-2step + Removal2 2,147,566 54 0.002514% 0.037624% 
S-2step + rPCR 1,502,810 161 0.010713% 0.000532% T-2step + rPCR 2,251,576 0 0.000000% 0.000178% 
S-2step + Removal2 + rPCR 1,525,072 141 0.009245% 0.000656% T-2step + Removal2 + rPCR 1,903,854 1 0.000053% 0.012028% 
* Conditions that were sequenced on the second MiSeq sequencing run (more details: see Section 2.5). 
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(A) 
 
(B) 
Figure S1: Depth of coverage plots for serum conditions: (A) Control2+Dnase (blue line) & 
Control2+DNase+Removal (red line), and (B) 2-step+rPCR (blue line) & 2-step & 2-
step+Removal2+rPCR (red line). Serum was each time spiked with 104 EID50/ml NDV. 
Control = no virion enrichment, 2-step = 2-step virion enrichment, DNase = DNase treatment 
on RNA extract, Removal = rRNA removal on RNA extract, rPCR = random PCR 
amplification. 
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Viral metagenomics, i.e. characterization of the complete viral diversity in a clinical sample 
or environment, is very promising for identifying viral pathogens in clinical and public health 
settings. Various workflows have been described in the literature and were discussed in 
Chapter 1. Briefly, viral metagenomic workflows can be divided into 5 main parts: sample 
preparation, sequence independent amplification, sequencing, data analysis and follow-up of 
the results.  At each step challenges remain, of which some have been addressed in the 
presented thesis.  
The first aim was to adopt a promising and widely applicable viral metagenomic workflow, 
which allows both sensitive virus detection and high quality full genome sequencing.  Based 
on a thorough literature review (Chapter 1), rPCR SISPA was selected as sequence 
independent amplification method.  
The initial viral metagenomic workflow was similar to the protocol presented by Djikeng et 
al. [1], and combines virion enrichment steps, rPCR SISPA amplification, molecular cloning 
and limited Sanger sequencing. After successful testing of different model viruses 
representing different genomic structures, the workflow was combined with NGS and applied 
to ongoing diagnostic and research projects. For the initial NGS technology, the 454 
pyrosequencing technology was selected. This was because at the start of this thesis 454 
pyrosequencing was the most accessible and appropriate NGS technology (at that time most 
alternative platforms produced insufficient read lengths) for metagenomic purposes [2]. That 
is why most NGS-based viral metagenomic studies use this technology (reviewed in Tables 2, 
3, 5 of Chapter 1).   
In Table 1 (of this Chapter) an overview is given of the different case studies that have been 
performed.  First, the method was successfully applied on 3 case studies, using virus cell 
culture samples (Chapters 3.2-3.4). Besides correct viral identification, it provided (nearly) 
complete genome sequences with only limited sequencing efforts (i.e. amount of sequencing 
output per sample; Table 1). Limited sequencing efforts ensure the economic feasibility of 
similar sequencing projects. When no or limited sequence information is available for a 
studied virus, performing a metagenomic workflow on virus isolates in order to obtain a full 
genome sequence is less cumbersome compared to a primer walking strategy, which entails 
extensive rounds of primer design and PCR amplification.  
Chapter 5  General discussion 
     
232 
 
Determination of full viral genomes has many advantages for outbreak management. It 
allows: 
• Proper phylogenetic analysis (which widens the understanding of genetic diversity of 
these viruses) 
• Pathotyping (e.g. documentation of known molecular markers of avian influenza 
viruses) 
• Detailed molecular epidemiology analysis 
• Outbreak tracing during (or after) disease outbreaks 
• Development of new molecular diagnostic tests 
The benefit of full viral genome sequening was clearly demonstrated by the identification of 
transhemispheric reassortment of genomic segments of avian influenza viruses in European 
gulls (Chapter 3.3).  
Traditional diagnostic methods may fail to properly identify certain variants and/or co-
infecting variants (as in Chapter 3.2) or unexpected viruses (as in Chapter 3.4) in a single 
sample.  
In chapter 3.4 the aim was to characterize RNA viruses (paramyxoviruses). Beside these 
viruses, co-existing DNA viruses possessing circular single stranded genomes could be 
identified using the same workflow (Table 1). These findings demonstrate that the NGS-based 
metagenomic workflow is of great use for quality control of biological samples like viral 
stocks. This approach has also been used for quality control of vaccines [3, 4] and cell culture 
substrates [5-7].  
In addition, NGS-based metagenomics allowed identification of genetic mutations and 
minority variants. For instance, in Chapter 3.4 a STOP codon in the matrix gene of the pigeon 
paramyxovirus genome was identified in 15 % of the viral population in one isolate. Although 
the exact virion concentrations were not known in all 3 virus isolate case studies, virions were 
well concentrated in cultured samples (often ≥ 107 virions/ml). Furthermore, the allantoic 
fluid containing these virus isolates (Table 1), was not significantly contaminated with genetic 
material from cells.  
The application of a NGS-based viral metagenomic workflow to samples rich in genetic 
material samples is much more challenging. Such samples contain limited amounts of viral 
nucleic acids compared to high amounts of background nucleic acids. This was clearly 
experienced in the SBV case study in Chapter 3.5. Using a relatively low sequencing effort 
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(454 technology), it was only possible to identify SBV in brain tissue samples containing high 
viral loads.  The two samples in which SBV could be identified, contained comparable viral 
RNA loads (circa 7.65 log10 RNA copies/µl), but more SBV reads were identified in one 
sample compared to the other, which resulted in a larger genome coverage. This was most 
likely due to differences in sequencing efforts between the two samples (95,000 reads versus 
25,000 reads), confirming previous findings of increased virus discovery sensitivity at larger 
sequencing efforts [8].  It is obvious that using NGS platforms generating higher amount of 
reads will increase the chance of detecting virus in clinical biopsy samples (e.g. Illumina 
platforms are generating millions of reads with acceptable read lengths up to 2×300 bp). 
Nevertheless, it was shown that, using only limited sequencing efforts (circa 60,000 reads), 
SBV identification was possible in brain tissue samples containing about 104 to 106 virions 
per ml. Although this observed sensitivity is consistent with sensitivities estimated in other 
studies (e.g. [1, 9]), it is extremely difficult to compare virus detection sensitivities between 
different case studies as this depends on many parameters. Besides the sequencing effort, 
sequencing platform, and sample type and condition (liquid versus tissue; targeted sample 
selection; stage in the viral life cycle; storage conditions), the applied virion enrichment steps, 
amplification method and studied virus type (genome length; RNA vs DNA genome; virion 
encapsidated vs integrated in host genome) will all influence the virus discovery sensitivity.  
After gaining initial experience with the viral metagenomic workflow (Chapters 3.2-3.5), the 
workflow was further optimized and applied to a case study where presence and type of virus 
were unknown. A cluster of diseased dairy cattle were selected for which the cause of the 
disease was unknown (Chapter 3.6). Diseased animals presented high fever, anorexia, milk 
drop, diarrhea, redness of nose and teat, and two animals had died. All animals tested negative 
following different diagnostic tests for possible causative pathogens. Serum and whole blood 
samples were taken from an animal that started to show high fever and a few days later 
presented with the clinical signs described above. Because it is known that a viremia (i.e. viral 
particles are present in the blood) is mostly accompanied by fever, we considered that these 
samples were ideally optimized to target potential disease related viruses. The contigs and 
singletons that were classified as viruses in the viral metagenomic workflow were further 
analyzed. Different potential pathogens were excluded by newly developed qPCR tests on 
original samples and controls. This follow-up allowed us to identify a laboratory contaminant 
(a previously sequenced library) and a reagent contaminant (from the extraction kit used). 
Although no possible causal virus was discovered, this study clearly demonstrated the 
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importance of potential contamination at different levels in metagenomic workflows, and of 
thorough follow-up diagnosis.  
Identification of potential viral sequences is only the first step and should be compared to 
complementary data from serology, pathology, epidemiology, PCR prevalence studies, 
isolation, electron microscopy, etc.  Comparing metagenomic outputs between samples of 
diseased and healthy animals will also help in identification of causal virus(es) of a certain 
disease or syndrome (e.g. [10]). Ultimately, the Koch’s postulates should be fulfilled to 
establish a causative relationship between the viral pathogen(s) and a disease [11]. 
Most recently, our optimized workflow, which was based on recommendations from Chapter 
4, was applied on a selection of unexplained abortion cases in cattle. Although a BVDV 
specific ELISA test gave negative results (based on antigen detections on the skin of the 
fetus), the applied metagenomic workflow allowed the identification of a type 1 BVDV in one 
sample. Follow-up investigations are still ongoing, but it can already be confirmed that 
besides the nearly full genome sequence of BVDV, the complete genome sequence of a type 1 
Bovine polyomavirus was also characterized. These data confirm the sensitivity and 
diagnostic potential of the workflow. However, a correlation with disease was not possible 
and difficult given the small sample size and a context of much dispersed epidemioligy of the 
symptoms. 
 
Table 1 (next page): Overview of the different case studies performed in the present thesis. 
Per case study sequencing effort, identified viruses, percentage genome covered and the 
added value of the viral metagenomic workflow are shown. 
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Case study Chapter 3.2 Chapter 3.3 Chapter 3.4 Chapter 3.5 Chapter 3.6 
Application Two avian parayxoviruses 
(APMV) isolated during a 
wildlife surveillance program 
in mallards 
9 different avian influenza 
(AIV) virus isolates from a 
surveillance program in wild 
gulls and shorebirds 
11 pigeon 
paramyxoviruses 
(PPMV1)  isolated during 
routine diagnostics in 
pigeons 
5 field samples of 
sheep infected with a 
novel emerging 
orthobunyavirus 
Undiagnosed cluster of 
diseased cattle showing 
symptoms of viral infection. 
Besides clear symptoms of 
illness, two animals died 
Sample type 
(workflow) 
Isolates -Allantoic fluid (RNA 
viruses) 
Isolates -Allantoic fluid (RNA 
viruses) 
Isolates -Allantoic fluid 
(RNA viruses) 
Brain tissues (RNA 
viruses) 
Blood and serum (DNA & 
RNA viruses) 
Sequencing effort 5,000 - 12,000 reads per virus 
library; multiplexed on a GS 
FLX 
3,300 - 12,000 reads per virus 
library; multiplexed on a GS 
FLX 
Average of 45,000 reads 
per virus library; 
multiplexed on a GS FLX 
Average of 59,400 
reads per virus library; 
multiplexed on a GS 
FLX 
32,000 reads each for the DNA 
& RNA virus discovery 
workflows; multiplexed on a 
GS Junior 
Identified viruses 
(family, genome 
type) 
APMV serotype 4 & 6 
(Paramyxoviridae,  -ssRNA) 
 
AIV subtypes H3N8, H5N2, 
H6N1, H11N9, H12N5, 
H13N6, H13N8 and H16N3 
(Orthomyxoviridae, -ssRNA, 
segmented) 
All 11 samples: PPMV1 
(Paramyxoviridae, -
ssRNA)  
In 4 samples also: pigeon 
circoviruses, PiCV 
(circoviridae, circular 
ssDNA) 
Schmallenberg virus, 
SBV (Bunyaviridae, -
ssRNA, segmented) 
Background: phages (dsDNA), 
herpesvirus-like (dsDNA), … 
Extraction kit contaminant: 
parvovirus-like (ssDNA) , 
circovirus-like (ssDNA) 
Lab contaminant: Goat pox 
(Poxviridae, dsDNA) 
% genome 
covered 
Sample1: AMPV4: 100% 
Sample2: AMPV4: 20%, 
AMPV6: 99% 
 
Ranging from 78% to 96%  PPMV1’s: 
mostly 92 - 100%,  
one sample 47.3% 
PiCV’s: 61 - 99% 
0% - 50% n/a 
Added value of 
approach 
Identification and full genome 
sequencing of (unknown) 
APMVs;  
Identification of co-existing 
viruses 
Subtyping influenza variants; 
Full genome sequencing of 
segmented viruses; 
Identification of  
transhemispheric reassortment 
Full genome sequencing; 
Identification of genetic 
variations and co-infecting 
viruses 
Viral identification in 
tissue samples; 
Illustrates importance 
of sample selection 
Identification of contaminating 
viral sequences;  
Illustrates importance of 
control strategy and follow-up 
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Another aim of this thesis was to investigate the nature and origin of amplification biases 
resulting from the most promising pre-amplification method, which was the rPCR SISPA 
method. The rPCR SISPA amplification technique relies on a primer consisting of a 3’ 
random part (to serve as primer in complementary DNA synthesis) and a 5’ defined tag 
sequence (used as primer annealing site in subsequent amplification). Own experience with 
this method and literature review revealed an uneven sequence depth along sequenced viral 
genomes. 
In Chapter 4.1, it was shown that the tag sequence was the main contributor to the observed 
uneven sequence depth. Furthermore, it was proven that this oligonucleotide annealing bias 
can be reduced by extending the random oligomer sequence and by combining sequence data 
from multiple rPCR SISPA reactions using different 5’ tag sequences. However, as long as 
there is an amplification step used, some kind of amplification bias will remain.  PCR 
amplification is known to produce amplification artefacts such chimeras, mutations, and 
heteroduplexes [12]. Karlsson and colleagues proved that direct sequencing of an unamplified 
viral metagenomic sample gives a more even distribution of sequencing reads along the 
complete genome [13].  
In Table 2, the viral metagenomic studies in the veterinary field are listed which were 
published during the time frame of this PhD. It is notable that various studies are no longer 
using a pre-amplification step. This is made possible by recent advances of NGS platforms 
and library preparation methods which enable less input DNA for sequencing and increased 
feasibility of direct sequencing while still allowing sufficient read length for data analysis 
(reviewed in [14]; [2] update http://www.molecularecologist.com/next-gen-fieldguide-2014/).  
Although truly amplification-free NGS library preparations still require considerable amounts 
of input material (e.g. 1 µg for Illumina TruSeq PCR-free kit), new library preparation 
strategies have been developed allowing ultra-low DNA input. One example is the Nextera 
XT kit from Illumina. Although this method is not completely PCR and bias free [15-17], it 
proved its usefulness in viral metagenomic studies in Chapter 4.2. Not only was the genome 
coverage much more evenly distributed compared to rPCR SISPA amplified template DNA, 
direct sequencing of low input DNA or cDNA was possible (< 0.5 pg/µl). Furthermore, an 
increased proportion of unassigned reads were found in the rPCR SISPA samples when 
compared to the direct cDNA sequenced samples, suggesting the creation of amplification 
artifacts. This is in accordance with other reports of increased unassigned reads following 
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sequence independent amplification of DNA for NGS sequencing [13, 18]. The usefulness of 
rPCR SISPA for virus identification and qualitative genome sequencing was proven by means 
of different case studies in this thesis (Chapter 3.2-3.6). However, these new insights suggest 
that even better and higher quality results would be obtained in these case studies if the rPCR 
SISPA pre-amplification step would be omitted and direct sequencing would be performed 
using an illumina sequencing based NGS platform with the Nextera library preparation 
method. 
It should be noted that some commercial available NGS library preparation kits are based on 
sequence independent amplification methods. For instance the Illumina ScriptSeq v2 RNA-
Seq library preparation kit (Epicenter) is based on the rPCR SISPA approach and uses a 
random hexamer with sequence tag for production of cDNA. This sequence tag is then used in 
subsequent rounds of PCR amplification to directly incorporate the sequencing adaptor. 
Cell culture samples containing high viral amounts and low levels of contaminating nucleic 
acids are the most accessible sample for sequence independent generation of full viral 
genomes (Table 2). However due to increased sequencing output, decreased sequencing costs 
and development of novel bioinformatics tools, it has also become possible to obtain full viral 
genomes in samples containing lower viral amounts or sample types containing more 
background nucleic acids like tissues (Table 2).  
A typical strategy for determining full viral genomes in a random manner is the following: (1) 
performing a NGS-based viral metagenomics workflow to identify as much as possible viral 
sequences; (2) designing PCR primers to close remaining gaps in the genome sequence, and 
then sequencing (Sanger technology) of these PCR amplicons; (3) optionally, perfoming a 
RACE or similar strategy to get the genome end sequences which are are typically difficult to 
cover (e.g. [19]).  
Even in a strong background of eukaryotic and prokaryotic DNA, viral sequences have been 
identified without the use of specific viral enrichment protocols (Table 2, e.g. [20]). However, 
in order to keep the sequencing effort limited and increase the chance of detecting viruses 
present at a very low level of abundance, pretreatment steps are still of great importance and 
can make the workflow more sensitive for virus discovery (Table 2).  Nevertheless, caution 
should be taken because sample preparation methods can have a large impact on the 
composition of the characterized virome (e.g. [21]).  
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At the start of this PhD, not much was known about the real value of different sample 
preparation methods and their relative sensitivity for virus discovery. Therefore, another aim 
of this PhD was to investigate the value of different sample preparation methods and their 
relative sensitivity for virus discovery.  
In Chapter 4.2, different convenient and widely used pretreatment steps for RNA virus 
identification in both a serum sample and lung tissue samples were compared. The Illumina 
MiSeq platform was selected as the NGS platform. In the past, 454 pyrosequencing platforms 
were the NGS platforms of choice for viral metagenomics due their long read lengths [2, 22]. 
However, other NGS technologies have evolved in producing longer reads and are more cost 
effective then 454, making them very suitable for viral metagenomics (Table 2). The Illumina 
MiSeq reagents with the longest possible read length of 2×300bp paired end was selected (i.e. 
one library DNA molecule is sequenced in both directions, keeping track of the link between 
the 300bp read for each strand). In addition, the bioinformatics data analysis workflow was 
optimized to cope with the relatively high sequencing output of the Illumina MiSeq platform 
(circa 44-50 million paired end reads per run using a V3 sequencing reagent kit). A 
paramyxovirus (-ssRNA, 15kb genome) was spiked in 2 clinical samples, serum and lung 
tissue, at a fixed virus concentration of 104 EID50/ml. In preliminary experiments with a 454 
GS Junior platform (output ranges from 100,000 to 200,000 reads per run), it was found that 
105 EID50/ml of this virus, spiked on lung tissue, was the limit of detection when using half 
of the sequencing capacity of this NGS platform (data not shown). The illumina MiSeq 
allowed us to multiplex 18 conditions on one run, and still generating circa 2 million reads per 
sample. The main conclusion of this comparative study was that the recommended 
pretreatment strategy depended strongly on the amount and composition of the sample 
background nucleic acids. A filtration and subsequent nuclease treatment step increased virus 
discovery sensitivity in both serum and tissue. Simple DNase treatment on the RNA extract 
resulted in the highest improvement in RNA virus discovery sensitivity in the serum sample, 
while an rRNA removal on the RNA extract had the biggest improvement in the tissue 
sample.  
The tissue samples of Chapter 4.2 were before homogenization incubated in buffer containing 
lytic antibiotics (i.e. kills bacteria directly). We included this step because we wanted to use 
0.45 µm pore size filters in the 2-step pretreatment condition in order to allow flow through of 
most virus types (“universal protocol”). As this filter pore size allows also flow through of 
small bacteria (e.g. of the genus Mycoplasma), we wanted to destroy these first and 
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subsequently degrade their nucleic acids in the nuclease treatment step. It should be noted that 
RNases are not very effective in the degradation of rRNA. Nevertheless, our lung tissue 
control sample contained mainly eukaryotic rRNA (bacterial rRNA <0.04% of all rRNA 
reads).  
During the completion of our optimization study (Chapter 4.2), two studies were published 
that compared the impact of alternative methods used to generate viral metagenomes [23, 24]. 
Li and colleagues used a low complexity biological sample (mixture of mainly cell culture 
supernatants and allantoic fluids) containing 25 different RNA and DNA viral pathogens [23]. 
Filtration and nuclease treatment were compared to a control sample without treatment, rPCR 
SISPA amplification was compared to no pre-amplification, and different RNA extraction kits 
were used. Filtration and nuclease treatment slightly decreased the number of viral reads and 
number of viruses identified. These results are probably a consequence of the use of a low 
complexity sample type as such samples contained limited background host and bacterial 
nucleic acids when compared to more complex clinical samples such as tissue, plasma, feces 
and respiratory secretions. As in Chapter 4.2, the authors also discourage the use of rPCR 
SISPA amplification if sufficient input DNA is available for NGS library preparation. Kohl 
and colleagues used a clinical sample (mixture of different organ tissues) containing 4 
different viral pathogens at different concentrations to compare methods of virus purification 
and enrichment for metagenomic virus detection [24]. Different homogenization, filtration, 
nucleic acid digestion, concentration, nucleic acid extraction and random amplification 
methods were compared based on qPCR results to an unprocessed control extract. 
Subsequently, they validated their optimized workflow on the tested clinical sample and a 
diagnostic lung tissue sample by sequencing on the Ion Torrent PGM platform. Although they 
were not able to identify all 4 viruses in the test sample, a good improvement was observed 
compared to some conventional pretreatment and direct sequencing approaches for the Ion 
Torrent PGM. 
The effect of different pretreatment/amplification methods seems to depend on various 
parameters like sample type, virus type/concentration, amount/quality of nucleic acids, etc. 
Evidence from this and other studies is increasingly indicating that no universal optimal viral 
metagenomic workflow exists. Results of protocol comparison studies (Chapter 4.2; [21, 23-
25]) are therefore difficult to compare as many variable parameters exist, but they all provide 
useful data. Their results emphasize that metagenomic workflows have to be flexible. 
Depending on the case study concerned, a variety of steps may be included or excluded from 
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the workflow. Here, I outline some recommendations which could be useful when planning 
future metagenomic virus discovery studies: 
• The clinical sample should be selected with great care. It is advisable to have good 
prior knowledge about: clinical symptoms, the epidemiological context of the disease 
or syndrome, sampling time and type of target in order to increase the chance of 
finding viruses in large amounts. Sample storage conditions and/or previously 
performed diagnostic tests should also be considered. 
• Inclusion of control samples may help to exclude possible contaminations during the 
workflow, or to identify the “normal virome” of the target host species. For instance, a 
similar sample type from a healthy animal could be processed and sequenced along 
with the clinical samples. 
• If large sample volumes are readily available, methods for concentration can be 
considered. For instance, our own experience of concentration using Amicon Ultra 
centrifugal filters (Merck Millipore) indicated similar concentration efficiencies to 
ultracentrifugation. Such filters provide a convenient and efficient way to improve 
virus discovery sensitivity. 
• Generally, virus enrichment steps like nuclease treatment work well, but are dependent 
on the virus target and sample type. For instance, nucleic acids not protected by a 
protein coat or lipid envelope may be of great importance (e.g. retrovirus integration). 
In such case it is recommended not to include a nuclease treatment step. 
• After the nucleic acid isolation, nucleic acid concentration should be measured and 
quality checked with the Agilent bioanalyzer (Agilent technologies) or equivalent 
instruments. This will help to make decisions on whether to perform additional 
treatments like rRNA removal (if clear ribosomal peaks are visible on the bioanalyzer 
profile) or DNase treatment (if high DNA concentration is measured in the total RNA 
extract of the RNA virus discovery workflow) etc. 
• The choice of NGS platform and library preparation method is of great importance. 
Recent library preparation methods allow sequencing with low inputs. However, as 
amplification is difficult to omit completely, amplification bias should be taken into 
account (coverage bias and biased representation of the different species present in 
sample). In the future, it will be important to critically evaluate the evolution of NGS 
technologies, because they are still evolving towards lower cost, greater flexibility, 
and increased accuracy. 
Chapter 5  General discussion 
     
241 
 
• For the data analysis part, it’s critical to realize that no ideal nucleic acid database 
exists. Databases will always be biased towards the known species and towards 
species which are most frequently sequenced. This will inevitably affect metagenomic 
analysis workflows that are based on similarity searching to know sequences. 
In conclusion, this PhD thesis realized the following achievements: 
• A universal and widely used diagnostic workflow based on random amplification and 
next generation DNA sequencing was successfully adapted, evaluated for virus 
diagnostics and characterization of high quality complete genome sequences through 
different case studies, and further optimized. Benefits and challenges were discussed. 
• The nature and origin of amplification bias of the rPCR SISPA pre-amplification 
method was identified and solutions were proposed to minimize the bias.  
• Different sample preparation methods and their relative sensitivity for virus discovery 
were compared. In addition, direct random-based viral genome sequencing without a 
preliminary pre-amplification step was evaluated. Guidelines have been provided for 
future metagenomic experimental design. 
The list of diseases caused by viral pathogens is ever changing and growing [26]. Although 
metagenomic approaches pre-dates next-generation sequencing, current evolutions in NGS 
technologies are about to revolutionize diagnostics of infectious diseases in both human 
health and veterinary medicine [27-29]. Metagenomic workflows enable comprehensive 
characterization of all viruses present in a clinical sample. Thorough follow-up analysis is 
required to exclude possible false-positive results. In the future, this strategy may complement 
a front-line diagnostic test for infectious diseases. Currently, it is recommended to use it in 
parallel with conventional diagnostic tests.   
The work presented in this thesis offers a clear documentation of the potential of NGS based 
methods for the identification of viruses and for the characterization of their complete genome 
sequences. Solid workflows, both for sample treatment and data analysis are now available to 
allow virus identification and further genome characterization.  
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Table 2: Review of viral metagenome studies in the veterinary field after 2011. Also studies on zoonosis vectors are included. Studies are listed 
according to sample type. S: sample type, C: cell culture (supernatants), R: respiratory/eye swabs, F: feces, B: blood, T: tissue, A: arthropod 
vectors, PT: pretreatment/viral enrichment methods were used, AM: amplification method, rPCR: random PCR, pWGA: primase-based whole 
genome amplification [30], SPIA: single primer isothermal amplification, DOP-PCR: degenerate-oligonucleotide primer PCR [31], rPCR 
TruSeq: variation of Illumina Truseq protocol where rPCR SISPA method is used to generate cDNA, *: novel virus or novel variant. 
S Ref Application Viruses (family) PT AM Sequencing 
C [32] Full genome characterization of a cytomegalovirus 
isolated from cynomolgus macaques  
Cynomolgus macaque cytomegalovirus* (Herpesviridae) yes none Illumina GAII 
C [33] Full genome characterization of reference isolate of 
bluetongue virus serotype 16  
Bluetongue virus type 16 (Reoviridae) no ligation-based 
SISPA 
Cloning + Sanger 
C [34] Full genome characterization of a reovirus isolated 
from liver of sick geese 
Goose orthoreovirus (Reoviridae) no ligation-based 
SISPA 
Cloning + Sanger 
C [35] Full genome characterization of bluetongue virus 
serotype 4 
Bluetongue virus subtype 4 (Reoviridae) yes ligation-based 
SISPA 
Illumina MiSeq 
C [36] Characterization of virus isolated from a liver tissue of 
a dog with idiopathic acute hepatitis 
Canine adenovirus type 1 (Adenoviridae) yes VIDISCA-
454 
454 GS FLX 
C [37] Characterization of a parapoxvirus ovis isolate for 
identification of useful ORFs 
Orf virus (Poxviridae) ? none Cloning + Sanger 
C [38] Characterization of Cotia virus isolate from mice in 
order to allow correct classification  
Cotia virus (Poxviridae) yes none 454 GS FLX 
& Illumina GAIIx 
C [39] Full genome characterization of rescued bluetongue 
viruses by reverse genetics 
Bluetongue virus type 6, 8 (Reoviridae) no ligation-based 
SISPA 
454 GS 20 
C [40] Full genome sequencing of Eubenangee viruses 
isolated from mosquitoes and Culicoides 
Eubenangee virus, Pata virus, Tilligerry virus (Reoviridae) no ligation-based 
SISPA 
Cloning + Sanger 
C [41] Full genome characterization of a viral isolate from an 
outbreak of disease in a collection of pythons 
Sunshine virus* (Paramyxoviridae) yes none Illumina 
C [42] Full genome characterization of a bat virus isolated Bat betaherpesvirus (Herpesviridae) yes none 454 GS FLX 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
C [43] Genome sequencing of c  owpox virus mutant lacking 
host range factor CP77 
Cowpox virus (Poxviridae) yes none 454 GS FLX 
C [44] Monitor virus evolution during serial passaging of the 
causative agent of Marek’s disease in chickens 
Gallid herpesvirus 2 (Herpesviridae) yes none 454 GS 20 
C [45] Full genome characterization of a duck virus isolate Avian Paramyxovirus type 4 (Paramyxoviridae) no rPCR 
SISPA 
Illumina 
C [46] Full genome characterization of a virus isolated from 
the brain of a civet displaying clinical signs of rabies 
Ikoma lyssavirus (Rhabdoviridae) yes none 454 GS FLX 
C [47] Full genome characterization virus isolated from pool 
of mosquitos 
Corriparta virus (Reoviridae) no ligation-
based 
SISPA 
Cloning + Sanger 
C [48] Full genome characterization virus isolated from 
tissues of bats 
Fikirini bat rhabdovirus* (Rhabdoviridae) yes SPIA Ion torrent PGM 
C [49] Full genome characterization of two viruses isolated 
from turkey and pheasant presenting diarrhea 
Pheasant rotavirus A, Turkey rotavirus A (Reoviridae) yes rPCR 
SISPA 
454 GS FLX 
C [50] Characterization of virus isolated from a dead bat Bokeloh bat lyssavirus (Rhabdoviridae) yes none Illumina HiSeq  
C [51] Genome characterization of a Fowl adenovirus strain Fowl adenovirus 5 (Adenoviridae) yes none Illumina GAIIx 
C [52] As a method of typing bluetongue virus isolates Bluetongue virus (Reoviridae) no none  Illumina GAII 
C [53] Genome haracterization of a virus in laryngeal tissue 
of a dead stranded dolphin 
Dolphin polyomavirus 1* (Polyomaviridae) yes none Ion torrent PGM 
C [54] Compare sensitivity for rotavirus A detection between 
antigen detection kits, rt-PCR and NGS 
Bovine rotavirus A (Reoviridae) yes none Illumina MiSeq 
C [55] Full genome characterization of a Schmallenberg virus 
isolated from the brain of a malformed lamb 
Schmallenberg virus (Bunyaviridae) yes none Illumina MiSeq 
C [56] Full genome characterization to investigate a 
contamination event in a bluetongue virus 
vaccination trial 
Bluetongue virus serotype 11 viruses (Reoviridae) no ligation-
based 
SISPA 
454 GS FLX 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
C [57-
59] 
Complete genome sequencing of a Bovine herpesvirus 
vaccine and field strains 
Bovine herpesviruses 1 (Herpesviridae) no none SOLiD & Illumina 
MiSeq 
C [60] Characterization of Lone Star Virus which was 
isolated from ticks 
Lone Star Virus* (Bunyaviridae) yes none Illumina MiSeq 
C [61] Genome characterization of Lyssaviruses from viral 
isolates (brain & cell culture) 
Different lyssavirus strains (Rhabdoviridae) yes none 454 GS FLX+ 
C [62] Genome characterization of nasal isolates from an 
acute respiratory outbreak in a baboon colony 
Simian adenovirus C* (Adenoviridae) yes none Illumina HiSeq 
C [63] Genome characterization of virus isolated from a green 
bush viper presenting with multiple disorders 
Bush viper reovirus (Reoviridae) yes rPCR SISPA Ion torrent PGM 
C [64] Genome characterization of 2 turkey adenovirus 
isolates 
Turkey adenovirus 4, 5 (Adenoviridae) yes none Illumina HiSeq & 
GAIIx 
C [65] Characterization of virus isolated from a deer with 
clinical signs of epizootic haemorrhagic disease 
Mobuck virus*, Epizootic haemorrhagic disease virus 
(Reoviridae) 
yes ligation-based 
SISPA 
Ion torrent PGM 
C [66] Genome characterization of virus isolated in a crow 
presenting neurological disorders 
Tvärminne avian virus (Reoviridae) yes rPCR SISPA Ion torrent PGM 
C [67, 
68] 
Characterization of guinea pig cytomegalovirus isolate 
or directly from salivary gland of infected animals  
Caviid herpesvirus 2 (Herpesviridae) yes none Illumina & 
PacBio RS 
C [69] Characterization of virus isolate, isolated from 
mosquitoes 
Tibet orbivirus* (Reoviridae) no rPCR SISPA 454 GS FLX 
C [70] Genome characterization of virus responsible for 
severe clinical distemper in dogs and wolves 
Canine distemper virus (Paramyxoviridae) yes none Ion Torrent PGM 
C [71] Characterization of virus isolated from ticks Hunter Island virus*  (Bunyaviridae) yes yes 454 GS FLX 
C [72] In depth investigation of isolates from a recent 
outbreak of a virulent bovine viral diarrhea virus 
Bovine viral diarrhea virus type 2 (Flaviviridae) no none 454 GS FLX & 
Illumina MiSeq 
C [73] Characterization of virus isolated from a diseased 
Mississippi sandhill crane 
Highlands J virus (Togaviridae) yes rPCR SISPA Illumina MiSeq 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
C [74] Genome characterization of a virus isolated from a 
wild sooty mangabey monkey found dead 
Monkeypox virus (Poxviridae) no none Ion Torrent PGM & 
Illumina HiSeq 
C [75] Genome characterization of a dolphin virus isolate  Dolphin rhabdovirus (Rhabdoviridae) yes rPCR SISPA 454 GS Junior 
C [76] Characterization of a virus isolated from a bat Fruit bat alphaherpesvirus 1* (Herpesviridae) no none 454 GS Junior 
C [77] Identification of viruses isolated from bats and which 
cause severe disease in mice 
Nairoviruses (Bunyaviridae) no rPCR SISPA 454 GS Junior 
C [78] Genome characterization of a West Nile virus strain 
isolated from ticks sampled from livestock 
West Nile virus (Flaviviridae) yes rPCR SISPA 454 GS FLX 
C [79] Australian mosquitos causing cytopathic effects in 
mammalian cell cultures 
Beaumont virus*, North Creek virus* (Rhabdoviridae); 
Murrumbidgee virus*, Salt Ash virus* (Bunyaviridae), 
Liao Ning virus, Warrego virus, Wallal virus 
(Reoviridae) … 
yes rPCR SISPA 454 GS FLX 
none Illumina MiSeq 
C [80] Characterization of a virus isolated from mosquitoes Nhumirim virus* (Flaviviridae) no rPCR SISPA-
like 
Illumina MiSeq 
C [81] Full genome sequencing of a novel simian adenovirus 
isolated from the urine of rhesus macaques 
Simian mastadenovirus D* (Adenoviridae) yes none Illumina MiSeq 
C [82] Studying quasispecies PRRSV variantions Porcine reproductive and respiratory syndrome virus 
(Arteriviridae) 
yes none Illumina MiSeq 
C [83] Characterization of virus which causes inclusion body 
rhinitis in newborn piglets 
Porcine cytomegalovirus (Herpesviridae) yes none Illumina GAIIX 
C [7, 
84] 
Test biological reagents and model cell culture 
substrates for adventitious agents 
Endogenous retroviruses (Retroviridae), Bovine viral 
diarrhoea virus (Flaviviridae), Hokovirus 
(Parvoviridae), nodavirus (Nodaviridae), bracovirus 
(Polydnaviridae) 
yes 
& 
no 
DOP-PCR 454 GS FLX & 
Illumina MiSeq 
& HiSeq 
R [85] Eye swab samples that were obtained from semi-
domesticated reindeer during an outbreak of 
infectious eye disease 
Rangifer tarandus papillomavirus 2,3* (Papillomaviridae), 
Cervid herpesvirus 3* (Herpesviridae) 
yes rPCR SISPA 454 GS Junior 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
R [86] Analysis for viruses in oral swab samples and 1 serum 
sample collected during outbreak of disease in seals 
Phocine herpesvirus 7* (Herpesviridae), Seal anellovirus 
4, 5, 6, 7* (Anelloviridae) 
yes rPCR SISPA 454 GS Junior 
R [87] Monitoring wild caribou for viruses in eye and nose 
swabs 
Rangifer tarandus granti: papillomavirus 
(Papillomaviridae), parvovirus* (Parvoviridae), 
polyomavirus (Polymaviridae), nidovirus* (unclassified 
Nidovirales) 
yes rPCR SISPA 454 GS Junior 
R [88] Metagenomics approach in the nasal swab of young 
dairy cattle with symptoms of bovine respiratory 
disease 
Bovine adenovirus-3 (Adenoviridae), Bovine adeno-
associated virus, Bovine parvovirus 2 (Parvoviridae), 
Bovine influenza D (Orthomyxoviridae) , Bovine 
herpesvirus 6 (Herpesviridae), Bovine rhinitis A and B 
(Picornaviridae), Bovine astrovirus* (Astroviridae) and 
picobirnaviruses* (Picobirnaviridae) 
yes rPCR Illumina HiSeq 
F [89] Analysis of the viral flora of pine marten and European 
badger feces 
i.a. Pine marten bocavirus* (Parvoviridae), Pine marten 
torque teno virus 1* (Anelloviridae), Meles meles fecal 
virus* (unclassified), Meles meles circovirus-like virus* 
(Circoviridae), paramyxoviridae-like 
yes rPCR SISPA 454 GS Junior 
F [90, 
91] 
Virome analysis for identification of novel mammalian 
viruses in pharyngeal and anal swab samples of bats  
i.a. Bat viruses* belonging to Herpesvirirdae, 
Papillomaviridae, Circoviridae, Parvoviridae, 
Picornaviridae, Flaviviridae, Retroviridae, 
Coronaviridae 
yes rPCR SISPA Illumina GA II 
F [92] Analysis of the viral flora in pig feces i.a. Pig stool-associated circular ssDNA 
virus*(unclassified), Pig kobuvirus, Pig enterovirus B 
(Picornaviridae), Pig rotavirus C (Reoviridae), Pig 
astrovirus (Astroviridae), Pig sapovirus (Caliciviridae), 
Pig picobirnavirus (Picobirnaviridae) 
yes rPCR SISPA 454 GS FLX 
F [93] Metagenomic analysis of viruses from bat fecal 
samples 
Bat: parvoviruses, AAV, feces associated picorna-like 
virus (Parvoviridae), circovirus (Circoviridae) … 
yes rPCR SISPA Illumina GA 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
F [94] Discovery of novel viruses in rectal swabs from bat, 
pigs, cattle, stray dogs, stray cats and monkeys 
i.a. Miniopterus schreibersii papillomavirus type 1* 
(Papillomaviridae) 
yes pWGA 454 GS FLX 
F [95] Analysis for causal virus of a high-mortality outbreak 
of enterocolitis in a colony of domestic rabbits 
Rabbit astrovirus (Astroviridae) yes rPCR SISPA Ion torrent PGM 
F [96-
98] 
Analysis of the viral flora in porcine fecal samples Parechovirus-like virus PLV-CHN* (Picornaviridae), 
astrovirus MLB1 (Astroviridae), Porcine bocavirus* 
(Parvoviridae) … 
yes rPCR SISPA 454 GS FLX 
F [99, 
100] 
Analysis of the viral flora in fecal samples of wild 
boars 
Porcine kobuvirus (Picornaviridae), Astrovirus wild boar 
(Astroviridae) 
yes rPCR SISPA 454 GS FLX 
F [101] Analysis of the viral flora in feces of 13 red foxes i.a. Fox: parvovirus*, bocavirus*, adeno-associated virus* 
(Parvoviridae), hepatitis E virus* (Hepeviridae), 
astroviruses* (Astroviridae), picobirnaviruses* 
(Picobirnaviridae) 
yes rPCR SISPA 454 GS FLX 
F [102] Analysis of intestinal content of freshwater carp Banna-like virus* (Reoviridae) yes rPCR SISPA 454 GS FLX 
F [103] Analysis of the viral flora in diarrheal fecal samples 
from sick pigs 
Porcine stool-associated circular virus 2, 3* (unclassified 
ssDNA virus) 
yes rPCR SISPA 454 GS FLX 
F [104] Metagenomic analysis of the ferret fecal viral flora Ferret: kobuviruses*, parechovirus* (Picornaviridae), 
papillomavirus* (Papillomaviridae), coronavirus 
(Coronaviridae), hepatitis E virus (Hepeviridae); 
Aleutian mink disease virus (Parvoviridae), Murine 
astrovirus STL1 (Astroviridae) … 
yes rPCR SISPA 454 GS Junior 
F [105] Analysis diversity of viral flora in pooled fecal 
samples of diarrhoeic piglets 
i.a. Porcine: stool-associated single-stranded DNA virus*, 
posavirus-1* (unclassified), circovirus-like virus* 
(Circoviridae), picobirnavirus*, kobuvirus 
(Picobirnaviridae), epidemic diarrhea virus, torovirus 
(Coronaviridae), sapovirus (Caliciviridae), bocavirus-4 
(Parvoviridae), Torque teno sus virus 2 (Anelloviridae) 
yes none Illumina HiSeq 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
F [106] Metagenomic analysis of the fecal viral flora of a 
healthy cat 
Feline: sakobuvirus A* (Picornaviridae), bocavirus 2*, 
astrovirus Viseu (Astroviridae), rotavirus Viseu* 
(Reoviridae) and picobirnavirus* (Picobirnaviridae) … 
yes rPCR SISPA Illumina MiSeq 
F [107, 
108] 
Identify novel DNA viruses associated with Adélie 
penguins 
Pygoscelis adeliae papillomavirus (Papillomaviridae), 
Adelie penguin polyomavirus (Polyomaviridae) 
yes RCA Illumina HiSeq 
F [109] Viral metagenomic analysis of 268 bat rectal swabs Bat coronaviruses* (Coronaviridae) yes rPCR SISPA Illumina 
F [110] Analysis of feces samples from an epizootic outbreak 
of diarrhea in cows 
Bovine rotavirus A* (Reoviridae) yes none Illumina MiSeq 
F [111] Analysis of viral flora in fecal samples collected from 
turkeys with light turkey syndrome 
Turkey picobirnavirus (Picobirnaviridae) no none Illumina HiSeq 
F [112] Genetic characterization of porcine group A 
rotaviruses in stool samples of asymptomatic pigs 
Rotaviruses A (Reoviridae) yes none Illumina MiSeq 
F [113] Analysis of viral flora in feces of 25 cats i.a. Feline astroviruses* (Astroviridae), feline bocaviruses* 
(Parvoviridae), Feline cyclovirus* (Circoviridae), feline 
coronavirus type 1 (Coronaviridae), felid herpes 1 
(Gerpesviridae) 
yes none Illumina MiSeq 
F [114] Analysis of viral diversity in feces of wild small 
carnivores 
Genet fecal theilovirus* (Picornaviridae), Otter fecal 
bunyavirus*, Fox fecal bunyaviru* (Bunyaviriae), Red 
fox fecal amdovirus*, Red fox fecal kobuvirus* 
(Parvovirinae), and Red fox fecal picobirnavirus* 
(Picobirnaviridae). 
yes rPCR SISPA 454 GS Junior 
F [115] Analysis of viral flora in feces of healthy dromedaries Viruses of the Picobirnaviridae, Circoviridae, 
Picornaviridae, Parvoviridae, Astroviridae, Hepeviridae 
… 
yes rPCR SISPA Illumina HiSeq 
B [116] Screening for viruses in sera of domestic pigs during 
surveillance for African swine fever 
African swine fever virus (Asfarviridae), Torque teno 
viruses (Anelloviridae), Ndumu virus (Togaviridae), P 
orcine endogenous retroviruses (Retroviridae) 
yes rPCR SISPA 454 GS FLX 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
B [117] Screening for viruses in sera of wild bush pigs as part 
of a research project on African swine fever 
Torque teno sus virus 1 & 2 * (Anelloviridae), Porcine 
parvovirus 4* (Parvoviridae) … 
yes rPCR SISPA 454 GS FLX 
B [118] Screening for causal agent of Theiler's disease in 
serum from horses in a recent outbreak 
Theiler's disease-associated virus (Flaviviridae) yes rPCR SISPA Illumina HiSeq 
B [119, 
120] 
Screen ing for viruses in serum of wild living monkeys Simian immunodeficiency viruses* (Retroviridae); 
Guereza hepacivirus* (Flaviviridae) 
yes none Illumina MiSeq & 
454 GS Junior 
B [121] Pilot detection of RNA viruses in feces of dead ducks Duck coronavirus* (Coronaviridae) yes none Ion Torrent PGM 
B [122] Virus discovery in a fibromatosis tumor from a female 
pig-tailed macaque 
Retroperitoneal fibromatosis-associated herpesvirus 
(Herpesviridae) 
no none Illumina GAII & 
HiSeq 
B [123] Screening for causal viruses in serum of aborted pig 
fetuses 
Porcine parvovirus 6 (Parvoviridae) no ligation-based 
SISPA 
Cloning + Sanger 
B [124] Screening for viruses in serum from a slow loris with 
diffuse histiocytic sarcoma 
Slow loris parvovirus 1* (Parvoviridae) yes VIDISCA-
454 
454 GS FLX 
B [125] Genome characterization of causal virus of viral 
erythrocytic necrosis in herring 
Erythrocytic necrosis virus (Iridoviridae) yes none 454 GS FLX 
B [126] Examination of simian arterivirus infections in baboon 
populations 
Mikumi yellow baboon virus 1*, Southwest baboon virus 
1* (Arteriviridae) 
yes none Illumina MiSeq 
T [127] Identify causative agent of a mass mortality event in 
wild and captive birds (liver and spleen samples) 
Usutu virus (Flaviviridae) no none 454 GS FLX 
T [128] Examination of tissues for candidate etiological agents 
for snake inclusion body disease 
Golden Gate virus*, CAS virus* (Arenaviridae) yes rPCR SISPA Illumina HiSeq 
T [129] Examination of kidney samples of snakes that were 
diagnosed with inclusion body disease 
Boa arenaviruses* (Arenaviridae) yes rPCR SISPA 454 GS Junior 
T [130] Analysis of central nervous system tissue of horses 
that died during an outbreak of neurologic disease 
Murray Valley encephalitis virus, West Nile virus 
(Flaviviridae) 
yes none Illumina HiSeq 
T [131] Identifying the causative agent in brain tissue samples 
from cattle presenting neurologic disease 
Bovine astrovirus NeuroS1* (Astroviridae) yes none Illumina MiSeq 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
T [132] Examination of viral flora in the hepatopancreas of 
shrimps 
Farfantepenaeus duorarum circovirus*(Circoviridae), 
Farfantepenaeus duorarum nodavirus* (Nodaviridae) 
yes MDA &   
rPCR SISPA 
Cloning + Sanger 
T [133] Examination for viruses in liver of a dog with disease 
of unknown cause 
Dog circovirus* (Circoviridae) yes rPCR SISPA 454 GS FLX 
T 
 
[134] Examination for viruses in liver of a dog with disease 
of unknown cause 
Canine bocavirus 3* (Parvoviridae) yes rPCR SISPA 454 GS FLX 
none Illumina MiSeq 
T [135] Characterization of new virus found in the cloacal 
bursa in dead gulls 
Gull adenovirus* (Adenoviridae) yes rPCR SISPA 454 GS Junior 
T [136] Identification of viruses in tissue of a harbor seal with 
chronic non-suppurative meningo-encephalitis 
Seal parvovirus* (Parvoviridae), Seal anelloviruses 2, 3 * 
(Anelloviridae) 
yes rPCR SISPA 454 GS Junior 
T [137] Metagenomic study of bat viruses in urine, throat 
swabs & lung tissue 
i.a. Eidolon helvum: kobuvirus* (Picornaviridae), 
parvoviruses* (Parvoviridae), poxvirus* (Poxviridae), 
herpesviruses*(Herpesviridae), adenoviriruses* 
(Adenoviridae), papillomaviruses* (Papillomaviridae), 
retroviruses* (Retroviridae) 
yes rPCR SISPA Illumina GAII 
T [138, 
139] 
Study virome in bat tissues i.a. Bat: astroviruses* (Astroviridae), bocaviruses* 
(Parvoviridae), circoviruses* (Circoviridae), 
Iflaviruses* (Iflaviridae), orthohepadnaviruses* 
(Hepadnaviridae) , Rotavirus A* (Reoviridae) 
yes rPCR SISPA Illumina 
T [140] Virus screening in postmortem tissue (lung & lever) 
samples from rabies-negative big brown bats 
American bat vesiculovirus* (Rhabdoviridae) yes (MDA +)  
rPCR SISPA 
454 & Illumina 
T [141] Characterization of viruses in fibroma tissue on the 
trunk of an African elephant 
African elephant polyomavirus 1* (Polyomaviridae) no RCA 454 GS FLX 
T [142] Virus screening in tissue samples for rabies-negative 
dead bats 
Bat bornaviruses* (Bornaviridae), Bat nairovirus* 
(Bunyaviridae), Bat rotavirus* (Reoviridae), Bat 
gammaretrovirus* (Retroviridae) … 
 
no rPCR SISPA Illumina HiSeq 
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Table 2 (continued)     
S Ref Application Viruses (family) PT AM Sequencing 
T [143] Characterization of virus associated with disease 
outbreak in pigs (intestine homogenate + 2 isolates) 
Porcine epidemic diarrhea virus (Coronaviridae) no none Illumina MiSeq 
T [144] Characterization of causal agent (in intestinal content) 
of an outbreak of fulminating enteritis in guinea fowl 
Guinea fowl coronavirus (Coronaviridae) yes rPCR SISPA Illumina MiSeq 
T [145] Characterization of virus associated with sick raccoon 
dogs in lesion tissues of spleens and kidneys 
Raccoon dog and fox amdoparvovirus* (Parvoviridae) ? rPCR SISPA Illumina MiSeq 
T [21] RNA viral community in a gut tissue of a healthy 
turkey 
Viruses belonging to Reoviridae, Astroviridae, 
Bunyaviridae, Paramyxoviridae, Rhabdoviridae … 
yes none Illumina MiSeq 
T [20, 
146] 
Virus screening for etiology agent associated with a 
fatal respiratory disease in pythons 
Ball python nidovirus* (unclassified Nidovirales) no 
 yes 
none Illumina HiSeq & 
Ion torrent PGM 
T [147, 
148] 
Complete viral genome sequencing from heart/tongue 
tissue of a diseased elephants (fatal case) 
Elephant endotheliotropic herpesvirus 1A, 1B, 5 
(Herpesviridae) 
no none Illumina HiSeq & 
MiSeq 
T [149] Virus screening in papilloma lesions of stranded sea 
otters 
Enhydra lutris papillomavirus 1* (Papillomaviridae) yes rPCR SISPA Illumina MiSeq 
T [10] Virus screening in tissue from chickens with 
transmissible viral proventriculitis disease 
Chicken proventriculitis virus *, Avian encephalomyelitis 
virus (Picornaviridae), Chicken anemia virus 
(Circoviridae), parvovirus (Parvoviridae), avastrovirus 
(Astroviridae), calicivirus (Caliciviridae), adenovirus 
(Adenoviridae) 
yes rPCR SISPA Illumina  
A [150] Identification of causal viruses in a diseased Spanish 
honeybee colony  
i.a. Aphid lethal paralysis virus, Israel acute paralysis 
virus* (Dicistroviridae), Lake sinai viruses 
(unclassified)  
yes rPCR SISPA 454 GS FLX 
A [151] Proof of principle – detecting viruses in infected 
mosquitoes 
Dengue virus, Yellow fever virus (Flaviviridae), 
Chikungunya virus (Togaviridae) 
no rPCR SISPA 
MDA 
Ion Torrent PGM 
A [152] Examine viromes of ticks Long Island tick rhabdovirus (Rhabdoviridae) yes none Ion Torrent PGM 
A [153] Metagenomics sequencing in wild-caught Aedes 
aegypti 
Phasi Charoen-like virus (Bunyaviridae) yes none Illumina GAII 
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Rapid diagnosis of infectious diseases is essential in order to take appropriate action to control 
livestock and human diseases. The development of novel molecular techniques like PCR and 
DNA sequencing has contributed to the advancement of disease diagnostics during the last 
decades. Most of these molecular virus detection approaches rely on minimal sequence 
knowledge of the target viral genome. DNA sequencing has become an important tool for 
virus identification and genome characterization.  
Since the beginning of this PhD project, much has changed in the field of DNA sequencing. 
“Next-generation” DNA sequencing technologies (NGS) became increasingly available; 
improving the sequencing throughput enormously and reducing costs dramatically when 
compared to the classical Sanger sequencing technology.  
Specific molecular tests target known regions of the viral genome. Such tests will fail to 
detect (and sequence) novel viruses with little or no available sequence information. 
Moreover, viruses (in particular RNA viruses) evolve quickly, making detection and control 
of viral infections more challenging.  
One promising solution to the vulnerability of specific diagnostics for the identification of 
unknown viruses is to directly sequence all the genetic material within a clinical sample, and 
subsequently analyse the data for the presence of viral sequences. Due to the small size of 
virus genomes and low virus concentrations, when compared to the enormous background 
genetic material from host and bacterial cells in typical clinical samples, enrichment and 
amplification of viral nucleic acids is of crucial importance. This virus-focused random 
sequencing is referred to as “viral metagenomics”. Various viral metagenomic workflows 
have been described, using different methodologies to optimise targeting of the viral nucleic 
acids within a sample. Strategies often include filtration, centrifugation and enzymatic 
digestion of non-viral DNA/RNA, but little is known about the true benefits or biases that 
these manipulations may introduce.  
Furthermore, various sequence independent amplification strategies are used to generate 
appropriate amounts of input DNA for sequencing. The nature of the amplification bias 
resulting from these strategies is often not fully understood. Moreover, viral metagenomic 
identification workflows are associated with low sensitivity compared to specific diagnostic 
tests due to their random sequencing process. The major challenge is to improve sensitivity of 
the metagenomic workflow in order to sequence viral nucleic acids in samples with a low 
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virus titer, and in clinical samples containing many contaminating background nucleic acids 
(e.g. tissues).   
Complementary to classical virology and specific molecular diagnostic tools, viral 
metagenomics provides an interesting new approach for the identification of unknown 
pathogens and the characterization of their genomic sequence. This thesis aimed to 
demonstrate the diagnostic potential of metagenomics for virus identification and the 
characterization of high quality genomes, whilst addressing some of the challenges associated 
with viral metagenomics.  
A promising and widely applicable viral metagenomics workflow was adopted from literature 
(Chapter 3.1). The method combined virion enrichment steps, a sequence independent pre-
amplification step, molecular cloning and Sanger sequencing. The random PCR sequence 
independent single primer amplification (rPCR SISPA) method was selected as a widely used 
and viral genome structure independent amplification approach. After successful 
implementation in the laboratory and testing with different model viruses, the workflow was 
combined with NGS (454 pyrosequencing) and applied to ongoing diagnostic and research 
projects.  
In the first case study described, the workflow was tested on two un-characterized avian 
paramyxoviruses (APMV) isolated during a wildlife screening program in mallards for avian 
influenza A viruses and APMV (Chapter 3.2). Traditional diagnostics failed to subtype these 
virus isolates, whereas the applied metagenomics workflow allowed characterization and full 
genome sequencing using only a moderate and economical sequencing effort. Furthermore, in 
one virus isolate, a multiple infection with two different APMV serotypes was identified.  
In the second case study, the workflow was used for the molecular characterization of nine 
different avian influenza virus (AIV) isolates from a surveillance program in wild gulls and 
shorebirds (Chapter 3.3). The obtained nearly full genome sequences of these segmented 
viruses allowed correct subtyping and a detailed phylogenetic analysis. A transhemispheric 
reassortment of the genomic segments of AIV’s in European gulls was documented.  
In the third case study the workflow was used to characterize 11 pigeon type 1 
paramyxoviruses (PPMV1) which were isolated during routine diagnostics for AIV and 
APMV in pigeons (Chapter 3.4). In addition to the full genome sequences of the PPMV1  
isolates (RNA virus), the obtained sequence information also documented considerable 
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genetic variability within multiple isolates and the presence of contaminating pigeon 
circovirus genome sequences (DNA virus) in four of these viral stocks. These findings 
demonstrate the value of NGS-based metagenomic workflows for quality control of biological 
products such as virus stocks. 
The three initial case studies targeted virus isolates, containing high virion concentrations and 
low background nucleic acid contaminants. A forth case study aimed to test the sensitivity of 
the workflow on clinical samples (Chapter 3.5). Brain tissue samples of sheep naturally 
infected with the recently emerging novel Schmallenberg virus (SBV) were selected. The 
metagenomic workflow only allowed identification of SBV in strong positive samples, 
illustrating the importance of properly targeted samples and demonstrating a limited virus 
discovery sensitivity of the workflow applied in theis chapter.  
After gaining experience with the protocol, the workflow was tested on a case study where the 
presence and type of virus were unknown (Chapter 3.6). In an attempt to increase the virus 
discovery sensitivity, the workflow was slightly adapted. A cluster of dairy cattle affected by 
a disease of unknown causality were selected as a case study. Using both a DNA and RNA 
virus specific discovery workflow, no viral sequences were found to be associated with the 
disease. However, careful follow-up analysis provided clear warnings for the potential of false 
positive results in metagenomics, as a laboratory contaminant and an extraction kit 
contaminant were identified.  
Another objective of this thesis was to fine-tune the workflow to address some of the 
remaining challenges. Firstly, potential bias and the added value of the pre-amplification 
method used were investigated (Chapter 4.1). Evidence is provided that the rPCR SISPA 
amplification method results in a biased distribution of the sequence reads along the full 
genome sequence. The rPCR SISPA primer consists of a random oligomer sequence at its 3’ 
end and a defined universal sequence tag at its 5’ end. It was shown that the tag sequence of 
the rPCR SISPA primer was the main contributor to the uneven sequence depth observed. 
Furthermore, it was proven that this primer annealing bias can be reduced by extending the 
random 3’ oligomer sequence and by combining sequence data from multiple different rPCR 
SISPA reactions using different 5’ tag sequences.  
Due to recent advances of NGS platforms and library preparation methods, direct sequencing 
of low amounts of input DNA without an extra pre-amplification step could be evaluated 
(Chapter 4.2). Illumina sequencing on the MiSeq platform, using the Nextera XT library 
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preparation kit, was selected as the preferred NGS technology. In addition, the bioinformatics 
data analysis pipeline was adjusted in anticipation of the higher sequencing output.  It was 
shown that rPCR SISPA amplification was not beneficial for viral identification, and that 
direct sequencing of the complementary DNA is recommended. In addition, different 
convenient and widely used pretreatment methods were compared and evaluated for their 
relative (RNA) virus discovery sensitivity in clinical samples by spiking a fixed (low) virus 
titer in serum and lung tissue samples. The main conclusion of this comparative study was 
that the recommended pretreatment strategy depended strongly on the amount and 
composition of the sample background nucleic acids. A filtration and subsequent nuclease 
treatment step increased virus discovery sensitivity in both serum and tissue. Simple DNase 
treatment on the RNA extract resulted in the highest improvement in the serum sample, 
whereas a ribosomal RNA removal on the RNA extract resulted in the biggest improvement 
in the tissue sample. Evidence from this and other studies in the literature is increasingly 
indicating that no universal optimal viral metagenomic workflow exists. Results of protocol 
comparison studies (including Chapter 4.2 and other published investigations) are therefore 
difficult to compare as many variables exist, but they all provide useful guidelines. Their 
results emphasize that metagenomic workflows have to be flexible. Depending on the case 
study concerned, a variety of steps may be included or excluded from the workflow. Some 
recommendations are provided which could be useful when planning future metagenomic 
virus discovery studies (Chapter 5). Furthermore, it was also shown that our optimized 
workflows can now easily detect viruses present at low virion concentrations (Chapter 4.2).  
The work presented in this thesis offers a clear documentation of the potential of NGS-based 
methods for the identification of viruses and for the characterization of their complete genome 
sequences. Solid workflows, both for sample treatment and data analysis are now available to 
allow virus identification and further genome characterization. Sequencing technologies are 
expected to continuously evolve and become more accurate, economical, and accessible. Viral 
metagenomics will be established as a complementary tool to traditional virological tools and 
specific molecular diagnostic methods for both the identification and characterization of viral 
pathogens. However, as with any diagnostic method, its weaknesses have to be properly 
monitored. An integrative approach should be used, combining the added values of classical 
virology, specific diagnostic tests, and novel sequencing approaches, in order to exploit the 
full complementarity of these approaches. 
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Voor het nemen van gepaste maatregelen om infectieziekten bij landbouwhuisdieren en 
mensen te bestrijden is een snelle diagnose essentieel. De ontwikkeling van nieuwe 
moleculaire technieken zoals PCR en DNA sequentiebepaling hebben de afgelopen decennia 
bijgedragen tot de vooruitgang van de diagnostiek van virale ziekten. De meeste van deze 
moleculaire virusdetectie benaderingen vertrouwen op ten minste een gedeeltelijke kennis van 
de virale genoomsequentie. De DNA sequentiebepalingstechniek is uitgegroeid tot een 
belangrijk instrument voor virus identificatie en genoomkarakterisatie. 
Sinds het begin van dit doctoraatsonderzoek is er veel veranderd op het gebied van DNA 
sequentiebepaling. "Next-generation" DNA sequentiebepalingstechnologieën (NGS) werden 
in toenemende mate beschikbaar. Vergeleken met de klassieke Sanger 
sequentiebepalingstechnologie genereren ze een hogere output en verminderen ze de kosten 
drastisch. 
Specifieke moleculair diagnostische testen richten zich op gekende regio’s in het virale 
genoom. Dergelijke testen zullen nieuwe virussen met weinig of geen beschikbare sequentie-
informatie moeilijk kunnen detecteren. Virussen (in het bijzonder RNA-virussen) evolueren 
ook snel, wat detectie en bestrijding van virale infecties nog uitdagender maakt. 
Een veelbelovende oplossing voor de kwetsbaarheid van deze specifieke diagnostische testen 
voor de identificatie van onbekende virussen is om de sequentie te bepalen van al het 
genetische materiaal in een staal, en vervolgens de sequentiegegevens te analyseren op de 
aanwezigheid van virale sequenties. Door de kleine afmetingen van virus genomen en de lage 
virusconcentraties vergeleken met de enorme hoeveelheid genetisch materiaal van gastheer en 
bacteriële cellen in typische klinische stalen, is de aanrijking en amplificatie van virale 
nucleïnezuren van cruciaal belang. Deze op virus gefocuste willekeurige sequentiebepaling 
wordt ook wel “virus metagenomics” genoemd. Diverse virus metagenomische workflows 
zijn beschreven in de literatuur, elk gebruik makend van verschillende methoden om de focus 
op virale nucleïnezuren in een staal te optimaliseren. Strategieën omvatten vaak stappen zoals 
filtratie, centrifugatie en enzymatische afbraak van niet-viraal DNA/RNA, maar er is weinig 
bekend over de echte meerwaarde of mogelijke bias die deze manipulaties kunnen 
introduceren. 
Verder bestaan er verschillende sequentie onafhankelijke amplificatiestrategieën om geschikte 
hoeveelheden input DNA voor de sequentiebepaling te genereren. De aard van de amplificatie 
bias als gevolg van deze strategieën is vaak niet volledig begrepen. Bovendien zijn virale 
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metagenoom workflows geassocieerd met een lagere virus detectie gevoeligheid vergeleken 
met specifieke diagnostische testen vanwege het willekeurig karakter van hun 
sequentiebepalingsproces. De grootste uitdaging is om de gevoeligheid van de 
metagenomische workflow voor sequentiebepaling van virale nucleïnezuren te verbeteren  in 
stalen met een lage virus titer en met veel contaminerende nucleïnezuren (bv weefsels). 
Aanvullend aan de klassieke virologie en specifieke moleculaire diagnostische instrumenten 
is virus metagenomics een interessante nieuwe benadering voor de identificatie van 
onbekende pathogenen en karakterisatie van hun genomische sequentie. Deze thesis had als 
doel om de diagnostische mogelijkheden van metagenomics voor virus identificatie en de 
karakterisatie te demonstreren en daarbij ook enkele uitdagingen geassocieerd met virus 
metagenomics aan te pakken. 
Een veelbelovend en breed toepasbaar virus metagenomisch protocol werd geïmplementeerd 
uit de literatuur (hoofdstuk 3.1). De workflow combineerde viruspartikel aanrijkingsstappen, 
een sequentie onafhankelijke pre-amplificatiestap, moleculaire klonering en Sanger 
sequentiebepaling. De random PCR sequence independent single primer amplification (rPCR 
SISPA) werd geselecteerd als een veelgebruikte en virale genoomstructuur onafhankelijke 
amplificatie methode. Na een succesvolle implementatie in het laboratorium en validatie met 
behulp van verschillende model virussen, werd de workflow in combinatie met NGS (454 
pyrosequencing) toegepast op enkele lopende diagnostische- en onderzoeksprojecten. 
In de eerste casus werd de workflow getest op twee niet gekarakteriseerde aviaire 
paramyxovirussen (APMV) geïsoleerd tijdens een screeningsprogramma in wilde eenden voor 
aviaire influenza A virussen en APMV (hoofdstuk 3.2). Traditionele diagnostische testen 
slaagde er niet in om deze virusisolaten te subtyperen, terwijl de toegepaste metagenomische 
workflow subtypering en volledige sequentiebepalingen van het genoom toeliet, gebruik 
makende van slechts een gemiddelde en economische sequenbepalingsinspanning. Daarnaast 
werd er in één virusisolaat een co-infectie met twee verschillende APMV serotypes 
geïdentificeerd. 
In de tweede casus werd de workflow gebruikt voor de moleculaire karakterisering van negen 
verschillende aviaire influenza A virussen (AIV) isolaten uit een bewakingsprogramma in 
wilde meeuwen en steltlopers (hoofdstuk 3.3). De verkregen, bijna volledige, genoom 
sequenties van deze gesegmenteerde virussen lieten een juiste subtypering en een 
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gedetailleerde fylogenetische analyse toe. Er werd ook een transhemisferische re-assortering 
van de AIV genoomsegmenten in Europese meeuwen gedocumenteerd. 
In de derde casus werd de workflow gebruikt om elf type 1 duif paramyxovirussen  (PPMV1) 
te karakteriseren die geïsoleerd werden tijdens routine diagnostiek voor AIV en APMV in 
duiven (hoofdstuk 3.4). Naast de volledige genoom sequenties van de PPMV1 isolaten (een 
RNA virus), werd in de verkregen sequentie-informatie ook een aanzienlijke genetische 
variabiliteit waargenomen bij meerdere isolaten, alsook de aanwezigheid van duif circovirus 
genoomsequenties (DNA virus) in vier van deze virusstocks. Deze bevindingen tonen aan dat 
NGS gebaseerde metagenomische workflows geschikt zijn voor kwaliteitscontrole van 
biologische producten zoals de controle van virusstocks. 
De drie eerste casestudies onderzochten virus isolaten die hoge viruspartikelconcentraties en 
lage hoeveelheden contaminerende nucleïnezuren bevatten. Een vierde casus had als doel de 
gevoeligheid van de workflow op klinische stalen te testen (hoofdstuk 3.5). Hersenweefsels 
van schapen werden geselecteerd welke op natuurlijke wijze besmet waren met het recente 
nieuwe Schmallenbergvirus (SBV). De metagenomische workflow liet enkel identificatie van 
SBV toe in sterk positieve stalen, hetgeen  het belang van gerichte staalname demonstreert en 
een beperkte gevoeligheid van het gebruikte protocol aantoont.  
Na ervaring te hebben opgedaan met het protocol, werd de workflow getest op een casus 
waarin de aanwezigheid en het virustype niet bekend waren (hoofdstuk 3.6). In een poging 
om het virus identificatiegevoeligheid te verhogen, werd de workflow enigszins aangepast. 
We onderzochten een cluster van melkkoeien, welke getroffen waren door een ziekte met een 
nog onbekende oorzaak. Gebruik makende van zowel een DNA als RNA virus specifieke 
identificatie workflow, konden geen virale sequenties gevonden worden die in verband 
konden gebracht worden met het ziektebeeld. Nauwkeurige opvolganalyse gaf duidelijke 
waarschuwingen voor mogelijke vals-positieve resultaten in de metagenomics analyse; er 
werden namelijk een laboratorium contaminant en een extractiekit contaminant 
geïdentificeerd. 
Een ander doel van deze thesis was de workflow te optimaliseren om zo enkele  resterende 
uitdagingen uit de virus metagenomics aan te pakken. Ten eerste werd mogelijke bias en de 
toegevoegde waarde van de gebruikte pre-amplificatiemethode onderzocht (hoofdstuk 4.1). 
We konden aantonen dat de rPCR SISPA amplificatie methode resulteert in een ongelijke 
verdeling van de sequenties over het genoom. De rPCR SISPA primersequentie bestaat uit 
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een random oligomeer sequentie aan zijn 3’ uiteinde en een vaste universele “tag”-sequentie 
aan zijn 5’ uiteinde. We toonden aan dat deze sequentietag van de rPCR SISPA primer de 
belangrijkste bijdrage leverde aan de waargenomen ongelijke sequentiediepte. Bovendien 
werd er aangetoond dat deze primer annealing bias kan worden verminderd door de 3' random 
oligomeersequentie te verlengen en door sequentiebepalingsgegevens van meerdere rPCR 
SISPA reacties met verschillende 5' sequentietags te combineren. 
Door recente ontwikkelingen van NGS platformen en kits, was het mogelijk geworden om 
rechtstreekse sequentiebepaling zonder een extra pre-amplificatie stap te evalueren van lage 
hoeveelheden input DNA (hoofdstuk 4.2). Illumina sequentiebepaling op het MiSeq 
platform, met behulp van de Nextera XT library preparatiekit, werd geselecteerd als 
aangewezen NGS technologie en reagentia. Daarenboven werd de bioinformatica analyse 
aangepast in anticipatie van een hogere sequentie output. Er werd aangetoond dat rPCR 
SISPA amplificatie niet gunstig is voor virus identificatie, en dat rechstreekse 
sequentiebepaling van het cDNA aanbevolen is. Verder werden verschillende gemakkelijke 
en veel gebruikte voorbehandelingsmethodes met elkaar vergeleken en geëvalueerd op hun 
relatieve gevoeligheid voor (RNA) virus identificatie in klinische stalen, door artificiëel 
serum en longweefsel te besmetten met een vaste (lage) virus titer. De belangrijkste conclusie 
van dit vergelijkend onderzoek was dat de aanbevolen voorbehandelingsstrategie sterk 
afhankelijk is van de hoeveelheid en de samenstelling van de achtergrondnucleïnezuren in het 
staal. Een filtratie en daaropvolgende nuclease behandelingsstap verhoogde de gevoeligheid 
voor virus identificatie in zowel serum en weefsel. Een DNase behandeling op het RNA 
extract leidde tot de hoogste verbetering  van de gevoeligheid voor RNA virus identificatie in 
het serum, terwijl een ribosomaal RNA verwijderingsbehandeling op het RNA extract tot de 
grootste verbetering leidde in het weefsel staal. De resultaten uit deze en andere studies uit de 
literatuur geven in toenemende mate aan dat er geen universele optimale virus 
metagenomische workflow bestaat. Resultaten uit verschillende studies (waaronder hoofdstuk 
4.2 en andere gepubliceerde onderzoeken) zijn moeilijk met elkaar te vergelijken omdat er 
zoveel variabelen zijn; maar ze bieden allemaal wel nuttige richtlijnen. Hun resultaten 
benadrukken dat metagenomische workflows flexibel moeten zijn. Afhankelijk van de 
betrokken casus kunnen verschillende  stappen worden opgenomen of uitgesloten uit de 
metagenomische workflow. Enkele aanbevelingen worden geformuleerd in deze thesis en 
kunnen nuttig zijn bij de planning van toekomstige virus metagenomische studies (hoofdstuk 
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5). Verder werd er ook aangetoond dat onze geoptimaliseerde protocols nu gemakkelijk 
virussen aanwezig in lage concentraties kunnen detecteren (hoofdstuk 4.2). 
Het in dit proefschrift gepresenteerde werk biedt een duidelijke documentatie van het 
potentieel van NGS-gebaseerde methoden voor de identificatie van virussen en voor de 
karakterisering van hun complete genoomsequenties. Degelijke protocols, zowel voor 
staalbehandeling en data analyse zijn nu beschikbaar, en kunnen gebruikt worden voorvirus 
identificatie en genoomkarakterisatie. Het ligt in de verwachtingen dat 
sequentiebepalingstechnologieën zullen blijven evolueren naar meer accuraatheid, een lagere 
kostprijs en een betere toegankelijkheid. Virus metagenomics zal zich profileren als een 
complementair instrument aan traditionele virologische tools en specifieke moleculaire 
diagnostische methoden, zowel voor de identificatie als voor karakterisering van virale 
ziekteverwekkers. Zoals met elke diagnostische methode moeten de zwakke punten ervan 
nauwlettend in het oog gehouden worden. Een geïntegreerde benadering zou beoogd moeten 
worden, waarin de toegevoede waarde van klassieke virologie, specifieke diagnostische testen 
en nieuwe sequentiebepalingsstrategieën gecombineerd worden, om zo de complementariteit 
van deze benaderingen ten volle te benutten. 
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